{"a7d01b5ef998b822ad326f3400a701abfc2f66ab": [["T he coronavirus disease 2019 (COVID-19) pandemic has impacted congenital cardiac surgical programs with significant reduction in case load, implementation of patient triage strategies, and development of personal protective equipment (PPE) guidelines.", [["cardiac", "ANATOMY", 74, 81], ["coronavirus disease", "DISEASE", 5, 24], ["COVID-19", "CHEMICAL", 31, 39], ["T he coronavirus", "ORGANISM", 0, 16], ["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["T he coronavirus disease 2019 (COVID-19", "SPECIES", 0, 39], ["T he coronavirus disease", "PROBLEM", 0, 24], ["COVID", "TEST", 31, 36], ["congenital cardiac surgical programs", "TREATMENT", 63, 99], ["significant reduction", "TREATMENT", 105, 126], ["patient triage strategies", "TREATMENT", 159, 184], ["personal protective equipment", "TREATMENT", 205, 234], ["coronavirus disease", "OBSERVATION", 5, 24], ["cardiac", "ANATOMY", 74, 81], ["surgical", "OBSERVATION", 82, 90], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["reduction", "OBSERVATION_MODIFIER", 117, 126]]], ["This document summarizes current status and implications of COVID-19 in congenital cardiac surgery outlining recommendations from the Congenital Cardiac Anesthesia Society (CCAS; Figure 1 ).REORGANIZATION OF HEART PROGRAM Decrease in Case Load and PrioritizationIn response to the rapid recognition of challenges faced by health care infrastructures related to the COVID-19 outbreak, a broad call to restrain \"elective\" surgical procedures was announced by the Center for Medicare and Medicaid Services (CMS) and the American College of Surgeons (ACS) in March 2020.", [["cardiac", "ANATOMY", 83, 90], ["Cardiac", "ANATOMY", 145, 152], ["Congenital Cardiac Anesthesia", "DISEASE", 134, 163], ["ACS", "DISEASE", 547, 550], ["cardiac", "ORGAN", 83, 90], ["COVID", "TEST", 60, 65], ["congenital cardiac surgery", "TREATMENT", 72, 98], ["elective\" surgical procedures", "TREATMENT", 410, 439], ["cardiac", "ANATOMY", 83, 90], ["surgery", "OBSERVATION", 91, 98], ["Cardiac", "ANATOMY", 145, 152], ["Anesthesia", "OBSERVATION", 153, 163], ["HEART", "ANATOMY", 208, 213], ["Decrease", "OBSERVATION_MODIFIER", 222, 230]]], ["1 Multidisciplinary committees should discuss cases prioritization based on ACS definition of emergent and urgent procedures, taking into consideration hospital capacity and local resources available during the COVID-19 pandemic (Table) .", [["ACS", "DISEASE", 76, 79], ["emergent and urgent procedures", "TREATMENT", 94, 124], ["the COVID", "TEST", 207, 216]]], ["2Heart TransplantationTo date, most pediatric heart transplant programs in the United States continue to deem heart transplant as an urgent/emergent surgical procedure.", [["heart", "ANATOMY", 46, 51], ["heart", "ANATOMY", 110, 115], ["heart", "ORGAN", 46, 51], ["heart", "ORGAN", 110, 115], ["heart transplant", "TREATMENT", 110, 126], ["an urgent/emergent surgical procedure", "TREATMENT", 130, 167], ["heart", "ANATOMY", 46, 51], ["transplant", "OBSERVATION", 52, 62], ["heart", "ANATOMY", 110, 115], ["transplant", "OBSERVATION", 116, 126]]], ["The recommendation from the International Society of Heart and Lung Transplantation states that the patient should report no new-onset clinical symptoms consistent with COVID-19, no close contact with a confirmed case, and no travel within 14 days (https://ishlt.org/ishlt/media/documents/SARS-CoV-2_-Guidance-for-Cardiothoracic-Transplant-and-VAD-centers.pdf).", [["Heart", "ANATOMY", 53, 58], ["Lung", "ANATOMY", 63, 67], ["Heart", "ORGAN", 53, 58], ["Lung", "ORGAN", 63, 67], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["Heart and Lung Transplantation", "TREATMENT", 53, 83], ["new-onset clinical symptoms", "PROBLEM", 125, 152], ["COVID", "TEST", 169, 174], ["Heart", "ANATOMY", 53, 58], ["Lung", "ANATOMY", 63, 67], ["Transplantation", "OBSERVATION", 68, 83]]], ["In addition, the document recommends COVID-19 testing before transplant, assuming a rapid turn-around assay is available.", [["COVID", "TEST", 37, 42], ["transplant", "TREATMENT", 61, 71], ["a rapid turn-around assay", "TEST", 82, 107]]], ["Patients with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection should not undergo transplantation.", [["acute respiratory syndrome coronavirus", "DISEASE", 30, 68], ["infection", "DISEASE", 84, 93], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 72, 82], ["Patients", "SPECIES", 0, 8], ["severe acute respiratory syndrome coronavirus", "SPECIES", 23, 68], ["SARS-CoV-2", "SPECIES", 72, 82], ["positive severe acute respiratory syndrome coronavirus", "PROBLEM", 14, 68], ["SARS", "PROBLEM", 72, 76], ["infection", "PROBLEM", 84, 93], ["transplantation", "TREATMENT", 113, 128], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory syndrome coronavirus", "OBSERVATION", 36, 68], ["infection", "OBSERVATION", 84, 93], ["transplantation", "OBSERVATION", 113, 128]]], ["In regard to the processes that surround donor offers and procurement, the surgical recovery of organs by the local teams should be promoted whenever possible to minimize potential exposure and traveling across the country.Monitoring the Wait ListMost congenital cardiac programs ceased scheduling elective procedures in anticipation of the surge in COVID-19-positive patients requiring hospitalization.Monitoring the Wait ListThis has resulted in a dynamic expanding procedural wait list which will have to be managed with consideration of the following:Monitoring the Wait List1.", [["organs", "ANATOMY", 96, 102], ["cardiac", "ANATOMY", 263, 270], ["organs", "ORGAN", 96, 102], ["cardiac", "ORGAN", 263, 270], ["COVID-19", "GENE_OR_GENE_PRODUCT", 350, 358], ["patients", "ORGANISM", 368, 376], ["patients", "SPECIES", 368, 376], ["scheduling elective procedures", "TREATMENT", 287, 317], ["COVID", "TEST", 350, 355], ["hospitalization", "TREATMENT", 387, 402], ["cardiac", "ANATOMY", 263, 270]]], ["Continuously reassessing and reprioritizing of all patients on list a.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["Implementing telehealth, virtual check-in, and/or remote monitoring 2.", [["virtual check", "TEST", 25, 38], ["remote monitoring", "TEST", 50, 67]]], ["Recognition that every patient's clinical status and pending procedure is unique and a decision to further postpone must be multidisciplinary based on: a.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["procedure", "TREATMENT", 61, 70]]], ["Potential for significant deterioration which could result in harm such as therapy otherwise not indicated, prolonged hospital stay, or mortality b.", [["significant deterioration", "PROBLEM", 14, 39], ["therapy", "TREATMENT", 75, 82], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["deterioration", "OBSERVATION", 26, 39]]], ["Institutional abilities to schedule cases (physical plant, human resources) c.", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64]]], ["Time course of COVID-19 crisis 3.", [["COVID", "TEST", 15, 20]]], ["Ongoing effective, timely communication with patients/families, referring physicians, and proceduralists As restrictions lessen, a plan needs to be in place not only for caring for the remaining patients on the wait list but also for addition of new patients.Resumption Of ActivityIn the COVID-19 outbreak, defining the transition of pandemic to postpandemic remains unclear.", [["pandemic", "DISEASE", 334, 342], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 195, 203], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 250, 258], ["COVID-19", "SPECIES", 288, 296], ["pandemic", "PROBLEM", 334, 342], ["Activity", "OBSERVATION_MODIFIER", 273, 281]]], ["The stringency and duration of strategies such as physical distancing and PPE use will impact the timing and magnitude of a potential \"second wave\" of infections which may prolong the pandemic phase.", [["infections", "DISEASE", 151, 161], ["The stringency", "PROBLEM", 0, 14], ["strategies", "TREATMENT", 31, 41], ["a potential \"second wave\" of infections", "PROBLEM", 122, 161], ["infections", "OBSERVATION", 151, 161]]], ["Formal documentation of herd immunity by testing individuals' immune status may help define a stable SARS-CoV-2 resilient health care workforce, allowing faster return to higher surgical volumes.", [["herd", "ORGANISM_SUBDIVISION", 24, 28]]], ["Prioritization based on medical needs across surgical specialties is important as many pediatric cardiac centers will share resources (eg, personnel) with other surgical specialties.", [["cardiac", "ANATOMY", 97, 104]]], ["Monitoring for clinical deterioration during recommended wait times mitigates harm, affords opportunities to inform future care plans, and provides a structured and just approach to return of surgical services.Resuming Activity in PracticeIn the recovery phase following the COVID-19 pandemic, delayed surgeries will need to be rescheduled.", [["clinical deterioration", "PROBLEM", 15, 37], ["surgical services", "TREATMENT", 192, 209], ["delayed surgeries", "TREATMENT", 294, 311]]], ["This will likely require overtime shifts and expanded utilization of currently available operating rooms and catheterization laboratories.", [["catheterization laboratories", "TEST", 109, 137]]], ["In some institutions, additional operating rooms may be allocated to meet this demand, but that approach assumes that perioperative personnel can be mobilized.", [["perioperative personnel", "TREATMENT", 118, 141]]], ["In many institutions, cardiac intensive care unit (CICU) and step-down cardiac floor capacities are a limiting factor in the number of cases that can be performed.", [["cardiac", "ANATOMY", 22, 29], ["cardiac", "ANATOMY", 71, 78], ["cardiac", "ANATOMY", 22, 29]]], ["Programs that have well-established \"fast-track\" protocols will be able to leverage that expertise to help relieve potential congestion in the CICU and stepdown floor.", [["congestion", "DISEASE", 125, 135], ["CICU", "CANCER", 143, 147], ["potential congestion", "PROBLEM", 115, 135], ["congestion", "OBSERVATION", 125, 135]]], ["To put a finer point on it, a program may not be able to justify performing a procedure with an average CICU stay of 6-7 days in place of performing multiple cases with an average CICU stay of 1-2 days.", [["a procedure", "TREATMENT", 76, 87]]], ["\"Fast-track\" surgical procedures and diagnostic catheterizations could be performed on the weekend to reduce the inpatient volume during the week.", [["surgical procedures", "TREATMENT", 13, 32], ["diagnostic catheterizations", "TEST", 37, 64]]], ["Alternatively, these patients could be recovered in an extended recovery room environment allowing the CICU and step-down units to handle a larger caseload.DIAGNOSTIC TESTING FOR SARS-COV-2The purpose of testing is to facilitate diagnosis to guide supportive patient management and to implement measures to limit the spread of the virus.", [["patients", "ORGANISM", 21, 29], ["patient", "ORGANISM", 259, 266], ["patients", "SPECIES", 21, 29], ["patient", "SPECIES", 259, 266], ["step-down units", "TREATMENT", 112, 127], ["a larger caseload", "TREATMENT", 138, 155], ["DIAGNOSTIC TESTING", "TEST", 156, 174], ["SARS-COV", "TEST", 179, 187], ["testing", "TEST", 204, 211], ["supportive patient management", "TREATMENT", 248, 277], ["the virus", "PROBLEM", 327, 336]]], ["There are 2 broad categories of SARS-CoV-2 tests: those that detect the virus itself and those that test for the immune response of the host to the virus.DIAGNOSTIC TESTING FOR SARS-COV-2Tests for Viral RNA The preferred testing method is the real-time reverse transcription-polymerase chain reaction (RT-PCR).", [["Viral RNA", "RNA", 197, 206], ["SARS", "TEST", 32, 36], ["CoV-2 tests", "TEST", 37, 48], ["the virus itself", "PROBLEM", 68, 84], ["the virus", "PROBLEM", 144, 153], ["DIAGNOSTIC TESTING", "TEST", 154, 172], ["SARS-", "TEST", 177, 182], ["COV", "TEST", 182, 185], ["Viral RNA", "PROBLEM", 197, 206], ["The preferred testing method", "TEST", 207, 235], ["polymerase chain reaction", "PROBLEM", 275, 300], ["RT-PCR", "TEST", 302, 308]]], ["Within 5 days of the onset of symptoms of COVID-19, patients have high viral loads in their upper and lower respiratory tracts.", [["lower respiratory tracts", "ANATOMY", 102, 126], ["patients", "ORGANISM", 52, 60], ["upper", "ORGANISM_SUBDIVISION", 92, 97], ["lower respiratory", "ORGANISM_SUBDIVISION", 102, 119], ["patients", "SPECIES", 52, 60], ["symptoms", "PROBLEM", 30, 38], ["COVID", "TEST", 42, 47], ["high viral loads in their upper and lower respiratory tracts", "PROBLEM", 66, 126], ["high viral loads", "OBSERVATION", 66, 82], ["upper", "ANATOMY_MODIFIER", 92, 97], ["lower", "ANATOMY_MODIFIER", 102, 107], ["respiratory tracts", "ANATOMY", 108, 126]]], ["3 A nasopharyngeal or oropharyngeal swab may be used to collect a specimen.", [["nasopharyngeal", "ANATOMY", 4, 18], ["oropharyngeal swab", "ANATOMY", 22, 40], ["specimen", "ANATOMY", 66, 74], ["nasopharyngeal", "CANCER", 4, 18], ["oropharyngeal swab", "CANCER", 22, 40], ["A nasopharyngeal or oropharyngeal swab", "PROBLEM", 2, 40], ["a specimen", "TEST", 64, 74], ["nasopharyngeal", "ANATOMY", 4, 18], ["oropharyngeal", "ANATOMY", 22, 35]]], ["For patients with pneumonia, lower respiratory tract secretions may be collected from bronchoalveolar lavage fluid.", [["lower respiratory tract secretions", "ANATOMY", 29, 63], ["bronchoalveolar lavage fluid", "ANATOMY", 86, 114], ["pneumonia", "DISEASE", 18, 27], ["patients", "ORGANISM", 4, 12], ["lower", "ORGANISM_SUBDIVISION", 29, 34], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["secretions", "ORGANISM_SUBSTANCE", 53, 63], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 86, 114], ["patients", "SPECIES", 4, 12], ["pneumonia", "PROBLEM", 18, 27], ["lower respiratory tract secretions", "PROBLEM", 29, 63], ["bronchoalveolar lavage fluid", "TEST", 86, 114], ["pneumonia", "OBSERVATION", 18, 27], ["lower", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["secretions", "OBSERVATION", 53, 63], ["bronchoalveolar lavage fluid", "OBSERVATION", 86, 114]]], ["Detection rates in each sample vary between patients and may change over the course of their illness.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Detection rates", "TEST", 0, 15]]], ["4 Testing patients for SARS-CoV-2 helps identify those who are infected, which is useful for individual patient management, as well as for implementing mitigation strategies to prevent spread in health care facilities and the community.", [["SARS", "DISEASE", 23, 27], ["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 104, 111], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 104, 111], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["individual patient management", "TREATMENT", 93, 122], ["mitigation strategies", "TREATMENT", 152, 173], ["infected", "OBSERVATION", 63, 71]]], ["It may also help with the appropriate choice of PPE for health care providers.", [["health care providers", "TREATMENT", 56, 77]]], ["Although these tests have become more widely available, the huge demand for them has created supply chain challenges.", [["these tests", "TEST", 9, 20], ["chain", "OBSERVATION_MODIFIER", 100, 105]]], ["One of the current limitations regarding preoperative testing for SARS-CoV-2 comes from the variability in sensitivity and specificity of the different tests available.", [["SARS", "DISEASE", 66, 70], ["preoperative testing", "TEST", 41, 61], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74], ["the different tests", "TEST", 138, 157]]], ["5 The rate of false negative for some of those tests can be as high as 30%.", [["those tests", "TEST", 41, 52], ["false negative", "OBSERVATION", 14, 28]]], ["It is therefore extremely important to consider the sensitivity and positive predictive value of the test used in each institution before a decision to deescalade the level of PPE can be made.", [["the sensitivity", "TEST", 48, 63], ["the test", "TEST", 97, 105]]], ["The vast majority of heart programs have started testing inpatients and outpatients scheduled for cardiac surgery and cardiac catheterization.Antibody TestsAntibody tests can identify individuals who have been exposed to SARS-CoV-2 and have developed immunity, which could protect them from future infections.", [["heart", "ANATOMY", 21, 26], ["cardiac", "ANATOMY", 98, 105], ["cardiac", "ANATOMY", 118, 125], ["SARS", "DISEASE", 221, 225], ["infections", "DISEASE", 298, 308], ["heart", "ORGAN", 21, 26], ["cardiac", "ORGAN", 98, 105], ["cardiac", "ORGAN", 118, 125], ["SARS-CoV-2", "ORGANISM", 221, 231], ["outpatients", "SPECIES", 72, 83], ["SARS-CoV", "SPECIES", 221, 229], ["cardiac surgery", "TREATMENT", 98, 113], ["cardiac catheterization", "TEST", 118, 141], ["Antibody TestsAntibody tests", "TEST", 142, 170], ["CoV", "TEST", 226, 229], ["future infections", "PROBLEM", 291, 308], ["heart", "ANATOMY", 21, 26], ["cardiac", "ANATOMY", 118, 125], ["catheterization", "OBSERVATION", 126, 141]]], ["6 Congenital heart programs could consider deployment of these individuals to environments where the risk of infection is highest thereby protecting nonimmune members of the workforce from infection.MINIMIZING THE IMPACT OF EXPOSURE TO COVID-POSITIVE INDIVIDUALS ON SMALL DEDICATED TEAMSCardiac anesthesia teams are composed of a small number of dedicated attendings and extended care providers.", [["heart", "ANATOMY", 13, 18], ["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 189, 198], ["heart", "ORGAN", 13, 18], ["Congenital heart programs", "TREATMENT", 2, 27], ["infection", "PROBLEM", 109, 118], ["infection", "PROBLEM", 189, 198], ["SMALL DEDICATED TEAMSCardiac anesthesia teams", "TREATMENT", 266, 311], ["heart", "ANATOMY", 13, 18], ["infection", "OBSERVATION", 109, 118], ["infection", "OBSERVATION", 189, 198], ["SMALL", "OBSERVATION_MODIFIER", 266, 271]]], ["If a substantial number of cardiac anesthesia team members become ill or need to self-isolate due to exposure to a COVID-19-positive patient, colleague or family member, normal care delivery cannot be sustained.", [["cardiac", "ANATOMY", 27, 34], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["cardiac anesthesia", "TREATMENT", 27, 45], ["a COVID", "TEST", 113, 120], ["substantial", "OBSERVATION_MODIFIER", 5, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["cardiac", "ANATOMY", 27, 34]]], ["Segregating anesthesia providers and other cardiac specialty members into teams that are kept isolated from each other minimizes the risk of virus transmission.", [["cardiac", "ANATOMY", 43, 50], ["Segregating anesthesia providers", "TREATMENT", 0, 32], ["virus transmission", "PROBLEM", 141, 159], ["virus", "OBSERVATION", 141, 146]]], ["Attempting to operationalize team separation is challenging when faced with 24/7/365 coverage, simultaneous emergencies and illness (COVID-19 or otherwise), or exposure of one or more team members to a positive patient.AIRWAY MANIPULATIONAerosol-generating medical procedures (AGMP), such as endotracheal intubation and extubation, mask ventilation, tracheal suctioning, and inadvertent lung injury during positive pressure ventilation produce significant amounts of aerosolization and may be a significant source for the spread of SARS-CoV-2.", [["endotracheal", "ANATOMY", 292, 304], ["tracheal", "ANATOMY", 350, 358], ["lung", "ANATOMY", 387, 391], ["illness", "DISEASE", 124, 131], ["lung injury", "DISEASE", 387, 398], ["SARS", "DISEASE", 532, 536], ["patient", "ORGANISM", 211, 218], ["tracheal", "MULTI-TISSUE_STRUCTURE", 350, 358], ["lung", "ORGAN", 387, 391], ["patient", "SPECIES", 211, 218], ["SARS-CoV", "SPECIES", 532, 540], ["AIRWAY MANIPULATIONAerosol", "TREATMENT", 219, 245], ["medical procedures (AGMP)", "TREATMENT", 257, 282], ["endotracheal intubation", "TREATMENT", 292, 315], ["extubation", "TREATMENT", 320, 330], ["mask ventilation", "TREATMENT", 332, 348], ["tracheal suctioning", "TREATMENT", 350, 369], ["inadvertent lung injury", "PROBLEM", 375, 398], ["positive pressure ventilation", "TREATMENT", 406, 435], ["aerosolization", "TREATMENT", 467, 481], ["SARS", "PROBLEM", 532, 536], ["tracheal", "ANATOMY", 350, 358], ["suctioning", "OBSERVATION", 359, 369], ["lung", "ANATOMY", 387, 391], ["injury", "OBSERVATION", 392, 398], ["significant", "OBSERVATION_MODIFIER", 444, 455], ["amounts", "OBSERVATION_MODIFIER", 456, 463], ["aerosolization", "OBSERVATION", 467, 481]]], ["7 Careful airway management of suspected or infected patients is therefore crucial.", [["airway", "ANATOMY", 10, 16], ["airway", "MULTI-TISSUE_STRUCTURE", 10, 16], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Careful airway management", "TREATMENT", 2, 27], ["airway", "ANATOMY", 10, 16], ["infected", "OBSERVATION", 44, 52]]], ["Adequate muscle relaxation and rapid sequence induction are recommended to avoid mask ventilation.", [["muscle", "ANATOMY", 9, 15], ["muscle", "ORGAN", 9, 15], ["rapid sequence induction", "TREATMENT", 31, 55], ["mask ventilation", "TREATMENT", 81, 97], ["muscle", "ANATOMY", 9, 15], ["relaxation", "OBSERVATION", 16, 26]]], ["8 Cuffed tubes should be utilized to minimize gas leaks.", [["8 Cuffed tubes", "TREATMENT", 0, 14], ["gas leaks", "PROBLEM", 46, 55], ["Cuffed tubes", "OBSERVATION", 2, 14], ["gas leaks", "OBSERVATION", 46, 55]]], ["Selection of the nasal or oral route for intubation should be based on institutional experience and preference with consideration given to the priority of rapidly securing the airway.", [["nasal", "ANATOMY", 17, 22], ["oral", "ANATOMY", 26, 30], ["airway", "ANATOMY", 176, 182], ["nasal", "ORGAN", 17, 22], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["airway", "MULTI-TISSUE_STRUCTURE", 176, 182], ["intubation", "TREATMENT", 41, 51], ["nasal", "ANATOMY", 17, 22], ["airway", "ANATOMY", 176, 182]]], ["Once the trachea is intubated and the endotracheal tube secured, an inline suction device should be placed to avoid inadvertent contamination of the environment during tracheal suctioning.", [["trachea", "ANATOMY", 9, 16], ["endotracheal tube", "ANATOMY", 38, 55], ["tracheal", "ANATOMY", 168, 176], ["trachea", "MULTI-TISSUE_STRUCTURE", 9, 16], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 38, 55], ["tracheal", "ORGAN", 168, 176], ["intubated", "TREATMENT", 20, 29], ["the endotracheal tube", "TREATMENT", 34, 55], ["an inline suction device", "TREATMENT", 65, 89], ["inadvertent contamination of the environment", "PROBLEM", 116, 160], ["tracheal suctioning", "TREATMENT", 168, 187], ["trachea", "ANATOMY", 9, 16], ["endotracheal tube", "OBSERVATION", 38, 55], ["tracheal", "ANATOMY", 168, 176], ["suctioning", "OBSERVATION", 177, 187]]], ["A high-efficiency particulate air (HEPA) filter should routinely be placed distal to the Y-connector of the circle system in addition to the filters normally placed on the inspiratory and expiratory limbs.", [["limbs", "ANATOMY", 199, 204], ["limbs", "ORGANISM_SUBDIVISION", 199, 204], ["A high-efficiency particulate air (HEPA) filter", "TREATMENT", 0, 47], ["the filters", "TREATMENT", 137, 148], ["high", "OBSERVATION_MODIFIER", 2, 6], ["-efficiency", "OBSERVATION_MODIFIER", 6, 17], ["particulate", "OBSERVATION_MODIFIER", 18, 29], ["air", "OBSERVATION", 30, 33], ["filters", "OBSERVATION", 141, 148], ["inspiratory", "ANATOMY", 172, 183], ["expiratory limbs", "ANATOMY", 188, 204]]], ["Regardless of the site of extubation, appropriate PPE and room decontamination is essential.PPE IN THE OPERATIVE ROOM OR THE CARDIAC CATHETERIZATION SUITEIn COVID-19-positive patients or suspected patients, PPE must be worn at all times.", [["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 197, 205], ["extubation", "TREATMENT", 26, 36], ["appropriate PPE", "TREATMENT", 38, 53], ["room decontamination", "TREATMENT", 58, 78], ["THE CARDIAC CATHETERIZATION", "TEST", 121, 148], ["COVID", "TEST", 157, 162], ["PPE", "TREATMENT", 207, 210], ["extubation", "OBSERVATION", 26, 36]]], ["In asymptomatic patients who have not undergone COVID-19 testing, PPE is recommended during AGMP.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["COVID", "TEST", 48, 53], ["PPE", "TREATMENT", 66, 69]]], ["Some institutions with well-established COVID-19 testing are relaxing the requirement for PPE during AGMP for patients who have tested negative in the preceding 24 hours.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["COVID", "TEST", 40, 45], ["PPE", "PROBLEM", 90, 93]]], ["PPE should, at a minimum, include properly fitted N95 masks, eye and face shields, fluid impervious gowns, and gloves.", [["eye", "ANATOMY", 61, 64], ["face", "ANATOMY", 69, 73], ["eye", "ORGAN", 61, 64], ["PPE", "TREATMENT", 0, 3], ["N95 masks", "TREATMENT", 50, 59], ["eye and face shields", "TREATMENT", 61, 81], ["fluid impervious gowns", "TREATMENT", 83, 105], ["gloves", "TREATMENT", 111, 117], ["eye", "ANATOMY", 61, 64], ["fluid", "OBSERVATION", 83, 88], ["impervious gowns", "OBSERVATION", 89, 105]]], ["When available, additional equipment such as positive airway purifying respirators should be considered to further reduce the risk of exposure.", [["airway", "ANATOMY", 54, 60], ["airway", "MULTI-TISSUE_STRUCTURE", 54, 60], ["additional equipment", "TREATMENT", 16, 36], ["positive airway purifying respirators", "TREATMENT", 45, 82]]], ["In all patients, except those tested to be negative for COVID-19, all nonessential personnel should be a minimum of 6 feet from the patient or ideally outside the room during AGMP.", [["patients", "ORGANISM", 7, 15], ["feet", "ORGANISM_SUBDIVISION", 118, 122], ["patient", "ORGANISM", 132, 139], ["patients", "SPECIES", 7, 15], ["patient", "SPECIES", 132, 139], ["COVID", "TEST", 56, 61]]], ["Only the minimum number of properly trained personnel should be in attendance during any AGMP.", [["minimum", "OBSERVATION_MODIFIER", 9, 16]]], ["The use of video laryngoscopes is highly recommended both to assist in airway visualization and to maximize the distance from the patient to the caregiver's face during the procedure.", [["airway", "ANATOMY", 71, 77], ["airway", "MULTI-TISSUE_STRUCTURE", 71, 77], ["patient", "ORGANISM", 130, 137], ["face", "ORGANISM_SUBDIVISION", 157, 161], ["patient", "SPECIES", 130, 137], ["video laryngoscopes", "TEST", 11, 30], ["airway visualization", "TEST", 71, 91], ["the procedure", "TREATMENT", 169, 182], ["airway", "ANATOMY", 71, 77]]], ["It is recommended that a \"COVID\" cart with all of the appropriate equipment be placed immediately outside the patient's room to minimize time acquiring the necessary items.", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["a \"COVID\" cart", "TREATMENT", 23, 37]]], ["Finally, it is the responsibility of the provider to properly dispose of all contaminated materials into a double-sealed bag at the conclusion of the procedure while gowned in PPE to avoid accidental contamination of environmental staff.PPE IN THE OPERATIVE ROOM OR THE CARDIAC CATHETERIZATION SUITETo prevent contamination of anesthesia and perioperative personnel and workspace equipment, perioperative simulation should be promoted.", [["all contaminated materials", "TREATMENT", 73, 99], ["a double-sealed bag", "TREATMENT", 105, 124], ["the procedure", "TREATMENT", 146, 159], ["THE CARDIAC CATHETERIZATION SUITETo", "TREATMENT", 266, 301], ["anesthesia", "TREATMENT", 327, 337], ["perioperative personnel", "TREATMENT", 342, 365], ["workspace equipment", "TREATMENT", 370, 389], ["perioperative simulation", "TREATMENT", 391, 415], ["CARDIAC", "ANATOMY", 270, 277], ["CATHETERIZATION", "OBSERVATION", 278, 293]]], ["Checklists should be created in collaboration with Surgical Quality and Safety teams.CARING OF NEWBORN WITH CONGENITAL HEART DISEASE BORN OF A COVID-19-POSITIVE MOTHERIn retrospective analyses of neonates born to mothers with suspected or confirmed COVID-19, many newborns remained COVID-19 negative, but several exhibited respiratory distress and death have XXX XXX \u2022 Volume XXX \u2022 Number XXX www.anesthesia-analgesia.org 5 been reported.", [["respiratory", "ANATOMY", 323, 334], ["respiratory distress", "DISEASE", 323, 343], ["death", "DISEASE", 348, 353], ["neonates", "ORGANISM", 196, 204], ["mothers", "ORGANISM", 213, 220], ["newborns", "ORGANISM", 264, 272], ["CONGENITAL HEART DISEASE", "PROBLEM", 108, 132], ["A COVID", "TEST", 141, 148], ["COVID", "TEST", 249, 254], ["COVID", "TEST", 282, 287], ["respiratory distress", "PROBLEM", 323, 343], ["death", "PROBLEM", 348, 353], ["anesthesia", "TREATMENT", 397, 407], ["analgesia.org", "TREATMENT", 408, 421], ["HEART", "ANATOMY", 119, 124], ["DISEASE", "OBSERVATION", 125, 132], ["respiratory distress", "OBSERVATION", 323, 343]]], ["9,10 In 1 cohort, 3 newborns who were infected with SARS-CoV-2 had positive nasal and anal swabs at days 2 and 4 of life.", [["nasal", "ANATOMY", 76, 81], ["anal swabs", "ANATOMY", 86, 96], ["SARS", "DISEASE", 52, 56], ["newborns", "ORGANISM", 20, 28], ["SARS-CoV-2", "ORGANISM", 52, 62], ["nasal", "ORGANISM_SUBDIVISION", 76, 81], ["anal swabs", "MULTI-TISSUE_STRUCTURE", 86, 96], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["positive nasal", "TREATMENT", 67, 81], ["nasal", "ANATOMY", 76, 81], ["anal swabs", "ANATOMY", 86, 96]]], ["All 3 experienced fever, lethargy, and pneumonia and were nasal swab negative by day 6 or 7 of life.", [["nasal swab", "ANATOMY", 58, 68], ["fever", "DISEASE", 18, 23], ["lethargy", "DISEASE", 25, 33], ["pneumonia", "DISEASE", 39, 48], ["fever", "PROBLEM", 18, 23], ["lethargy", "PROBLEM", 25, 33], ["pneumonia", "PROBLEM", 39, 48], ["nasal swab", "TEST", 58, 68], ["fever", "OBSERVATION", 18, 23], ["lethargy", "OBSERVATION", 25, 33], ["pneumonia", "OBSERVATION", 39, 48], ["nasal", "ANATOMY", 58, 63]]], ["10 The most likely route of transmission of SARS-CoV-2 from mother to newborn is via respiratory droplets during close contact.", [["respiratory droplets", "ANATOMY", 85, 105], ["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "ORGANISM", 44, 54], ["mother", "ORGANISM", 60, 66], ["SARS-CoV", "SPECIES", 44, 52], ["most likely", "UNCERTAINTY", 7, 18], ["respiratory droplets", "OBSERVATION", 85, 105]]], ["In the setting of acute maternal COVID-19 shortly before birth, maternal antibody production and fetal passive immunity may not have had time to develop, leaving the neonate relatively defenseless.", [["fetal", "ANATOMY", 97, 102], ["fetal", "ORGANISM_SUBDIVISION", 97, 102], ["acute maternal COVID", "PROBLEM", 18, 38], ["maternal antibody production", "PROBLEM", 64, 92], ["fetal passive immunity", "PROBLEM", 97, 119], ["acute", "OBSERVATION_MODIFIER", 18, 23]]], ["11 There is currently no evidence of vertical transmission of SARS-CoV-2 from mother to fetus.CARING OF NEWBORN WITH CONGENITAL HEART DISEASE BORN OF A COVID-19-POSITIVE MOTHERMultidisciplinary planning must occur ideally before and certainly after the birth of a child with CHD who is born of a suspected or confirmed COVID-19 mother.", [["fetus", "ANATOMY", 88, 93], ["SARS", "DISEASE", 62, 66], ["CHD", "DISEASE", 275, 278], ["SARS-CoV-2", "ORGANISM", 62, 72], ["mother", "ORGANISM", 78, 84], ["fetus", "ORGAN", 88, 93], ["SARS-CoV", "SPECIES", 62, 70], ["vertical transmission of SARS", "PROBLEM", 37, 66], ["CONGENITAL HEART DISEASE", "PROBLEM", 117, 141], ["A COVID", "TEST", 150, 157], ["POSITIVE MOTHERMultidisciplinary planning", "TREATMENT", 161, 202], ["CHD", "PROBLEM", 275, 278], ["no evidence of", "UNCERTAINTY", 22, 36], ["vertical", "OBSERVATION_MODIFIER", 37, 45], ["SARS", "OBSERVATION", 62, 66], ["HEART", "ANATOMY", 128, 133], ["DISEASE", "OBSERVATION", 134, 141]]], ["Severe COVID-19 symptoms in the mother may lead to fetal distress and preterm labor and delivery, which may gravely impact the newborn cardiopulmonary physiology.", [["fetal", "ANATOMY", 51, 56], ["fetal distress", "DISEASE", 51, 65], ["preterm labor", "DISEASE", 70, 83], ["fetal", "ANATOMICAL_SYSTEM", 51, 56], ["Severe COVID-19 symptoms", "PROBLEM", 0, 24], ["fetal distress", "PROBLEM", 51, 65], ["preterm labor", "PROBLEM", 70, 83], ["delivery", "TREATMENT", 88, 96], ["the newborn cardiopulmonary physiology", "PROBLEM", 123, 161], ["cardiopulmonary physiology", "OBSERVATION", 135, 161]]], ["9 After delivery, the cord should be immediately clamped and the neonate isolated from the mother.", [["cord", "ANATOMY", 22, 26], ["cord", "ORGAN", 22, 26], ["neonate", "ORGANISM", 65, 72], ["delivery", "TREATMENT", 8, 16], ["cord", "ANATOMY", 22, 26]]], ["If transport is required to the pediatric hospital after birth, full PPE is required throughout all phases.", [["full PPE", "TREATMENT", 64, 72]]], ["The newborn should be isolated and closely monitored for symptoms for 14 days.", [["symptoms", "PROBLEM", 57, 65]]], ["If emergent surgery is required, the operating room team must treat the newborn as SARS-CoV-2 infected and observe strict isolation procedures.", [["SARS-CoV-2 infected", "DISEASE", 83, 102], ["CoV-2", "ORGANISM", 88, 93], ["emergent surgery", "TREATMENT", 3, 19], ["CoV", "TEST", 88, 91], ["infected", "PROBLEM", 94, 102], ["strict isolation procedures", "TREATMENT", 115, 142]]], ["In the middle ground are the neonates with lesions typically treated nonemergently within the first few days of life, such as the Norwood or arterial switch operations.", [["lesions", "ANATOMY", 43, 50], ["arterial", "ANATOMY", 141, 149], ["neonates", "ORGANISM", 29, 37], ["lesions", "PATHOLOGICAL_FORMATION", 43, 50], ["arterial", "MULTI-TISSUE_STRUCTURE", 141, 149], ["lesions", "PROBLEM", 43, 50], ["the Norwood", "TREATMENT", 126, 137], ["arterial switch operations", "TREATMENT", 141, 167], ["middle", "ANATOMY_MODIFIER", 7, 13], ["neonates", "OBSERVATION", 29, 37], ["lesions", "OBSERVATION", 43, 50], ["arterial", "ANATOMY", 141, 149]]], ["The risks and benefits of proceeding with surgery versus waiting must be carefully weighed by a multidisciplinary team on a case by case basis.CARDIOVASCULAR IMAGINGEchocardiography represents the primary imaging modality for diagnosis, management, and longterm surveillance of these patients.", [["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292], ["surgery", "TREATMENT", 42, 49], ["CARDIOVASCULAR IMAGINGEchocardiography", "TEST", 143, 181], ["the primary imaging modality", "TEST", 193, 221], ["management", "TREATMENT", 237, 247]]], ["In response to the spread of COVID-19, the American Society of Echocardiography (ASE) has recently published a statement addressing protection of patients and echocardiography service providers to prevent viral transmission.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["COVID", "TEST", 29, 34], ["Echocardiography", "TEST", 63, 79], ["viral transmission", "PROBLEM", 205, 223]]], ["Based on the recognition that children and those affected by CHD represent potential confounding elements in this pandemic, recommendations specific to the pediatric, fetal, and CHD populations have also been outlined in a supplement statement.", [["fetal", "ANATOMY", 167, 172], ["CHD", "DISEASE", 61, 64], ["CHD", "DISEASE", 178, 181], ["children", "ORGANISM", 30, 38], ["fetal", "ANATOMICAL_SYSTEM", 167, 172], ["children", "SPECIES", 30, 38]]], ["12 These are based on acknowledging known differences between the pediatric and adult populations in terms of COVID-19 prevalence, symptomatology, and disease severity and other factors that impact imaging.", [["COVID", "TEST", 110, 115], ["symptomatology", "PROBLEM", 131, 145], ["disease severity", "PROBLEM", 151, 167], ["imaging", "TEST", 198, 205]]], ["13 Most echocardiography laboratories have adopted these ASE recommendations which CCAS supports.", [["Most echocardiography laboratories", "TEST", 3, 37]]], ["Key points of these continually updated guidelines suggest that echocardiographic studies be performed when they are expected to provide clinical patient benefit based on established appropriate use criteria with other examinations to be deferred/rescheduled.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["echocardiographic studies", "TEST", 64, 89], ["other examinations", "TEST", 213, 231]]], ["14 It is desirable to determine patient COVID-19 status whenever possible, to limit provider exposure during the examination, and to prevent equipment/ reading room transmission.CARDIOVASCULAR IMAGINGPerformance of transesophageal echocardiography (TEE) imaging is considered to increase the risk of SARS-CoV-2 spread secondary to both droplet and aerosol transmission.", [["SARS", "DISEASE", 300, 304], ["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["patient COVID", "TEST", 32, 45], ["the examination", "TEST", 109, 124], ["transesophageal echocardiography", "TEST", 215, 247], ["TEE", "TEST", 249, 252], ["imaging", "TEST", 254, 261], ["SARS", "PROBLEM", 300, 304], ["CoV", "PROBLEM", 305, 308], ["aerosol transmission", "TREATMENT", 348, 368], ["droplet", "OBSERVATION_MODIFIER", 336, 343], ["aerosol transmission", "OBSERVATION", 348, 368]]], ["Currently, nonessential TEE examinations and those unlikely to impact clinical care have been or are being postponed or canceled.", [["nonessential TEE examinations", "TEST", 11, 40]]], ["In many adults with CHD, these studies take place in sedated, nonintubated patients, a circumstance that could provoke aerosolization of a significant number of viral particles in infected patients.", [["CHD", "DISEASE", 20, 23], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 189, 197], ["CHD", "PROBLEM", 20, 23], ["these studies", "TEST", 25, 38], ["sedated", "TREATMENT", 53, 60], ["viral particles", "PROBLEM", 161, 176], ["significant", "OBSERVATION_MODIFIER", 139, 150], ["number", "OBSERVATION_MODIFIER", 151, 157], ["viral particles", "OBSERVATION", 161, 176], ["infected", "OBSERVATION_MODIFIER", 180, 188]]], ["Consequently, alternative imaging modalities should be considered outside clinical settings that strongly merit the use of TEE such as during urgent or emergent cardiac surgery in neonates, children, and adults with CHD, and selected nonelective catheter-based interventions.", [["cardiac", "ANATOMY", 161, 168], ["CHD", "DISEASE", 216, 219], ["cardiac", "ORGAN", 161, 168], ["neonates", "ORGANISM", 180, 188], ["children", "ORGANISM", 190, 198], ["children", "SPECIES", 190, 198], ["alternative imaging modalities", "TEST", 14, 44], ["TEE", "TEST", 123, 126], ["emergent cardiac surgery", "TREATMENT", 152, 176], ["CHD", "TREATMENT", 216, 219], ["selected nonelective catheter-based interventions", "TREATMENT", 225, 274], ["cardiac", "ANATOMY", 161, 168], ["surgery", "OBSERVATION", 169, 176], ["catheter", "OBSERVATION", 246, 254]]], ["Other situations require careful assessment of the benefit of the TEE study versus risks related to potential COVID-19 exposure and should also consider available PPE resources.", [["COVID-19", "CHEMICAL", 110, 118], ["careful assessment", "TEST", 25, 43], ["the TEE study", "TEST", 62, 75], ["potential COVID-19 exposure", "TREATMENT", 100, 127], ["available PPE resources", "TREATMENT", 153, 176]]], ["Although epicardial echocardiography is considered a valuable adjunct to intraoperative imaging, TEE is known to overcome many of its limitations.", [["epicardial", "ANATOMY", 9, 19], ["epicardial", "MULTI-TISSUE_STRUCTURE", 9, 19], ["epicardial echocardiography", "TEST", 9, 36], ["intraoperative imaging", "TEST", 73, 95], ["TEE", "TEST", 97, 100]]], ["Accordingly, during the COVID-19 pandemic, standardized TEE algorithms should be developed in conjunction with all stakeholders and influenced by local institutional policies, that consider study indications and COVID-19 status to guide procedural precautions and the use of PPE, as well as protocols for equipment handling, allowing for ongoing patient benefits and the safest application of the imaging modality.", [["patient", "ORGANISM", 346, 353], ["patient", "SPECIES", 346, 353], ["the COVID", "TEST", 20, 29], ["standardized TEE algorithms", "TEST", 43, 70], ["study indications", "TEST", 190, 207], ["COVID", "TEST", 212, 217], ["procedural precautions", "TREATMENT", 237, 259], ["PPE", "TREATMENT", 275, 278], ["equipment handling", "TREATMENT", 305, 323], ["the imaging modality", "TEST", 393, 413]]], ["12, 15 CARDIOPULMONARY BYPASS AND ANTICOAGULATION FOR COVID-19 PATIENTS There are currently no reported cases of children with known COVID-19 undergoing cardiac surgery with cardiopulmonary bypass (CPB).", [["cardiac", "ANATOMY", 153, 160], ["cardiopulmonary", "ANATOMY", 174, 189], ["children", "ORGANISM", 113, 121], ["cardiac", "ORGAN", 153, 160], ["children", "SPECIES", 113, 121], ["CARDIOPULMONARY BYPASS", "TREATMENT", 7, 29], ["ANTICOAGULATION", "TREATMENT", 34, 49], ["COVID", "TEST", 54, 59], ["cardiac surgery", "TREATMENT", 153, 168], ["cardiopulmonary bypass", "TREATMENT", 174, 196], ["CPB", "TREATMENT", 198, 201], ["CARDIOPULMONARY", "ANATOMY", 7, 22], ["BYPASS", "OBSERVATION", 23, 29], ["cardiac", "ANATOMY", 153, 160], ["surgery", "OBSERVATION", 161, 168], ["cardiopulmonary", "ANATOMY", 174, 189], ["bypass", "OBSERVATION", 190, 196]]], ["There is no evidence that the anticoagulation strategy for a patient undergoing a procedure on CPB should be altered due to COVID-19, but the cardiac care team should be aware that the thrombosis risk is increased in this population.", [["cardiac", "ANATOMY", 142, 149], ["thrombosis", "DISEASE", 185, 195], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["the anticoagulation strategy", "TREATMENT", 26, 54], ["a procedure", "TREATMENT", 80, 91], ["CPB", "TREATMENT", 95, 98], ["COVID", "TEST", 124, 129], ["the thrombosis risk", "PROBLEM", 181, 200], ["no evidence", "UNCERTAINTY", 9, 20], ["cardiac", "ANATOMY", 142, 149], ["thrombosis", "OBSERVATION", 185, 195], ["increased", "OBSERVATION_MODIFIER", 204, 213]]], ["16 In the event CPB is utilized in a patient with COVID-19, scavenging of exhaust gas from the CPB machine is recommended.", [["COVID-19", "CHEMICAL", 50, 58], ["COVID-19", "CHEMICAL", 50, 58], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["COVID", "TEST", 50, 55], ["exhaust gas", "PROBLEM", 74, 85], ["the CPB machine", "TREATMENT", 91, 106], ["CPB", "OBSERVATION", 16, 19], ["exhaust gas", "OBSERVATION", 74, 85], ["CPB", "ANATOMY", 95, 98]]], ["Currently, there are publications from China showing the COVID-19 virus in the blood.", [["blood", "ANATOMY", 79, 84], ["COVID-19 virus", "ORGANISM", 57, 71], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["COVID-19 virus", "SPECIES", 57, 71], ["the COVID", "TEST", 53, 62], ["blood", "ANATOMY", 79, 84]]], ["17 This would indicate it may be possible to transmit the virus to the exhaust ports of an oxygenator and out into the environment.", [["the virus", "PROBLEM", 54, 63], ["an oxygenator", "TREATMENT", 88, 101], ["may be possible", "UNCERTAINTY", 26, 41], ["oxygenator", "OBSERVATION", 91, 101]]], ["However, plasma leakage into the hollow fiber oxygenator is the most likely way for the virus to be aerosolized from the CPB circuit.", [["plasma", "ANATOMY", 9, 15], ["hollow fiber", "ANATOMY", 33, 45], ["plasma", "ORGANISM_SUBSTANCE", 9, 15], ["plasma leakage", "PROBLEM", 9, 23], ["the hollow fiber oxygenator", "TREATMENT", 29, 56], ["the virus", "PROBLEM", 84, 93], ["the CPB circuit", "TREATMENT", 117, 132], ["hollow fiber oxygenator", "OBSERVATION", 33, 56], ["most likely", "UNCERTAINTY", 64, 75], ["virus", "OBSERVATION", 88, 93], ["aerosolized", "OBSERVATION", 100, 111], ["CPB circuit", "OBSERVATION", 121, 132]]], ["Fortunately, when oxygenators are www.anesthesia-analgesia.orgCARDIOVASCULAR IMAGINGANeSTheSiA & ANALGeSiA COVID-19 and Pediatric Heart Programs used as recommended, plasma leakage is extremely uncommon.", [["plasma", "ANATOMY", 166, 172], ["Heart", "ORGAN", 130, 135], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["anesthesia-analgesia.orgCARDIOVASCULAR IMAGINGANeSTheSiA", "TREATMENT", 38, 94], ["ANALGeSiA COVID", "TREATMENT", 97, 112], ["Pediatric Heart Programs", "TREATMENT", 120, 144], ["plasma leakage", "PROBLEM", 166, 180], ["Heart", "ANATOMY", 130, 135]]], ["Scavenging systems are easy to apply and already utilized in many centers that routinely deliver inhaled anesthetic gases during CPB.BLOOD SHORTAGE AND CONSERVATIONAlthough the reduction in elective cases has decreased blood product utilization, social isolation measures have resulted in a rapid decrease in overall blood donations.", [["blood", "ANATOMY", 219, 224], ["blood", "ANATOMY", 317, 322], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["blood", "ORGANISM_SUBSTANCE", 317, 322], ["Scavenging systems", "PROBLEM", 0, 18], ["inhaled anesthetic gases", "TREATMENT", 97, 121], ["CPB", "TREATMENT", 129, 132], ["the reduction", "TREATMENT", 173, 186], ["elective cases", "TREATMENT", 190, 204], ["blood product utilization", "TREATMENT", 219, 244], ["social isolation measures", "TREATMENT", 246, 271], ["a rapid decrease in overall blood donations", "PROBLEM", 289, 332], ["reduction", "OBSERVATION_MODIFIER", 177, 186], ["decreased", "OBSERVATION_MODIFIER", 209, 218], ["rapid", "OBSERVATION_MODIFIER", 291, 296], ["decrease", "OBSERVATION_MODIFIER", 297, 305]]], ["Daily communication with the blood center and key clinical teams is necessary to predict whether inventory is available to cover daily needs.BLOOD SHORTAGE AND CONSERVATIONAs cardiac anesthesiologists, it is our duty to implement perioperative blood conservation strategies.", [["blood", "ANATOMY", 29, 34], ["cardiac", "ANATOMY", 175, 182], ["blood", "ANATOMY", 244, 249], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["perioperative blood conservation strategies", "TREATMENT", 230, 273]]], ["Blood conservation guidelines for neonates and children undergoing cardiac surgery have been published and provide a resource to help develop institutional protocols.", [["Blood", "ANATOMY", 0, 5], ["cardiac", "ANATOMY", 67, 74], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["neonates", "ORGANISM", 34, 42], ["children", "ORGANISM", 47, 55], ["cardiac", "ORGAN", 67, 74], ["children", "SPECIES", 47, 55], ["Blood conservation guidelines", "TREATMENT", 0, 29], ["cardiac surgery", "TREATMENT", 67, 82], ["institutional protocols", "TREATMENT", 142, 165]]], ["18 Although not well studied in children with CHD, preoperative treatment of anemia and iron deficiency should be considered with either oral or intravenous iron.", [["oral", "ANATOMY", 137, 141], ["intravenous", "ANATOMY", 145, 156], ["CHD", "DISEASE", 46, 49], ["anemia", "DISEASE", 77, 83], ["iron deficiency", "DISEASE", 88, 103], ["iron", "CHEMICAL", 157, 161], ["iron", "CHEMICAL", 88, 92], ["iron", "CHEMICAL", 157, 161], ["children", "ORGANISM", 32, 40], ["iron", "SIMPLE_CHEMICAL", 88, 92], ["oral", "ORGANISM_SUBDIVISION", 137, 141], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 145, 156], ["iron", "SIMPLE_CHEMICAL", 157, 161], ["children", "SPECIES", 32, 40], ["CHD", "PROBLEM", 46, 49], ["preoperative treatment", "TREATMENT", 51, 73], ["anemia", "PROBLEM", 77, 83], ["iron deficiency", "PROBLEM", 88, 103], ["oral or intravenous iron", "TREATMENT", 137, 161], ["anemia", "OBSERVATION", 77, 83], ["iron deficiency", "OBSERVATION", 88, 103]]], ["An erythropoietin stimulating agent may be considered in specific cases.", [["erythropoietin", "GENE_OR_GENE_PRODUCT", 3, 17], ["erythropoietin", "PROTEIN", 3, 17], ["An erythropoietin stimulating agent", "TREATMENT", 0, 35], ["erythropoietin", "OBSERVATION", 3, 17]]], ["Prophylactic administration of an antifibrinolytic should be used when appropriate.", [["Prophylactic administration", "TREATMENT", 0, 27], ["an antifibrinolytic", "TREATMENT", 31, 50]]], ["Efforts should also be made to minimize the resultant hemodilution of CPB, including reduction of the prime volume and the use of a nonblood prime in infants weighing >5 to 7 kg.", [["nonblood", "ANATOMY", 132, 140], ["hemodilution", "DISEASE", 54, 66], ["infants", "ORGANISM", 150, 157], ["infants", "SPECIES", 150, 157], ["the resultant hemodilution of CPB", "TREATMENT", 40, 73], ["the prime volume", "TREATMENT", 98, 114], ["a nonblood prime in infants weighing", "TREATMENT", 130, 166], ["resultant", "OBSERVATION_MODIFIER", 44, 53], ["hemodilution", "OBSERVATION", 54, 66], ["CPB", "OBSERVATION", 70, 73], ["reduction", "OBSERVATION_MODIFIER", 85, 94]]], ["19 Because units of red blood cells are aging, blood banks may not be able to provide fresh blood for neonatal cardiac patients.", [["red blood cells", "ANATOMY", 20, 35], ["blood", "ANATOMY", 47, 52], ["blood", "ANATOMY", 92, 97], ["cardiac", "ANATOMY", 111, 118], ["red blood cells", "CELL", 20, 35], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["patients", "ORGANISM", 119, 127], ["red blood cells", "CELL_TYPE", 20, 35], ["patients", "SPECIES", 119, 127], ["red blood cells", "TREATMENT", 20, 35], ["blood banks", "TREATMENT", 47, 58], ["neonatal cardiac patients", "TREATMENT", 102, 127]]], ["Due to the risk of hyperkalemia associated with older and large volume transfusions, physicians should be vigilant regarding the age of blood products received, the need for irradiation, and the use of washing techniques before transfusion.", [["blood", "ANATOMY", 136, 141], ["hyperkalemia", "DISEASE", 19, 31], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["hyperkalemia", "PROBLEM", 19, 31], ["large volume transfusions", "TREATMENT", 58, 83], ["blood products", "TREATMENT", 136, 150], ["irradiation", "TREATMENT", 174, 185], ["washing techniques", "TREATMENT", 202, 220], ["transfusion", "TREATMENT", 228, 239], ["hyperkalemia", "OBSERVATION", 19, 31], ["large", "OBSERVATION_MODIFIER", 58, 63], ["volume transfusions", "OBSERVATION", 64, 83]]], ["Nonallogeneic coagulation agents, like desmopressin, fibrinogen concentrate, 20 or prothrombin thrombin complex concentrate, may be considered based on underlying coagulopathy.", [["desmopressin", "CHEMICAL", 39, 51], ["coagulopathy", "DISEASE", 163, 175], ["desmopressin", "CHEMICAL", 39, 51], ["desmopressin", "SIMPLE_CHEMICAL", 39, 51], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 53, 63], ["prothrombin thrombin complex", "GENE_OR_GENE_PRODUCT", 83, 111], ["prothrombin thrombin complex", "PROTEIN", 83, 111], ["Nonallogeneic coagulation agents", "TREATMENT", 0, 32], ["desmopressin", "TREATMENT", 39, 51], ["fibrinogen concentrate", "TEST", 53, 75], ["prothrombin thrombin complex concentrate", "PROBLEM", 83, 123], ["underlying coagulopathy", "PROBLEM", 152, 175], ["coagulopathy", "OBSERVATION", 163, 175]]], ["Multimodal center-specific transfusion algorithms ( Figure 2 ) using a restrictive approach and coagulation assessment based on either standard coagulation tests or viscoelastic tests have been shown to be effective in reducing transfusion requirements.SUMMARYThe COVID-19 pandemic has impacted congenital cardiac surgical programs with significant reduction in case load, implementation of patient triage strategies, and development of PPE guidelines.", [["cardiac", "ANATOMY", 306, 313], ["patient", "ORGANISM", 391, 398], ["patient", "SPECIES", 391, 398], ["specific transfusion algorithms", "TREATMENT", 18, 49], ["a restrictive approach", "TREATMENT", 69, 91], ["coagulation assessment", "TEST", 96, 118], ["standard coagulation tests", "TEST", 135, 161], ["viscoelastic tests", "TEST", 165, 183], ["reducing transfusion requirements", "TREATMENT", 219, 252], ["congenital cardiac surgical programs", "TREATMENT", 295, 331], ["significant reduction", "TREATMENT", 337, 358], ["patient triage strategies", "TREATMENT", 391, 416], ["PPE guidelines", "TREATMENT", 437, 451], ["cardiac", "ANATOMY", 306, 313], ["surgical", "OBSERVATION", 314, 322], ["significant", "OBSERVATION_MODIFIER", 337, 348], ["reduction", "OBSERVATION_MODIFIER", 349, 358]]], ["It is important that congenital cardiac surgical programs collect data to understand the impact of the COVID-19 pandemic on the incidence of adverse events and resource utilization.", [["cardiac", "ANATOMY", 32, 39], ["congenital cardiac surgical programs", "TREATMENT", 21, 57], ["adverse events", "PROBLEM", 141, 155], ["resource utilization", "TREATMENT", 160, 180], ["cardiac", "ANATOMY", 32, 39], ["surgical", "OBSERVATION", 40, 48]]], ["Toolbox for blood conservation that can be used as an example to design institutional toolbox.", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["blood conservation", "TREATMENT", 12, 30], ["institutional toolbox", "TREATMENT", 72, 93]]], ["CT indicates clotting time; EACA, epsilon amino caproic acid; EXTEM, extrinsic test from thromboelastometry; FC, fibrinogen concentrate; FEIBA, factor eight inhibitor bypassing activity; FFP , fresh frozen plasma; FIBTEM, fibrinogen test from thromboelastometry; IDA, iron-deficiency anemia; MUF, modified ultrafiltration; PCC, prothrombin complex concentrate; PLT, platelets; RBC, red blood cell; TXA, tranexamic acid.", [["plasma", "ANATOMY", 206, 212], ["platelets", "ANATOMY", 366, 375], ["RBC", "ANATOMY", 377, 380], ["red blood cell", "ANATOMY", 382, 396], ["EACA", "CHEMICAL", 28, 32], ["epsilon amino caproic acid", "CHEMICAL", 34, 60], ["IDA", "DISEASE", 263, 266], ["iron-deficiency anemia", "DISEASE", 268, 290], ["TXA", "CHEMICAL", 398, 401], ["tranexamic acid", "CHEMICAL", 403, 418], ["EACA", "CHEMICAL", 28, 32], ["amino caproic acid", "CHEMICAL", 42, 60], ["tranexamic acid", "CHEMICAL", 403, 418], ["EACA", "SIMPLE_CHEMICAL", 28, 32], ["epsilon amino caproic acid", "SIMPLE_CHEMICAL", 34, 60], ["EXTEM", "SIMPLE_CHEMICAL", 62, 67], ["FC", "SIMPLE_CHEMICAL", 109, 111], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 113, 123], ["FEIBA", "SIMPLE_CHEMICAL", 137, 142], ["FFP", "SIMPLE_CHEMICAL", 187, 190], ["plasma", "ORGANISM_SUBSTANCE", 206, 212], ["FIBTEM", "SIMPLE_CHEMICAL", 214, 220], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 222, 232], ["IDA", "SIMPLE_CHEMICAL", 263, 266], ["prothrombin complex concentrate", "GENE_OR_GENE_PRODUCT", 328, 359], ["PLT", "CELL", 361, 364], ["platelets", "CELL", 366, 375], ["RBC", "CELL", 377, 380], ["red blood cell", "CELL", 382, 396], ["TXA", "SIMPLE_CHEMICAL", 398, 401], ["tranexamic acid", "SIMPLE_CHEMICAL", 403, 418], ["fibrinogen concentrate", "PROTEIN", 113, 135], ["FEIBA", "PROTEIN", 137, 142], ["FFP", "PROTEIN", 187, 190], ["fibrinogen", "PROTEIN", 222, 232], ["prothrombin complex concentrate", "PROTEIN", 328, 359], ["PLT", "PROTEIN", 361, 364], ["platelets", "CELL_TYPE", 366, 375], ["RBC", "CELL_TYPE", 377, 380], ["red blood cell", "CELL_TYPE", 382, 396], ["CT", "TEST", 0, 2], ["clotting time", "PROBLEM", 13, 26], ["EACA", "TREATMENT", 28, 32], ["epsilon amino caproic acid", "TREATMENT", 34, 60], ["extrinsic test", "TEST", 69, 83], ["thromboelastometry", "TEST", 89, 107], ["FC", "TEST", 109, 111], ["fibrinogen concentrate", "TEST", 113, 135], ["FEIBA", "TEST", 137, 142], ["factor eight inhibitor", "TREATMENT", 144, 166], ["FFP", "TREATMENT", 187, 190], ["fresh frozen plasma", "TEST", 193, 212], ["FIBTEM", "TEST", 214, 220], ["fibrinogen test", "TEST", 222, 237], ["thromboelastometry", "TEST", 243, 261], ["IDA", "PROBLEM", 263, 266], ["iron-deficiency anemia", "PROBLEM", 268, 290], ["MUF", "TREATMENT", 292, 295], ["modified ultrafiltration", "TREATMENT", 297, 321], ["PCC", "TREATMENT", 323, 326], ["prothrombin complex concentrate", "TREATMENT", 328, 359], ["PLT", "TEST", 361, 364], ["platelets", "TEST", 366, 375], ["RBC", "TEST", 377, 380], ["red blood cell", "TEST", 382, 396], ["TXA", "TREATMENT", 398, 401], ["tranexamic acid", "TREATMENT", 403, 418], ["clotting", "OBSERVATION", 13, 21], ["iron-deficiency anemia", "OBSERVATION", 268, 290]]]], "7f9d314c11f5ff104aef2df198ae8b70912dcaa9": [["Pathogen reduction can eliminate or reduce the risk for any nucleic acid containing agent, including bacteria, and thus will be effective for all but prion diseases.", [["nucleic acid", "CHEMICAL", 60, 72], ["prion diseases", "DISEASE", 150, 164], ["Pathogen reduction", "TREATMENT", 0, 18], ["any nucleic acid containing agent", "PROBLEM", 56, 89], ["bacteria", "PROBLEM", 101, 109], ["prion diseases", "PROBLEM", 150, 164]]], ["It is possible to introduce PR for platelets and plasma now and to concentrate resources on developing PR for red cells.", [["platelets", "ANATOMY", 35, 44], ["plasma", "ANATOMY", 49, 55], ["red cells", "ANATOMY", 110, 119], ["platelets", "CELL", 35, 44], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["red cells", "CELL", 110, 119], ["PR", "PROTEIN", 28, 30], ["platelets", "CELL_TYPE", 35, 44], ["PR", "PROTEIN", 103, 105], ["red cells", "CELL_TYPE", 110, 119], ["PR for platelets", "TREATMENT", 28, 44], ["plasma", "TREATMENT", 49, 55], ["red cells", "PROBLEM", 110, 119]]], ["This will require an intellectual and financial commitment from the National Institutes of Health, the Food and Drug Administration, industry, and the blood bank establishment, just as occurred for nucleic acid testing (NAT) technology.", [["blood", "ANATOMY", 151, 156], ["nucleic acid", "CHEMICAL", 198, 210], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["nucleic acid", "SIMPLE_CHEMICAL", 198, 210], ["the blood bank establishment", "TEST", 147, 175], ["nucleic acid testing", "TEST", 198, 218]]]], "PMC6995632": [], "afa975433d975405099629f3eac5ba4600ba2508": [["A new coronavirus named severe acute respiratory syndrome coronavirus (SARS) 2, or SARS-CoV-2, caused a world pandemic disease called COVID-19 [1] [2] [3] [4] .", [["coronavirus", "DISEASE", 6, 17], ["acute respiratory syndrome coronavirus", "DISEASE", 31, 69], ["SARS", "DISEASE", 71, 75], ["COVID-19", "CHEMICAL", 134, 142], ["coronavirus", "ORGANISM", 6, 17], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 24, 69], ["SARS-CoV-2", "ORGANISM", 83, 93], ["COVID-19 [1] [2] [3] [4]", "SIMPLE_CHEMICAL", 134, 158], ["coronavirus", "SPECIES", 6, 17], ["coronavirus named severe acute respiratory syndrome coronavirus", "SPECIES", 6, 69], ["SARS-CoV", "SPECIES", 83, 91], ["A new coronavirus named severe acute respiratory syndrome coronavirus (SARS)", "PROBLEM", 0, 76], ["SARS", "PROBLEM", 83, 87], ["a world pandemic disease", "PROBLEM", 102, 126], ["COVID", "TEST", 134, 139], ["new", "OBSERVATION_MODIFIER", 2, 5], ["coronavirus", "OBSERVATION", 6, 17], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["respiratory syndrome coronavirus", "OBSERVATION", 37, 69]]], ["A significant research push is now underway to repurpose existing drugs and to design new therapeutic agents targeting various components of the virus 5 .", [["virus 5", "ORGANISM", 145, 152], ["A significant research push", "PROBLEM", 0, 27], ["existing drugs", "TREATMENT", 57, 71], ["new therapeutic agents", "TREATMENT", 86, 108], ["the virus", "PROBLEM", 141, 150], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["The viral single-stranded RNA genome is 82% identical to the earlier SARS coronavirus (SARS-CoV) with some viral proteins being more than 90% homologous to SARS-CoV 6 .", [["SARS coronavirus", "DISEASE", 69, 85], ["SARS", "DISEASE", 156, 160], ["SARS coronavirus", "ORGANISM", 69, 85], ["SARS-CoV", "ORGANISM", 87, 95], ["SARS-CoV 6", "ORGANISM", 156, 166], ["viral single-stranded RNA genome", "DNA", 4, 36], ["viral proteins", "PROTEIN", 107, 121], ["SARS coronavirus", "SPECIES", 69, 85], ["SARS coronavirus", "SPECIES", 69, 85], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 156, 164], ["The viral single-stranded RNA genome", "TEST", 0, 36], ["the earlier SARS coronavirus", "PROBLEM", 57, 85], ["some viral proteins", "PROBLEM", 102, 121], ["CoV", "TEST", 161, 164], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["RNA genome", "OBSERVATION", 26, 36], ["viral proteins", "OBSERVATION", 107, 121]]], ["SARS-CoV-2, similar to many other single-stranded RNA viruses, employs a chymotrypsin-like protease (3CL main protease, or 3CL M pro ) to enable the production of non-structural proteins essential for viral replication [7] [8] [9] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 73, 99], ["3CL M pro", "GENE_OR_GENE_PRODUCT", 123, 132], ["chymotrypsin-like protease", "PROTEIN", 73, 99], ["3CL main protease", "PROTEIN", 101, 118], ["3CL M pro", "PROTEIN", 123, 132], ["non-structural proteins", "PROTEIN", 163, 186], ["stranded RNA viruses", "PROBLEM", 41, 61], ["a chymotrypsin", "TREATMENT", 71, 85], ["protease (3CL main protease", "TREATMENT", 91, 118], ["3CL M pro", "TREATMENT", 123, 132], ["non-structural proteins", "TREATMENT", 163, 186], ["viral replication", "TREATMENT", 201, 218], ["RNA viruses", "OBSERVATION", 50, 61]]]], "PMC7468764": [], "ab95e77d34dd05045b5f06dc9283f57a2d6341c5": [["For many midwives, visualizing the care we provide during labor and birth likely conjures images of a caring professional face-to-face with a patient, holding a hand, rubbing a back, fostering the initial bonds of a new family.", [["hand", "ANATOMY", 161, 165], ["patient", "ORGANISM", 142, 149], ["hand", "ORGANISM_SUBDIVISION", 161, 165], ["patient", "SPECIES", 142, 149], ["labor", "PROBLEM", 58, 63], ["back", "ANATOMY", 177, 181]]], ["But since early 2020, the news has been filled with concerns about rampant coronavirus disease 2019 (COVID-19) and images of health care providers in their personal protective equipment, or worse, makeshift pseudo-protective gear.", [["coronavirus disease", "DISEASE", 75, 94], ["rampant coronavirus disease", "PROBLEM", 67, 94], ["COVID", "TEST", 101, 106]]], ["There are stories of births (and deaths) unattended by partners or family.", [["deaths", "DISEASE", 33, 39]]], ["Health care providers themselves have COVID-19 and are quarantined from patients or even from their own families.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["Health care providers, including midwives, are dying, along with their patients.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["1,2 How does one live the philosophy of midwifery, working in close and caring partnership with individual patients and pregnant families, giving of ourselves, in the midst of such a crisis?", [["1,2", "CHEMICAL", 0, 3], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["a crisis", "PROBLEM", 181, 189]]], ["How do we protect the essence of midwifery care from 6 feet away, behind face shields and N95 masks?", [["midwifery care", "TREATMENT", 33, 47], ["N95 masks", "TREATMENT", 90, 99]]]], "ca55d7e9367c3358ba650c80c299c092a284b7f4": [["CoagulopathyOne of the emerging hallmarks of severe COVID-19 is a coagulopathy that has been termed \"sepsis-induced coagulopathy\" (SIC) with high D-dimer levels and elevated fibrinogen [3, 4] .", [["COVID", "DISEASE", 52, 57], ["coagulopathy", "DISEASE", 66, 78], ["sepsis", "DISEASE", 101, 107], ["coagulopathy", "DISEASE", 116, 128], ["SIC", "DISEASE", 131, 134], ["COVID-19", "CHEMICAL", 52, 60], ["D-dimer", "SIMPLE_CHEMICAL", 146, 153], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 174, 184], ["fibrinogen", "PROTEIN", 174, 184], ["severe COVID", "PROBLEM", 45, 57], ["a coagulopathy", "PROBLEM", 64, 78], ["sepsis", "PROBLEM", 101, 107], ["induced coagulopathy", "PROBLEM", 108, 128], ["high D-dimer levels", "PROBLEM", 141, 160], ["elevated fibrinogen", "PROBLEM", 165, 184], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["coagulopathy", "OBSERVATION", 66, 78], ["sepsis", "OBSERVATION", 101, 107], ["coagulopathy", "OBSERVATION", 116, 128], ["elevated", "OBSERVATION_MODIFIER", 165, 173], ["fibrinogen", "OBSERVATION", 174, 184]]], ["SIC is a precursor state to DIC and associated with elevated prothrombin time (PT), elevated D-dimer, and thrombocytopenia, but without hypofibrinogenemia.", [["SIC", "DISEASE", 0, 3], ["DIC", "DISEASE", 28, 31], ["thrombocytopenia", "DISEASE", 106, 122], ["hypofibrinogenemia", "DISEASE", 136, 154], ["prothrombin", "GENE_OR_GENE_PRODUCT", 61, 72], ["D-dimer", "GENE_OR_GENE_PRODUCT", 93, 100], ["prothrombin", "PROTEIN", 61, 72], ["D-dimer", "PROTEIN", 93, 100], ["DIC", "PROBLEM", 28, 31], ["elevated prothrombin time", "PROBLEM", 52, 77], ["PT", "TEST", 79, 81], ["elevated D-dimer", "PROBLEM", 84, 100], ["thrombocytopenia", "PROBLEM", 106, 122], ["hypofibrinogenemia", "PROBLEM", 136, 154], ["elevated", "OBSERVATION_MODIFIER", 84, 92], ["D-dimer", "OBSERVATION_MODIFIER", 93, 100], ["thrombocytopenia", "OBSERVATION", 106, 122], ["without", "UNCERTAINTY", 128, 135], ["hypofibrinogenemia", "OBSERVATION", 136, 154]]], ["It is related to an infection-induced systemic inflammatory response with endothelial dysfunction and microthrombosis with organ failure and usually no bleeding [4] .", [["endothelial", "ANATOMY", 74, 85], ["organ", "ANATOMY", 123, 128], ["infection", "DISEASE", 20, 29], ["endothelial dysfunction", "DISEASE", 74, 97], ["microthrombosis", "DISEASE", 102, 117], ["organ failure", "DISEASE", 123, 136], ["bleeding", "DISEASE", 152, 160], ["endothelial", "TISSUE", 74, 85], ["organ", "ORGAN", 123, 128], ["an infection", "PROBLEM", 17, 29], ["systemic inflammatory response", "PROBLEM", 38, 68], ["endothelial dysfunction", "PROBLEM", 74, 97], ["microthrombosis", "PROBLEM", 102, 117], ["organ failure", "PROBLEM", 123, 136], ["bleeding", "PROBLEM", 152, 160], ["related to", "UNCERTAINTY", 6, 16], ["infection", "OBSERVATION", 20, 29], ["systemic", "OBSERVATION_MODIFIER", 38, 46], ["inflammatory", "OBSERVATION", 47, 59], ["endothelial dysfunction", "OBSERVATION", 74, 97], ["organ", "ANATOMY", 123, 128], ["failure", "OBSERVATION", 129, 136], ["no", "UNCERTAINTY", 149, 151], ["bleeding", "OBSERVATION", 152, 160]]], ["In a multivariate analysis of a retrospective series of 440 severe COVID-19 patients, the predictors of 28-day mortality were age, prothrombin time, D-dimer levels, and thrombocytopenia.", [["COVID", "DISEASE", 67, 72], ["thrombocytopenia", "DISEASE", 169, 185], ["patients", "ORGANISM", 76, 84], ["prothrombin", "GENE_OR_GENE_PRODUCT", 131, 142], ["D-dimer", "SIMPLE_CHEMICAL", 149, 156], ["patients", "SPECIES", 76, 84], ["a retrospective series", "TEST", 30, 52], ["severe COVID", "TEST", 60, 72], ["prothrombin time", "TEST", 131, 147], ["D-dimer levels", "TEST", 149, 163], ["thrombocytopenia", "PROBLEM", 169, 185], ["thrombocytopenia", "OBSERVATION", 169, 185]]], ["Patients with elevated D-dimer or SIC score had lower mortality when treated with heparin (mostly low molecular weight) compared with those not treated with heparin.", [["heparin", "CHEMICAL", 82, 89], ["heparin", "CHEMICAL", 157, 164], ["Patients", "ORGANISM", 0, 8], ["D-dimer", "GENE_OR_GENE_PRODUCT", 23, 30], ["heparin", "SIMPLE_CHEMICAL", 82, 89], ["heparin", "SIMPLE_CHEMICAL", 157, 164], ["D-dimer", "PROTEIN", 23, 30], ["Patients", "SPECIES", 0, 8], ["elevated D-dimer", "PROBLEM", 14, 30], ["SIC score", "PROBLEM", 34, 43], ["heparin", "TREATMENT", 82, 89], ["heparin", "TREATMENT", 157, 164]]], ["A case series of 3 patients with respiratory failure and high D-dimer levels reported transient improvement in respiratory parameters with the use of tissue plasminogen activator [5] .", [["respiratory", "ANATOMY", 33, 44], ["respiratory", "ANATOMY", 111, 122], ["respiratory failure", "DISEASE", 33, 52], ["patients", "ORGANISM", 19, 27], ["D-dimer", "SIMPLE_CHEMICAL", 62, 69], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 150, 178], ["tissue plasminogen activator", "PROTEIN", 150, 178], ["patients", "SPECIES", 19, 27], ["A case series", "TEST", 0, 13], ["respiratory failure", "PROBLEM", 33, 52], ["high D-dimer levels", "PROBLEM", 57, 76], ["tissue plasminogen activator", "TREATMENT", 150, 178], ["respiratory", "ANATOMY", 33, 44], ["failure", "OBSERVATION", 45, 52], ["transient", "OBSERVATION_MODIFIER", 86, 95], ["improvement", "OBSERVATION_MODIFIER", 96, 107], ["respiratory parameters", "OBSERVATION", 111, 133]]], ["The lung pathology in one COVID-19 patient revealed microvascular thrombosis suggesting that the lung microvascular thrombosis in COVID-19 patients may contribute to respiratory failure and ARDS [5] .CoagulopathyAntiphospholipid antibodies (aPL) were reported in 3 COVID-19 patients. aPL are antibodies directed to phosphoproteins and associated with both arterial and venous thrombotic events.", [["lung", "ANATOMY", 4, 8], ["microvascular", "ANATOMY", 52, 65], ["lung microvascular", "ANATOMY", 97, 115], ["respiratory", "ANATOMY", 166, 177], ["arterial", "ANATOMY", 356, 364], ["venous", "ANATOMY", 369, 375], ["microvascular thrombosis", "DISEASE", 52, 76], ["microvascular thrombosis", "DISEASE", 102, 126], ["respiratory failure", "DISEASE", 166, 185], ["ARDS", "DISEASE", 190, 194], ["Antiphospholipid antibodies", "DISEASE", 212, 239], ["aPL", "DISEASE", 284, 287], ["arterial and venous thrombotic", "DISEASE", 356, 386], ["lung", "ORGAN", 4, 8], ["patient", "ORGANISM", 35, 42], ["microvascular", "MULTI-TISSUE_STRUCTURE", 52, 65], ["lung microvascular", "MULTI-TISSUE_STRUCTURE", 97, 115], ["patients", "ORGANISM", 139, 147], ["Antiphospholipid antibodies", "GENE_OR_GENE_PRODUCT", 212, 239], ["aPL", "GENE_OR_GENE_PRODUCT", 241, 244], ["patients", "ORGANISM", 274, 282], ["aPL", "GENE_OR_GENE_PRODUCT", 284, 287], ["arterial", "MULTI-TISSUE_STRUCTURE", 356, 364], ["venous", "MULTI-TISSUE_STRUCTURE", 369, 375], ["Antiphospholipid antibodies", "PROTEIN", 212, 239], ["aPL", "PROTEIN", 241, 244], ["aPL", "PROTEIN", 284, 287], ["antibodies", "PROTEIN", 292, 302], ["phosphoproteins", "PROTEIN", 315, 330], ["patient", "SPECIES", 35, 42], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 274, 282], ["The lung pathology", "TEST", 0, 18], ["one COVID", "TEST", 22, 31], ["microvascular thrombosis", "PROBLEM", 52, 76], ["the lung microvascular thrombosis", "PROBLEM", 93, 126], ["COVID", "TEST", 130, 135], ["respiratory failure", "PROBLEM", 166, 185], ["ARDS", "PROBLEM", 190, 194], ["Coagulopathy", "PROBLEM", 200, 212], ["Antiphospholipid antibodies", "TEST", 212, 239], ["aPL are antibodies", "TREATMENT", 284, 302], ["phosphoproteins", "TEST", 315, 330], ["both arterial and venous thrombotic events", "PROBLEM", 351, 393], ["lung", "ANATOMY", 4, 8], ["pathology", "OBSERVATION", 9, 18], ["microvascular", "ANATOMY", 52, 65], ["thrombosis", "OBSERVATION", 66, 76], ["lung", "ANATOMY", 97, 101], ["microvascular", "ANATOMY_MODIFIER", 102, 115], ["thrombosis", "OBSERVATION", 116, 126], ["respiratory failure", "OBSERVATION", 166, 185], ["ARDS", "OBSERVATION", 190, 194], ["both", "ANATOMY_MODIFIER", 351, 355], ["arterial", "ANATOMY", 356, 364], ["venous", "ANATOMY", 369, 375], ["thrombotic", "OBSERVATION", 376, 386]]], ["All 3 patients suffered multiple cerebral infarcts and one had multiple limb ischemia.", [["cerebral", "ANATOMY", 33, 41], ["limb", "ANATOMY", 72, 76], ["cerebral infarcts", "DISEASE", 33, 50], ["limb ischemia", "DISEASE", 72, 85], ["patients", "ORGANISM", 6, 14], ["cerebral infarcts", "PATHOLOGICAL_FORMATION", 33, 50], ["limb", "ORGANISM_SUBDIVISION", 72, 76], ["patients", "SPECIES", 6, 14], ["multiple cerebral infarcts", "PROBLEM", 24, 50], ["multiple limb ischemia", "PROBLEM", 63, 85], ["multiple", "OBSERVATION_MODIFIER", 24, 32], ["cerebral", "ANATOMY", 33, 41], ["infarcts", "OBSERVATION", 42, 50], ["multiple", "OBSERVATION_MODIFIER", 63, 71], ["limb", "ANATOMY", 72, 76], ["ischemia", "OBSERVATION", 77, 85]]], ["All had elevated IgA anticardiolipin antibodies and elevated IgA and IgG beta 2 glycoprotein I antibodies with prolonged activated partial thromboplastin times and prothrombin times but no lupus anticoagulant.", [["IgA", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgA", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgG beta 2 glycoprotein I antibodies", "GENE_OR_GENE_PRODUCT", 69, 105], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 139, 153], ["prothrombin", "GENE_OR_GENE_PRODUCT", 164, 175], ["IgA anticardiolipin antibodies", "PROTEIN", 17, 47], ["IgA", "PROTEIN", 61, 64], ["IgG beta 2 glycoprotein I antibodies", "PROTEIN", 69, 105], ["prothrombin", "PROTEIN", 164, 175], ["elevated IgA anticardiolipin antibodies", "PROBLEM", 8, 47], ["elevated IgA", "PROBLEM", 52, 64], ["IgG beta 2 glycoprotein I antibodies", "PROBLEM", 69, 105], ["prolonged activated partial thromboplastin times", "PROBLEM", 111, 159], ["prothrombin times", "PROBLEM", 164, 181], ["lupus anticoagulant", "PROBLEM", 189, 208], ["elevated", "OBSERVATION_MODIFIER", 8, 16], ["IgA anticardiolipin antibodies", "OBSERVATION", 17, 47], ["partial thromboplastin times", "OBSERVATION", 131, 159], ["no", "UNCERTAINTY", 186, 188], ["lupus anticoagulant", "OBSERVATION", 189, 208]]], ["Two of the 3 patients had thrombocytopenia and all had high C-reactive protein levels [6] .", [["thrombocytopenia", "DISEASE", 26, 42], ["patients", "ORGANISM", 13, 21], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 60, 78], ["C-reactive protein", "PROTEIN", 60, 78], ["patients", "SPECIES", 13, 21], ["thrombocytopenia", "PROBLEM", 26, 42], ["high C-reactive protein levels", "PROBLEM", 55, 85], ["thrombocytopenia", "OBSERVATION", 26, 42]]], ["It is not clear if the strokes and thrombotic events were related to SIC or the aPL.", [["strokes", "DISEASE", 23, 30], ["thrombotic", "DISEASE", 35, 45], ["SIC", "DISEASE", 69, 72], ["aPL", "DISEASE", 80, 83], ["aPL", "GENE_OR_GENE_PRODUCT", 80, 83], ["aPL", "PROTEIN", 80, 83], ["the strokes", "PROBLEM", 19, 30], ["thrombotic events", "PROBLEM", 35, 52], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION_MODIFIER", 10, 15], ["strokes", "OBSERVATION", 23, 30], ["thrombotic", "OBSERVATION", 35, 45], ["aPL", "ANATOMY", 80, 83]]], ["There is an association of aPL with viral infections especially HIV-1 and hepatitis C and a subgroup of these are associated with thrombotic events [7, 8] .Depletion of ACE2 and Endothelial DysfunctionThe COVID-19 pandemic is caused by the SARS-CoV-2 virus, a member of the coronavirus family.", [["Endothelial", "ANATOMY", 178, 189], ["aPL", "DISEASE", 27, 30], ["viral infections", "DISEASE", 36, 52], ["HIV-1 and hepatitis C", "DISEASE", 64, 85], ["thrombotic", "DISEASE", 130, 140], ["aPL", "GENE_OR_GENE_PRODUCT", 27, 30], ["HIV-1", "ORGANISM", 64, 69], ["hepatitis C", "ORGANISM", 74, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["Endothelial", "TISSUE", 178, 189], ["COVID-19", "GENE_OR_GENE_PRODUCT", 205, 213], ["SARS-CoV-2 virus", "ORGANISM", 240, 256], ["coronavirus", "ORGANISM", 274, 285], ["aPL", "PROTEIN", 27, 30], ["ACE2", "PROTEIN", 169, 173], ["HIV-1", "SPECIES", 64, 69], ["CoV-2 virus", "SPECIES", 245, 256], ["coronavirus", "SPECIES", 274, 285], ["HIV-1", "SPECIES", 64, 69], ["SARS-CoV-2 virus", "SPECIES", 240, 256], ["viral infections", "PROBLEM", 36, 52], ["HIV", "PROBLEM", 64, 67], ["hepatitis C", "PROBLEM", 74, 85], ["thrombotic events", "PROBLEM", 130, 147], ["ACE2", "PROBLEM", 169, 173], ["Endothelial Dysfunction", "PROBLEM", 178, 201], ["The COVID", "TEST", 201, 210], ["pandemic", "PROBLEM", 214, 222], ["the SARS", "PROBLEM", 236, 244], ["aPL", "OBSERVATION", 27, 30], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infections", "OBSERVATION", 42, 52], ["associated with", "UNCERTAINTY", 114, 129], ["thrombotic", "OBSERVATION", 130, 140], ["ACE2", "OBSERVATION", 169, 173], ["Endothelial Dysfunction", "OBSERVATION", 178, 201]]], ["The SARS-CoV-2 virus binds to the angiotensin-converting enzyme 2 (ACE2) via its spike (S) protein [9] .", [["angiotensin", "CHEMICAL", 34, 45], ["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 34, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["angiotensin-converting enzyme 2", "PROTEIN", 34, 65], ["ACE2", "PROTEIN", 67, 71], ["spike (S) protein", "PROTEIN", 81, 98], ["CoV-2 virus", "SPECIES", 9, 20], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["the angiotensin", "TEST", 30, 45], ["converting enzyme", "TEST", 46, 63], ["ACE2", "TEST", 67, 71], ["protein", "TEST", 91, 98]]], ["Transmembrane protein serine protease 2 (TMPRSS2) is also required for viral entry into cells [10] .", [["cells", "ANATOMY", 88, 93], ["serine", "CHEMICAL", 22, 28], ["Transmembrane protein serine protease 2", "GENE_OR_GENE_PRODUCT", 0, 39], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 41, 48], ["cells", "CELL", 88, 93], ["Transmembrane protein serine protease 2", "PROTEIN", 0, 39], ["TMPRSS2", "PROTEIN", 41, 48], ["Transmembrane protein serine protease", "TREATMENT", 0, 37], ["viral entry into cells", "PROBLEM", 71, 93]]], ["Similarly, the virus that caused the SARS pandemic in 2003, SARS-CoV-1, also binds to ACE2 [11, 12] .", [["SARS", "DISEASE", 37, 41], ["SARS", "DISEASE", 60, 64], ["SARS-CoV-1", "ORGANISM", 60, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["ACE2", "PROTEIN", 86, 90], ["SARS-CoV-1", "SPECIES", 60, 70], ["the virus", "PROBLEM", 11, 20], ["the SARS pandemic", "PROBLEM", 33, 50], ["ACE2", "TEST", 86, 90], ["virus", "OBSERVATION", 15, 20]]], ["ACE2 is a dipeptidyl carboxydipeptidase, a homologue of angiotensinconverting enzyme 1 (ACE1), and part of the renin angiotensin system (RAS).", [["angiotensin", "CHEMICAL", 117, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["dipeptidyl carboxydipeptidase", "GENE_OR_GENE_PRODUCT", 10, 39], ["angiotensinconverting enzyme 1", "GENE_OR_GENE_PRODUCT", 56, 86], ["ACE1", "GENE_OR_GENE_PRODUCT", 88, 92], ["renin angiotensin system", "GENE_OR_GENE_PRODUCT", 111, 135], ["RAS", "GENE_OR_GENE_PRODUCT", 137, 140], ["ACE2", "PROTEIN", 0, 4], ["dipeptidyl carboxydipeptidase", "PROTEIN", 10, 39], ["angiotensinconverting enzyme 1", "PROTEIN", 56, 86], ["ACE1", "PROTEIN", 88, 92], ["renin", "PROTEIN", 111, 116], ["a dipeptidyl carboxydipeptidase", "TREATMENT", 8, 39], ["angiotensinconverting enzyme", "TEST", 56, 84], ["the renin angiotensin system", "TREATMENT", 107, 135]]], ["Renin secreted from juxtaglomerular cells in the kidney cleaves angiotensinogen produced by the liver to angiotensin I. Angiotensin I is cleaved by ACE1 to angiotensin II.", [["juxtaglomerular cells", "ANATOMY", 20, 41], ["kidney", "ANATOMY", 49, 55], ["liver", "ANATOMY", 96, 101], ["angiotensin", "CHEMICAL", 105, 116], ["Angiotensin", "CHEMICAL", 120, 131], ["angiotensin II", "CHEMICAL", 156, 170], ["Renin", "GENE_OR_GENE_PRODUCT", 0, 5], ["juxtaglomerular cells", "CELL", 20, 41], ["kidney", "ORGAN", 49, 55], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 64, 79], ["liver", "ORGAN", 96, 101], ["angiotensin I.", "GENE_OR_GENE_PRODUCT", 105, 119], ["Angiotensin I", "GENE_OR_GENE_PRODUCT", 120, 133], ["ACE1", "GENE_OR_GENE_PRODUCT", 148, 152], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 156, 170], ["Renin", "PROTEIN", 0, 5], ["juxtaglomerular cells", "CELL_TYPE", 20, 41], ["angiotensinogen", "PROTEIN", 64, 79], ["ACE1", "PROTEIN", 148, 152], ["angiotensin II", "PROTEIN", 156, 170], ["Renin secreted from juxtaglomerular cells", "PROBLEM", 0, 41], ["juxtaglomerular cells", "OBSERVATION", 20, 41], ["kidney", "ANATOMY", 49, 55], ["angiotensinogen", "OBSERVATION", 64, 79], ["liver", "ANATOMY", 96, 101]]], ["Angiotensin II binds to angiotensin 1 (AT1) and angiotensin 2 (AT2) receptors and its binding to AT1 leads to vasoconstriction, aldosterone secretion with sodium and water retention, proinflammatory and procoagulation effects, and elevated blood pressure.", [["blood", "ANATOMY", 240, 245], ["Angiotensin II", "CHEMICAL", 0, 14], ["angiotensin", "CHEMICAL", 24, 35], ["angiotensin", "CHEMICAL", 48, 59], ["aldosterone", "CHEMICAL", 128, 139], ["sodium", "CHEMICAL", 155, 161], ["aldosterone", "CHEMICAL", 128, 139], ["sodium", "CHEMICAL", 155, 161], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["angiotensin 1", "GENE_OR_GENE_PRODUCT", 24, 37], ["AT1", "GENE_OR_GENE_PRODUCT", 39, 42], ["angiotensin 2", "GENE_OR_GENE_PRODUCT", 48, 61], ["AT2) receptors", "GENE_OR_GENE_PRODUCT", 63, 77], ["AT1", "GENE_OR_GENE_PRODUCT", 97, 100], ["aldosterone", "SIMPLE_CHEMICAL", 128, 139], ["sodium", "SIMPLE_CHEMICAL", 155, 161], ["water", "SIMPLE_CHEMICAL", 166, 171], ["blood", "ORGANISM_SUBSTANCE", 240, 245], ["Angiotensin II", "PROTEIN", 0, 14], ["angiotensin 1 (AT1) and angiotensin 2 (AT2) receptors", "PROTEIN", 24, 77], ["Angiotensin II binds", "TREATMENT", 0, 20], ["angiotensin 1 (AT1)", "TREATMENT", 24, 43], ["angiotensin 2 (AT2) receptors", "TREATMENT", 48, 77], ["vasoconstriction", "PROBLEM", 110, 126], ["aldosterone secretion", "PROBLEM", 128, 149], ["sodium and water retention", "TREATMENT", 155, 181], ["proinflammatory and procoagulation effects", "TREATMENT", 183, 225], ["elevated blood pressure", "PROBLEM", 231, 254]]], ["Angiotensin II worsens heart failure and worsens ARDS.", [["heart", "ANATOMY", 23, 28], ["Angiotensin II", "CHEMICAL", 0, 14], ["heart failure", "DISEASE", 23, 36], ["ARDS", "DISEASE", 49, 53], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["heart", "ORGAN", 23, 28], ["Angiotensin II", "PROTEIN", 0, 14], ["Angiotensin II worsens heart failure", "PROBLEM", 0, 36], ["ARDS", "PROBLEM", 49, 53], ["heart", "ANATOMY", 23, 28], ["failure", "OBSERVATION", 29, 36], ["worsens", "OBSERVATION_MODIFIER", 41, 48], ["ARDS", "OBSERVATION", 49, 53]]], ["AT1 blockers are widely used antihypertensive drugs and have beneficial effects in organ protection including the brain.Depletion of ACE2 and Endothelial DysfunctionACE2 counteracts ACE1 and angiotensin II.", [["organ", "ANATOMY", 83, 88], ["brain", "ANATOMY", 114, 119], ["Endothelial", "ANATOMY", 142, 153], ["angiotensin II", "CHEMICAL", 191, 205], ["AT1 blockers", "GENE_OR_GENE_PRODUCT", 0, 12], ["organ", "ORGAN", 83, 88], ["brain", "ORGAN", 114, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["Endothelial DysfunctionACE2", "GENE_OR_GENE_PRODUCT", 142, 169], ["ACE1", "GENE_OR_GENE_PRODUCT", 182, 186], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 191, 205], ["ACE2", "PROTEIN", 133, 137], ["Endothelial DysfunctionACE2", "PROTEIN", 142, 169], ["ACE1", "PROTEIN", 182, 186], ["angiotensin II", "PROTEIN", 191, 205], ["AT1 blockers", "TREATMENT", 0, 12], ["antihypertensive drugs", "TREATMENT", 29, 51], ["beneficial effects", "TREATMENT", 61, 79], ["organ protection", "TREATMENT", 83, 99], ["ACE2", "PROBLEM", 133, 137], ["Endothelial DysfunctionACE2 counteracts ACE1", "TREATMENT", 142, 186], ["angiotensin II", "TREATMENT", 191, 205], ["brain", "ANATOMY", 114, 119], ["ACE2", "OBSERVATION", 133, 137], ["Endothelial DysfunctionACE2", "OBSERVATION", 142, 169]]], ["ACE2 directly cleaves angiotensin II to angiotensin (1-7) and cleaves angiotensin I to angiotensin (1-9) which is then further cleaved to angiotensin (1-7).", [["angiotensin II", "CHEMICAL", 22, 36], ["angiotensin (1-7)", "CHEMICAL", 40, 57], ["angiotensin I", "CHEMICAL", 70, 83], ["angiotensin (1-9", "CHEMICAL", 87, 103], ["angiotensin", "CHEMICAL", 138, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 22, 36], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 40, 56], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 70, 83], ["angiotensin", "SIMPLE_CHEMICAL", 87, 98], ["1-9", "SIMPLE_CHEMICAL", 100, 103], ["1-7", "GENE_OR_GENE_PRODUCT", 151, 154], ["ACE2", "PROTEIN", 0, 4], ["angiotensin II", "PROTEIN", 22, 36], ["ACE2", "TREATMENT", 0, 4], ["angiotensin II to angiotensin", "TREATMENT", 22, 51], ["angiotensin", "TEST", 87, 98], ["angiotensin", "TEST", 138, 149]]], ["Angiotensin (1-7) produces vasodilatation and has anti-inflammatory effects via its binding to the Mas receptor.", [["Angiotensin (1-7)", "CHEMICAL", 0, 17], ["Angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 0, 16], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 99, 111], ["Mas receptor", "PROTEIN", 99, 111], ["Angiotensin", "TEST", 0, 11], ["vasodilatation", "PROBLEM", 27, 41], ["anti-inflammatory effects", "TREATMENT", 50, 75], ["anti-inflammatory effects", "OBSERVATION", 50, 75]]], ["Activation of ACE2/Ang (1-7)/Mas axis leads to beneficial cardioprotective and neuroprotective actions that counter-regulate the harmful actions of ACE1/ angiotensin II/AT1 axis (reviewed in [13, 14] ).", [["Ang", "CHEMICAL", 19, 22], ["angiotensin II", "CHEMICAL", 154, 168], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["Ang (1-7", "GENE_OR_GENE_PRODUCT", 19, 27], ["Mas", "GENE_OR_GENE_PRODUCT", 29, 32], ["ACE1", "GENE_OR_GENE_PRODUCT", 148, 152], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 154, 168], ["AT1", "GENE_OR_GENE_PRODUCT", 169, 172], ["ACE2", "PROTEIN", 14, 18], ["ACE1", "PROTEIN", 148, 152], ["angiotensin II", "PROTEIN", 154, 168], ["ACE2/Ang (1-7)/Mas axis leads", "TREATMENT", 14, 43], ["cardioprotective and neuroprotective actions", "TREATMENT", 58, 102], ["ACE1/ angiotensin II/AT1 axis", "TREATMENT", 148, 177]]], ["In rodent models of stroke, angiotensin (1-7) is neuroprotective and anti-inflammatory [15] [16] [17] .Depletion of ACE2 and Endothelial DysfunctionACE2 is expressed in human lung, small intestine, and endothelial and smooth muscle cells in the human brain [18] .", [["Endothelial", "ANATOMY", 125, 136], ["lung", "ANATOMY", 175, 179], ["small intestine", "ANATOMY", 181, 196], ["endothelial", "ANATOMY", 202, 213], ["smooth muscle cells", "ANATOMY", 218, 237], ["brain", "ANATOMY", 251, 256], ["stroke", "DISEASE", 20, 26], ["angiotensin (1-7)", "CHEMICAL", 28, 45], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 28, 44], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 87, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["Endothelial DysfunctionACE2", "GENE_OR_GENE_PRODUCT", 125, 152], ["human", "ORGANISM", 169, 174], ["lung", "ORGAN", 175, 179], ["intestine", "ORGAN", 187, 196], ["endothelial", "CELL", 202, 213], ["smooth muscle cells", "CELL", 218, 237], ["human", "ORGANISM", 245, 250], ["brain", "ORGAN", 251, 256], ["ACE2", "PROTEIN", 116, 120], ["Endothelial DysfunctionACE2", "PROTEIN", 125, 152], ["endothelial and smooth muscle cells", "CELL_TYPE", 202, 237], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 245, 250], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 245, 250], ["stroke", "PROBLEM", 20, 26], ["angiotensin", "TREATMENT", 28, 39], ["ACE2", "PROBLEM", 116, 120], ["Endothelial DysfunctionACE2", "TEST", 125, 152], ["stroke", "OBSERVATION", 20, 26], ["ACE2", "OBSERVATION", 116, 120], ["Endothelial DysfunctionACE2", "OBSERVATION", 125, 152], ["human", "ANATOMY_MODIFIER", 169, 174], ["lung", "ANATOMY", 175, 179], ["small intestine", "ANATOMY", 181, 196], ["endothelial", "ANATOMY", 202, 213], ["smooth muscle cells", "OBSERVATION", 218, 237], ["human brain", "ANATOMY", 245, 256]]], ["ACE2 is also expressed in neurons in mice [18] .", [["neurons", "ANATOMY", 26, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["neurons", "CELL", 26, 33], ["mice", "ORGANISM", 37, 41], ["ACE2", "PROTEIN", 0, 4], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41]]], ["Overexpression of ACE2 in neuronal cells or endothelial progenitor cells protects the brain from ischemic stroke [19, 20] .Depletion of ACE2 and Endothelial DysfunctionSARS-CoV-1 and 2 viruses deplete ACE2 through receptor endocytosis upon viral entry, leaving ACE1 unopposed with generation of angiotensin II.", [["neuronal cells", "ANATOMY", 26, 40], ["endothelial progenitor cells", "ANATOMY", 44, 72], ["brain", "ANATOMY", 86, 91], ["ischemic stroke", "DISEASE", 97, 112], ["angiotensin II", "CHEMICAL", 295, 309], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["neuronal cells", "CELL", 26, 40], ["endothelial progenitor cells", "CELL", 44, 72], ["brain", "ORGAN", 86, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 136, 140], ["Endothelial DysfunctionSARS-CoV-1", "GENE_OR_GENE_PRODUCT", 145, 178], ["ACE2", "GENE_OR_GENE_PRODUCT", 201, 205], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 295, 309], ["ACE2", "PROTEIN", 18, 22], ["neuronal cells", "CELL_TYPE", 26, 40], ["endothelial progenitor cells", "CELL_TYPE", 44, 72], ["ACE2", "PROTEIN", 136, 140], ["ACE2", "PROTEIN", 201, 205], ["ACE1", "PROTEIN", 261, 265], ["angiotensin II", "PROTEIN", 295, 309], ["ACE2 in neuronal cells", "PROBLEM", 18, 40], ["endothelial progenitor cells", "TEST", 44, 72], ["ischemic stroke", "PROBLEM", 97, 112], ["ACE2", "TEST", 136, 140], ["Endothelial DysfunctionSARS", "TEST", 145, 172], ["CoV", "TEST", 173, 176], ["ACE2 through receptor endocytosis", "PROBLEM", 201, 234], ["viral entry", "PROBLEM", 240, 251], ["ACE1 unopposed", "TREATMENT", 261, 275], ["angiotensin II", "TREATMENT", 295, 309], ["neuronal cells", "OBSERVATION", 26, 40], ["endothelial", "ANATOMY", 44, 55], ["progenitor cells", "OBSERVATION", 56, 72], ["brain", "ANATOMY", 86, 91], ["ischemic", "OBSERVATION_MODIFIER", 97, 105], ["stroke", "OBSERVATION", 106, 112], ["ACE2", "OBSERVATION", 136, 140], ["Endothelial", "ANATOMY", 145, 156], ["viral entry", "OBSERVATION", 240, 251]]], ["Angiotensin II worsens lung injury and also worsens endothelial function in organs like the heart and brain.", [["lung", "ANATOMY", 23, 27], ["endothelial", "ANATOMY", 52, 63], ["organs", "ANATOMY", 76, 82], ["heart", "ANATOMY", 92, 97], ["brain", "ANATOMY", 102, 107], ["Angiotensin II", "CHEMICAL", 0, 14], ["lung injury", "DISEASE", 23, 34], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["lung", "ORGAN", 23, 27], ["endothelial", "TISSUE", 52, 63], ["organs", "ORGAN", 76, 82], ["heart", "ORGAN", 92, 97], ["brain", "ORGAN", 102, 107], ["Angiotensin II", "PROTEIN", 0, 14], ["Angiotensin II worsens lung injury", "PROBLEM", 0, 34], ["endothelial function in organs like the heart and brain", "PROBLEM", 52, 107], ["lung", "ANATOMY", 23, 27], ["injury", "OBSERVATION", 28, 34], ["worsens", "OBSERVATION_MODIFIER", 44, 51], ["endothelial function", "OBSERVATION", 52, 72], ["heart", "ANATOMY", 92, 97], ["brain", "ANATOMY", 102, 107]]], ["ACE2 in the lung declines with age and the decrease in males with age is greater than that in females [21] .", [["lung", "ANATOMY", 12, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung", "ORGAN", 12, 16], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["lung", "ANATOMY", 12, 16], ["declines", "OBSERVATION_MODIFIER", 17, 25], ["decrease", "OBSERVATION_MODIFIER", 43, 51], ["greater", "OBSERVATION_MODIFIER", 73, 80]]], ["Meanwhile, the ACE1-angiotensin II system activity increases with age [22] .", [["angiotensin II", "CHEMICAL", 20, 34], ["ACE1-angiotensin II", "GENE_OR_GENE_PRODUCT", 15, 34], ["ACE1", "PROTEIN", 15, 19], ["angiotensin II", "PROTEIN", 20, 34], ["the ACE1-angiotensin II system", "TREATMENT", 11, 41]]], ["The depletion of ACE2 by the SARS-CoV-2 virus coupled with the age-related decline in ACE2 and increase of ACE-1-Ang II tips the balance in favor of ACE-1/ angiotensin II with proinflammatory and organ damaging effects.", [["organ", "ANATOMY", 196, 201], ["Ang II", "CHEMICAL", 113, 119], ["angiotensin II", "CHEMICAL", 156, 170], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["SARS-CoV-2 virus", "ORGANISM", 29, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["ACE-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["Ang II", "GENE_OR_GENE_PRODUCT", 113, 119], ["ACE-1", "GENE_OR_GENE_PRODUCT", 149, 154], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 156, 170], ["organ", "ORGAN", 196, 201], ["ACE2", "PROTEIN", 17, 21], ["ACE2", "PROTEIN", 86, 90], ["ACE", "PROTEIN", 107, 110], ["Ang II", "PROTEIN", 113, 119], ["ACE", "PROTEIN", 149, 152], ["angiotensin II", "PROTEIN", 156, 170], ["SARS-CoV-2 virus", "SPECIES", 29, 45], ["The depletion of ACE2", "TREATMENT", 0, 21], ["the SARS", "TEST", 25, 33], ["CoV", "TEST", 34, 37], ["ACE2", "TEST", 86, 90], ["ACE", "TEST", 107, 110], ["Ang II tips", "TREATMENT", 113, 124], ["ACE", "TEST", 149, 152], ["angiotensin II", "TREATMENT", 156, 170], ["proinflammatory and organ damaging effects", "TREATMENT", 176, 218], ["depletion", "OBSERVATION", 4, 13], ["increase", "OBSERVATION_MODIFIER", 95, 103]]], ["This may explain the higher mortality in the elderly and in men seen in the COVID-19 pandemic.Depletion of ACE2 and Endothelial DysfunctionOne of the obstacles to COVID-19 research is the lack of rodent models.", [["Endothelial", "ANATOMY", 116, 127], ["men", "ORGANISM", 60, 63], ["COVID-19", "ORGANISM", 76, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["Endothelial", "CELL", 116, 127], ["ACE2", "PROTEIN", 107, 111], ["men", "SPECIES", 60, 63], ["the COVID", "TEST", 72, 81], ["pandemic", "PROBLEM", 85, 93], ["Depletion of ACE2", "PROBLEM", 94, 111], ["COVID", "TEST", 163, 168], ["higher", "OBSERVATION_MODIFIER", 21, 27], ["mortality", "OBSERVATION", 28, 37], ["ACE2", "OBSERVATION", 107, 111], ["Endothelial DysfunctionOne", "OBSERVATION", 116, 142]]], ["SARS 1 and 2 bind to ACE2 but mouse and rat ACE2 does not avidly bind the spike protein and mice do not develop severe illness.", [["SARS", "DISEASE", 0, 4], ["illness", "DISEASE", 119, 126], ["SARS 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["2", "GENE_OR_GENE_PRODUCT", 11, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["mouse", "ORGANISM", 30, 35], ["rat", "ORGANISM", 40, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["mice", "ORGANISM", 92, 96], ["ACE2", "PROTEIN", 21, 25], ["mouse and rat ACE2", "PROTEIN", 30, 48], ["spike protein", "PROTEIN", 74, 87], ["mouse", "SPECIES", 30, 35], ["rat", "SPECIES", 40, 43], ["mice", "SPECIES", 92, 96], ["mouse", "SPECIES", 30, 35], ["rat", "SPECIES", 40, 43], ["mice", "SPECIES", 92, 96], ["severe illness", "PROBLEM", 112, 126], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["illness", "OBSERVATION", 119, 126]]], ["A humanized ACE2 transgenic mouse developed after the SARS pandemic is associated with severe Fig. 1 ACE2 is expressed in human brain endothelium.", [["brain endothelium", "ANATOMY", 128, 145], ["SARS pandemic", "DISEASE", 54, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["mouse", "ORGANISM", 28, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["human", "ORGANISM", 122, 127], ["brain endothelium", "TISSUE", 128, 145], ["ACE2", "PROTEIN", 12, 16], ["ACE2", "PROTEIN", 101, 105], ["mouse", "SPECIES", 28, 33], ["human", "SPECIES", 122, 127], ["mouse", "SPECIES", 28, 33], ["human", "SPECIES", 122, 127], ["A humanized ACE2 transgenic mouse", "TREATMENT", 0, 33], ["the SARS pandemic", "PROBLEM", 50, 67], ["severe Fig.", "PROBLEM", 87, 98], ["human", "ANATOMY_MODIFIER", 122, 127], ["brain endothelium", "ANATOMY", 128, 145]]], ["SARS-CoV-2 binds ACE2, depleting ACE2 on the endothelium SARS infection in the lung that models human disease [23] .", [["endothelium", "ANATOMY", 45, 56], ["lung", "ANATOMY", 79, 83], ["SARS", "DISEASE", 0, 4], ["SARS infection", "DISEASE", 57, 71], ["human disease", "DISEASE", 96, 109], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["endothelium", "TISSUE", 45, 56], ["lung", "ORGAN", 79, 83], ["human", "ORGANISM", 96, 101], ["ACE2", "PROTEIN", 17, 21], ["ACE2", "PROTEIN", 33, 37], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["SARS", "TEST", 0, 4], ["depleting ACE2", "TREATMENT", 23, 37], ["the endothelium SARS infection", "PROBLEM", 41, 71], ["human disease", "PROBLEM", 96, 109], ["endothelium", "ANATOMY", 45, 56], ["SARS", "OBSERVATION_MODIFIER", 57, 61], ["infection", "OBSERVATION", 62, 71], ["lung", "ANATOMY", 79, 83]]], ["Working with SARS-CoV-1 and 2 requires a BSL-3 facility.", [["SARS", "DISEASE", 13, 17], ["SARS-CoV-1", "SPECIES", 13, 23]]], ["Stroke models in rodents will need to use humanized ACE2 mice or move to other animals such as ferrets that are commonly used in influenza models of disease.TreatmentsFor patients with COVID-19 and stroke, it seems reasonable to treat with tPA.", [["Stroke", "DISEASE", 0, 6], ["stroke", "DISEASE", 198, 204], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["mice", "ORGANISM", 57, 61], ["ferrets", "ORGANISM", 95, 102], ["patients", "ORGANISM", 171, 179], ["tPA", "GENE_OR_GENE_PRODUCT", 240, 243], ["ACE2", "PROTEIN", 52, 56], ["tPA", "PROTEIN", 240, 243], ["mice", "SPECIES", 57, 61], ["ferrets", "SPECIES", 95, 102], ["patients", "SPECIES", 171, 179], ["mice", "SPECIES", 57, 61], ["ferrets", "SPECIES", 95, 102], ["Stroke models", "PROBLEM", 0, 13], ["humanized ACE2 mice", "TREATMENT", 42, 61], ["disease", "PROBLEM", 149, 156], ["Treatments", "TREATMENT", 157, 167], ["COVID", "TEST", 185, 190], ["stroke", "PROBLEM", 198, 204], ["tPA", "TREATMENT", 240, 243]]], ["It is not clear if other anticoagulants such as low molecular weight heparin (LMWH) or full dose heparin should be used.", [["heparin", "CHEMICAL", 69, 76], ["LMWH", "CHEMICAL", 78, 82], ["heparin", "CHEMICAL", 97, 104], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 48, 76], ["LMWH", "SIMPLE_CHEMICAL", 78, 82], ["heparin", "SIMPLE_CHEMICAL", 97, 104], ["anticoagulants", "TREATMENT", 25, 39], ["low molecular weight heparin (LMWH", "TREATMENT", 48, 82], ["full dose heparin", "TREATMENT", 87, 104]]], ["There is some evidence that LMWH may be useful in SIC.", [["LMWH", "CHEMICAL", 28, 32], ["SIC", "DISEASE", 50, 53], ["LMWH", "SIMPLE_CHEMICAL", 28, 32], ["LMWH", "TREATMENT", 28, 32], ["LMWH", "OBSERVATION", 28, 32]]], ["For a more \"targeted\" COVID-19 therapy, one promising treatment is to supply exogenous ACE2 by administering human recombinant soluble ACE2 (hrsACE2) which inhibited SARS-CoV-2 infections in engineered human blood vessel organoids [24] .", [["blood vessel organoids", "ANATOMY", 208, 230], ["infections", "DISEASE", 177, 187], ["COVID-19", "CHEMICAL", 22, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["human", "ORGANISM", 109, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["hrsACE2", "GENE_OR_GENE_PRODUCT", 141, 148], ["SARS-CoV-2", "ORGANISM", 166, 176], ["human", "ORGANISM", 202, 207], ["blood vessel organoids", "CELL", 208, 230], ["ACE2", "PROTEIN", 87, 91], ["human recombinant soluble ACE2", "PROTEIN", 109, 139], ["hrsACE2", "PROTEIN", 141, 148], ["engineered human blood vessel organoids", "CELL_TYPE", 191, 230], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 202, 207], ["COVID-19 therapy", "TREATMENT", 22, 38], ["exogenous ACE2", "TREATMENT", 77, 91], ["human recombinant soluble ACE2 (hrsACE2", "TREATMENT", 109, 148], ["SARS", "PROBLEM", 166, 170], ["vessel", "ANATOMY", 214, 220]]], ["Recombinant human soluble ACE2 was safe in a pilot clinical trial in ARDS [25] and is entering clinical trial for COVID-19.", [["ARDS", "DISEASE", 69, 73], ["COVID-19", "CHEMICAL", 114, 122], ["human", "ORGANISM", 12, 17], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["Recombinant human soluble ACE2", "PROTEIN", 0, 30], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Recombinant human soluble ACE2", "TREATMENT", 0, 30], ["a pilot clinical trial", "TREATMENT", 43, 65], ["ARDS", "PROBLEM", 69, 73], ["COVID", "TEST", 114, 119]]], ["(ClinicalTrials.gov number NCT04335136).TreatmentsRecombinant ACE2 may work primarily in two ways: (1) competing with the SARS S protein for binding to lung and endothelial endogenous ACE2 thereby acting as a decoy to reduce infection of host cells; (2) preventing the ACE2 depletion by the SARS2 virus.", [["lung", "ANATOMY", 152, 156], ["endothelial", "ANATOMY", 161, 172], ["cells", "ANATOMY", 243, 248], ["infection", "DISEASE", 225, 234], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS S protein", "GENE_OR_GENE_PRODUCT", 122, 136], ["lung", "ORGAN", 152, 156], ["endothelial", "CELL", 161, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["host cells", "CELL", 238, 248], ["ACE2", "GENE_OR_GENE_PRODUCT", 269, 273], ["SARS2 virus", "ORGANISM", 291, 302], ["ACE2", "PROTEIN", 62, 66], ["SARS S protein", "PROTEIN", 122, 136], ["ACE2", "PROTEIN", 184, 188], ["host cells", "CELL_TYPE", 238, 248], ["ACE2", "PROTEIN", 269, 273], ["SARS2 virus", "SPECIES", 291, 302], ["the SARS S protein", "TREATMENT", 118, 136], ["endothelial endogenous ACE2 thereby", "TREATMENT", 161, 196], ["a decoy", "TREATMENT", 207, 214], ["infection of host cells", "PROBLEM", 225, 248], ["the ACE2 depletion", "PROBLEM", 265, 283], ["the SARS2 virus", "PROBLEM", 287, 302], ["lung", "ANATOMY", 152, 156], ["host cells", "OBSERVATION", 238, 248], ["ACE2 depletion", "OBSERVATION", 269, 283]]], ["Since ACE2 is expressed by brain endothelium and neurons, it is likely that viral mediated depletion of ACE2 impairs endothelial function and predisposes to or worsens acute stroke (Fig. 1) .TreatmentsOther treatments that target the RAS system such as angiotensin (1-7) and that have already shown promise in stroke preclinical models may also be promising therapies for COVID-19.", [["brain endothelium", "ANATOMY", 27, 44], ["neurons", "ANATOMY", 49, 56], ["endothelial", "ANATOMY", 117, 128], ["acute stroke", "DISEASE", 168, 180], ["angiotensin (1-7)", "CHEMICAL", 253, 270], ["stroke", "DISEASE", 310, 316], ["COVID-19", "CHEMICAL", 372, 380], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["brain endothelium", "TISSUE", 27, 44], ["neurons", "CELL", 49, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["endothelial", "CELL", 117, 128], ["RAS", "GENE_OR_GENE_PRODUCT", 234, 237], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 253, 269], ["ACE2", "PROTEIN", 6, 10], ["ACE2", "PROTEIN", 104, 108], ["viral mediated depletion", "PROBLEM", 76, 100], ["ACE2 impairs endothelial function", "PROBLEM", 104, 137], ["acute stroke", "PROBLEM", 168, 180], ["TreatmentsOther treatments", "TREATMENT", 191, 217], ["angiotensin", "TEST", 253, 264], ["stroke preclinical models", "PROBLEM", 310, 335], ["COVID", "TEST", 372, 377], ["brain endothelium", "ANATOMY", 27, 44], ["neurons", "ANATOMY", 49, 56], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["stroke", "OBSERVATION", 174, 180]]], ["Angiotensin (1-7) is in clinical trial for COVID-19 (ClinicalTrials.gov NCT04332666).", [["Angiotensin (1-7)", "CHEMICAL", 0, 17], ["Angiotensin", "SIMPLE_CHEMICAL", 0, 11], ["Angiotensin", "TREATMENT", 0, 11], ["COVID", "TEST", 43, 48]]], ["Moreover, blockers of the AT1 receptor (ARBs), such as losartan, may be protective in stroke.", [["losartan", "CHEMICAL", 55, 63], ["stroke", "DISEASE", 86, 92], ["losartan", "CHEMICAL", 55, 63], ["AT1 receptor", "GENE_OR_GENE_PRODUCT", 26, 38], ["losartan", "SIMPLE_CHEMICAL", 55, 63], ["AT1 receptor", "PROTEIN", 26, 38], ["blockers", "TREATMENT", 10, 18], ["the AT1 receptor (ARBs", "TREATMENT", 22, 44], ["losartan", "TREATMENT", 55, 63], ["stroke", "PROBLEM", 86, 92], ["stroke", "OBSERVATION", 86, 92]]], ["While there has been some concern that ARBs and ACE inhibitors may be harmful in COVID-19 patients by increasing expression of ACE2 and SARS-CoV-2 binding, a joint statement from the American Heart Association, American College of Cardiology, and Heart Failure Society of American has recommended ARBs and antagonists of the RAS system be continued in COVID-19 patients as they may be effective. https://www.acc.org/latest-in-cardiology/articles/ 2020/03/17/08/59/hfsa-acc-aha-statement-addressesconcerns-re-using-raas-antagonists-in-covid-19SummaryStrokes are being reported as a complication of COVID-19.", [["ACE inhibitors", "CHEMICAL", 48, 62], ["Heart Failure", "DISEASE", 247, 260], ["COVID-19", "CHEMICAL", 597, 605], ["ARBs", "SIMPLE_CHEMICAL", 39, 43], ["ACE", "GENE_OR_GENE_PRODUCT", 48, 51], ["patients", "ORGANISM", 90, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 127, 131], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["ARBs", "SIMPLE_CHEMICAL", 297, 301], ["RAS", "GENE_OR_GENE_PRODUCT", 325, 328], ["patients", "ORGANISM", 361, 369], ["ACE2", "PROTEIN", 127, 131], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 361, 369], ["ARBs", "TREATMENT", 39, 43], ["ACE inhibitors", "TREATMENT", 48, 62], ["COVID", "TEST", 81, 86], ["ACE2", "PROBLEM", 127, 131], ["SARS", "PROBLEM", 136, 140], ["CoV-2 binding", "PROBLEM", 141, 154], ["ARBs", "TREATMENT", 297, 301], ["antagonists", "TREATMENT", 306, 317], ["the RAS system", "TREATMENT", 321, 335], ["COVID", "TEST", 597, 602], ["joint", "ANATOMY", 158, 163], ["Heart", "ANATOMY", 192, 197], ["Heart", "ANATOMY", 247, 252], ["Failure", "OBSERVATION", 253, 260]]], ["The cause is not clear but SIC is associated with COVID-19 and may contribute to endothelial dysfunction, microthrombosis, and stroke.", [["endothelial", "ANATOMY", 81, 92], ["SIC", "DISEASE", 27, 30], ["endothelial dysfunction", "DISEASE", 81, 104], ["microthrombosis", "DISEASE", 106, 121], ["stroke", "DISEASE", 127, 133], ["COVID-19", "GENE_OR_GENE_PRODUCT", 50, 58], ["endothelial", "TISSUE", 81, 92], ["COVID", "TEST", 50, 55], ["endothelial dysfunction", "PROBLEM", 81, 104], ["microthrombosis", "PROBLEM", 106, 121], ["stroke", "PROBLEM", 127, 133], ["not", "UNCERTAINTY", 13, 16], ["clear", "OBSERVATION", 17, 22], ["may contribute to", "UNCERTAINTY", 63, 80], ["endothelial dysfunction", "OBSERVATION", 81, 104], ["stroke", "OBSERVATION", 127, 133]]], ["The role of aPL, likely triggered by the viral infection, is unclear and may be related to SIC.SummaryBinding to and depletion of ACE2 may tip the RAS balance in favor of the ACE-1-angiotensin II-AT1 axis and contribute to endothelial dysfunction, organ damage, and stroke.", [["endothelial", "ANATOMY", 223, 234], ["organ", "ANATOMY", 248, 253], ["aPL", "DISEASE", 12, 15], ["viral infection", "DISEASE", 41, 56], ["SIC", "DISEASE", 91, 94], ["angiotensin II", "CHEMICAL", 181, 195], ["endothelial dysfunction", "DISEASE", 223, 246], ["organ damage", "DISEASE", 248, 260], ["stroke", "DISEASE", 266, 272], ["aPL", "GENE_OR_GENE_PRODUCT", 12, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 130, 134], ["RAS", "GENE_OR_GENE_PRODUCT", 147, 150], ["ACE-1", "GENE_OR_GENE_PRODUCT", 175, 180], ["angiotensin II-AT1", "GENE_OR_GENE_PRODUCT", 181, 199], ["endothelial", "TISSUE", 223, 234], ["organ", "ORGAN", 248, 253], ["aPL", "PROTEIN", 12, 15], ["ACE2", "PROTEIN", 130, 134], ["the viral infection", "PROBLEM", 37, 56], ["ACE2", "TREATMENT", 130, 134], ["the RAS balance", "TEST", 143, 158], ["the ACE", "TEST", 171, 178], ["angiotensin II-AT1 axis", "PROBLEM", 181, 204], ["endothelial dysfunction", "PROBLEM", 223, 246], ["organ damage", "PROBLEM", 248, 260], ["stroke", "PROBLEM", 266, 272], ["aPL", "OBSERVATION", 12, 15], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56], ["endothelial", "ANATOMY", 223, 234], ["dysfunction", "OBSERVATION", 235, 246], ["organ", "ANATOMY", 248, 253], ["damage", "OBSERVATION", 254, 260], ["stroke", "OBSERVATION", 266, 272]]]], "4b0e46132d732c95227b56078862394fa829ac6d": [["The continuing threat of the virus has prevented travel and forced meetings and conferences to go virtual.", [["the virus", "PROBLEM", 25, 34], ["virus", "OBSERVATION", 29, 34]]]], "33355ba8c22e57e1fff5db90f3f9677101dec05a": [["As is known, during the past month Italy has been struck by the SARS-CoV-2 epidemic, and this, as expected, strongly impacted our health care system, where many hospitals have been turned into \"COVID-19 hospitals.\"", [["SARS", "DISEASE", 64, 68]]]], "969a004955da2d2aca700f5c4303d8d89a039dc5": [["IntroductionDuring the past 15 years a number of new virus infections have emerged or re-emerged.", [["infections", "DISEASE", 59, 69], ["new virus infections", "PROBLEM", 49, 69], ["new", "OBSERVATION_MODIFIER", 49, 52], ["virus", "OBSERVATION_MODIFIER", 53, 58], ["infections", "OBSERVATION", 59, 69]]], ["Most of them, such as Sin Nombre and Andes hantaviruses, SARS coronavirus, avian influenza, Nipah and Hendra viruses, have appeared in subtropical or tropical regions.", [["SARS coronavirus", "DISEASE", 57, 73], ["avian influenza", "DISEASE", 75, 90], ["Nipah and Hendra viruses", "DISEASE", 92, 116], ["Sin Nombre", "ORGANISM", 22, 32], ["Andes hantaviruses", "ORGANISM", 37, 55], ["SARS coronavirus", "ORGANISM", 57, 73], ["avian influenza", "ORGANISM", 75, 90], ["Nipah", "ORGANISM", 92, 97], ["Hendra viruses", "ORGANISM", 102, 116], ["SARS coronavirus", "SPECIES", 57, 73], ["avian influenza", "SPECIES", 75, 90], ["Nipah", "SPECIES", 92, 97], ["SARS coronavirus", "SPECIES", 57, 73], ["Hendra viruses", "SPECIES", 102, 116], ["Andes hantaviruses", "PROBLEM", 37, 55], ["SARS coronavirus", "PROBLEM", 57, 73], ["influenza", "PROBLEM", 81, 90], ["Nipah", "PROBLEM", 92, 97], ["Hendra viruses", "PROBLEM", 102, 116], ["Hendra viruses", "OBSERVATION", 102, 116], ["subtropical", "ANATOMY_MODIFIER", 135, 146], ["tropical", "ANATOMY_MODIFIER", 150, 158], ["regions", "ANATOMY_MODIFIER", 159, 166]]], ["Dengue is spreading to new areas and West Nile virus has reached the New World.", [["Dengue", "DISEASE", 0, 6], ["Dengue", "ORGANISM", 0, 6], ["West Nile virus", "ORGANISM", 37, 52], ["West Nile virus", "SPECIES", 37, 52], ["Dengue", "PROBLEM", 0, 6], ["West Nile virus", "PROBLEM", 37, 52], ["new", "OBSERVATION_MODIFIER", 23, 26], ["New", "OBSERVATION_MODIFIER", 69, 72]]], ["Infections by several of these viruses may lead to high mortality and also attract attention because they are potential bioweapons.", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["these viruses", "PROBLEM", 25, 38], ["high mortality", "PROBLEM", 51, 65], ["viruses", "OBSERVATION", 31, 38]]], ["Some viruses such as tick-borne encephalitis virus are spreading to new areas along with climate and environmental changes.", [["tick-borne encephalitis", "DISEASE", 21, 44], ["tick-borne encephalitis virus", "ORGANISM", 21, 50], ["tick-borne encephalitis virus", "SPECIES", 21, 50], ["tick-borne encephalitis virus", "SPECIES", 21, 50], ["Some viruses", "PROBLEM", 0, 12], ["tick-borne encephalitis virus", "PROBLEM", 21, 50], ["viruses", "OBSERVATION", 5, 12], ["borne", "OBSERVATION_MODIFIER", 26, 31], ["encephalitis", "OBSERVATION", 32, 44], ["new", "OBSERVATION_MODIFIER", 68, 71], ["areas", "OBSERVATION_MODIFIER", 72, 77], ["environmental changes", "OBSERVATION", 101, 122]]], ["Most of these infections are zoonoses and clearly viruses shared by animals and humans are, unlike human-only viruses, much more difficult to eradicate.", [["infections", "DISEASE", 14, 24], ["zoonoses", "DISEASE", 29, 37], ["humans", "ORGANISM", 80, 86], ["human", "ORGANISM", 99, 104], ["humans", "SPECIES", 80, 86], ["human", "SPECIES", 99, 104], ["humans", "SPECIES", 80, 86], ["human", "SPECIES", 99, 104], ["these infections", "PROBLEM", 8, 24], ["zoonoses", "PROBLEM", 29, 37], ["infections", "OBSERVATION", 14, 24]]], ["Here, we review zoonotic virus infections occurring in Europe.", [["zoonotic virus infections", "DISEASE", 16, 41], ["zoonotic virus infections", "PROBLEM", 16, 41], ["zoonotic", "OBSERVATION_MODIFIER", 16, 24]]], ["The infections like Lassa fever and dengue that are imported to Europe but are not indigenous to European nature will not be discussed in detail in the review.", [["infections", "DISEASE", 4, 14], ["Lassa fever", "DISEASE", 20, 31], ["dengue", "DISEASE", 36, 42], ["Lassa", "ORGANISM", 20, 25], ["Lassa fever", "SPECIES", 20, 31], ["The infections", "PROBLEM", 0, 14], ["Lassa fever", "PROBLEM", 20, 31], ["dengue", "PROBLEM", 36, 42], ["infections", "OBSERVATION", 4, 14], ["Lassa", "OBSERVATION_MODIFIER", 20, 25]]], ["We have divided the virus infections into two categories, those that are transmitted to humans directly from vertebrate animals (like rodents, foxes, bats and birds) and those that are primarily transmitted by arthropods (mosquitoes, ticks, sandflies).", [["infections", "DISEASE", 26, 36], ["humans", "ORGANISM", 88, 94], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["the virus infections", "PROBLEM", 16, 36]]], ["The latter class is formed by arboviruses but notably they have vertebrate hosts in nature..", [["arboviruses", "PROBLEM", 30, 41], ["arboviruses", "OBSERVATION", 30, 41], ["vertebrate", "OBSERVATION_MODIFIER", 64, 74], ["hosts", "OBSERVATION", 75, 80]]], ["VirologyHantaviruses are enveloped viruses with a tri-segmented negative-stranded genome and belong to the family Bunyaviridae [1, 2] .", [["Bunyaviridae", "DISEASE", 114, 126], ["tri-segmented negative-stranded genome", "DNA", 50, 88], ["VirologyHantaviruses", "PROBLEM", 0, 20], ["stranded genome", "OBSERVATION_MODIFIER", 73, 88]]], ["The 6.4 kb L (large) segment RNA encodes the 250 kDa RNA polymerase, the 3.6 kb M (medium) segment the two glycoproteins 68-76 kDa Gn and 52-58 kDa Gc, -formerly known as G1 and G2; and the 1.7 kb S (small) segment the 50-54 kDa nucleocapsid protein (N) ( Table 1 , Fig. 1 ).", [["Gn", "GENE_OR_GENE_PRODUCT", 131, 133], ["Gc", "GENE_OR_GENE_PRODUCT", 148, 150], ["6.4 kb L (large) segment RNA", "RNA", 4, 32], ["250 kDa RNA polymerase", "PROTEIN", 45, 67], ["glycoproteins 68-76 kDa Gn", "PROTEIN", 107, 133], ["52", "PROTEIN", 138, 140], ["Gc", "PROTEIN", 148, 150], ["G1", "PROTEIN", 171, 173], ["G2", "PROTEIN", 178, 180], ["50-54 kDa nucleocapsid protein", "PROTEIN", 219, 249], ["N", "PROTEIN", 251, 252], ["The 6.4 kb L (large) segment RNA", "PROBLEM", 0, 32], ["RNA polymerase", "TEST", 53, 67], ["segment the two glycoproteins", "TEST", 91, 120], ["kDa", "TEST", 127, 130], ["Gn", "TEST", 131, 133], ["kDa Gc", "TEST", 144, 150], ["G2", "TEST", 178, 180], ["kb S", "TEST", 194, 198], ["segment", "TEST", 207, 214], ["kDa nucleocapsid protein", "TEST", 225, 249], ["6.4 kb", "OBSERVATION_MODIFIER", 4, 10], ["large", "OBSERVATION_MODIFIER", 14, 19], ["segment RNA", "ANATOMY_MODIFIER", 21, 32], ["250 kDa", "OBSERVATION_MODIFIER", 45, 52]]], ["In addition, the S segment of some hantaviruses has another open reading frame named Ns but its product or function remains to be discovered.", [["hantaviruses", "DISEASE", 35, 47], ["S segment", "DNA", 17, 26], ["open reading frame", "DNA", 60, 78], ["Ns", "DNA", 85, 87], ["some hantaviruses", "PROBLEM", 30, 47], ["Ns", "TREATMENT", 85, 87], ["some", "OBSERVATION_MODIFIER", 30, 34], ["hantaviruses", "OBSERVATION", 35, 47]]], ["Viral messenger RNAs of the members of the Bunyaviridae are not polyadenylated and are truncated relative to the genome RNAs at the 3 0 termini.", [["Bunyaviridae", "ORGANISM", 43, 55], ["Viral messenger RNAs", "RNA", 0, 20], ["genome RNAs", "RNA", 113, 124], ["3 0 termini", "DNA", 132, 143], ["the Bunyaviridae", "PROBLEM", 39, 55], ["messenger RNAs", "OBSERVATION", 6, 20], ["not", "UNCERTAINTY", 60, 63], ["polyadenylated", "OBSERVATION", 64, 78], ["genome RNAs", "OBSERVATION", 113, 124]]], ["Messenger RNAs have 5 0 -methylated caps and 10-18 nontemplated nucleotides which are derived from host cell mRNAs.", [["cell", "ANATOMY", 104, 108], ["nucleotides", "CHEMICAL", 64, 75], ["host cell", "CELL", 99, 108], ["Messenger RNAs", "RNA", 0, 14], ["host cell mRNAs", "RNA", 99, 114], ["Messenger RNAs", "TEST", 0, 14], ["methylated caps", "TEST", 25, 40], ["nontemplated nucleotides", "TREATMENT", 51, 75], ["host cell mRNAs", "OBSERVATION", 99, 114]]], ["The termini of all three segments are conserved and complementary to each other, a feature that has assisted in cloning and discovery of new hantaviruses.", [["hantaviruses", "DISEASE", 141, 153], ["new hantaviruses", "PROBLEM", 137, 153], ["termini", "ANATOMY_MODIFIER", 4, 11], ["three segments", "ANATOMY_MODIFIER", 19, 33], ["new", "OBSERVATION_MODIFIER", 137, 140], ["hantaviruses", "OBSERVATION", 141, 153]]], ["Unlike most other Bunyaviridae, hantaviruses are not arthropod-borne (arboviruses), but are ROdent-BOrne, roboviruses.", [["Bunyaviridae", "DISEASE", 18, 30], ["hantaviruses", "DISEASE", 32, 44], ["arboviruses", "DISEASE", 70, 81], ["hantaviruses", "ORGANISM", 32, 44], ["hantaviruses", "PROBLEM", 32, 44], ["hantaviruses", "OBSERVATION", 32, 44]]], ["Each hantavirus is primarily carried by a distinct rodent/insectivore species although a few host switches seem to have occurred during the tens of millions of years of their co-evolution with their carrier animals [3] .", [["hantavirus", "DISEASE", 5, 15], ["hantavirus", "ORGANISM", 5, 15], ["rodent", "SPECIES", 51, 57], ["Each hantavirus", "PROBLEM", 0, 15], ["a distinct rodent/insectivore species", "PROBLEM", 40, 77], ["hantavirus", "OBSERVATION", 5, 15]]], ["We now know that the genetic diversity of hantaviruses is generated partly by (i) genetic drift (accumulation of point mutations and insertions/deletions) leading to quasispecies [4, 5] , (ii) genetic shifts (reassortments of genome fragments within the same virus genotype/species), and (iii) according to recent findings [6, 7] , by homologous recombination, a mechanism not previously observed for negative-strand RNA viruses.Ecology and epidemiologyHantaviruses, which cause hemorrhagic fevers with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome (HCPS) in the Americas, are prime examples of emerging and re-emerging infectious agents.", [["renal", "ANATOMY", 503, 508], ["hantaviruses", "DISEASE", 42, 54], ["Hantaviruses", "DISEASE", 453, 465], ["hemorrhagic fevers", "DISEASE", 479, 497], ["renal syndrome", "DISEASE", 503, 517], ["HFRS", "DISEASE", 519, 523], ["hantavirus cardiopulmonary syndrome", "DISEASE", 540, 575], ["HCPS", "DISEASE", 577, 581], ["renal", "ORGAN", 503, 508], ["genome fragments", "DNA", 226, 242], ["hantaviruses", "PROBLEM", 42, 54], ["genetic drift (accumulation of point mutations", "PROBLEM", 82, 128], ["insertions/deletions", "TREATMENT", 133, 153], ["quasispecies", "PROBLEM", 166, 178], ["genetic shifts (reassortments of genome fragments", "PROBLEM", 193, 242], ["strand RNA viruses", "PROBLEM", 410, 428], ["hemorrhagic fevers", "PROBLEM", 479, 497], ["renal syndrome", "PROBLEM", 503, 517], ["HFRS", "PROBLEM", 519, 523], ["hantavirus cardiopulmonary syndrome", "PROBLEM", 540, 575], ["hantaviruses", "OBSERVATION", 42, 54], ["RNA viruses", "OBSERVATION", 417, 428], ["hemorrhagic", "OBSERVATION_MODIFIER", 479, 490], ["fevers", "OBSERVATION", 491, 497], ["renal", "ANATOMY", 503, 508], ["syndrome", "OBSERVATION", 509, 517], ["hantavirus", "OBSERVATION_MODIFIER", 540, 550], ["cardiopulmonary syndrome", "OBSERVATION", 551, 575]]], ["Like most of these infections hantaviral diseases are zoonoses.", [["infections", "DISEASE", 19, 29], ["hantaviral diseases", "DISEASE", 30, 49], ["zoonoses", "DISEASE", 54, 62], ["these infections hantaviral diseases", "PROBLEM", 13, 49], ["infections", "OBSERVATION", 19, 29]]], ["With the exception of the South-American Andes virus, which can be transmitted directly from human to human, hantavirus infections are thought to be transmitted to humans primarily from aerosols of rodent excreta.", [["hantavirus infections", "DISEASE", 109, 130], ["South-American Andes virus", "ORGANISM", 26, 52], ["human", "ORGANISM", 93, 98], ["human", "ORGANISM", 102, 107], ["hantavirus infections", "ORGANISM", 109, 130], ["humans", "ORGANISM", 164, 170], ["rodent", "ORGANISM", 198, 204], ["excreta", "ORGANISM_SUBDIVISION", 205, 212], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 102, 107], ["humans", "SPECIES", 164, 170], ["rodent", "SPECIES", 198, 204], ["American Andes virus", "SPECIES", 32, 52], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 102, 107], ["humans", "SPECIES", 164, 170], ["hantavirus infections", "PROBLEM", 109, 130], ["hantavirus", "OBSERVATION", 109, 119]]], ["Topografov hantavirus isolated from Siberian lemmings (Lemmus sibiricus) has not been detected in North European lemmings (Lemmus lemmus) although it can grow in them [11] .", [["hantavirus", "DISEASE", 11, 21], ["Topografov hantavirus", "ORGANISM", 0, 21], ["Siberian lemmings", "ORGANISM", 36, 53], ["Lemmus sibiricus", "ORGANISM", 55, 71], ["Lemmus lemmus", "ORGANISM", 123, 136], ["Lemmus sibiricus", "SPECIES", 55, 71], ["Lemmus lemmus", "SPECIES", 123, 136], ["Topografov hantavirus", "SPECIES", 0, 21], ["Siberian lemmings", "SPECIES", 36, 53], ["Lemmus sibiricus", "SPECIES", 55, 71], ["Lemmus lemmus", "SPECIES", 123, 136], ["Topografov hantavirus", "TREATMENT", 0, 21]]], ["Infections in rodents are mainly asymptomatic and persistent.", [["Infections", "DISEASE", 0, 10], ["Infections in rodents", "PROBLEM", 0, 21], ["asymptomatic", "PROBLEM", 33, 45], ["mainly", "OBSERVATION_MODIFIER", 26, 32], ["asymptomatic", "OBSERVATION_MODIFIER", 33, 45], ["persistent", "OBSERVATION_MODIFIER", 50, 60]]], ["Hantavirus infections are quite common in Europe [8] (Table 3) , Puumala virus is common in Northern Europe, European Russia and parts of Central-Western Europe (Fig. 2) .", [["Hantavirus infections", "DISEASE", 0, 21], ["Puumala virus", "DISEASE", 65, 78], ["Hantavirus", "ORGANISM", 0, 10], ["Puumala virus", "ORGANISM", 65, 78], ["Puumala virus", "SPECIES", 65, 78], ["Hantavirus infections", "PROBLEM", 0, 21], ["Puumala virus", "PROBLEM", 65, 78], ["infections", "OBSERVATION", 11, 21], ["Puumala virus", "OBSERVATION", 65, 78], ["Central", "ANATOMY_MODIFIER", 138, 145]]], ["Dobrava virus is found mainly in the Balkans (Fig. 2) .", [["Dobrava virus", "ORGANISM", 0, 13], ["Dobrava virus", "SPECIES", 0, 13], ["Dobrava virus", "PROBLEM", 0, 13], ["virus", "OBSERVATION", 8, 13], ["mainly", "OBSERVATION_MODIFIER", 23, 29], ["Balkans", "ANATOMY_MODIFIER", 37, 44]]], ["Saaremaa virus has been detected in Eastern and Central Europe but its epidemiology is not well defined (Fig. 2) .", [["Saaremaa", "CHEMICAL", 0, 8], ["Saaremaa virus", "ORGANISM", 0, 14], ["Saaremaa virus", "SPECIES", 0, 14], ["Saaremaa virus", "SPECIES", 0, 14], ["Saaremaa virus", "PROBLEM", 0, 14], ["virus", "OBSERVATION", 9, 14], ["Central", "ANATOMY_MODIFIER", 48, 55]]], ["Apart from laboratory infections [12, 13] Seoul virus has been detected in wild rats, only in France [14] .", [["infections", "DISEASE", 22, 32], ["Seoul virus", "ORGANISM", 42, 53], ["rats", "ORGANISM", 80, 84], ["rats", "SPECIES", 80, 84], ["Seoul virus", "SPECIES", 42, 53], ["laboratory infections", "PROBLEM", 11, 32], ["Seoul virus", "PROBLEM", 42, 53], ["infections", "OBSERVATION", 22, 32]]], ["It is also apparent that many parts of Europe, such as Britain, Poland and Byelorussia, remain ''white'' on the European hantavirus map [8] .", [["hantavirus", "DISEASE", 121, 131]]], ["This means either that HFRS is rare or nonexistent in these regions or is not widely recognized and diagnosed by the biomedical community.Ecology and epidemiologyIn Northern Europe HFRS as well as the carrier rodents exhibit peaks in 3-4 year cycles [15] while in Central Europe the HFRS incidence follows the fluctuations of ''mast years'', i.e. the availability of beech and oak seeds for the hantavirus-carrying rodents.", [["HFRS", "DISEASE", 23, 27], ["HFRS", "DISEASE", 181, 185], ["HFRS", "DISEASE", 283, 287], ["hantavirus", "DISEASE", 395, 405], ["beech", "ORGANISM_SUBDIVISION", 367, 372], ["oak", "ORGANISM_SUBDIVISION", 377, 380], ["seeds", "ORGANISM_SUBDIVISION", 381, 386], ["HFRS", "PROBLEM", 23, 27], ["the hantavirus", "PROBLEM", 391, 405], ["HFRS", "OBSERVATION", 23, 27], ["HFRS", "OBSERVATION", 283, 287]]], ["In Central Europe HFRS peaks in the summer while in Northern Europe most cases occur in late autumn and early winter, from November to January.", [["HFRS", "DISEASE", 18, 22], ["Central", "OBSERVATION_MODIFIER", 3, 10], ["Europe", "OBSERVATION_MODIFIER", 11, 17], ["HFRS", "OBSERVATION", 18, 22], ["peaks", "OBSERVATION_MODIFIER", 23, 28]]], ["Risk factors to catch hantavirus infections and HFRS include professions such as forestry, farming, and military, or activities such as camping, and the use of summer cottages.", [["hantavirus infections", "DISEASE", 22, 43], ["HFRS", "DISEASE", 48, 52], ["Risk factors", "PROBLEM", 0, 12], ["catch hantavirus infections", "PROBLEM", 16, 43], ["HFRS", "PROBLEM", 48, 52]]], ["Males are more likely to be exposed than females [15, 16] .Clinical picture and pathogenesisPuumala and Dobrava viruses both cause HFRS but the infections differ considerably in severity [17] : both are characterized by acute-onset fever, headache, abdominal pains, backache, temporary renal insufficiency -first oliguria, proteinuria and increase in serum creatinine and then polyuria -and thrombocytopenia but the extent of hemorrhages (hematuria, petecchiae, internal hemorrhages), requirement for dialysis treatment, hypotension and mortality are much higher in [19] .", [["abdominal", "ANATOMY", 249, 258], ["renal", "ANATOMY", 286, 291], ["serum", "ANATOMY", 351, 356], ["HFRS", "DISEASE", 131, 135], ["infections", "DISEASE", 144, 154], ["fever", "DISEASE", 232, 237], ["headache", "DISEASE", 239, 247], ["abdominal pains", "DISEASE", 249, 264], ["backache", "DISEASE", 266, 274], ["renal insufficiency", "DISEASE", 286, 305], ["oliguria", "DISEASE", 313, 321], ["proteinuria", "DISEASE", 323, 334], ["creatinine", "CHEMICAL", 357, 367], ["polyuria", "DISEASE", 377, 385], ["thrombocytopenia", "DISEASE", 391, 407], ["hemorrhages", "DISEASE", 426, 437], ["hematuria", "DISEASE", 439, 448], ["internal hemorrhages", "DISEASE", 462, 482], ["hypotension", "DISEASE", 521, 532], ["creatinine", "CHEMICAL", 357, 367], ["Dobrava viruses", "ORGANISM", 104, 119], ["abdominal", "ORGANISM_SUBDIVISION", 249, 258], ["renal", "ORGAN", 286, 291], ["serum", "ORGANISM_SUBSTANCE", 351, 356], ["creatinine", "SIMPLE_CHEMICAL", 357, 367], ["Dobrava viruses", "SPECIES", 104, 119], ["Clinical picture", "TEST", 59, 75], ["pathogenesisPuumala", "PROBLEM", 80, 99], ["Dobrava viruses", "PROBLEM", 104, 119], ["HFRS", "PROBLEM", 131, 135], ["the infections", "PROBLEM", 140, 154], ["acute-onset fever", "PROBLEM", 220, 237], ["headache", "PROBLEM", 239, 247], ["abdominal pains", "PROBLEM", 249, 264], ["backache", "PROBLEM", 266, 274], ["temporary renal insufficiency", "PROBLEM", 276, 305], ["first oliguria", "PROBLEM", 307, 321], ["proteinuria", "PROBLEM", 323, 334], ["increase in serum creatinine", "PROBLEM", 339, 367], ["polyuria", "PROBLEM", 377, 385], ["thrombocytopenia", "PROBLEM", 391, 407], ["hemorrhages", "PROBLEM", 426, 437], ["hematuria", "PROBLEM", 439, 448], ["petecchiae", "PROBLEM", 450, 460], ["internal hemorrhages", "PROBLEM", 462, 482], ["dialysis treatment", "TREATMENT", 501, 519], ["hypotension", "PROBLEM", 521, 532], ["mortality", "PROBLEM", 537, 546], ["more likely to be", "UNCERTAINTY", 10, 27], ["infections", "OBSERVATION", 144, 154], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["onset", "OBSERVATION_MODIFIER", 226, 231], ["fever", "OBSERVATION", 232, 237], ["abdominal", "ANATOMY", 249, 258], ["pains", "OBSERVATION", 259, 264], ["backache", "OBSERVATION", 266, 274], ["renal", "ANATOMY", 286, 291], ["insufficiency", "OBSERVATION", 292, 305], ["oliguria", "OBSERVATION", 313, 321], ["proteinuria", "OBSERVATION", 323, 334], ["increase", "OBSERVATION_MODIFIER", 339, 347], ["polyuria", "OBSERVATION", 377, 385], ["thrombocytopenia", "OBSERVATION", 391, 407], ["extent", "OBSERVATION_MODIFIER", 416, 422], ["hemorrhages", "OBSERVATION", 426, 437], ["hematuria", "OBSERVATION", 439, 448], ["internal", "OBSERVATION_MODIFIER", 462, 470], ["hemorrhages", "OBSERVATION", 471, 482]]], ["This is important since the infection is so common in many areas of Europe [8] (Table 3 , Fig. 2 ).", [["infection", "DISEASE", 28, 37], ["the infection", "PROBLEM", 24, 37], ["infection", "OBSERVATION", 28, 37]]], ["In addition, in some patients Puumala virus infection may invade the pituitary gland and lead to mortality or at least hypophyseal insufficiency requiring hormone-replacement therapy [20] .", [["pituitary gland", "ANATOMY", 69, 84], ["hypophyseal", "ANATOMY", 119, 130], ["Puumala virus infection", "DISEASE", 30, 53], ["hypophyseal insufficiency", "DISEASE", 119, 144], ["patients", "ORGANISM", 21, 29], ["Puumala virus", "ORGANISM", 30, 43], ["pituitary gland", "ORGAN", 69, 84], ["hypophyseal", "ORGAN", 119, 130], ["patients", "SPECIES", 21, 29], ["Puumala virus", "SPECIES", 30, 43], ["Puumala virus", "SPECIES", 30, 43], ["some patients Puumala virus infection", "PROBLEM", 16, 53], ["the pituitary gland", "PROBLEM", 65, 84], ["hypophyseal insufficiency", "PROBLEM", 119, 144], ["hormone-replacement therapy", "TREATMENT", 155, 182], ["Puumala virus", "OBSERVATION", 30, 43], ["pituitary gland", "ANATOMY", 69, 84], ["hypophyseal insufficiency", "OBSERVATION", 119, 144]]], ["The pathogenesis of HFRS is poorly understood [17, 21] .", [["HFRS", "DISEASE", 20, 24], ["HFRS", "PROBLEM", 20, 24]]], ["However, it is known that b3 integrins can mediate the entry of pathogenic hantaviruses [22] and that hantaviruses can regulate apoptosis [23] [24] [25] [26] 28] .", [["b3 integrins", "GENE_OR_GENE_PRODUCT", 26, 38], ["hantaviruses", "ORGANISM", 102, 114], ["24] [25] [26] 28", "SIMPLE_CHEMICAL", 144, 160], ["b3 integrins", "PROTEIN", 26, 38], ["pathogenic hantaviruses", "PROBLEM", 64, 87]]], ["Also there is evidence [17, 21] that increased capillary permeability is an essential component in the pathogenesis of both HFRS and HCPS, although different target tissues, kidneys and lungs are affected in the two diseases.", [["capillary", "ANATOMY", 47, 56], ["tissues", "ANATOMY", 165, 172], ["kidneys", "ANATOMY", 174, 181], ["lungs", "ANATOMY", 186, 191], ["HFRS", "DISEASE", 124, 128], ["HCPS", "DISEASE", 133, 137], ["capillary", "TISSUE", 47, 56], ["tissues", "TISSUE", 165, 172], ["kidneys", "ORGAN", 174, 181], ["lungs", "ORGAN", 186, 191], ["increased capillary permeability", "PROBLEM", 37, 69], ["the two diseases", "PROBLEM", 208, 224], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["capillary permeability", "OBSERVATION", 47, 69], ["essential", "OBSERVATION_MODIFIER", 76, 85], ["component", "OBSERVATION_MODIFIER", 86, 95], ["both", "OBSERVATION_MODIFIER", 119, 123], ["HFRS", "OBSERVATION", 124, 128], ["different", "OBSERVATION_MODIFIER", 148, 157], ["target tissues", "OBSERVATION", 158, 172], ["kidneys", "ANATOMY", 174, 181], ["lungs", "ANATOMY", 186, 191], ["affected", "OBSERVATION_MODIFIER", 196, 204], ["two", "OBSERVATION_MODIFIER", 212, 215], ["diseases", "OBSERVATION", 216, 224]]], ["HFRS patients show locally increased levels of TNF-a in the plasma and kidneys [27, 28] and high levels of urinary secretion of the proinflammatory cytokine IL-6 [29] .", [["plasma", "ANATOMY", 60, 66], ["kidneys", "ANATOMY", 71, 78], ["urinary", "ANATOMY", 107, 114], ["HFRS", "DISEASE", 0, 4], ["patients", "ORGANISM", 5, 13], ["TNF-a", "GENE_OR_GENE_PRODUCT", 47, 52], ["plasma", "ORGANISM_SUBSTANCE", 60, 66], ["kidneys", "ORGAN", 71, 78], ["urinary", "ORGANISM_SUBSTANCE", 107, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["TNF", "PROTEIN", 47, 50], ["proinflammatory cytokine", "PROTEIN", 132, 156], ["IL", "PROTEIN", 157, 159], ["patients", "SPECIES", 5, 13], ["locally increased levels of TNF", "PROBLEM", 19, 50], ["high levels of urinary secretion", "PROBLEM", 92, 124], ["the proinflammatory cytokine IL", "TEST", 128, 159], ["locally", "OBSERVATION_MODIFIER", 19, 26], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["kidneys", "ANATOMY", 71, 78], ["urinary secretion", "ANATOMY", 107, 124]]], ["Studies with a monkey model mimicking human Puumala virus infection [30] may assist in elucidating the mechanism of pathogenesis.", [["Puumala virus infection", "DISEASE", 44, 67], ["monkey", "ORGANISM", 15, 21], ["human", "ORGANISM", 38, 43], ["Puumala virus", "ORGANISM", 44, 57], ["human", "SPECIES", 38, 43], ["Puumala virus", "SPECIES", 44, 57], ["human Puumala virus", "SPECIES", 38, 57], ["Studies", "TEST", 0, 7], ["a monkey model mimicking human Puumala virus infection", "PROBLEM", 13, 67], ["pathogenesis", "PROBLEM", 116, 128], ["Puumala virus", "OBSERVATION", 44, 57], ["pathogenesis", "OBSERVATION", 116, 128]]], ["Of the four structural proteins, both in humoral and cellular immunity, the N protein appears to be the principal immunogen [31] .", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["structural proteins", "PROTEIN", 12, 31], ["N protein", "PROTEIN", 76, 85], ["the N protein", "TREATMENT", 72, 85], ["four structural", "OBSERVATION_MODIFIER", 7, 22], ["proteins", "OBSERVATION", 23, 31], ["cellular immunity", "OBSERVATION", 53, 70]]], ["Cytotoxic T-lymphocyte (CTL) responses are seen [32] and may be important both for protective immunity and pathogenesis of hantavirus infections [21] .Diagnostics and preventionThe diagnosis of acute HFRS is primarily based on serology, since viral RNA cannot be regularly detected in the blood or urine of patients [33, 34] .", [["Cytotoxic T-lymphocyte", "ANATOMY", 0, 22], ["blood", "ANATOMY", 289, 294], ["urine", "ANATOMY", 298, 303], ["hantavirus infections", "DISEASE", 123, 144], ["HFRS", "DISEASE", 200, 204], ["Cytotoxic T-lymphocyte", "CELL", 0, 22], ["CTL", "CELL", 24, 27], ["hantavirus", "ORGANISM", 123, 133], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["urine", "ORGANISM_SUBSTANCE", 298, 303], ["patients", "ORGANISM", 307, 315], ["viral RNA", "RNA", 243, 252], ["patients", "SPECIES", 307, 315], ["Cytotoxic T", "TEST", 0, 11], ["hantavirus infections", "PROBLEM", 123, 144], ["Diagnostics", "TEST", 151, 162], ["acute HFRS", "PROBLEM", 194, 204], ["serology", "TEST", 227, 235], ["viral RNA", "PROBLEM", 243, 252], ["hantavirus", "OBSERVATION", 123, 133], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["HFRS", "OBSERVATION", 200, 204]]], ["Both immunofluorescence tests and enzyme immunoassays are widely used for detection of specific IgM or low-avidity IgG antibodies, characteristic of acute infection [35] [36] [37] .", [["acute infection", "DISEASE", 149, 164], ["IgM", "GENE_OR_GENE_PRODUCT", 96, 99], ["IgM", "PROTEIN", 96, 99], ["IgG antibodies", "PROTEIN", 115, 129], ["Both immunofluorescence tests", "TEST", 0, 29], ["enzyme immunoassays", "TEST", 34, 53], ["specific IgM", "TEST", 87, 99], ["low-avidity IgG antibodies", "PROBLEM", 103, 129], ["acute infection", "PROBLEM", 149, 164], ["acute", "OBSERVATION_MODIFIER", 149, 154], ["infection", "OBSERVATION", 155, 164]]], ["In addition, immunochromatographic 5-min IgM-antibody tests [38, 39] have been developed.", [["IgM", "PROTEIN", 41, 44], ["immunochromatographic", "TEST", 13, 34], ["IgM-antibody tests", "TEST", 41, 59]]], ["Vaccines against hantavirus infections have been used for years in China and Korea, but not in Europe or the Americas [40] .", [["hantavirus infections", "DISEASE", 17, 38], ["hantavirus", "ORGANISM", 17, 27], ["Vaccines", "TREATMENT", 0, 8], ["hantavirus infections", "PROBLEM", 17, 38]]], ["No specific therapy is used in Europe, although both ribavirin and interferon-a have been successfully used in trials in China [41, 42] .", [["ribavirin", "CHEMICAL", 53, 62], ["interferon", "CHEMICAL", 67, 77], ["ribavirin", "CHEMICAL", 53, 62], ["ribavirin", "SIMPLE_CHEMICAL", 53, 62], ["interferon-a", "SIMPLE_CHEMICAL", 67, 79], ["interferon", "PROTEIN", 67, 77], ["specific therapy", "TREATMENT", 3, 19], ["ribavirin", "TREATMENT", 53, 62], ["interferon", "TREATMENT", 67, 77], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["therapy", "OBSERVATION", 12, 19]]], ["A major problem is that at the time HFRS patients are hospitalized, virus replication is already disappearing.VirologyMembers of the genus Lyssavirus within the family Rhabdoviridae are bullet-shaped, enveloped viruses approximately 60 nm in diameter and 200 nm in length.", [["HFRS", "DISEASE", 36, 40], ["patients", "ORGANISM", 41, 49], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 168, 181], ["patients", "SPECIES", 41, 49], ["A major problem", "PROBLEM", 0, 15], ["virus replication", "TREATMENT", 68, 85], ["the genus Lyssavirus", "PROBLEM", 129, 149], ["major", "OBSERVATION_MODIFIER", 2, 7], ["problem", "OBSERVATION", 8, 15], ["genus Lyssavirus", "OBSERVATION", 133, 149], ["bullet", "OBSERVATION", 186, 192], ["shaped", "OBSERVATION_MODIFIER", 193, 199], ["enveloped", "OBSERVATION_MODIFIER", 201, 210], ["viruses", "OBSERVATION_MODIFIER", 211, 218], ["approximately", "OBSERVATION_MODIFIER", 219, 232], ["60 nm", "OBSERVATION_MODIFIER", 233, 238], ["200 nm", "OBSERVATION_MODIFIER", 255, 261]]], ["The 12 kb non-segmented negative-strand genome encodes five proteins (starting from the 3 0 end): the 58-62 kDa nucleoprotein (N), the 35-40 kDa phosphoprotein (P), the 22-25 kDa matrix protein (M), the trimeric 65-80 kDa glycoprotein (G) and the 190 kDa polymerase protein (L) ( Table 1 , Fig. 1 ).", [["matrix protein", "GENE_OR_GENE_PRODUCT", 179, 193], ["G", "GENE_OR_GENE_PRODUCT", 236, 237], ["12 kb non-segmented negative-strand genome", "DNA", 4, 46], ["58-62 kDa nucleoprotein", "PROTEIN", 102, 125], ["N", "PROTEIN", 127, 128], ["35-40 kDa phosphoprotein", "PROTEIN", 135, 159], ["P", "PROTEIN", 161, 162], ["22-25 kDa matrix protein", "PROTEIN", 169, 193], ["M", "PROTEIN", 195, 196], ["trimeric 65-80 kDa glycoprotein", "PROTEIN", 203, 234], ["G", "PROTEIN", 236, 237], ["190 kDa polymerase protein", "PROTEIN", 247, 273], ["L", "PROTEIN", 275, 276], ["The 12 kb non-segmented", "TEST", 0, 23], ["strand genome encodes five proteins", "PROBLEM", 33, 68], ["kDa phosphoprotein", "TEST", 141, 159], ["kDa matrix protein", "TEST", 175, 193], ["the trimeric", "TEST", 199, 211], ["the 190 kDa polymerase protein", "TEST", 243, 273]]], ["Proteins are separately transcribed in cascade by a special mechanism from a single 3 0 -end promoter which results in a decreasing transcription and expression gradient for proteins encoded from the 3 0 to 5 0 end.VirologyThe major antigen with neutralizing epitopes and pathogenetic determinants is the glycoprotein, which is responsible for receptor recognition and membrane fusion.", [["membrane", "ANATOMY", 369, 377], ["membrane", "CELLULAR_COMPONENT", 369, 377], ["3 0 -end promoter", "DNA", 84, 101], ["3 0 to 5 0 end", "DNA", 200, 214], ["neutralizing epitopes", "PROTEIN", 246, 267], ["pathogenetic determinants", "PROTEIN", 272, 297], ["glycoprotein", "PROTEIN", 305, 317], ["a single 3 0 -end promoter", "TREATMENT", 75, 101], ["a decreasing transcription", "PROBLEM", 119, 145], ["expression gradient for proteins", "PROBLEM", 150, 182], ["neutralizing epitopes", "PROBLEM", 246, 267], ["receptor recognition", "PROBLEM", 344, 364], ["membrane fusion", "TREATMENT", 369, 384], ["neutralizing epitopes", "OBSERVATION", 246, 267], ["responsible for", "UNCERTAINTY", 328, 343], ["membrane fusion", "OBSERVATION", 369, 384]]], ["After endocytosis the viral envelope fuses with endosomal membranes provoking the release of the internal viral nucleocapsid in the cytoplasm where transcription and replication takes place.", [["endosomal membranes", "ANATOMY", 48, 67], ["cytoplasm", "ANATOMY", 132, 141], ["endosomal membranes", "CELLULAR_COMPONENT", 48, 67], ["cytoplasm", "ORGANISM_SUBSTANCE", 132, 141], ["internal viral nucleocapsid", "PROTEIN", 97, 124], ["endocytosis", "PROBLEM", 6, 17], ["endosomal membranes", "TREATMENT", 48, 67], ["the internal viral nucleocapsid", "PROBLEM", 93, 124], ["viral envelope", "OBSERVATION", 22, 36], ["endosomal membranes", "OBSERVATION", 48, 67], ["internal", "ANATOMY", 97, 105], ["viral nucleocapsid", "OBSERVATION", 106, 124]]], ["The helically wound nucleocapsid results from the intimate association of the nucleocapsid protein and the RNA genome.", [["wound", "ANATOMY", 14, 19], ["wound", "PATHOLOGICAL_FORMATION", 14, 19], ["nucleocapsid protein", "PROTEIN", 78, 98], ["RNA genome", "DNA", 107, 117], ["The helically wound nucleocapsid", "PROBLEM", 0, 32], ["the nucleocapsid protein", "PROBLEM", 74, 98], ["nucleocapsid protein", "OBSERVATION", 78, 98], ["RNA genome", "OBSERVATION", 107, 117]]], ["It serves as template for the polymerase (L protein and P cofactor) for transcription and replication.", [["L protein", "GENE_OR_GENE_PRODUCT", 42, 51], ["polymerase", "PROTEIN", 30, 40], ["L protein", "PROTEIN", 42, 51], ["P cofactor", "PROTEIN", 56, 66], ["the polymerase (L protein and P cofactor)", "TREATMENT", 26, 67], ["transcription and replication", "TREATMENT", 72, 101]]], ["It buds to intracytoplamic membranes in infected neurons, but on plasma membranes in salivary gland epithelial cells.VirologyThe lyssaviruses currently consist of 7 established genotypes, or lineages, of rabies(-like) viruses [56] of which the classical rabies virus, found throughout the world and associated with terrestrial mammalian hosts and American bats, forms genotype 1 ( Table 2 , Fig. 3 ).", [["buds", "ANATOMY", 3, 7], ["intracytoplamic membranes", "ANATOMY", 11, 36], ["neurons", "ANATOMY", 49, 56], ["plasma membranes", "ANATOMY", 65, 81], ["salivary gland epithelial cells", "ANATOMY", 85, 116], ["rabies", "DISEASE", 204, 210], ["rabies virus", "DISEASE", 254, 266], ["intracytoplamic membranes", "CELLULAR_COMPONENT", 11, 36], ["neurons", "CELL", 49, 56], ["plasma membranes", "CELLULAR_COMPONENT", 65, 81], ["salivary gland epithelial cells", "CELL", 85, 116], ["rabies(-like) viruses", "ORGANISM", 204, 225], ["rabies virus", "ORGANISM", 254, 266], ["infected neurons", "CELL_TYPE", 40, 56], ["salivary gland epithelial cells", "CELL_TYPE", 85, 116], ["rabies virus", "SPECIES", 254, 266], ["rabies virus", "SPECIES", 254, 266], ["American bats", "SPECIES", 347, 360], ["intracytoplamic membranes in infected neurons", "PROBLEM", 11, 56], ["plasma membranes", "TEST", 65, 81], ["rabies(-like) viruses", "PROBLEM", 204, 225], ["the classical rabies virus", "PROBLEM", 240, 266], ["terrestrial mammalian hosts", "TREATMENT", 315, 342], ["intracytoplamic membranes", "OBSERVATION", 11, 36], ["infected neurons", "OBSERVATION", 40, 56], ["salivary gland", "ANATOMY", 85, 99], ["epithelial cells", "OBSERVATION", 100, 116], ["rabies virus", "OBSERVATION", 254, 266]]], ["Other lineages, or genotypes, are found in bats, of which Mokola and Lagos bat viruses seem to be less pathogenic, and towards which the vaccines based on the classical genotype 1 rabies virus are not protective [43a,43b] .", [["Lagos bat viruses", "ORGANISM", 69, 86], ["genotype 1 rabies virus", "ORGANISM", 169, 192], ["1 rabies virus", "SPECIES", 178, 192], ["Lagos bat viruses", "SPECIES", 69, 86], ["rabies virus", "SPECIES", 180, 192], ["Lagos bat viruses", "PROBLEM", 69, 86], ["the vaccines", "TREATMENT", 133, 145], ["the classical genotype 1 rabies virus", "PROBLEM", 155, 192]]], ["In addition to the 7 genotypes, new bat lyssa- virus genotypes have been recently found, e.g. from Russia [43c].Epidemiology and ecologyDuring the past 100 years or more in Europe, classical rabies virus has made two major host shifts, firstly from the dog to red foxes, and then to racoon dogs brought from East Asia to be raised for fur; this species then became widely established in the wild (Fig. 3) .", [["rabies virus", "DISEASE", 191, 203], ["bat lyssa- virus", "ORGANISM", 36, 52], ["rabies virus", "ORGANISM", 191, 203], ["dog", "ORGANISM", 253, 256], ["fur", "GENE_OR_GENE_PRODUCT", 335, 338], ["bat lyssa- virus", "SPECIES", 36, 52], ["rabies virus", "SPECIES", 191, 203], ["dog", "SPECIES", 253, 256], ["dogs", "SPECIES", 290, 294], ["bat lyssa- virus", "SPECIES", 36, 52], ["rabies virus", "SPECIES", 191, 203], ["red foxes", "SPECIES", 260, 269], ["the 7 genotypes", "PROBLEM", 15, 30], ["new bat lyssa- virus genotypes", "PROBLEM", 32, 62], ["classical rabies virus", "PROBLEM", 181, 203], ["host shifts", "OBSERVATION_MODIFIER", 223, 234]]], ["Phylogenetic data also suggest that westand southward spread of rabies virus occurred during the last century [44a] .", [["rabies virus", "DISEASE", 64, 76], ["rabies virus", "ORGANISM", 64, 76], ["rabies virus", "SPECIES", 64, 76], ["Phylogenetic data", "TEST", 0, 17], ["rabies virus", "PROBLEM", 64, 76], ["southward", "OBSERVATION_MODIFIER", 44, 53], ["rabies virus", "OBSERVATION", 64, 76]]], ["Although in Europe the most important carriers of classical rabies virus are foxes and racoon dogs, the virus can be transmitted to secondary hosts such as domestic animals (dog, cat, cattle, horse, sheep) or e.g. deer -practically any mammal species could be a potential carrier.", [["rabies virus", "DISEASE", 60, 72], ["rabies virus", "ORGANISM", 60, 72], ["foxes", "ORGANISM", 77, 82], ["racoon dogs", "ORGANISM", 87, 98], ["dog", "ORGANISM_SUBDIVISION", 174, 177], ["cat", "ORGANISM", 179, 182], ["cattle", "ORGANISM", 184, 190], ["horse", "ORGANISM_SUBDIVISION", 192, 197], ["sheep", "ORGANISM", 199, 204], ["rabies virus", "SPECIES", 60, 72], ["dogs", "SPECIES", 94, 98], ["dog", "SPECIES", 174, 177], ["cat", "SPECIES", 179, 182], ["cattle", "SPECIES", 184, 190], ["horse", "SPECIES", 192, 197], ["sheep", "SPECIES", 199, 204], ["rabies virus", "SPECIES", 60, 72], ["dog", "SPECIES", 174, 177], ["cattle", "SPECIES", 184, 190], ["horse", "SPECIES", 192, 197], ["sheep", "SPECIES", 199, 204], ["deer", "SPECIES", 214, 218], ["classical rabies virus", "PROBLEM", 50, 72], ["racoon dogs", "TREATMENT", 87, 98], ["the virus", "PROBLEM", 100, 109], ["any mammal species", "PROBLEM", 232, 250]]], ["Bats are a special case; lyssaviruses are maintained in bats, even in the absence of classical rabies in carnivores; thus in countries where classical rabies has been eliminated, bat rabies has become the dominating or only source of rabies virus and retains the potential for host-switching into the carnivore reservoir which constitutes a more direct threat for public health [44b].Epidemiology and ecologyAs many bats are protected species, the detection or ''absence'' of bat rabies is dependent also on the intensity of screening efforts [45, 46] .", [["rabies", "DISEASE", 95, 101], ["rabies", "DISEASE", 151, 157], ["rabies", "DISEASE", 183, 189], ["rabies", "DISEASE", 480, 486], ["Bats", "CELL", 0, 4], ["lyssaviruses", "CANCER", 25, 37], ["rabies", "ORGANISM", 151, 157], ["bat rabies", "ORGANISM", 179, 189], ["rabies virus", "ORGANISM", 234, 246], ["bats", "ORGANISM", 416, 420], ["bat rabies", "ORGANISM", 476, 486], ["rabies", "SPECIES", 95, 101], ["rabies", "SPECIES", 151, 157], ["rabies", "SPECIES", 183, 189], ["rabies virus", "SPECIES", 234, 246], ["rabies virus", "PROBLEM", 234, 246], ["host-switching into the carnivore reservoir", "TREATMENT", 277, 320]]], ["As of the beginning of 2004, the following countries in Europe were declared ''rabies-free'' by WHO (meaning no indigenous cases occurred during the last two years): Belgium, Cyprus, Finland, Greece, Iceland, Ireland, Italy, Luxembourg, Norway, Portugal and Sweden (Fig. 3) .", [["rabies", "DISEASE", 79, 85], ["Cyprus", "OBSERVATION", 175, 181]]], ["In 2003, rabies virus was detected in Europe in 7095 wild animals (excluding bats), 3951 domestic animals; 33 bat and 6 human rabies cases were diagnosed (see Table 4 ).", [["rabies virus", "DISEASE", 9, 21], ["rabies", "DISEASE", 126, 132], ["rabies virus", "ORGANISM", 9, 21], ["human", "ORGANISM", 120, 125], ["rabies", "ORGANISM", 126, 132], ["human", "SPECIES", 120, 125], ["rabies virus", "SPECIES", 9, 21], ["human", "SPECIES", 120, 125], ["rabies virus", "PROBLEM", 9, 21]]], ["The countries where rabies was circulating include (in diminishing order of cases) Russia, Ukraine, Lithuania, Belarus, Latvia, Estonia, Croatia, Poland, Slovakia, Serbia-Montenegro and Turkey with hundred(s) to thousands of (animal) cases, Romania, Bosnia-Herzegovina, Germany, Moldova and Bulgaria with dozens of cases, and individual cases were registered (some imported and not affecting the rabies-free status) in Slovenia, the Netherlands, Denmark, France, Albania, Finland, Austria and Switzerland (Clinical picture in man and pathogenesisMembers of 6 out of the 7 lyssavirus genotypes (except Lagos bat virus, i.e. genotype 2) have caused rabies disease in man.", [["rabies", "DISEASE", 20, 26], ["rabies disease", "DISEASE", 647, 661], ["rabies", "ORGANISM", 20, 26], ["man", "ORGANISM", 526, 529], ["Lagos bat virus", "ORGANISM", 601, 616], ["rabies", "ORGANISM", 647, 653], ["man", "ORGANISM", 665, 668], ["man", "SPECIES", 526, 529], ["bat virus", "SPECIES", 607, 616], ["man", "SPECIES", 665, 668], ["rabies", "SPECIES", 20, 26], ["Lagos bat virus", "SPECIES", 601, 616], ["pathogenesisMembers", "TEST", 534, 553], ["the 7 lyssavirus genotypes", "TREATMENT", 566, 592], ["Lagos bat virus", "TREATMENT", 601, 616], ["rabies disease", "PROBLEM", 647, 661], ["rabies disease", "OBSERVATION", 647, 661]]], ["The infection is inevitably fatal in humans or other mammals unless immune intervention (vaccination and administration of antibodies) is used.", [["infection", "DISEASE", 4, 13], ["humans", "ORGANISM", 37, 43], ["antibodies", "PROTEIN", 123, 133], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["The infection", "PROBLEM", 0, 13], ["immune intervention", "TREATMENT", 68, 87], ["vaccination and administration of antibodies)", "TREATMENT", 89, 134], ["infection", "OBSERVATION", 4, 13]]], ["Transmission may occur though the bite of an animal delivering the virus deep in to striated muscle or connective tissue, but infection may also occur after abrasion of the skin or licking of mucous membranes.", [["striated muscle", "ANATOMY", 84, 99], ["connective tissue", "ANATOMY", 103, 120], ["skin", "ANATOMY", 173, 177], ["mucous membranes", "ANATOMY", 192, 208], ["infection", "DISEASE", 126, 135], ["striated muscle", "TISSUE", 84, 99], ["connective tissue", "TISSUE", 103, 120], ["skin", "ORGAN", 173, 177], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 192, 208], ["the virus", "PROBLEM", 63, 72], ["connective tissue", "PROBLEM", 103, 120], ["infection", "PROBLEM", 126, 135], ["abrasion of the skin", "PROBLEM", 157, 177], ["licking of mucous membranes", "PROBLEM", 181, 208], ["virus", "OBSERVATION", 67, 72], ["striated muscle", "ANATOMY", 84, 99], ["connective tissue", "ANATOMY", 103, 120], ["infection", "OBSERVATION", 126, 135], ["abrasion", "OBSERVATION", 157, 165], ["skin", "ANATOMY", 173, 177], ["licking", "OBSERVATION_MODIFIER", 181, 188], ["mucous membranes", "ANATOMY", 192, 208]]], ["The bite of a bat with small teeth may go unnoticed; on the other hand the bat lyssaviruses may infect human skin more easily than has been recognised.", [["teeth", "ANATOMY", 29, 34], ["skin", "ANATOMY", 109, 113], ["bat", "ORGANISM", 14, 17], ["teeth", "ORGAN", 29, 34], ["bat", "ORGANISM", 75, 78], ["lyssaviruses", "GENE_OR_GENE_PRODUCT", 79, 91], ["human", "ORGANISM", 103, 108], ["skin", "ORGAN", 109, 113], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["small teeth", "PROBLEM", 23, 34]]], ["The classical picture of rabies includes prodromal illness with fever and non-specific symptoms, as well as itching and local paresthesia.", [["rabies", "DISEASE", 25, 31], ["prodromal illness", "DISEASE", 41, 58], ["fever", "DISEASE", 64, 69], ["itching", "DISEASE", 108, 115], ["paresthesia", "DISEASE", 126, 137], ["rabies", "ORGANISM", 25, 31], ["prodromal illness", "PROBLEM", 41, 58], ["fever", "PROBLEM", 64, 69], ["non-specific symptoms", "PROBLEM", 74, 95], ["itching", "PROBLEM", 108, 115], ["local paresthesia", "PROBLEM", 120, 137], ["paresthesia", "OBSERVATION", 126, 137]]], ["This is followed by neurological signs, consisting of either encephalitic ''furious rabies'' or paralytic ''dumb rabies''.", [["neurological", "ANATOMY", 20, 32], ["rabies", "DISEASE", 84, 90], ["paralytic ''dumb rabies", "DISEASE", 96, 119], ["neurological signs", "TEST", 20, 38]]], ["In the former, episodic hyperactivity and excitation of the CNS manifest as, e.g. hydrophobia, hypersalivation and convulsions.", [["CNS", "ANATOMY", 60, 63], ["hyperactivity", "DISEASE", 24, 37], ["hydrophobia", "DISEASE", 82, 93], ["hypersalivation", "DISEASE", 95, 110], ["convulsions", "DISEASE", 115, 126], ["CNS", "ANATOMICAL_SYSTEM", 60, 63], ["episodic hyperactivity", "PROBLEM", 15, 37], ["hydrophobia", "PROBLEM", 82, 93], ["hypersalivation", "PROBLEM", 95, 110], ["convulsions", "PROBLEM", 115, 126], ["episodic", "OBSERVATION_MODIFIER", 15, 23], ["hyperactivity", "OBSERVATION", 24, 37]]], ["The patient finally develops paralysis, coma and cardiorespiratory failure.", [["paralysis", "DISEASE", 29, 38], ["coma", "DISEASE", 40, 44], ["cardiorespiratory failure", "DISEASE", 49, 74], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["paralysis", "PROBLEM", 29, 38], ["coma", "PROBLEM", 40, 44], ["cardiorespiratory failure", "PROBLEM", 49, 74], ["paralysis", "OBSERVATION", 29, 38], ["cardiorespiratory failure", "OBSERVATION", 49, 74]]], ["In the paralytic form, no excitation is seen, but paralytic disease develops to coma and death [45,52a,52b] .Clinical picture in man and pathogenesisAfter entry of the virus to the body, the virus must gain access to peripheral nerves and to be transported towards the CNS.", [["body", "ANATOMY", 181, 185], ["peripheral nerves", "ANATOMY", 217, 234], ["CNS", "ANATOMY", 269, 272], ["paralytic disease", "DISEASE", 50, 67], ["coma", "DISEASE", 80, 84], ["death", "DISEASE", 89, 94], ["man", "ORGANISM", 129, 132], ["body", "ORGANISM_SUBDIVISION", 181, 185], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 217, 234], ["CNS", "ANATOMICAL_SYSTEM", 269, 272], ["man", "SPECIES", 129, 132], ["excitation", "PROBLEM", 26, 36], ["paralytic disease", "PROBLEM", 50, 67], ["coma", "PROBLEM", 80, 84], ["death", "PROBLEM", 89, 94], ["pathogenesis", "PROBLEM", 137, 149], ["the virus", "PROBLEM", 187, 196], ["no", "UNCERTAINTY", 23, 25], ["excitation", "OBSERVATION", 26, 36], ["virus", "OBSERVATION", 168, 173], ["body", "ANATOMY", 181, 185], ["virus", "OBSERVATION", 191, 196], ["peripheral", "ANATOMY_MODIFIER", 217, 227], ["nerves", "ANATOMY", 228, 234]]], ["Rabies virus components are attached either directly or by encapsulated vesicles to the dynein motor carrying the ''cargo'' along the axonal microtubular system towards the cell stroma, approximately at a speed of 25 mm/day [45, 53, 54] .", [["vesicles", "ANATOMY", 72, 80], ["dynein", "ANATOMY", 88, 94], ["axonal microtubular system", "ANATOMY", 134, 160], ["cell stroma", "ANATOMY", 173, 184], ["Rabies virus", "ORGANISM", 0, 12], ["vesicles", "CELLULAR_COMPONENT", 72, 80], ["dynein", "GENE_OR_GENE_PRODUCT", 88, 94], ["'cargo''", "CELLULAR_COMPONENT", 115, 123], ["axonal microtubular system", "CELLULAR_COMPONENT", 134, 160], ["cell stroma", "TISSUE", 173, 184], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus components", "PROBLEM", 0, 23], ["virus", "OBSERVATION", 7, 12], ["axonal", "ANATOMY_MODIFIER", 134, 140], ["microtubular", "ANATOMY_MODIFIER", 141, 153], ["cell stroma", "OBSERVATION", 173, 184]]], ["It is transmitted after replication on neuronal membranes transsynaptically to adjacent neurons and finally invades the CNS where it first disturbs the limbic system associated with the excitation, and later neocortex, with little histopathological changes in neurons.", [["neuronal membranes", "ANATOMY", 39, 57], ["neurons", "ANATOMY", 88, 95], ["CNS", "ANATOMY", 120, 123], ["limbic system", "ANATOMY", 152, 165], ["neocortex", "ANATOMY", 208, 217], ["neurons", "ANATOMY", 260, 267], ["neuronal membranes", "CELLULAR_COMPONENT", 39, 57], ["neurons", "CELL", 88, 95], ["CNS", "ANATOMICAL_SYSTEM", 120, 123], ["limbic system", "ANATOMICAL_SYSTEM", 152, 165], ["neocortex", "MULTI-TISSUE_STRUCTURE", 208, 217], ["neurons", "CELL", 260, 267], ["adjacent neurons", "CELL_TYPE", 79, 95], ["neuronal membranes", "TREATMENT", 39, 57], ["little histopathological changes in neurons", "PROBLEM", 224, 267], ["neurons", "ANATOMY", 88, 95], ["CNS", "ANATOMY", 120, 123], ["limbic system", "ANATOMY", 152, 165], ["neurons", "ANATOMY", 260, 267]]], ["Centrifugal spread of the virus from the CNS to many tissues through somatic and autonomic nerves also occurs, where the salivary glands are especially important for the spread of the virus to the next victim.", [["CNS", "ANATOMY", 41, 44], ["tissues", "ANATOMY", 53, 60], ["somatic", "ANATOMY", 69, 76], ["autonomic nerves", "ANATOMY", 81, 97], ["salivary glands", "ANATOMY", 121, 136], ["CNS", "ANATOMICAL_SYSTEM", 41, 44], ["tissues", "TISSUE", 53, 60], ["autonomic nerves", "MULTI-TISSUE_STRUCTURE", 81, 97], ["salivary glands", "ORGAN", 121, 136], ["the virus", "PROBLEM", 22, 31], ["somatic and autonomic nerves", "PROBLEM", 69, 97], ["the virus", "PROBLEM", 180, 189], ["spread", "OBSERVATION_MODIFIER", 12, 18], ["virus", "OBSERVATION", 26, 31], ["CNS", "ANATOMY", 41, 44], ["autonomic nerves", "ANATOMY", 81, 97], ["salivary glands", "ANATOMY", 121, 136]]], ["Immunological responses do not occur before CNS involvement.Clinical picture in man and pathogenesisAll the viruses in phylogroup I are also pathogenic to mice by i.m. injection, and can cross-neutralize each other.", [["CNS", "ANATOMY", 44, 47], ["CNS", "ANATOMICAL_SYSTEM", 44, 47], ["man", "ORGANISM", 80, 83], ["phylogroup I", "ORGANISM", 119, 131], ["mice", "ORGANISM", 155, 159], ["man", "SPECIES", 80, 83], ["mice", "SPECIES", 155, 159], ["phylogroup I", "SPECIES", 119, 131], ["mice", "SPECIES", 155, 159], ["pathogenesis", "PROBLEM", 88, 100], ["viruses", "OBSERVATION", 108, 115]]], ["This has practical implications, as fortunately the vaccine strains (of genotype 1) also appear to protect against the EBVL viruses [55] .", [["EBVL viruses", "ORGANISM", 119, 131], ["the vaccine strains", "TREATMENT", 48, 67], ["the EBVL viruses", "PROBLEM", 115, 131]]], ["A pathogenic determinant common to phylogroup I viruses seems to be amino acid R333 in the glycoprotein [56] ; substitution of this amino acid also abolishes the retrograde transport [57] .Clinical picture in man and pathogenesisWhen symptoms develop, no cure is available.", [["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 132, 142], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 132, 142], ["phylogroup I viruses", "ORGANISM", 35, 55], ["amino acid", "AMINO_ACID", 68, 78], ["R333", "AMINO_ACID", 79, 83], ["amino acid", "AMINO_ACID", 132, 142], ["man", "ORGANISM", 209, 212], ["man", "SPECIES", 209, 212], ["phylogroup I viruses", "SPECIES", 35, 55], ["A pathogenic determinant common to phylogroup I viruses", "PROBLEM", 0, 55], ["amino acid", "TEST", 68, 78], ["this amino acid", "TREATMENT", 127, 142], ["pathogenesis", "PROBLEM", 217, 229], ["symptoms", "PROBLEM", 234, 242]]], ["However, after exposure to a bite or scratch of a potentially rabid animal, rabies must and can effectively be prevented by post-exposure prophylaxis, originally developed by Louis Pasteur.", [["rabies", "DISEASE", 76, 82], ["rabies", "ORGANISM", 76, 82], ["Louis Pasteur", "ORGANISM", 175, 188], ["rabies", "SPECIES", 76, 82], ["a bite or scratch", "PROBLEM", 27, 44], ["post-exposure prophylaxis", "TREATMENT", 124, 149]]], ["The treatment includes in a non-vaccinated person (a) washing (with water and detergent) and disinfecting the wound to minimize the amount of cell-free virus (this alone can increase survival 50%), (b) starting a post-exposure vaccine regimen which includes (in Europe) five doses of cell-culture derived vaccine intramuscularly into the deltoid muscle on days 0, 3, 7, 14, 28 and (c) in case of severe or deep injury additional passive anti-rabies immunoglobulin, which should be administered principally to the wound area.", [["wound", "ANATOMY", 110, 115], ["cell", "ANATOMY", 142, 146], ["cell", "ANATOMY", 284, 288], ["intramuscularly", "ANATOMY", 313, 328], ["deltoid muscle", "ANATOMY", 338, 352], ["wound area", "ANATOMY", 513, 523], ["wound", "PATHOLOGICAL_FORMATION", 110, 115], ["cell", "CELL", 142, 146], ["cell", "CELL", 284, 288], ["deltoid muscle", "TISSUE", 338, 352], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 449, 463], ["wound area", "PATHOLOGICAL_FORMATION", 513, 523], ["anti-rabies immunoglobulin", "PROTEIN", 437, 463], ["person", "SPECIES", 43, 49], ["The treatment", "TREATMENT", 0, 13], ["a) washing (with water and detergent", "TREATMENT", 51, 87], ["the wound", "PROBLEM", 106, 115], ["cell-free virus", "PROBLEM", 142, 157], ["a post-exposure vaccine regimen", "TREATMENT", 211, 242], ["cell-culture derived vaccine", "TREATMENT", 284, 312], ["severe or deep injury", "PROBLEM", 396, 417], ["passive anti-rabies immunoglobulin", "TREATMENT", 429, 463], ["wound", "ANATOMY", 110, 115], ["free virus", "OBSERVATION", 147, 157], ["deltoid muscle", "ANATOMY", 338, 352], ["severe", "OBSERVATION_MODIFIER", 396, 402], ["deep", "ANATOMY_MODIFIER", 406, 410], ["injury", "OBSERVATION", 411, 417], ["wound", "ANATOMY", 513, 518]]], ["If the person was pre-vaccinated or the animal can be caught and studied for the presence of rabies, the protocol can be adjusted accordingly [45,52a] .Diagnosis and preventionClinical suspicion of rabies in a case of encephalitis of unknown origin is the starting point.", [["rabies", "DISEASE", 93, 99], ["rabies", "DISEASE", 198, 204], ["encephalitis", "DISEASE", 218, 230], ["person", "ORGANISM", 7, 13], ["rabies", "ORGANISM", 93, 99], ["rabies", "ORGANISM", 198, 204], ["person", "SPECIES", 7, 13], ["rabies", "SPECIES", 93, 99], ["the protocol", "TREATMENT", 101, 113], ["rabies", "PROBLEM", 198, 204], ["encephalitis", "PROBLEM", 218, 230], ["encephalitis", "OBSERVATION", 218, 230]]], ["Ante mortem diagnostics can be achieved most easily with RT-PCR from saliva.", [["saliva", "ORGANISM_SUBSTANCE", 69, 75], ["Ante mortem diagnostics", "TEST", 0, 23], ["RT-PCR", "TEST", 57, 63]]], ["In addition, rabies antigen can be detected in brain or nuchal skin biopsies, and in some cases antibodies in serum or CSF may be found.", [["brain", "ANATOMY", 47, 52], ["nuchal skin biopsies", "ANATOMY", 56, 76], ["serum", "ANATOMY", 110, 115], ["rabies", "ORGANISM", 13, 19], ["antigen", "GENE_OR_GENE_PRODUCT", 20, 27], ["brain", "ORGAN", 47, 52], ["nuchal skin biopsies", "TISSUE", 56, 76], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["CSF", "GENE_OR_GENE_PRODUCT", 119, 122], ["rabies antigen", "PROTEIN", 13, 27], ["antibodies", "PROTEIN", 96, 106], ["CSF", "PROTEIN", 119, 122], ["rabies", "SPECIES", 13, 19], ["rabies antigen", "TEST", 13, 27], ["nuchal skin biopsies", "TEST", 56, 76], ["some cases antibodies in serum or CSF", "TEST", 85, 122], ["brain", "ANATOMY", 47, 52], ["nuchal skin", "ANATOMY", 56, 67]]], ["Post-mortem diagnostics is most rapid with antigen detection or RT-PCR from the brain, virus isolation is also possible.Diagnosis and preventionIn addition to post-exposure prophylaxis, vaccines in humans can be used for pre-exposure prophylaxis (3 doses) in risk groups (veterinarians, wildlife workers, travellers to endemic areas; especially small children who may be unable to explain a potential exposure to a rabid animal) [45,52a,58] .Diagnosis and preventionThe primary method for control of rabies is vaccination of dogs (and cats).", [["brain", "ANATOMY", 80, 85], ["rabies", "DISEASE", 500, 506], ["brain", "ORGAN", 80, 85], ["humans", "ORGANISM", 198, 204], ["children", "ORGANISM", 351, 359], ["rabies", "ORGANISM", 500, 506], ["dogs", "ORGANISM", 525, 529], ["cats", "ORGANISM", 535, 539], ["humans", "SPECIES", 198, 204], ["children", "SPECIES", 351, 359], ["dogs", "SPECIES", 525, 529], ["cats", "SPECIES", 535, 539], ["humans", "SPECIES", 198, 204], ["rabies", "SPECIES", 500, 506], ["Post-mortem diagnostics", "TEST", 0, 23], ["antigen detection", "TEST", 43, 60], ["RT-PCR", "TEST", 64, 70], ["virus isolation", "TREATMENT", 87, 102], ["preventionIn", "TREATMENT", 134, 146], ["post-exposure prophylaxis", "TREATMENT", 159, 184], ["vaccines", "TREATMENT", 186, 194], ["pre-exposure prophylaxis", "TREATMENT", 221, 245], ["The primary method", "TREATMENT", 466, 484], ["vaccination of dogs", "TREATMENT", 510, 529], ["brain", "ANATOMY", 80, 85], ["virus isolation", "OBSERVATION", 87, 102]]], ["This practice was established at the beginning of the last century in most of Europe, but has not yet been achieved in many developing countries, where annually 60 000 people still die of rabies.", [["rabies", "DISEASE", 188, 194], ["people", "ORGANISM", 168, 174], ["rabies", "ORGANISM", 188, 194], ["people", "SPECIES", 168, 174], ["rabies", "SPECIES", 188, 194]]], ["In most of Europe (excluding Eastern Europe) rabies has been eradicated from terrestrial wildlife species (carnivores) by aerial distribution of vaccine baits across the countryside.", [["rabies", "DISEASE", 45, 51], ["rabies", "ORGANISM", 45, 51], ["carnivores", "ORGANISM_SUBDIVISION", 107, 117], ["aerial", "ORGANISM_SUBDIVISION", 122, 128], ["vaccine baits", "TREATMENT", 145, 158]]], ["The vaccines used to protect wildlife species include attenuated vaccines as well as a recombinant vaccinia virus carrying the rabies virus glycoprotein (the latter has in one case caused a skin infection in man).", [["skin", "ANATOMY", 190, 194], ["skin infection", "DISEASE", 190, 204], ["vaccinia virus", "ORGANISM", 99, 113], ["rabies virus glycoprotein", "ORGANISM", 127, 152], ["skin", "ORGAN", 190, 194], ["man", "ORGANISM", 208, 211], ["rabies virus glycoprotein", "PROTEIN", 127, 152], ["rabies virus", "SPECIES", 127, 139], ["man", "SPECIES", 208, 211], ["vaccinia virus", "SPECIES", 99, 113], ["rabies virus", "SPECIES", 127, 139], ["The vaccines", "TREATMENT", 0, 12], ["wildlife species", "TREATMENT", 29, 45], ["attenuated vaccines", "TREATMENT", 54, 73], ["a recombinant vaccinia virus", "TREATMENT", 85, 113], ["the rabies virus glycoprotein", "TREATMENT", 123, 152], ["a skin infection", "PROBLEM", 188, 204], ["skin", "ANATOMY", 190, 194], ["infection", "OBSERVATION", 195, 204]]], ["Although rabies in terrestrial animals can be controlled efficiently, eradication from the bat reservoir is not currently feasible.VirologyArenaviruses are the only members of the RNA virus family Arenaviridae.", [["rabies", "DISEASE", 9, 15], ["rabies", "ORGANISM", 9, 15], ["bat", "ORGANISM", 91, 94], ["Arenaviruses", "GENE_OR_GENE_PRODUCT", 139, 151], ["rabies", "SPECIES", 9, 15], ["eradication", "TREATMENT", 70, 81], ["the bat reservoir", "TREATMENT", 87, 104], ["Arenaviridae", "TREATMENT", 197, 209], ["terrestrial animals", "OBSERVATION", 19, 38]]], ["These viruses are enveloped, lipid solvent-sensitive, pleomorphic particles with a mean diameter of 120 nm (ranging between 50 and 300 nm).", [["pleomorphic particles", "ANATOMY", 54, 75], ["These viruses", "PROBLEM", 0, 13], ["lipid solvent", "TEST", 29, 42], ["a mean diameter", "TEST", 81, 96], ["viruses", "OBSERVATION", 6, 13], ["mean diameter", "OBSERVATION_MODIFIER", 83, 96], ["120 nm", "OBSERVATION_MODIFIER", 100, 106]]], ["Host cell-derived ribosomes are present in the virions, and give the virus particles a ''sandy'' appearance under the electron microscope, hence the name arenavirus (arena: sand in Latin).", [["cell", "ANATOMY", 5, 9], ["ribosomes", "ANATOMY", 18, 27], ["virions", "ANATOMY", 47, 54], ["Host cell", "CELL", 0, 9], ["ribosomes", "CELLULAR_COMPONENT", 18, 27], ["arenavirus", "ORGANISM", 154, 164], ["the virus particles", "PROBLEM", 65, 84], ["the electron microscope", "TEST", 114, 137], ["virions", "ANATOMY", 47, 54]]], ["The virion structure of arenaviruses is quite simple, virus particles contain two RNA segments (S and L) linked to nucleocapsid proteins and viral polymerase molecules, and these nucleocapsidpolymerase complexes are surrounded by a lipid envelope into which two glycoproteins (G1 and G2) are linked protruding on the outside of the virion.", [["virion", "ANATOMY", 332, 338], ["arenaviruses", "ORGANISM", 24, 36], ["nucleocapsid proteins", "GENE_OR_GENE_PRODUCT", 115, 136], ["nucleocapsidpolymerase", "GENE_OR_GENE_PRODUCT", 179, 201], ["virion", "CELLULAR_COMPONENT", 332, 338], ["RNA segments", "PROTEIN", 82, 94], ["nucleocapsid proteins", "PROTEIN", 115, 136], ["viral polymerase molecules", "PROTEIN", 141, 167], ["nucleocapsidpolymerase complexes", "PROTEIN", 179, 211], ["glycoproteins", "PROTEIN", 262, 275], ["G1", "PROTEIN", 277, 279], ["G2", "PROTEIN", 284, 286], ["The virion structure of arenaviruses", "PROBLEM", 0, 36], ["virus particles", "PROBLEM", 54, 69], ["nucleocapsid proteins", "TEST", 115, 136], ["viral polymerase molecules", "PROBLEM", 141, 167], ["these nucleocapsidpolymerase complexes", "PROBLEM", 173, 211], ["a lipid envelope", "TREATMENT", 230, 246], ["virion structure", "OBSERVATION", 4, 20], ["arenaviruses", "OBSERVATION", 24, 36], ["simple", "OBSERVATION_MODIFIER", 46, 52], ["two", "OBSERVATION_MODIFIER", 78, 81], ["RNA", "OBSERVATION_MODIFIER", 82, 85], ["segments", "OBSERVATION_MODIFIER", 86, 94], ["nucleocapsid proteins", "OBSERVATION", 115, 136], ["viral polymerase molecules", "OBSERVATION", 141, 167], ["lipid envelope", "OBSERVATION", 232, 246], ["protruding", "OBSERVATION_MODIFIER", 299, 309], ["virion", "ANATOMY", 332, 338]]], ["Arenaviral RNA segments have an ambisense coding arrangement, the S segment (3.5 kb) encoding a 63-kDa nucleocapsid protein (N) in the viral complementary sequence, and in the viral-sense 5 0 -end sequence a 75-kDa glycoprotein precursor (GPC) which is posttranslationally cleaved to two glycosylated proteins 34-44 kDa G1 and G2; and the L segment (7.2 kb) encoding a 180-kDa viral polymerase (L) in the viral complementary sequence, and in the viral-sense 5 0 -end of the sequence a 10-14 kDa RING finger Z protein, which has been shown to have a role in arenavirus budding [59a] (Table 1 , Fig. 1 ).", [["Da viral polymerase (L)", "GENE_OR_GENE_PRODUCT", 374, 397], ["RING finger Z", "GENE_OR_GENE_PRODUCT", 495, 508], ["arenavirus", "ORGANISM", 557, 567], ["Arenaviral RNA segments", "RNA", 0, 23], ["S segment", "DNA", 66, 75], ["63-kDa nucleocapsid protein", "PROTEIN", 96, 123], ["N", "PROTEIN", 125, 126], ["viral complementary sequence", "DNA", 135, 163], ["viral-sense 5 0 -end sequence", "DNA", 176, 205], ["75-kDa glycoprotein precursor", "PROTEIN", 208, 237], ["GPC", "PROTEIN", 239, 242], ["glycosylated proteins 34-44 kDa G1", "PROTEIN", 288, 322], ["G2", "PROTEIN", 327, 329], ["L segment", "DNA", 339, 348], ["viral polymerase", "PROTEIN", 377, 393], ["viral complementary sequence", "DNA", 405, 433], ["viral-sense 5 0 -end", "DNA", 446, 466], ["10-14 kDa RING finger Z protein", "PROTEIN", 485, 516], ["Arenaviral RNA segments", "PROBLEM", 0, 23], ["the viral complementary sequence", "TEST", 131, 163], ["GPC", "TEST", 239, 242], ["glycosylated proteins", "TEST", 288, 309], ["G2", "TEST", 327, 329], ["Da viral polymerase", "TEST", 374, 393], ["the viral complementary sequence", "TEST", 401, 433], ["RING finger Z protein", "TEST", 495, 516], ["segments", "ANATOMY_MODIFIER", 15, 23], ["L", "ANATOMY_MODIFIER", 339, 340], ["segment", "ANATOMY_MODIFIER", 341, 348]]], ["Initiation of transcription may involve cap-snatching, although the transcription mechanism is not yet fully elucidated.Ecology and epidemiologyArenaviruses include 23 viruses all carried by different rodent hosts (except Tacaribe virus which has been isolated only from fruit bats) [59b].", [["Arenaviruses", "GENE_OR_GENE_PRODUCT", 144, 156], ["Tacaribe virus", "ORGANISM", 222, 236], ["rodent", "SPECIES", 201, 207], ["Tacaribe virus", "SPECIES", 222, 236], ["Tacaribe virus", "SPECIES", 222, 236], ["transcription", "TREATMENT", 14, 27], ["Arenaviruses", "PROBLEM", 144, 156], ["23 viruses", "TREATMENT", 165, 175], ["Tacaribe virus", "TREATMENT", 222, 236], ["23 viruses", "OBSERVATION_MODIFIER", 165, 175]]], ["Arenaviruses are capable of causing chronic infections in their rodent hosts, and infectious virus is present in the blood and is also secreted into body fluids (saliva, urine, semen), which is presumably the route of transmission to humans.", [["blood", "ANATOMY", 117, 122], ["body fluids", "ANATOMY", 149, 160], ["saliva", "ANATOMY", 162, 168], ["urine", "ANATOMY", 170, 175], ["semen", "ANATOMY", 177, 182], ["infections", "DISEASE", 44, 54], ["Arenaviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["infectious virus", "ORGANISM", 82, 98], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["body fluids", "ORGANISM_SUBSTANCE", 149, 160], ["saliva", "ORGANISM_SUBSTANCE", 162, 168], ["urine", "ORGANISM_SUBSTANCE", 170, 175], ["semen", "ORGANISM_SUBSTANCE", 177, 182], ["humans", "ORGANISM", 234, 240], ["rodent", "SPECIES", 64, 70], ["humans", "SPECIES", 234, 240], ["humans", "SPECIES", 234, 240], ["Arenaviruses", "PROBLEM", 0, 12], ["chronic infections in their rodent hosts", "PROBLEM", 36, 76], ["infectious virus", "PROBLEM", 82, 98], ["saliva, urine, semen", "TEST", 162, 182], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["infections", "OBSERVATION", 44, 54], ["infectious", "OBSERVATION_MODIFIER", 82, 92], ["virus", "OBSERVATION", 93, 98]]], ["The appearance and incidence of arenaviral infections are closely associated with the distribution of the rodent host species and the rodent population dynamics.Ecology and epidemiologyArenaviruses have co-evolved with their specific host species during millions of years, and have been divided into Old World and New World groups first on a serological bass, and later into evolutionary lineages (New World group) using genetic analysis [60a,60b,60c].", [["infections", "DISEASE", 43, 53], ["Arenaviruses", "GENE_OR_GENE_PRODUCT", 185, 197], ["rodent", "SPECIES", 106, 112], ["rodent", "SPECIES", 134, 140], ["arenaviral infections", "PROBLEM", 32, 53], ["the rodent host species", "PROBLEM", 102, 125], ["Arenaviruses", "PROBLEM", 185, 197], ["genetic analysis", "TEST", 421, 437], ["incidence", "OBSERVATION_MODIFIER", 19, 28], ["arenaviral", "OBSERVATION_MODIFIER", 32, 42], ["infections", "OBSERVATION", 43, 53], ["rodent host species", "OBSERVATION", 106, 125], ["rodent", "OBSERVATION_MODIFIER", 134, 140], ["population", "OBSERVATION_MODIFIER", 141, 151]]], ["Both groups contain viruses that are included in the Category A pathogen list (defined by CDC, USA), which means that the propagation of these agents is allowed only in Biosafety Level 4 laboratories.", [["viruses", "PROBLEM", 20, 27], ["these agents", "TREATMENT", 137, 149], ["viruses", "OBSERVATION", 20, 27]]], ["These highly pathogenic arenaviruses include the South American Junin, Machupo, Guanarito, and Sabia viruses from the New World group, and the African Lassa virus from the Old World group.", [["Lassa virus", "DISEASE", 151, 162], ["arenaviruses", "ORGANISM", 24, 36], ["Sabia viruses", "ORGANISM", 95, 108], ["Lassa virus", "ORGANISM", 151, 162], ["Lassa virus", "SPECIES", 151, 162], ["African Lassa virus", "SPECIES", 143, 162], ["Sabia viruses", "PROBLEM", 95, 108], ["the African Lassa virus", "PROBLEM", 139, 162], ["highly", "OBSERVATION_MODIFIER", 6, 12], ["pathogenic", "OBSERVATION", 13, 23]]], ["All these viruses can cause hemorrhagic fevers in humans, and are considered potential bioterrorism agents being thus included in biohazard preparedness programs.", [["hemorrhagic fevers", "DISEASE", 28, 46], ["humans", "ORGANISM", 50, 56], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["hemorrhagic fevers", "PROBLEM", 28, 46], ["bioterrorism agents", "TREATMENT", 87, 106], ["biohazard preparedness programs", "TREATMENT", 130, 161], ["viruses", "OBSERVATION", 10, 17], ["hemorrhagic", "OBSERVATION_MODIFIER", 28, 39], ["fevers", "OBSERVATION", 40, 46]]], ["In Europe, these viruses occur only rarely as imported cases.", [["these viruses", "PROBLEM", 11, 24], ["viruses", "OBSERVATION", 17, 24]]], ["The only arenavirus endemic in Europe is lymphocytic choriomeningitis virus (LCMV), shown to circulate in Mus musculus populations (Table 2) , and associated with pet hamster derived epidemics [59b,61a].", [["arenavirus", "DISEASE", 9, 19], ["lymphocytic choriomeningitis virus", "DISEASE", 41, 75], ["lymphocytic choriomeningitis virus", "ORGANISM", 41, 75], ["LCMV", "ORGANISM", 77, 81], ["Mus musculus", "ORGANISM", 106, 118], ["lymphocytic choriomeningitis virus", "SPECIES", 41, 75], ["Mus musculus", "SPECIES", 106, 118], ["lymphocytic choriomeningitis virus", "SPECIES", 41, 75], ["LCMV", "SPECIES", 77, 81], ["Mus musculus", "SPECIES", 106, 118], ["hamster", "SPECIES", 167, 174], ["arenavirus endemic", "PROBLEM", 9, 27], ["lymphocytic choriomeningitis virus", "PROBLEM", 41, 75], ["arenavirus", "OBSERVATION_MODIFIER", 9, 19], ["endemic", "OBSERVATION_MODIFIER", 20, 27], ["lymphocytic choriomeningitis virus", "OBSERVATION", 41, 75], ["Mus musculus", "ANATOMY", 106, 118]]], ["Relatively few epidemiological data are available concerning the actual distribution of LCMV in Europe, but in addition to serological evidence from Mus sp. material from Spain [61b], antibodies against LCMV have been detected in rodent species other than Mus musculus (our unpublished data), which indicates that other yet unknown arenaviruses may circulate in Europe.Clinical picture and pathogenesisAt least ten arenaviruses have been reported to be able to cause disease in humans.", [["arenaviruses", "DISEASE", 332, 344], ["LCMV", "ORGANISM", 88, 92], ["Mus sp", "ORGANISM", 149, 155], ["LCMV", "ORGANISM", 203, 207], ["Mus musculus", "ORGANISM", 256, 268], ["arenaviruses", "ORGANISM", 332, 344], ["arenaviruses", "ORGANISM", 415, 427], ["humans", "ORGANISM", 478, 484], ["antibodies", "PROTEIN", 184, 194], ["rodent", "SPECIES", 230, 236], ["Mus musculus", "SPECIES", 256, 268], ["humans", "SPECIES", 478, 484], ["LCMV", "SPECIES", 88, 92], ["LCMV", "SPECIES", 203, 207], ["Mus musculus", "SPECIES", 256, 268], ["humans", "SPECIES", 478, 484], ["LCMV", "PROBLEM", 88, 92], ["Mus sp", "PROBLEM", 149, 155], ["antibodies", "TREATMENT", 184, 194], ["LCMV", "PROBLEM", 203, 207], ["Clinical picture", "PROBLEM", 369, 385], ["pathogenesis", "PROBLEM", 390, 402], ["disease in humans", "PROBLEM", 467, 484], ["few", "OBSERVATION_MODIFIER", 11, 14], ["LCMV", "OBSERVATION", 88, 92], ["arenaviruses", "OBSERVATION", 332, 344], ["arenaviruses", "OBSERVATION", 415, 427]]], ["As mentioned above, five arenaviruses (Lassa, Junin, Machupo, Guanarito, and Sabia viruses) are even capable of causing a lifethreatening viral hemorrhagic fever [62a,62b] .", [["arenaviruses", "DISEASE", 25, 37], ["viral hemorrhagic fever", "DISEASE", 138, 161], ["arenaviruses", "ORGANISM", 25, 37], ["Lassa", "ORGANISM", 39, 44], ["Machupo, Guanarito", "ORGANISM", 53, 71], ["Sabia viruses", "ORGANISM", 77, 90], ["Sabia viruses", "SPECIES", 77, 90], ["Lassa", "TREATMENT", 39, 44], ["Junin", "TREATMENT", 46, 51], ["Machupo", "TREATMENT", 53, 60], ["Guanarito", "TREATMENT", 62, 71], ["Sabia viruses", "TREATMENT", 77, 90], ["a lifethreatening viral hemorrhagic fever", "PROBLEM", 120, 161]]], ["None of these five viruses are endemic in Europe, but a few imported Lassa virus infections have been diagnosed in Germany and Great Britain during the last few years with no secondary infections detected [63] [64] [65] .", [["Lassa virus infections", "DISEASE", 69, 91], ["infections", "DISEASE", 185, 195], ["Lassa virus", "ORGANISM", 69, 80], ["Lassa virus", "SPECIES", 69, 80], ["Lassa virus", "SPECIES", 69, 80], ["these five viruses", "PROBLEM", 8, 26], ["a few imported Lassa virus infections", "PROBLEM", 54, 91], ["secondary infections", "PROBLEM", 175, 195], ["five", "OBSERVATION_MODIFIER", 14, 18], ["viruses", "OBSERVATION", 19, 26], ["few", "OBSERVATION_MODIFIER", 56, 59], ["Lassa virus", "OBSERVATION", 69, 80], ["no", "UNCERTAINTY", 172, 174], ["secondary", "OBSERVATION_MODIFIER", 175, 184], ["infections", "OBSERVATION", 185, 195]]], ["Increased travelling increases also the risk for transmission of exotic arenaviruses to non-endemic areas such as Europe.Clinical picture and pathogenesisLCMV is thus far the only known endemic arenavirus in Europe [62b].", [["arenaviruses", "DISEASE", 72, 84], ["arenavirus", "DISEASE", 194, 204], ["Increased travelling", "PROBLEM", 0, 20], ["exotic arenaviruses", "PROBLEM", 65, 84], ["Clinical picture", "TEST", 121, 137], ["pathogenesisLCMV", "PROBLEM", 142, 158], ["known endemic arenavirus", "PROBLEM", 180, 204], ["exotic arenaviruses", "OBSERVATION", 65, 84], ["endemic", "OBSERVATION_MODIFIER", 186, 193], ["arenavirus", "OBSERVATION", 194, 204]]], ["In humans LCMV infections are mostly either asymptomatic or influenza-like diseases.", [["LCMV infections", "DISEASE", 10, 25], ["influenza-like diseases", "DISEASE", 60, 83], ["humans", "ORGANISM", 3, 9], ["LCMV", "ORGANISM", 10, 14], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["LCMV", "SPECIES", 10, 14], ["humans LCMV infections", "PROBLEM", 3, 25], ["asymptomatic", "PROBLEM", 44, 56], ["influenza", "PROBLEM", 60, 69], ["diseases", "PROBLEM", 75, 83], ["LCMV infections", "OBSERVATION", 10, 25], ["asymptomatic", "OBSERVATION_MODIFIER", 44, 56], ["influenza", "OBSERVATION", 60, 69]]], ["In some cases aseptic meningitis or meningoencephalomyelitis is seen.", [["meningitis", "DISEASE", 22, 32], ["meningoencephalomyelitis", "DISEASE", 36, 60], ["some cases aseptic meningitis", "PROBLEM", 3, 32], ["meningoencephalomyelitis", "PROBLEM", 36, 60], ["aseptic", "OBSERVATION_MODIFIER", 14, 21], ["meningitis", "OBSERVATION", 22, 32], ["meningoencephalomyelitis", "OBSERVATION", 36, 60]]], ["LCMV is also capable of causing congenital infections manifested by hydrocephalus, microcephalus, chorioretinitis, and mental or psychomotor retardation [66,67a,67b] .", [["congenital infections", "DISEASE", 32, 53], ["hydrocephalus", "DISEASE", 68, 81], ["microcephalus", "DISEASE", 83, 96], ["chorioretinitis", "DISEASE", 98, 113], ["psychomotor retardation", "DISEASE", 129, 152], ["LCMV", "ORGANISM", 0, 4], ["LCMV", "SPECIES", 0, 4], ["LCMV", "PROBLEM", 0, 4], ["congenital infections", "PROBLEM", 32, 53], ["hydrocephalus", "PROBLEM", 68, 81], ["microcephalus", "PROBLEM", 83, 96], ["chorioretinitis", "PROBLEM", 98, 113], ["mental or psychomotor retardation", "PROBLEM", 119, 152], ["congenital", "OBSERVATION_MODIFIER", 32, 42], ["infections", "OBSERVATION", 43, 53], ["hydrocephalus", "OBSERVATION", 68, 81], ["chorioretinitis", "OBSERVATION", 98, 113]]], ["LCMV infections are rarely fatal for humans.Diagnostics and preventionThe diagnosis of arenaviral infections is based on serology and/or direct detection of the virus [68] .", [["LCMV infections", "DISEASE", 0, 15], ["arenaviral infections", "DISEASE", 87, 108], ["LCMV", "ORGANISM", 0, 4], ["humans", "ORGANISM", 37, 43], ["arenaviral", "CANCER", 87, 97], ["humans", "SPECIES", 37, 43], ["LCMV", "SPECIES", 0, 4], ["humans", "SPECIES", 37, 43], ["LCMV infections", "PROBLEM", 0, 15], ["Diagnostics", "TEST", 44, 55], ["arenaviral infections", "PROBLEM", 87, 108], ["serology", "TEST", 121, 129], ["the virus", "PROBLEM", 157, 166], ["infections", "OBSERVATION", 5, 15], ["arenaviral", "OBSERVATION_MODIFIER", 87, 97], ["infections", "OBSERVATION", 98, 108]]], ["For serodiagnosis methods using immunofluorescence assay (IFA) as well as enzyme immunoassay (EIA) have been described.", [["serodiagnosis methods", "TEST", 4, 25], ["immunofluorescence assay", "TEST", 32, 56], ["IFA", "TEST", 58, 61], ["enzyme immunoassay", "TEST", 74, 92], ["EIA", "TEST", 94, 97]]], ["Either a four-fold rise in IgG antibody titers or presence of IgM antibodies is considered indicative of acute infection.", [["infection", "DISEASE", 111, 120], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 27, 39], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 62, 76], ["IgG antibody", "PROTEIN", 27, 39], ["IgM antibodies", "PROTEIN", 62, 76], ["a four-fold rise", "PROBLEM", 7, 23], ["IgG antibody titers", "TEST", 27, 46], ["IgM antibodies", "PROBLEM", 62, 76], ["acute infection", "PROBLEM", 105, 120], ["IgG antibody", "OBSERVATION", 27, 39], ["IgM antibodies", "OBSERVATION", 62, 76], ["considered indicative of", "UNCERTAINTY", 80, 104], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["infection", "OBSERVATION", 111, 120]]], ["The antibodies that appear first in the acute phase of infection are directed against the nucleocapsid protein; neutralizing antibodies against the glycoproteins appear later in the convalescent phase (if at all).", [["infection", "DISEASE", 55, 64], ["antibodies", "PROTEIN", 4, 14], ["nucleocapsid protein", "PROTEIN", 90, 110], ["neutralizing antibodies", "PROTEIN", 112, 135], ["glycoproteins", "PROTEIN", 148, 161], ["The antibodies", "TEST", 0, 14], ["infection", "PROBLEM", 55, 64], ["the nucleocapsid protein", "PROBLEM", 86, 110], ["neutralizing antibodies", "TEST", 112, 135], ["the glycoproteins", "PROBLEM", 144, 161], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["phase", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 55, 64]]], ["This means that typing of the causative agent is difficult on a serological basis at the early stage of infection, and is actually possible only in the convalescent phase due to the slow rise of virus typespecific neutralizing antibodies.", [["infection", "DISEASE", 104, 113], ["virus typespecific neutralizing antibodies", "PROTEIN", 195, 237], ["the causative agent", "PROBLEM", 26, 45], ["a serological basis", "TEST", 62, 81], ["infection", "PROBLEM", 104, 113], ["the slow rise of virus typespecific neutralizing antibodies", "PROBLEM", 178, 237], ["early stage", "OBSERVATION_MODIFIER", 89, 100], ["infection", "OBSERVATION", 104, 113], ["actually possible", "UNCERTAINTY", 122, 139], ["neutralizing antibodies", "OBSERVATION", 214, 237]]], ["For direct detection of the virus, antigen detection assays are useful in the early diagnosis of Lassa fever especially.", [["Lassa fever", "DISEASE", 97, 108], ["Lassa", "ORGANISM", 97, 102], ["Lassa fever", "SPECIES", 97, 108], ["direct detection", "TEST", 4, 20], ["the virus", "PROBLEM", 24, 33], ["antigen detection assays", "TEST", 35, 59], ["Lassa fever", "PROBLEM", 97, 108], ["virus", "OBSERVATION", 28, 33], ["Lassa", "OBSERVATION", 97, 102]]], ["Also reverse transcriptase (RT)-PCR tests have been developed to detect arenaviral RNA in patient samples [69a,69b,70a,70b,70c].", [["samples", "ANATOMY", 98, 105], ["patient", "ORGANISM", 90, 97], ["reverse transcriptase", "PROTEIN", 5, 26], ["arenaviral RNA", "RNA", 72, 86], ["patient", "SPECIES", 90, 97], ["reverse transcriptase (RT", "TREATMENT", 5, 30], ["PCR tests", "TEST", 32, 41], ["arenaviral RNA", "PROBLEM", 72, 86]]], ["Virus isolation attempts can also be successful.Diagnostics and preventionThe supportive treatment of arenaviral infections includes ensuring the fluid, electrolyte and osmotic balance.", [["fluid", "ANATOMY", 146, 151], ["infections", "DISEASE", 113, 123], ["Virus", "ORGANISM", 0, 5], ["arenaviral", "SPECIES", 102, 112], ["Virus isolation attempts", "TREATMENT", 0, 24], ["Diagnostics", "TEST", 48, 59], ["arenaviral infections", "PROBLEM", 102, 123], ["the fluid", "TEST", 142, 151], ["electrolyte and osmotic balance", "PROBLEM", 153, 184], ["supportive", "OBSERVATION_MODIFIER", 78, 88], ["infections", "OBSERVATION", 113, 123], ["fluid", "OBSERVATION", 146, 151], ["osmotic balance", "OBSERVATION", 169, 184]]], ["In severe hemorrhagic fever-cases early diagnosis is important because the use of ribavirin has been found effective if the treatment commences within the first six days after onset of symptoms [71] .", [["hemorrhagic fever", "DISEASE", 10, 27], ["ribavirin", "CHEMICAL", 82, 91], ["ribavirin", "CHEMICAL", 82, 91], ["ribavirin", "SIMPLE_CHEMICAL", 82, 91], ["severe hemorrhagic fever", "PROBLEM", 3, 27], ["ribavirin", "TREATMENT", 82, 91], ["symptoms", "PROBLEM", 185, 193], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["hemorrhagic", "OBSERVATION_MODIFIER", 10, 21], ["fever", "OBSERVATION", 22, 27]]], ["Immune plasma containing neutralizing antibodies has also been useful in some cases.Diagnostics and preventionFor prevention of arenaviral diseases, several attempts to develop vaccines have been made [72a] .", [["Immune plasma", "ANATOMY", 0, 13], ["arenaviral diseases", "DISEASE", 128, 147], ["plasma", "ORGANISM_SUBSTANCE", 7, 13], ["neutralizing antibodies", "PROTEIN", 25, 48], ["arenaviral", "SPECIES", 128, 138], ["Immune plasma containing neutralizing antibodies", "PROBLEM", 0, 48], ["Diagnostics", "TEST", 84, 95], ["arenaviral diseases", "PROBLEM", 128, 147], ["vaccines", "TREATMENT", 177, 185], ["neutralizing antibodies", "OBSERVATION", 25, 48]]], ["One vaccine, Candid 1, has been successfully used in the prevention of Argentine hemorrhagic fever caused by Junin virus with a clear reduction in the number of infections observed in humans [72b,73].VirologyThe genus Orthopoxvirus in the family Poxviridae consists of large 220-450 nm brick-shaped viruses, with a double-stranded DNA genome (160-220 kb) ( Table 1) , that are serologically cross-reactive and -protective.", [["Candid 1", "CHEMICAL", 13, 21], ["Argentine hemorrhagic fever", "DISEASE", 71, 98], ["Junin virus", "DISEASE", 109, 120], ["infections", "DISEASE", 161, 171], ["Junin virus", "ORGANISM", 109, 120], ["humans", "ORGANISM", 184, 190], ["DNA", "CELLULAR_COMPONENT", 331, 334], ["double-stranded DNA genome", "DNA", 315, 341], ["Junin virus", "SPECIES", 109, 120], ["humans", "SPECIES", 184, 190], ["Junin virus", "SPECIES", 109, 120], ["humans", "SPECIES", 184, 190], ["Candid", "TREATMENT", 13, 19], ["Argentine hemorrhagic fever", "PROBLEM", 71, 98], ["Junin virus", "PROBLEM", 109, 120], ["infections", "PROBLEM", 161, 171], ["brick-shaped viruses", "TREATMENT", 286, 306], ["a double-stranded DNA genome", "TREATMENT", 313, 341], ["hemorrhagic", "OBSERVATION_MODIFIER", 81, 92], ["fever", "OBSERVATION", 93, 98], ["Junin virus", "OBSERVATION", 109, 120], ["clear", "OBSERVATION_MODIFIER", 128, 133], ["reduction", "OBSERVATION_MODIFIER", 134, 143], ["number", "OBSERVATION_MODIFIER", 151, 157], ["infections", "OBSERVATION", 161, 171], ["genus Orthopoxvirus", "OBSERVATION", 212, 231], ["large", "OBSERVATION_MODIFIER", 269, 274], ["shaped", "OBSERVATION_MODIFIER", 292, 298], ["viruses", "OBSERVATION", 299, 306], ["serologically", "OBSERVATION_MODIFIER", 377, 390], ["cross-reactive", "OBSERVATION", 391, 405]]], ["The middle part of the genome is very conserved among orthopoxviruses encoding structural proteins and replication machinery whereas the ends are more variable comprising genes involved with host-specificity and counteracting the immune response [74] .", [["genome", "CELLULAR_COMPONENT", 23, 29], ["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 54, 69], ["orthopoxviruses", "DNA", 54, 69], ["structural proteins", "PROTEIN", 79, 98], ["replication machinery", "TREATMENT", 103, 124], ["middle", "ANATOMY_MODIFIER", 4, 10], ["genome", "OBSERVATION", 23, 29]]], ["Replication of orthopoxviruses occurs in the cytoplasm and includes translation of early mRNAs (such as DNA polymerases and immune defense molecules), DNA replication, translation of intermediate mRNAs (for late transcription factors), and late mRNAs encoding structural proteins and late enzymes, respectively.", [["cytoplasm", "ANATOMY", 45, 54], ["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 15, 30], ["cytoplasm", "ORGANISM_SUBSTANCE", 45, 54], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["immune defense molecules", "GENE_OR_GENE_PRODUCT", 124, 148], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["late transcription factors", "GENE_OR_GENE_PRODUCT", 207, 233], ["late enzymes", "GENE_OR_GENE_PRODUCT", 284, 296], ["early mRNAs", "RNA", 83, 94], ["DNA polymerases", "PROTEIN", 104, 119], ["immune defense molecules", "PROTEIN", 124, 148], ["intermediate mRNAs", "RNA", 183, 201], ["transcription factors", "PROTEIN", 212, 233], ["late mRNAs", "RNA", 240, 250], ["structural proteins", "PROTEIN", 260, 279], ["late enzymes", "PROTEIN", 284, 296], ["orthopoxviruses", "TREATMENT", 15, 30], ["early mRNAs", "PROBLEM", 83, 94], ["DNA polymerases", "TREATMENT", 104, 119], ["immune defense molecules", "TREATMENT", 124, 148], ["DNA replication", "TREATMENT", 151, 166], ["late transcription factors", "PROBLEM", 207, 233], ["late enzymes", "TEST", 284, 296], ["orthopoxviruses", "OBSERVATION", 15, 30]]], ["Altogether, e.g. the cowpox virus genome encodes nearly 200 open reading frames.", [["cowpox virus", "ORGANISM", 21, 33], ["cowpox virus genome", "DNA", 21, 40], ["open reading frames", "DNA", 60, 79], ["cowpox virus", "SPECIES", 21, 33], ["the cowpox virus genome encodes", "PROBLEM", 17, 48]]], ["Intracellular non-enveloped virions are first formed, comprising the majority of the infectious viral progeny; some particles develop in ER/Golgi into enveloped, either cell-attached or extracellular viral particles, often motile due to attached actin tails [75] .", [["Intracellular", "ANATOMY", 0, 13], ["virions", "ANATOMY", 28, 35], ["progeny", "ANATOMY", 102, 109], ["ER/Golgi", "ANATOMY", 137, 145], ["cell", "ANATOMY", 169, 173], ["extracellular", "ANATOMY", 186, 199], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["ER", "GENE_OR_GENE_PRODUCT", 137, 139], ["Golgi", "CELLULAR_COMPONENT", 140, 145], ["cell", "CELL", 169, 173], ["extracellular viral particles", "CELLULAR_COMPONENT", 186, 215], ["actin", "GENE_OR_GENE_PRODUCT", 246, 251], ["ER", "PROTEIN", 137, 139], ["actin tails", "PROTEIN", 246, 257], ["Intracellular non-enveloped virions", "PROBLEM", 0, 35], ["the infectious viral progeny", "PROBLEM", 81, 109], ["some particles", "PROBLEM", 111, 125], ["extracellular viral particles", "PROBLEM", 186, 215], ["non-enveloped virions", "OBSERVATION", 14, 35], ["infectious", "OBSERVATION_MODIFIER", 85, 95], ["viral progeny", "OBSERVATION", 96, 109], ["particles", "OBSERVATION_MODIFIER", 116, 125], ["viral particles", "OBSERVATION", 200, 215]]], ["Homologous recombination occurs readily between orthopoxvirus sequences which has raised some concerns about the use of vaccinia virus-based vaccines in wild animals [76] .Epidemiology and ecologySome orthopoxviruses are host-specific, whereas some are more promiscuous but have a distinct reservoir.", [["vaccinia virus", "ORGANISM", 120, 134], ["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 201, 216], ["orthopoxvirus sequences", "DNA", 48, 71], ["vaccinia virus", "SPECIES", 120, 134], ["Homologous recombination", "PROBLEM", 0, 24], ["orthopoxvirus sequences", "TREATMENT", 48, 71], ["vaccinia virus", "TREATMENT", 120, 134], ["based vaccines", "TREATMENT", 135, 149], ["Some orthopoxviruses", "PROBLEM", 196, 216], ["orthopoxviruses", "OBSERVATION", 201, 216], ["more promiscuous", "OBSERVATION_MODIFIER", 253, 269], ["distinct", "OBSERVATION_MODIFIER", 281, 289], ["reservoir", "OBSERVATION", 290, 299]]], ["Their nomenclature may be misleading; e.g. monkeypox is not carried by monkeys, neither is cowpox carried by cows.", [["monkeypox", "DISEASE", 43, 52], ["monkeypox", "ORGANISM", 43, 52], ["monkeys", "ORGANISM", 71, 78], ["cowpox", "ORGANISM", 91, 97], ["cows", "ORGANISM_SUBDIVISION", 109, 113], ["may be", "UNCERTAINTY", 19, 25]]], ["Smallpox or variola virus, now eradicated and historically the cause of one of the most feared human diseases, was specific to man.", [["variola virus", "DISEASE", 12, 25], ["variola virus", "ORGANISM", 12, 25], ["human", "ORGANISM", 95, 100], ["man", "ORGANISM", 127, 130], ["variola virus", "SPECIES", 12, 25], ["human", "SPECIES", 95, 100], ["man", "SPECIES", 127, 130], ["variola virus", "SPECIES", 12, 25], ["human", "SPECIES", 95, 100], ["Smallpox", "PROBLEM", 0, 8], ["variola virus", "PROBLEM", 12, 25], ["variola virus", "OBSERVATION", 12, 25], ["diseases", "OBSERVATION", 101, 109]]], ["Many other orthopoxviruses circulate in wildlife species and are often zoonotic.", [["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 11, 26], ["orthopoxviruses", "OBSERVATION", 11, 26], ["wildlife species", "OBSERVATION", 40, 56]]], ["Examples include the vaccinia virus, the modern smallpox vaccine, the origins of which are unclear but was originally described as cowpox by Edward Jenner [77] in late 18th century England, and which later has also re-escaped to nature in other parts of the world [78] ; monkeypox virus, pathogenic to primates, including humans, causing a smallpox-like disease with secondary transmission and with a likely reservoir in small rodents in Central Africa; cowpox virus, which is the main orthopoxvirus in Europe and may be transmitted to man either directly from rodents or from a secondary carrier, typically cat.", [["monkeypox virus", "DISEASE", 271, 286], ["smallpox-like disease", "DISEASE", 340, 361], ["cowpox virus", "DISEASE", 454, 466], ["vaccinia virus", "ORGANISM", 21, 35], ["cowpox", "ORGANISM", 131, 137], ["monkeypox virus", "ORGANISM", 271, 286], ["primates", "ORGANISM", 302, 310], ["humans", "ORGANISM", 322, 328], ["cowpox virus", "ORGANISM", 454, 466], ["man", "ORGANISM", 536, 539], ["cat", "ORGANISM", 608, 611], ["monkeypox virus", "SPECIES", 271, 286], ["humans", "SPECIES", 322, 328], ["cowpox virus", "SPECIES", 454, 466], ["man", "SPECIES", 536, 539], ["vaccinia virus", "SPECIES", 21, 35], ["monkeypox virus", "SPECIES", 271, 286], ["humans", "SPECIES", 322, 328], ["cowpox virus", "SPECIES", 454, 466], ["the vaccinia virus", "TREATMENT", 17, 35], ["the modern smallpox vaccine", "TREATMENT", 37, 64], ["monkeypox virus", "PROBLEM", 271, 286], ["a smallpox-like disease", "PROBLEM", 338, 361], ["secondary transmission", "PROBLEM", 367, 389], ["Central Africa", "PROBLEM", 438, 452], ["cowpox virus", "PROBLEM", 454, 466], ["vaccinia virus", "OBSERVATION", 21, 35], ["smallpox", "OBSERVATION", 340, 348], ["small rodents", "OBSERVATION", 421, 434], ["Central Africa", "ANATOMY", 438, 452], ["cowpox virus", "OBSERVATION", 454, 466], ["main", "OBSERVATION_MODIFIER", 481, 485], ["orthopoxvirus", "OBSERVATION", 486, 499]]], ["Cowpox virus has been detected in Western Eurasia and in Europe, voles of Clethrionomys and Microtus species and Apodemus mice are the main reservoir hosts [79] ( Table 2) .", [["Cowpox virus", "ORGANISM", 0, 12], ["Clethrionomys", "ORGANISM", 74, 87], ["Microtus species", "ORGANISM", 92, 108], ["Apodemus mice", "ORGANISM", 113, 126], ["Apodemus", "SPECIES", 113, 121], ["mice", "SPECIES", 122, 126], ["Cowpox virus", "SPECIES", 0, 12], ["mice", "SPECIES", 122, 126], ["Cowpox virus", "PROBLEM", 0, 12], ["Microtus species", "PROBLEM", 92, 108]]], ["Shedding of the virus from rodents is apparently transient.", [["the virus", "PROBLEM", 12, 21], ["virus", "OBSERVATION", 16, 21], ["transient", "OBSERVATION_MODIFIER", 49, 58]]], ["Infection of cattle is rare; domestic cats relatively frequently present with clinical disease, but infection of zoo animals, e.g. elephants, has also been reported [80] .", [["infection", "DISEASE", 100, 109], ["cattle", "ORGANISM", 13, 19], ["cats", "ORGANISM", 38, 42], ["cattle", "SPECIES", 13, 19], ["cats", "SPECIES", 38, 42], ["cattle", "SPECIES", 13, 19], ["Infection of cattle", "PROBLEM", 0, 19], ["clinical disease", "PROBLEM", 78, 94], ["infection of zoo animals", "PROBLEM", 100, 124], ["infection", "OBSERVATION", 100, 109]]], ["Following the cessation of smallpox vaccination, more than 25 years ago, the number of humans susceptible to cowpox has increased.", [["cowpox", "DISEASE", 109, 115], ["humans", "ORGANISM", 87, 93], ["cowpox", "ORGANISM", 109, 115], ["humans", "SPECIES", 87, 93], ["humans", "SPECIES", 87, 93], ["cowpox", "SPECIES", 109, 115], ["smallpox vaccination", "TREATMENT", 27, 47], ["cowpox", "PROBLEM", 109, 115], ["cowpox", "OBSERVATION", 109, 115], ["increased", "OBSERVATION_MODIFIER", 120, 129]]], ["More than 60 human cowpox cases have been reported in the literature since 1969 [81, 82] .Clinical picture and pathogenesis of cowpoxAll age groups may acquire cowpox, but most cases have been in girls under 12 years of age, who have had a cat or e.g. a field mouse as a pet.", [["cowpox", "DISEASE", 127, 133], ["cowpox", "DISEASE", 160, 166], ["human", "ORGANISM", 13, 18], ["cowpox", "ORGANISM", 19, 25], ["cowpox", "ORGANISM", 127, 133], ["cowpox", "ORGANISM", 160, 166], ["cat", "ORGANISM", 240, 243], ["mouse", "ORGANISM", 260, 265], ["human", "SPECIES", 13, 18], ["girls", "SPECIES", 196, 201], ["mouse", "SPECIES", 260, 265], ["human cowpox", "SPECIES", 13, 25], ["cowpox", "SPECIES", 127, 133], ["mouse", "SPECIES", 260, 265], ["Clinical picture", "PROBLEM", 90, 106], ["cowpox", "PROBLEM", 127, 133], ["cowpox", "PROBLEM", 160, 166], ["cowpox", "OBSERVATION", 127, 133], ["cowpox", "OBSERVATION", 160, 166]]], ["Infection probably occurs through abrasions in the skin; persons with atopic eczema are more prone to the infection.", [["skin", "ANATOMY", 51, 55], ["Infection probably occurs through abrasions in the skin", "DISEASE", 0, 55], ["atopic eczema", "DISEASE", 70, 83], ["infection", "DISEASE", 106, 115], ["skin", "ORGAN", 51, 55], ["persons", "ORGANISM", 57, 64], ["persons", "SPECIES", 57, 64], ["Infection", "PROBLEM", 0, 9], ["abrasions in the skin", "PROBLEM", 34, 55], ["atopic eczema", "PROBLEM", 70, 83], ["the infection", "PROBLEM", 102, 115], ["abrasions", "OBSERVATION", 34, 43], ["skin", "ANATOMY", 51, 55], ["atopic eczema", "OBSERVATION", 70, 83], ["infection", "OBSERVATION", 106, 115]]], ["[81] [82] [83] [84] .", [["[81] [82] [83] [84]", "SIMPLE_CHEMICAL", 0, 19]]], ["The incubation period is 5-7 days, after which papules develop into lesions 1-3 cm in diameter which proceed through pustular, ulceral and eschar stages over a period of a about two weeks.", [["papules", "ANATOMY", 47, 54], ["lesions", "ANATOMY", 68, 75], ["pustular", "ANATOMY", 117, 125], ["ulceral", "ANATOMY", 127, 134], ["pustular, ulceral and eschar", "DISEASE", 117, 145], ["papules", "PATHOLOGICAL_FORMATION", 47, 54], ["lesions", "PROBLEM", 68, 75], ["pustular, ulceral and eschar stages", "PROBLEM", 117, 152], ["lesions", "OBSERVATION", 68, 75], ["1-3 cm", "OBSERVATION_MODIFIER", 76, 82], ["pustular", "OBSERVATION_MODIFIER", 117, 125], ["ulceral", "ANATOMY", 127, 134], ["eschar", "OBSERVATION", 139, 145]]], ["They may be painful and vary in number, size and severity.", [["painful", "PROBLEM", 12, 19], ["may be", "UNCERTAINTY", 5, 11], ["painful", "OBSERVATION_MODIFIER", 12, 19], ["vary", "OBSERVATION_MODIFIER", 24, 28], ["number", "OBSERVATION_MODIFIER", 32, 38], ["size", "OBSERVATION_MODIFIER", 40, 44], ["severity", "OBSERVATION_MODIFIER", 49, 57]]], ["Local lymphadenopathy, pyrexia and nausea may occur; secondary bacterial infections are common.", [["lymphadenopathy", "DISEASE", 6, 21], ["pyrexia", "DISEASE", 23, 30], ["nausea", "DISEASE", 35, 41], ["bacterial infections", "DISEASE", 63, 83], ["Local lymphadenopathy", "PROBLEM", 0, 21], ["pyrexia", "PROBLEM", 23, 30], ["nausea", "PROBLEM", 35, 41], ["secondary bacterial infections", "PROBLEM", 53, 83], ["lymphadenopathy", "OBSERVATION", 6, 21], ["pyrexia", "OBSERVATION", 23, 30], ["bacterial", "OBSERVATION_MODIFIER", 63, 72], ["infections", "OBSERVATION", 73, 83]]], ["Typically, solitary lesions are found, located mainly in fingers, hands or face (e.g. eyelid) [81, 85] .", [["solitary lesions", "ANATOMY", 11, 27], ["fingers", "ANATOMY", 57, 64], ["hands", "ANATOMY", 66, 71], ["face", "ANATOMY", 75, 79], ["eyelid", "ANATOMY", 86, 92], ["solitary lesions", "CANCER", 11, 27], ["fingers", "ORGANISM_SUBDIVISION", 57, 64], ["hands", "ORGANISM_SUBDIVISION", 66, 71], ["eyelid", "ORGAN", 86, 92], ["solitary lesions", "PROBLEM", 11, 27], ["solitary", "OBSERVATION_MODIFIER", 11, 19], ["lesions", "OBSERVATION", 20, 27], ["fingers", "ANATOMY", 57, 64], ["hands", "ANATOMY", 66, 71], ["face", "ANATOMY", 75, 79], ["eyelid", "ANATOMY", 86, 92]]], ["In 6-8 weeks the lesions heal gradually, some residual scars may remain.", [["lesions", "ANATOMY", 17, 24], ["scars", "ANATOMY", 55, 60], ["lesions", "PATHOLOGICAL_FORMATION", 17, 24], ["scars", "PATHOLOGICAL_FORMATION", 55, 60], ["the lesions heal", "PROBLEM", 13, 29], ["some residual scars", "PROBLEM", 41, 60], ["lesions", "OBSERVATION", 17, 24], ["heal", "OBSERVATION_MODIFIER", 25, 29], ["gradually", "OBSERVATION_MODIFIER", 30, 39], ["residual", "OBSERVATION_MODIFIER", 46, 54], ["scars", "OBSERVATION", 55, 60]]], ["In some cases severe generalized skin infection occurs [83] , especially in atopic and in immunocompromised individuals and may in extreme cases lead to death [86] .", [["skin", "ANATOMY", 33, 37], ["skin infection", "DISEASE", 33, 47], ["atopic", "DISEASE", 76, 82], ["death", "DISEASE", 153, 158], ["skin", "ORGAN", 33, 37], ["severe generalized skin infection", "PROBLEM", 14, 47], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["generalized", "OBSERVATION_MODIFIER", 21, 32], ["skin", "ANATOMY", 33, 37], ["infection", "OBSERVATION", 38, 47]]], ["Cidofovir (a phosphorylated nucleoside analog of cytosine) may have potential as an antiviral against cowpox virus [87] .", [["Cidofovir", "CHEMICAL", 0, 9], ["nucleoside", "CHEMICAL", 28, 38], ["cytosine", "CHEMICAL", 49, 57], ["Cidofovir", "CHEMICAL", 0, 9], ["nucleoside", "CHEMICAL", 28, 38], ["cytosine", "CHEMICAL", 49, 57], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["nucleoside", "SIMPLE_CHEMICAL", 28, 38], ["cytosine", "SIMPLE_CHEMICAL", 49, 57], ["cowpox virus", "ORGANISM", 102, 114], ["cowpox virus", "SPECIES", 102, 114], ["cowpox virus", "SPECIES", 102, 114], ["Cidofovir", "TREATMENT", 0, 9], ["a phosphorylated nucleoside analog of cytosine)", "TREATMENT", 11, 58], ["an antiviral", "TREATMENT", 81, 93], ["cowpox virus", "PROBLEM", 102, 114]]], ["Man-to-man transmission of cowpox virus (unlike for monkeypox) has not been reported.Diagnostics and preventionIt is usually possible to detect orthopoxvirus particles directly from the skin lesions by electron microscopy.", [["skin lesions", "ANATOMY", 186, 198], ["cowpox virus", "DISEASE", 27, 39], ["man", "ORGANISM", 7, 10], ["cowpox virus", "ORGANISM", 27, 39], ["monkeypox", "ORGANISM", 52, 61], ["skin lesions", "PATHOLOGICAL_FORMATION", 186, 198], ["Man", "SPECIES", 0, 3], ["man", "SPECIES", 7, 10], ["cowpox virus", "SPECIES", 27, 39], ["cowpox virus", "SPECIES", 27, 39], ["cowpox virus", "PROBLEM", 27, 39], ["monkeypox", "PROBLEM", 52, 61], ["Diagnostics", "TEST", 85, 96], ["orthopoxvirus particles", "PROBLEM", 144, 167], ["the skin lesions", "PROBLEM", 182, 198], ["electron microscopy", "TEST", 202, 221], ["cowpox virus", "OBSERVATION", 27, 39], ["usually possible", "UNCERTAINTY", 117, 133], ["orthopoxvirus", "OBSERVATION", 144, 157], ["skin", "ANATOMY", 186, 190], ["lesions", "OBSERVATION", 191, 198]]], ["The virus can also be readily isolated in e.g. Vero cells or chorioallantoic membrane of chicken embryos from the lesions and subsequently characterised [80] .", [["Vero cells", "ANATOMY", 47, 57], ["chorioallantoic membrane", "ANATOMY", 61, 85], ["embryos", "ANATOMY", 97, 104], ["lesions", "ANATOMY", 114, 121], ["Vero cells", "CELL", 47, 57], ["chorioallantoic membrane", "MULTI-TISSUE_STRUCTURE", 61, 85], ["chicken", "ORGANISM", 89, 96], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 97, 104], ["lesions", "CANCER", 114, 121], ["Vero cells", "CELL_LINE", 47, 57], ["chicken", "SPECIES", 89, 96], ["chicken", "SPECIES", 89, 96], ["The virus", "PROBLEM", 0, 9], ["Vero cells", "PROBLEM", 47, 57], ["chorioallantoic membrane of chicken embryos", "PROBLEM", 61, 104], ["the lesions", "PROBLEM", 110, 121], ["virus", "OBSERVATION", 4, 9], ["can also be", "UNCERTAINTY", 10, 21], ["chorioallantoic membrane", "OBSERVATION", 61, 85], ["chicken embryos", "OBSERVATION", 89, 104], ["lesions", "OBSERVATION", 114, 121]]], ["Several sensitive PCR approaches have been described, some related to the bioterrorism (smallpox) preparedness [88] [89] [90] ; in each case further typing at the species level is needed.", [["smallpox", "DISEASE", 88, 96], ["Several sensitive PCR approaches", "PROBLEM", 0, 32], ["further typing", "TEST", 141, 155]]], ["In addition, during acute cowpox infection, IgM antibodies and low-avidity IgG antibodies have been detected [83] .Diagnostics and preventionFollowing the cessation of smallpox vaccination approximately 30 years ago, the younger age groups are the most susceptible population, both to smallpox and to cowpox, which is more closely related to vaccinia virus.", [["cowpox infection", "DISEASE", 26, 42], ["smallpox", "DISEASE", 168, 176], ["smallpox", "DISEASE", 285, 293], ["cowpox", "DISEASE", 301, 307], ["cowpox", "ORGANISM", 26, 32], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 44, 58], ["cowpox", "ORGANISM", 301, 307], ["vaccinia virus", "ORGANISM", 342, 356], ["IgM antibodies", "PROTEIN", 44, 58], ["IgG antibodies", "PROTEIN", 75, 89], ["cowpox", "SPECIES", 26, 32], ["cowpox", "SPECIES", 301, 307], ["vaccinia virus", "SPECIES", 342, 356], ["acute cowpox infection", "PROBLEM", 20, 42], ["IgM antibodies", "TEST", 44, 58], ["low-avidity IgG antibodies", "PROBLEM", 63, 89], ["Diagnostics", "TEST", 115, 126], ["smallpox vaccination", "TREATMENT", 168, 188], ["smallpox", "TREATMENT", 285, 293], ["cowpox", "PROBLEM", 301, 307], ["vaccinia virus", "PROBLEM", 342, 356], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["cowpox", "OBSERVATION_MODIFIER", 26, 32], ["infection", "OBSERVATION", 33, 42], ["most susceptible", "OBSERVATION_MODIFIER", 248, 264]]], ["Recent estimates indicate as low as 40% protection levels among Europeans.", [["low", "OBSERVATION_MODIFIER", 29, 32]]], ["For instance in Finland, in the age group over 50, everybody had orthopoxvirus antibodies as measured by immunofluorescence assay.Diagnostics and preventionThe seroprevalence decreased gradually towards younger age groups reflecting the gradual cessation of smallpox vaccination, with the last vaccinations in Finland occurring in 1977 [83] .", [["smallpox", "DISEASE", 258, 266], ["orthopoxvirus antibodies", "PROTEIN", 65, 89], ["orthopoxvirus antibodies", "PROBLEM", 65, 89], ["immunofluorescence assay", "TEST", 105, 129], ["Diagnostics", "TEST", 130, 141], ["The seroprevalence", "PROBLEM", 156, 174], ["smallpox vaccination", "TREATMENT", 258, 278]]], ["Smallpox was finally declared to be eradicated from the world in 1980 [91] after which few people in Europe have received the vaccine.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["Smallpox", "TREATMENT", 0, 8], ["the vaccine", "TREATMENT", 122, 133]]], ["In addition to wild rodents carrying cowpox, import of exotic pets may also pose a risk for orthropoxvirus transmission, as was seen in a recent outbreak of monkeypox virus in the USA [92] .VirologyOrthomyxoviruses are enveloped, negative-strand RNA viruses with 6-8 genome segments, of which avian influenza, (i.e. influenza A) viruses may cause severe disease in domestic poultry and cause zoonotic infections.", [["monkeypox virus", "DISEASE", 157, 172], ["avian influenza", "DISEASE", 293, 308], ["influenza A) viruses", "DISEASE", 316, 336], ["disease in domestic poultry", "DISEASE", 354, 381], ["zoonotic infections", "DISEASE", 392, 411], ["cowpox", "ORGANISM", 37, 43], ["monkeypox virus", "ORGANISM", 157, 172], ["VirologyOrthomyxoviruses", "GENE_OR_GENE_PRODUCT", 190, 214], ["avian influenza", "ORGANISM", 293, 308], ["i.e. influenza A", "ORGANISM", 311, 327], ["6-8 genome segments", "DNA", 263, 282], ["avian influenza", "SPECIES", 293, 308], ["monkeypox virus", "SPECIES", 157, 172], ["poultry", "SPECIES", 374, 381], ["exotic pets", "TREATMENT", 55, 66], ["orthropoxvirus transmission", "PROBLEM", 92, 119], ["monkeypox virus", "PROBLEM", 157, 172], ["VirologyOrthomyxoviruses", "TEST", 190, 214], ["strand RNA viruses", "PROBLEM", 239, 257], ["influenza", "PROBLEM", 299, 308], ["influenza A) viruses", "PROBLEM", 316, 336], ["severe disease in domestic poultry", "PROBLEM", 347, 381], ["zoonotic infections", "PROBLEM", 392, 411], ["strand RNA viruses", "OBSERVATION", 239, 257], ["segments", "OBSERVATION_MODIFIER", 274, 282], ["influenza", "OBSERVATION", 299, 308], ["severe", "OBSERVATION_MODIFIER", 347, 353], ["disease", "OBSERVATION", 354, 361], ["domestic poultry", "OBSERVATION", 365, 381], ["zoonotic", "OBSERVATION_MODIFIER", 392, 400], ["infections", "OBSERVATION", 401, 411]]], ["The influenza viruses in wild aquatic birds are the source of these epidemics in chickens as well as providing a gene pool for reassortants with human influenza A viruses which then may become established in humanto-human transmission resulting in influenza pandemics.", [["influenza viruses", "DISEASE", 4, 21], ["influenza A viruses", "DISEASE", 151, 170], ["influenza pandemics", "DISEASE", 248, 267], ["influenza viruses", "ORGANISM", 4, 21], ["birds", "ORGANISM", 38, 43], ["chickens", "ORGANISM", 81, 89], ["human influenza A viruses", "ORGANISM", 145, 170], ["human", "ORGANISM", 216, 221], ["chickens", "SPECIES", 81, 89], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 216, 221], ["chickens", "SPECIES", 81, 89], ["human influenza A viruses", "SPECIES", 145, 170], ["human", "SPECIES", 216, 221], ["The influenza viruses", "PROBLEM", 0, 21], ["a gene pool", "TREATMENT", 111, 122], ["human influenza A viruses", "PROBLEM", 145, 170], ["influenza pandemics", "PROBLEM", 248, 267], ["influenza viruses", "OBSERVATION", 4, 21]]], ["In addition, influenza A viruses are known pathogens of pigs, horses, mink, seals and whales [93, 94] .VirologyInfluenza A virus is 80-120 nm in diameter and has 8 genome segments varying in size from 0.89 to 2.3 kb.", [["influenza A viruses", "DISEASE", 13, 32], ["Influenza A virus", "DISEASE", 111, 128], ["influenza A viruses", "ORGANISM", 13, 32], ["pigs", "ORGANISM", 56, 60], ["horses", "ORGANISM_SUBDIVISION", 62, 68], ["mink", "ORGANISM", 70, 74], ["Virology", "ORGANISM", 103, 111], ["Influenza A virus", "ORGANISM", 111, 128], ["pigs", "SPECIES", 56, 60], ["mink", "SPECIES", 70, 74], ["Influenza A virus", "SPECIES", 111, 128], ["influenza A viruses", "SPECIES", 13, 32], ["pigs", "SPECIES", 56, 60], ["mink", "SPECIES", 70, 74], ["Influenza A virus", "SPECIES", 111, 128], ["influenza", "PROBLEM", 13, 22], ["VirologyInfluenza A virus", "TEST", 103, 128], ["influenza", "OBSERVATION", 13, 22], ["8 genome", "OBSERVATION_MODIFIER", 162, 170], ["segments", "OBSERVATION_MODIFIER", 171, 179], ["varying", "OBSERVATION_MODIFIER", 180, 187], ["size", "OBSERVATION_MODIFIER", 191, 195]]], ["The three largest segments 1-3 encode the polymerase subunits PA (83 kDa), PB1 (87 kDa) and PB2 (84 kDa), respectively; whereas the segments 4-6 each encode one viral protein, namely the 63 kDa hemagglutinin (HA), the 56 kDa nucleoprotein (NP), and the 50 kDa neuraminidase (NA), respectively (Table 1 , Fig. 1 ).", [["1-3", "GENE_OR_GENE_PRODUCT", 27, 30], ["PA", "GENE_OR_GENE_PRODUCT", 62, 64], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 194, 207], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 260, 273], ["polymerase subunits", "PROTEIN", 42, 61], ["PA", "PROTEIN", 62, 64], ["83 kDa", "PROTEIN", 66, 72], ["PB1", "PROTEIN", 75, 78], ["87 kDa", "PROTEIN", 80, 86], ["PB2", "PROTEIN", 92, 95], ["84 kDa", "PROTEIN", 97, 103], ["segments 4-6", "PROTEIN", 132, 144], ["viral protein", "PROTEIN", 161, 174], ["63 kDa hemagglutinin", "PROTEIN", 187, 207], ["HA", "PROTEIN", 209, 211], ["56 kDa nucleoprotein", "PROTEIN", 218, 238], ["NP", "PROTEIN", 240, 242], ["50 kDa neuraminidase", "PROTEIN", 253, 273], ["NA", "PROTEIN", 275, 277], ["PA", "TEST", 62, 64], ["kDa", "TEST", 69, 72], ["PB1", "TEST", 75, 78], ["kDa", "TEST", 83, 86], ["PB2", "TEST", 92, 95], ["kDa", "TEST", 100, 103], ["viral protein", "TEST", 161, 174], ["HA", "TEST", 209, 211], ["NP", "TEST", 240, 242], ["the 50 kDa neuraminidase", "TEST", 249, 273], ["NA", "TEST", 275, 277], ["three", "OBSERVATION_MODIFIER", 4, 9], ["largest", "OBSERVATION_MODIFIER", 10, 17], ["segments 1-3", "ANATOMY_MODIFIER", 18, 30]]], ["The two smallest segments, 7 and 8, encode each two proteins, the 28 kDa matrix protein (M1) and the 11 kDa membrane protein (M2), and the 27 kDa NS1 and the 14 kDa NS2 proteins, respectively (Table 1 , Fig. 1 ).", [["matrix", "CELLULAR_COMPONENT", 73, 79], ["membrane", "CELLULAR_COMPONENT", 108, 116], ["M2", "GENE_OR_GENE_PRODUCT", 126, 128], ["NS1", "GENE_OR_GENE_PRODUCT", 146, 149], ["28 kDa matrix protein", "PROTEIN", 66, 87], ["M1", "PROTEIN", 89, 91], ["11 kDa membrane protein", "PROTEIN", 101, 124], ["M2", "PROTEIN", 126, 128], ["27 kDa NS1", "PROTEIN", 139, 149], ["14 kDa NS2 proteins", "PROTEIN", 158, 177], ["the 28 kDa matrix protein", "TEST", 62, 87], ["the 11 kDa membrane protein", "TEST", 97, 124], ["the 27 kDa NS1", "TEST", 135, 149], ["the 14 kDa NS2 proteins", "TEST", 154, 177], ["two", "OBSERVATION_MODIFIER", 4, 7], ["smallest", "OBSERVATION_MODIFIER", 8, 16], ["segments", "ANATOMY_MODIFIER", 17, 25]]], ["In common with the Bunyaviridae, the genomic RNA is packed in the nucleoprotein which carries polymerase subunits, and the 5 0 and 3 0 -ends are conserved and complementary to each other and thus able to form panhandle structures in which the promoter regions reside.", [["Bunyaviridae", "DISEASE", 19, 31], ["genomic RNA", "RNA", 37, 48], ["polymerase subunits", "PROTEIN", 94, 113], ["5 0 and 3 0 -ends", "DNA", 123, 140], ["promoter regions", "DNA", 243, 259], ["the Bunyaviridae", "TREATMENT", 15, 31], ["polymerase subunits", "TREATMENT", 94, 113], ["genomic RNA", "OBSERVATION", 37, 48], ["packed", "OBSERVATION_MODIFIER", 52, 58]]], ["''Cap-snatching'' from cellular mRNAs and an oligo-U motif are used to create viral mRNAs starting with a cap structure and ending in a poly-A region.", [["cellular", "ANATOMY", 23, 31], ["Cap-snatching''", "GENE_OR_GENE_PRODUCT", 2, 17], ["cellular", "CELL", 23, 31], ["cellular mRNAs", "RNA", 23, 37], ["oligo-U motif", "DNA", 45, 58], ["viral mRNAs", "RNA", 78, 89], ["poly-A region", "DNA", 136, 149], ["Cap", "TEST", 2, 5], ["cellular mRNAs", "TREATMENT", 23, 37], ["an oligo-U motif", "TREATMENT", 42, 58], ["viral mRNAs", "PROBLEM", 78, 89], ["a cap structure", "TREATMENT", 104, 119], ["viral mRNAs", "OBSERVATION", 78, 89]]], ["The virus enters the cells after binding to the sialic acid receptors by endocytosis, which is followed by acidification of the endocytic vesicle and, mediated by the ion channel forming M2 protein, of the interior of the virus, which leads then to fusion of the viral and endosomal membrane and release of the viral nucleocapsids to the cytoplasm, respectively.", [["cells", "ANATOMY", 21, 26], ["endocytic vesicle", "ANATOMY", 128, 145], ["endosomal membrane", "ANATOMY", 273, 291], ["cytoplasm", "ANATOMY", 338, 347], ["sialic acid", "CHEMICAL", 48, 59], ["sialic acid", "CHEMICAL", 48, 59], ["cells", "CELL", 21, 26], ["sialic acid receptors", "GENE_OR_GENE_PRODUCT", 48, 69], ["endocytic vesicle", "CELLULAR_COMPONENT", 128, 145], ["M2", "GENE_OR_GENE_PRODUCT", 187, 189], ["endosomal membrane", "CELLULAR_COMPONENT", 273, 291], ["cytoplasm", "ORGANISM_SUBSTANCE", 338, 347], ["sialic acid receptors", "PROTEIN", 48, 69], ["ion channel", "PROTEIN", 167, 178], ["M2 protein", "PROTEIN", 187, 197], ["The virus enters the cells", "PROBLEM", 0, 26], ["the sialic acid receptors", "TEST", 44, 69], ["the virus", "PROBLEM", 218, 227], ["fusion", "TREATMENT", 249, 255], ["the viral and endosomal membrane", "TREATMENT", 259, 291], ["the viral nucleocapsids", "PROBLEM", 307, 330], ["virus", "OBSERVATION", 4, 9], ["endocytic vesicle", "OBSERVATION", 128, 145], ["interior", "ANATOMY_MODIFIER", 206, 214], ["virus", "OBSERVATION", 222, 227], ["viral", "OBSERVATION", 263, 268], ["endosomal membrane", "OBSERVATION", 273, 291], ["viral nucleocapsids", "OBSERVATION", 311, 330]]], ["However, untypically for an RNA virus, the replication, transcription and nucleprotein assembly occur in the nucleus.", [["nucleus", "ANATOMY", 109, 116], ["nucleprotein", "GENE_OR_GENE_PRODUCT", 74, 86], ["nucleus", "CELLULAR_COMPONENT", 109, 116], ["an RNA virus", "PROBLEM", 25, 37], ["the replication", "TREATMENT", 39, 54], ["nucleprotein", "TREATMENT", 74, 86], ["nucleus", "ANATOMY", 109, 116]]], ["The envelope proteins are processed to the plasma membrane, where budding of the virions finally occurs.", [["plasma membrane", "ANATOMY", 43, 58], ["virions", "ANATOMY", 81, 88], ["plasma membrane", "CELLULAR_COMPONENT", 43, 58], ["virions", "CELLULAR_COMPONENT", 81, 88], ["envelope proteins", "PROTEIN", 4, 21], ["The envelope proteins", "PROBLEM", 0, 21], ["the plasma membrane", "TREATMENT", 39, 58], ["envelope proteins", "OBSERVATION", 4, 21], ["plasma membrane", "OBSERVATION", 43, 58], ["virions", "ANATOMY", 81, 88]]], ["The envelope proteins are also the most important antigenic determinants.", [["envelope proteins", "PROTEIN", 4, 21], ["antigenic determinants", "PROTEIN", 50, 72], ["The envelope proteins", "PROBLEM", 0, 21], ["envelope proteins", "OBSERVATION", 4, 21]]], ["The homotrimeric hemagglutinin (HA), defines the ''H type'' which is responsible for the binding to the sialic-acid containing host cell receptors and membrane fusion properties.", [["cell", "ANATOMY", 132, 136], ["membrane", "ANATOMY", 151, 159], ["sialic-acid", "CHEMICAL", 104, 115], ["sialic-acid", "CHEMICAL", 104, 115], ["homotrimeric hemagglutinin", "GENE_OR_GENE_PRODUCT", 4, 30], ["HA", "GENE_OR_GENE_PRODUCT", 32, 34], ["sialic-acid", "SIMPLE_CHEMICAL", 104, 115], ["host cell receptors", "GENE_OR_GENE_PRODUCT", 127, 146], ["membrane", "CELLULAR_COMPONENT", 151, 159], ["homotrimeric hemagglutinin", "PROTEIN", 4, 30], ["HA", "PROTEIN", 32, 34], ["sialic-acid containing host cell receptors", "PROTEIN", 104, 146], ["The homotrimeric hemagglutinin (HA)", "TREATMENT", 0, 35], ["the binding", "PROBLEM", 85, 96], ["host cell receptors", "TREATMENT", 127, 146], ["membrane fusion properties", "TREATMENT", 151, 177], ["host cell receptors", "OBSERVATION", 127, 146], ["membrane fusion", "OBSERVATION", 151, 166]]], ["The neuraminidase (NA) defines the ''N type'', and cleaves terminal sialic acid residues from glycoconjugates enabling the virus to reach target cells in the mucin-rich epithelium and facilitating release of the virus from the cells [93, 94] .", [["cells", "ANATOMY", 145, 150], ["mucin-rich epithelium", "ANATOMY", 158, 179], ["cells", "ANATOMY", 227, 232], ["NA", "CHEMICAL", 19, 21], ["sialic acid", "CHEMICAL", 68, 79], ["sialic acid", "CHEMICAL", 68, 79], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 4, 17], ["NA", "SIMPLE_CHEMICAL", 19, 21], ["sialic acid", "AMINO_ACID", 68, 79], ["cells", "CELL", 145, 150], ["mucin-rich epithelium", "TISSUE", 158, 179], ["cells", "CELL", 227, 232], ["target cells", "CELL_TYPE", 138, 150], ["The neuraminidase (NA)", "TREATMENT", 0, 22], ["the ''N type''", "TREATMENT", 31, 45], ["terminal sialic acid residues", "PROBLEM", 59, 88], ["the virus", "PROBLEM", 119, 128], ["the virus", "PROBLEM", 208, 217]]], ["The catalytic site of the neuraminidase is a target for antivirals oseltamivir and zanamivir, and the M2 protein is a target for amantadine and rimantadine.VirologyTo become active, the hemagglutinin protein needs to be cleaved by trypsin-like proteases found in respiratory and gastrointestinal epithelia.", [["respiratory", "ANATOMY", 263, 274], ["gastrointestinal epithelia", "ANATOMY", 279, 305], ["oseltamivir", "CHEMICAL", 67, 78], ["zanamivir", "CHEMICAL", 83, 92], ["amantadine", "CHEMICAL", 129, 139], ["rimantadine", "CHEMICAL", 144, 155], ["oseltamivir", "CHEMICAL", 67, 78], ["zanamivir", "CHEMICAL", 83, 92], ["amantadine", "CHEMICAL", 129, 139], ["rimantadine", "CHEMICAL", 144, 155], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 26, 39], ["oseltamivir", "SIMPLE_CHEMICAL", 67, 78], ["zanamivir", "SIMPLE_CHEMICAL", 83, 92], ["M2", "GENE_OR_GENE_PRODUCT", 102, 104], ["amantadine", "SIMPLE_CHEMICAL", 129, 139], ["rimantadine", "SIMPLE_CHEMICAL", 144, 155], ["trypsin", "GENE_OR_GENE_PRODUCT", 231, 238], ["gastrointestinal epithelia", "TISSUE", 279, 305], ["neuraminidase", "PROTEIN", 26, 39], ["M2 protein", "PROTEIN", 102, 112], ["hemagglutinin protein", "PROTEIN", 186, 207], ["trypsin-like proteases", "PROTEIN", 231, 253], ["the neuraminidase", "TREATMENT", 22, 39], ["antivirals oseltamivir", "TREATMENT", 56, 78], ["zanamivir", "TREATMENT", 83, 92], ["the M2 protein", "TREATMENT", 98, 112], ["amantadine", "TREATMENT", 129, 139], ["rimantadine", "TREATMENT", 144, 155], ["the hemagglutinin protein", "PROBLEM", 182, 207], ["trypsin", "TEST", 231, 238], ["respiratory and gastrointestinal epithelia", "PROBLEM", 263, 305], ["neuraminidase", "OBSERVATION", 26, 39], ["active", "OBSERVATION_MODIFIER", 174, 180], ["respiratory", "ANATOMY", 263, 274], ["gastrointestinal epithelia", "ANATOMY", 279, 305]]], ["Human-adapted influenza viruses replicate in the respiratory tract, whereas in avians the virus replicates primarily in the gut.", [["respiratory tract", "ANATOMY", 49, 66], ["gut", "ANATOMY", 124, 127], ["influenza viruses", "DISEASE", 14, 31], ["Human", "ORGANISM", 0, 5], ["influenza viruses", "ORGANISM", 14, 31], ["respiratory tract", "ORGANISM_SUBDIVISION", 49, 66], ["gut", "ORGANISM_SUBDIVISION", 124, 127], ["Human", "SPECIES", 0, 5], ["Human-adapted influenza viruses", "SPECIES", 0, 31], ["Human-adapted influenza viruses", "TREATMENT", 0, 31], ["the virus", "PROBLEM", 86, 95], ["respiratory tract", "ANATOMY", 49, 66], ["virus", "OBSERVATION", 90, 95], ["gut", "ANATOMY", 124, 127]]], ["When transmitted to and within poultry, the normal hemagglutinin of influenza A virus H5 or H7 of wild aquatic birds of the ''low pathogenic type (LPAI) may be mutated.", [["LPAI", "DISEASE", 147, 151], ["hemagglutinin of", "ORGANISM", 51, 67], ["influenza A virus H5", "ORGANISM", 68, 88], ["H7", "ORGANISM", 92, 94], ["wild aquatic birds", "ORGANISM", 98, 116], ["LPAI", "ORGANISM", 147, 151], ["influenza A virus H5", "SPECIES", 68, 88], ["influenza A virus H5", "SPECIES", 68, 88], ["influenza A virus H5", "PROBLEM", 68, 88]]], ["Accumulation of basic residues at the cleavage site makes the HA cleavable by most proteases of cells, such as furin, and results in ''highly-pathogenic avian influenza'' (HPAI) virus able to replicate in most tissues killing rapidly up to 100% of chickens [93] [94] [95] .", [["cells", "ANATOMY", 96, 101], ["tissues", "ANATOMY", 210, 217], ["avian influenza''", "DISEASE", 153, 170], ["HPAI", "DISEASE", 172, 176], ["cells", "CELL", 96, 101], ["furin", "GENE_OR_GENE_PRODUCT", 111, 116], ["avian influenza'' (HPAI) virus", "ORGANISM", 153, 183], ["tissues", "TISSUE", 210, 217], ["chickens", "ORGANISM", 248, 256], ["cleavage site", "PROTEIN", 38, 51], ["proteases", "PROTEIN", 83, 92], ["furin", "PROTEIN", 111, 116], ["avian influenza", "SPECIES", 153, 168], ["chickens", "SPECIES", 248, 256], ["HPAI) virus", "SPECIES", 172, 183], ["chickens", "SPECIES", 248, 256], ["basic residues", "PROBLEM", 16, 30], ["the cleavage site", "PROBLEM", 34, 51], ["the HA cleavable", "PROBLEM", 58, 74], ["most proteases of cells", "PROBLEM", 78, 101], ["pathogenic avian influenza'' (HPAI) virus", "PROBLEM", 142, 183], ["basic residues", "OBSERVATION", 16, 30]]], ["HPAI, also known as ''fowl plague'' was first described in 1878 and the virus was first isolated in 1901 suggesting that humans have been directly exposed to avian influenza A viruses for centuries [96] .Epidemiology, clinical aspects and treatmentInfluenza A virus gene pools reside in wild aquatic birds where at least 15 HA types and 9 NA types are found, as compared to 3 HA (H1-H3) and 2 NA (N1, N2) types circulating in man.", [["HPAI", "DISEASE", 0, 4], ["influenza A viruses", "DISEASE", 164, 183], ["HPAI", "ORGANISM", 0, 4], ["humans", "ORGANISM", 121, 127], ["avian", "ORGANISM", 158, 163], ["influenza A viruses", "ORGANISM", 164, 183], ["Influenza A virus", "ORGANISM", 248, 265], ["H1-H3", "GENE_OR_GENE_PRODUCT", 380, 385], ["man", "ORGANISM", 426, 429], ["humans", "SPECIES", 121, 127], ["avian influenza A", "SPECIES", 158, 175], ["Influenza A virus", "SPECIES", 248, 265], ["man", "SPECIES", 426, 429], ["humans", "SPECIES", 121, 127], ["Influenza A virus", "SPECIES", 248, 265], ["HPAI", "PROBLEM", 0, 4], ["''fowl plague", "PROBLEM", 20, 33], ["the virus", "PROBLEM", 68, 77], ["treatmentInfluenza A virus gene pools", "TREATMENT", 239, 276]]], ["Also, the genes in aquatic birds are in evolutionary stasis without undergoing changes due to selective pressures.", [["birds", "ORGANISM", 27, 32], ["evolutionary stasis", "PROBLEM", 40, 59], ["selective pressures", "TEST", 94, 113], ["aquatic birds", "OBSERVATION", 19, 32], ["stasis", "OBSERVATION", 53, 59]]], ["Influenza A viruses in man are under constant selective pressure imposed by population immunity causing the hemagglutinin of influenza A virus to change its antigenic properties by accumulation of mutations (genetic drift).", [["Influenza A viruses", "DISEASE", 0, 19], ["Influenza A viruses", "ORGANISM", 0, 19], ["man", "ORGANISM", 23, 26], ["influenza A virus", "ORGANISM", 125, 142], ["man", "SPECIES", 23, 26], ["influenza A virus", "SPECIES", 125, 142], ["Influenza A viruses", "SPECIES", 0, 19], ["influenza A virus", "SPECIES", 125, 142], ["Influenza A viruses", "PROBLEM", 0, 19], ["constant selective pressure", "TREATMENT", 37, 64], ["the hemagglutinin of influenza A virus", "PROBLEM", 104, 142], ["its antigenic properties", "TREATMENT", 153, 177], ["mutations (genetic drift", "PROBLEM", 197, 221], ["viruses", "OBSERVATION", 12, 19]]], ["However, through double infection and reassortment (genetic shift), novel (e.g. hemagglutinin) genes from aquatic birds may become established in human influenza viruses giving rise to pandemics due to lack of adaptation to and immunity in, humans.Epidemiology, clinical aspects and treatmentPreviously, it was thought that the different receptor specificity -favoring different side chains of sialic acid -of human and avian influenza viruses would make direct transmission of avian viruses to humans unlikely, but both could be expected to infect swine, which carry receptors for both.", [["infection", "DISEASE", 24, 33], ["influenza viruses", "DISEASE", 152, 169], ["pandemics", "DISEASE", 185, 194], ["sialic acid", "CHEMICAL", 394, 405], ["influenza viruses", "DISEASE", 426, 443], ["sialic acid", "CHEMICAL", 394, 405], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 80, 93], ["aquatic birds", "ORGANISM", 106, 119], ["human", "ORGANISM", 146, 151], ["influenza viruses", "ORGANISM", 152, 169], ["humans", "ORGANISM", 241, 247], ["sialic acid", "SIMPLE_CHEMICAL", 394, 405], ["human", "ORGANISM", 410, 415], ["avian influenza viruses", "ORGANISM", 420, 443], ["avian viruses", "ORGANISM", 478, 491], ["humans", "ORGANISM", 495, 501], ["swine", "ORGANISM", 549, 554], ["novel (e.g. hemagglutinin) genes", "DNA", 68, 100], ["human", "SPECIES", 146, 151], ["humans", "SPECIES", 241, 247], ["human", "SPECIES", 410, 415], ["avian influenza viruses", "SPECIES", 420, 443], ["humans", "SPECIES", 495, 501], ["swine", "SPECIES", 549, 554], ["human influenza viruses", "SPECIES", 146, 169], ["humans", "SPECIES", 241, 247], ["human", "SPECIES", 410, 415], ["humans", "SPECIES", 495, 501], ["swine", "SPECIES", 549, 554], ["double infection", "PROBLEM", 17, 33], ["novel (e.g. hemagglutinin) genes", "TREATMENT", 68, 100], ["human influenza viruses", "PROBLEM", 146, 169], ["pandemics", "PROBLEM", 185, 194], ["treatment", "TREATMENT", 283, 292], ["the different receptor specificity", "PROBLEM", 324, 358], ["sialic acid", "TEST", 394, 405], ["human and avian influenza viruses", "PROBLEM", 410, 443], ["infection", "OBSERVATION", 24, 33]]], ["Thus pigs are considered to be potential reservoirs for generating new influenza virus variants.", [["pigs", "ORGANISM", 5, 9], ["influenza virus", "ORGANISM", 71, 86], ["pigs", "SPECIES", 5, 9], ["pigs", "SPECIES", 5, 9], ["potential reservoirs", "PROBLEM", 31, 51], ["new influenza virus variants", "PROBLEM", 67, 95], ["new", "OBSERVATION_MODIFIER", 67, 70], ["influenza", "OBSERVATION", 71, 80]]], ["It has only recently been discovered that viruses considered unique to avian species may also infect man, although this may involve change in receptor specificities [97] .", [["avian", "ORGANISM", 71, 76], ["man", "ORGANISM", 101, 104], ["man", "SPECIES", 101, 104], ["viruses", "PROBLEM", 42, 49], ["receptor specificities", "TEST", 142, 164], ["viruses", "OBSERVATION", 42, 49]]], ["In 1996 conjunctivitis in UK caused by avian influenza viruses (and previously, by seal influenza A viruses) was reported [98, 99] (Table 2) .", [["conjunctivitis", "DISEASE", 8, 22], ["avian influenza viruses", "DISEASE", 39, 62], ["influenza A viruses", "DISEASE", 88, 107], ["UK", "GENE_OR_GENE_PRODUCT", 26, 28], ["avian influenza viruses", "ORGANISM", 39, 62], ["seal influenza A viruses", "ORGANISM", 83, 107], ["avian influenza viruses", "SPECIES", 39, 62], ["conjunctivitis", "PROBLEM", 8, 22], ["avian influenza viruses", "PROBLEM", 39, 62], ["seal influenza A viruses", "PROBLEM", 83, 107], ["conjunctivitis", "OBSERVATION", 8, 22], ["influenza viruses", "OBSERVATION", 45, 62]]], ["Direct zoonotic transmission of avian influenza viruses to man resulting in human respiratory illness, was not known to occur or had not been diagnosed before the outbreak of H5N1 avian influenza virus in Hong Kong in 1997 where 6/18 patients died of lower respiratory tract infection [100] .", [["respiratory", "ANATOMY", 82, 93], ["lower respiratory tract", "ANATOMY", 251, 274], ["avian influenza viruses", "DISEASE", 32, 55], ["respiratory illness", "DISEASE", 82, 101], ["H5N1 avian influenza virus", "DISEASE", 175, 201], ["respiratory tract infection", "DISEASE", 257, 284], ["avian influenza viruses", "ORGANISM", 32, 55], ["man", "ORGANISM", 59, 62], ["human", "ORGANISM", 76, 81], ["H5N1", "ORGANISM", 175, 179], ["avian influenza virus", "ORGANISM", 180, 201], ["patients", "ORGANISM", 234, 242], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 251, 274], ["avian influenza viruses", "SPECIES", 32, 55], ["man", "SPECIES", 59, 62], ["human", "SPECIES", 76, 81], ["H5N1", "SPECIES", 175, 179], ["avian influenza virus", "SPECIES", 180, 201], ["patients", "SPECIES", 234, 242], ["human", "SPECIES", 76, 81], ["H5N1 avian influenza virus", "SPECIES", 175, 201], ["avian influenza viruses", "PROBLEM", 32, 55], ["human respiratory illness", "PROBLEM", 76, 101], ["H5N1 avian influenza virus", "PROBLEM", 175, 201], ["lower respiratory tract infection", "PROBLEM", 251, 284], ["respiratory illness", "OBSERVATION", 82, 101], ["lower", "ANATOMY_MODIFIER", 251, 256], ["respiratory tract", "ANATOMY", 257, 274], ["infection", "OBSERVATION", 275, 284]]], ["After this, in Europe, an outbreak of H7N1 HPAI avian influenza was encountered in Italy (1999) (2000) without reported transmission to humans [101] .", [["avian influenza", "DISEASE", 48, 63], ["H7N1 HPAI", "ORGANISM", 38, 47], ["humans", "ORGANISM", 136, 142], ["H7N1 HPAI avian influenza", "SPECIES", 38, 63], ["humans", "SPECIES", 136, 142], ["H7N1", "SPECIES", 38, 42], ["humans", "SPECIES", 136, 142], ["influenza", "PROBLEM", 54, 63]]], ["In 2003, a major H7N7 HPAI avian influenza outbreak occurred in the Netherlands [102, 103] .", [["avian influenza", "DISEASE", 27, 42], ["H7N7 HPAI", "ORGANISM", 17, 26], ["HPAI avian influenza", "SPECIES", 22, 42], ["a major H7N7 HPAI avian influenza outbreak", "PROBLEM", 9, 51]]], ["During this epidemic, veterinarians and people who culled infected poultry were at greatest risk of infection.", [["infection", "DISEASE", 100, 109], ["people", "ORGANISM", 40, 46], ["poultry", "ORGANISM", 67, 74], ["people", "SPECIES", 40, 46], ["infection", "PROBLEM", 100, 109], ["infection", "OBSERVATION", 100, 109]]], ["It was noted by active surveillance that human H7 infections (and simultaneous H3 infections) were occurring, and consequently prophylactic treatment with oseltamivir was started.", [["infections", "DISEASE", 50, 60], ["infections", "DISEASE", 82, 92], ["oseltamivir", "CHEMICAL", 155, 166], ["oseltamivir", "CHEMICAL", 155, 166], ["human", "ORGANISM", 41, 46], ["H7", "ORGANISM", 47, 49], ["oseltamivir", "SIMPLE_CHEMICAL", 155, 166], ["human", "SPECIES", 41, 46], ["human H7", "SPECIES", 41, 49], ["human H7 infections", "PROBLEM", 41, 60], ["simultaneous H3 infections", "PROBLEM", 66, 92], ["prophylactic treatment", "TREATMENT", 127, 149], ["oseltamivir", "TREATMENT", 155, 166], ["active", "OBSERVATION_MODIFIER", 16, 22]]], ["The H7 virus was confirmed to be transmitted to 85 humans of which the majority had conjunctivitis, seven had an influenza-like illness; one veterinarian (who did not receive prophylactic oseltamivir) died.", [["conjunctivitis", "DISEASE", 84, 98], ["influenza-like illness", "DISEASE", 113, 135], ["oseltamivir", "CHEMICAL", 188, 199], ["oseltamivir", "CHEMICAL", 188, 199], ["H7 virus", "ORGANISM", 4, 12], ["humans", "ORGANISM", 51, 57], ["humans", "SPECIES", 51, 57], ["H7 virus", "SPECIES", 4, 12], ["humans", "SPECIES", 51, 57], ["The H7 virus", "PROBLEM", 0, 12], ["conjunctivitis", "PROBLEM", 84, 98], ["an influenza-like illness", "PROBLEM", 110, 135], ["prophylactic oseltamivir)", "TREATMENT", 175, 200], ["conjunctivitis", "OBSERVATION", 84, 98], ["influenza", "OBSERVATION", 113, 122]]], ["His symptoms started with high fever and headache two days after visiting a farm with infected chickens.", [["fever", "DISEASE", 31, 36], ["headache", "DISEASE", 41, 49], ["chickens", "ORGANISM", 95, 103], ["chickens", "SPECIES", 95, 103], ["chickens", "SPECIES", 95, 103], ["His symptoms", "PROBLEM", 0, 12], ["high fever", "PROBLEM", 26, 36], ["headache", "PROBLEM", 41, 49], ["infected chickens", "PROBLEM", 86, 103], ["infected", "OBSERVATION", 86, 94]]], ["One week later, he was admitted to hospital with pneumonia, where his status deteriorated to multi-organ failure, with death due to respiratory insufficiency 2 weeks after onset of symptoms.", [["multi-organ", "ANATOMY", 93, 104], ["respiratory", "ANATOMY", 132, 143], ["pneumonia", "DISEASE", 49, 58], ["multi-organ failure", "DISEASE", 93, 112], ["death", "DISEASE", 119, 124], ["respiratory insufficiency", "DISEASE", 132, 157], ["multi-organ", "ORGAN", 93, 104], ["pneumonia", "PROBLEM", 49, 58], ["multi-organ failure", "PROBLEM", 93, 112], ["death", "PROBLEM", 119, 124], ["respiratory insufficiency", "PROBLEM", 132, 157], ["symptoms", "PROBLEM", 181, 189], ["pneumonia", "OBSERVATION", 49, 58], ["multi-organ", "ANATOMY", 93, 104], ["failure", "OBSERVATION", 105, 112], ["respiratory", "ANATOMY", 132, 143], ["insufficiency", "OBSERVATION", 144, 157]]], ["In addition, in three cases household primary contacts were shown to have the disease by human-to-human transmission [102] .Epidemiology, clinical aspects and treatmentBoth NA inhibitors, zanamivir and oseltamivir inhibited virus obtained from humans during this outbreak and a significant difference was found in avian influenza virus detection between oseltamivir users (1/38) and those who had not taken prophylactic medication (5/52) [102] .Epidemiology, clinical aspects and treatmentOutbreaks of avian influenza have continued to occur in other parts of the world, especially the devastating ongoing H5N1 epidemic in South-East Asia since late 2003 with as of June 2005 a total of 54 deaths/107 cases in Viet Nam, Thailand and Cambodia.", [["NA", "CHEMICAL", 173, 175], ["zanamivir", "CHEMICAL", 188, 197], ["oseltamivir", "CHEMICAL", 202, 213], ["avian influenza virus", "DISEASE", 314, 335], ["oseltamivir", "CHEMICAL", 354, 365], ["avian influenza", "DISEASE", 502, 517], ["H5N1", "DISEASE", 606, 610], ["deaths", "DISEASE", 690, 696], ["zanamivir", "CHEMICAL", 188, 197], ["oseltamivir", "CHEMICAL", 202, 213], ["oseltamivir", "CHEMICAL", 354, 365], ["human", "ORGANISM", 89, 94], ["human", "ORGANISM", 98, 103], ["NA inhibitors", "SIMPLE_CHEMICAL", 173, 186], ["zanamivir", "SIMPLE_CHEMICAL", 188, 197], ["oseltamivir", "SIMPLE_CHEMICAL", 202, 213], ["humans", "ORGANISM", 244, 250], ["avian influenza virus", "ORGANISM", 314, 335], ["oseltamivir", "SIMPLE_CHEMICAL", 354, 365], ["avian influenza", "ORGANISM", 502, 517], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 98, 103], ["humans", "SPECIES", 244, 250], ["avian influenza virus", "SPECIES", 314, 335], ["avian influenza", "SPECIES", 502, 517], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 98, 103], ["humans", "SPECIES", 244, 250], ["avian influenza virus", "SPECIES", 314, 335], ["the disease", "PROBLEM", 74, 85], ["treatment", "TREATMENT", 159, 168], ["Both NA inhibitors", "TREATMENT", 168, 186], ["zanamivir", "TREATMENT", 188, 197], ["oseltamivir", "TREATMENT", 202, 213], ["virus", "PROBLEM", 224, 229], ["avian influenza virus detection", "PROBLEM", 314, 345], ["oseltamivir users", "TREATMENT", 354, 371], ["prophylactic medication", "TREATMENT", 407, 430], ["treatment", "TREATMENT", 480, 489], ["avian influenza", "PROBLEM", 502, 517], ["devastating", "OBSERVATION_MODIFIER", 586, 597]]], ["The epidemic has had a dramatic impact on poultry farming and industry with million birds dying or being destroyed to reduce virus dispersal.", [["dramatic", "OBSERVATION_MODIFIER", 23, 31]]], ["This ongoing epidemic clearly has ''pandemic potential''.Diagnosis and preventionAvian influenza viruses may be detected by virus isolation (in cell culture or embryonated eggs) or RT-PCR which may be targeted at the specific HA subtype or may be generic to influenza A viruses (e.g. targeting the matrix protein gene) [104] .", [["cell culture", "ANATOMY", 144, 156], ["eggs", "ANATOMY", 172, 176], ["influenza viruses", "DISEASE", 87, 104], ["preventionAvian influenza viruses", "ORGANISM", 71, 104], ["cell culture", "CELL", 144, 156], ["influenza A viruses", "ORGANISM", 258, 277], ["matrix", "CELLULAR_COMPONENT", 298, 304], ["matrix protein gene", "DNA", 298, 317], ["influenza A viruses", "SPECIES", 258, 277], ["preventionAvian influenza viruses", "PROBLEM", 71, 104], ["virus isolation", "PROBLEM", 124, 139], ["cell culture", "TEST", 144, 156], ["embryonated eggs", "PROBLEM", 160, 176], ["RT-PCR", "TEST", 181, 187], ["influenza A viruses", "PROBLEM", 258, 277], ["the matrix protein gene", "TREATMENT", 294, 317], ["influenza viruses", "OBSERVATION", 87, 104]]], ["Also, serological tests such as. hemagglutination inhibition may be used.Diagnosis and preventionTyping may be based on serological methods (such as hemagglutination inhibition), specific primers/probes or sequencing.", [["serological tests", "TEST", 6, 23], ["hemagglutination inhibition", "TREATMENT", 33, 60], ["preventionTyping", "TEST", 87, 103], ["serological methods", "TEST", 120, 139], ["hemagglutination inhibition", "TEST", 149, 176], ["specific primers/probes", "TEST", 179, 202]]], ["Many commercial influenza A antigen tests detect the nucleoprotein or NA activity and should be applicable to the avian viruses, although this is poorly studied and documented.", [["influenza A antigen", "GENE_OR_GENE_PRODUCT", 16, 35], ["avian", "ORGANISM", 114, 119], ["Many commercial influenza A antigen tests", "TEST", 0, 41], ["the avian viruses", "PROBLEM", 110, 127], ["influenza", "OBSERVATION", 16, 25]]], ["Furthermore, it should be noted that RT-PCR from throat swabs of the lethal case in the Netherlands were negative [102] .Diagnosis and preventionAvian influenza, or ''fowl plague'' outbreaks usually arise following contact with wild aquatic birds, such as mallards and ducks, in which the virus replicates as a rule without causing symptoms.", [["throat swabs", "ANATOMY", 49, 61], ["Avian influenza", "DISEASE", 145, 160], ["fowl plague", "DISEASE", 167, 178], ["mallards", "ORGANISM", 256, 264], ["ducks", "ORGANISM", 269, 274], ["Avian influenza", "SPECIES", 145, 160], ["fowl", "SPECIES", 167, 171], ["mallards", "SPECIES", 256, 264], ["ducks", "SPECIES", 269, 274], ["mallards", "SPECIES", 256, 264], ["RT-PCR", "TEST", 37, 43], ["throat swabs", "TEST", 49, 61], ["Avian influenza", "PROBLEM", 145, 160], ["the virus", "PROBLEM", 285, 294], ["symptoms", "PROBLEM", 332, 340]]], ["The virus that is excreted in the gut can typically be isolated (or detected by RT-PCR) from cloacal swabs.", [["gut", "ANATOMY", 34, 37], ["cloacal swabs", "ANATOMY", 93, 106], ["gut", "ORGANISM_SUBDIVISION", 34, 37], ["cloacal swabs", "MULTI-TISSUE_STRUCTURE", 93, 106], ["The virus", "PROBLEM", 0, 9], ["RT-PCR", "TEST", 80, 86], ["cloacal swabs", "TEST", 93, 106], ["virus", "OBSERVATION", 4, 9], ["excreted", "OBSERVATION_MODIFIER", 18, 26], ["gut", "ANATOMY", 34, 37]]], ["Hinshaw et al. [105] studied over nine thousand birds and detected 30% prevalence in young and 11% prevalence in adult birds.", [["birds", "ORGANISM", 48, 53], ["birds", "ORGANISM", 119, 124]]], ["Influenza virus is readily transmitted in cold environments and is stable for 126-207 days at +17\u00b0C, or in wet faeces (as shown for H5N1 virus) for at least 4 days at 25\u00b0C and more than 40 days at +4\u00b0C [106, 107] .Diagnosis and preventionThe main preventive and control measures include proofing the chicken breeding facilities against wild birds.", [["wet faeces", "ANATOMY", 107, 117], ["Influenza virus", "DISEASE", 0, 15], ["Influenza virus", "ORGANISM", 0, 15], ["faeces", "ORGANISM_SUBDIVISION", 111, 117], ["H5N1 virus", "ORGANISM", 132, 142], ["chicken", "ORGANISM", 300, 307], ["Influenza virus", "SPECIES", 0, 15], ["H5N1 virus", "SPECIES", 132, 142], ["chicken", "SPECIES", 300, 307], ["Influenza virus", "SPECIES", 0, 15], ["H5N1 virus", "SPECIES", 132, 142], ["chicken", "SPECIES", 300, 307], ["Influenza virus", "PROBLEM", 0, 15], ["H5N1 virus", "PROBLEM", 132, 142], ["control measures", "TREATMENT", 262, 278], ["the chicken breeding facilities", "TREATMENT", 296, 327], ["virus", "OBSERVATION", 10, 15], ["stable", "OBSERVATION_MODIFIER", 67, 73], ["main", "OBSERVATION_MODIFIER", 242, 246]]], ["Raising chickens and turkeys in the open is a risk, minimizing secondary spread of outbreaks by stamping out the infected poultry, followed by cleaning, disinfection and controlling movements of humans and animals, trade embargoes and reporting the outbreaks (''fowl plague'' is in the top priority ''list A'' of the International Animal Health Code of the Office International des Epizooties).", [["chickens", "ORGANISM", 8, 16], ["turkeys", "ORGANISM", 21, 28], ["humans", "ORGANISM", 195, 201], ["chickens", "SPECIES", 8, 16], ["turkeys", "SPECIES", 21, 28], ["humans", "SPECIES", 195, 201], ["chickens", "SPECIES", 8, 16], ["turkeys", "SPECIES", 21, 28], ["humans", "SPECIES", 195, 201], ["disinfection", "TREATMENT", 153, 165]]], ["Vaccination of poultry has been used as an additional control measure but may lead to undetected shedding and transmission of mutant virus selected under the pressure imposed by the vaccine [94] .Diagnosis and preventionTo prevent further transmission to humans, rapid measures are needed due to the short incubation period.", [["mutant virus", "ORGANISM", 126, 138], ["humans", "ORGANISM", 255, 261], ["humans", "SPECIES", 255, 261], ["poultry", "SPECIES", 15, 22], ["humans", "SPECIES", 255, 261], ["Vaccination of poultry", "TREATMENT", 0, 22], ["an additional control measure", "TREATMENT", 40, 69], ["undetected shedding", "PROBLEM", 86, 105], ["mutant virus", "PROBLEM", 126, 138], ["rapid measures", "TREATMENT", 263, 277]]], ["The Dutch experience suggests that results can be achieved by personal protection (e.g. protective eye glasses, masks) for all workers who screen and cull poultry, vaccination with regular inactivated influenza virus vaccine and prophylactic oseltamivir for those handling potentially infected poultry, to be continued for 2 days after last exposure [102] .", [["eye", "ANATOMY", 99, 102], ["oseltamivir", "CHEMICAL", 242, 253], ["oseltamivir", "CHEMICAL", 242, 253], ["eye", "ORGAN", 99, 102], ["influenza virus", "ORGANISM", 201, 216], ["influenza virus vaccine", "SPECIES", 201, 224], ["protective eye glasses", "TREATMENT", 88, 110], ["cull poultry", "TREATMENT", 150, 162], ["vaccination", "TREATMENT", 164, 175], ["regular inactivated influenza virus vaccine", "TREATMENT", 181, 224], ["prophylactic oseltamivir", "TREATMENT", 229, 253], ["infected poultry", "TREATMENT", 285, 301]]], ["For humans, specific vaccines containing H5 and H7 antigens would be welcome.VirologyThe only known zoonotic agent of the Togaviridae family to cause human disease in Europe is the mosquito-borne Sindbis virus (SINV), in the genus Alphavirus.", [["human disease", "DISEASE", 150, 163], ["Sindbis virus", "DISEASE", 196, 209], ["humans", "ORGANISM", 4, 10], ["H7 antigens", "ORGANISM", 48, 59], ["Togaviridae", "ORGANISM", 122, 133], ["human", "ORGANISM", 150, 155], ["mosquito-borne", "ORGANISM", 181, 195], ["Sindbis virus", "ORGANISM", 196, 209], ["SINV", "ORGANISM", 211, 215], ["H5 and H7 antigens", "PROTEIN", 41, 59], ["humans", "SPECIES", 4, 10], ["human", "SPECIES", 150, 155], ["Sindbis virus", "SPECIES", 196, 209], ["humans", "SPECIES", 4, 10], ["human", "SPECIES", 150, 155], ["Sindbis virus", "SPECIES", 196, 209], ["SINV", "SPECIES", 211, 215], ["specific vaccines", "TREATMENT", 12, 29], ["H5 and H7 antigens", "TREATMENT", 41, 59], ["human disease", "PROBLEM", 150, 163], ["the mosquito-borne Sindbis virus", "PROBLEM", 177, 209], ["zoonotic", "OBSERVATION_MODIFIER", 100, 108], ["genus Alphavirus", "ANATOMY", 225, 241]]], ["SINV is distributed throughout the Old World and Australia and causes rashes and polyarthritis outbreaks in Northern Europe, similar to Chikungunya, O\u00d5nyong-nyong virus and Ross River virus in Far East Asia, Africa and Australia, respectively, whereas other alphaviruses causing encephalitic infections in man (Venezuelan, Western and Eastern equine encephalitis virus) are found in the New World.VirologyAlphaviruses are enveloped, positive-strand RNA viruses with an 11 kb genome.", [["rashes", "DISEASE", 70, 76], ["polyarthritis", "DISEASE", 81, 94], ["Chikungunya", "DISEASE", 136, 147], ["alphaviruses", "DISEASE", 258, 270], ["encephalitic infections", "DISEASE", 279, 302], ["encephalitis", "DISEASE", 350, 362], ["SINV", "ORGANISM", 0, 4], ["Chikungunya", "ORGANISM", 136, 147], ["O\u00d5nyong-nyong virus", "ORGANISM", 149, 168], ["Ross River virus", "ORGANISM", 173, 189], ["man", "ORGANISM", 306, 309], ["Eastern equine encephalitis virus", "ORGANISM", 335, 368], ["VirologyAlphaviruses", "GENE_OR_GENE_PRODUCT", 397, 417], ["11 kb genome", "DNA", 469, 481], ["man", "SPECIES", 306, 309], ["equine encephalitis virus", "SPECIES", 343, 368], ["SINV", "SPECIES", 0, 4], ["O\u00d5nyong-nyong virus", "SPECIES", 149, 168], ["Ross River virus", "SPECIES", 173, 189], ["Eastern equine encephalitis virus", "SPECIES", 335, 368], ["rashes", "PROBLEM", 70, 76], ["polyarthritis outbreaks", "PROBLEM", 81, 104], ["Chikungunya", "PROBLEM", 136, 147], ["nyong virus", "PROBLEM", 157, 168], ["Ross River virus", "PROBLEM", 173, 189], ["encephalitic infections", "PROBLEM", 279, 302], ["Eastern equine encephalitis virus", "PROBLEM", 335, 368], ["VirologyAlphaviruses", "TEST", 397, 417], ["strand RNA viruses", "PROBLEM", 442, 460], ["an 11 kb genome", "PROBLEM", 466, 481], ["distributed", "OBSERVATION_MODIFIER", 8, 19], ["rashes", "OBSERVATION", 70, 76], ["polyarthritis", "OBSERVATION", 81, 94], ["River virus", "OBSERVATION", 178, 189], ["encephalitic", "OBSERVATION_MODIFIER", 279, 291], ["strand RNA viruses", "OBSERVATION", 442, 460], ["11 kb", "OBSERVATION_MODIFIER", 469, 474], ["genome", "OBSERVATION", 475, 481]]], ["The non-structural proteins (NSP1-4) are encoded from the 5 0 -terminus of the genome, and a separate subgenomic 26S RNA from the 3 0 -end is used as a messenger for the structural proteins: the 30-33 kDa capsid protein (C), and the 45-58 kDa envelope glycoproteins (E1 and E2) [94] (Table 1 , Fig. 1 ).Epidemiology and ecologySINV was first isolated in the Nile Delta in the 1950s from a pool of mosquitoes without knowledge of any disease association.", [["NSP1-4", "GENE_OR_GENE_PRODUCT", 29, 35], ["genome", "CELLULAR_COMPONENT", 79, 85], ["26S", "GENE_OR_GENE_PRODUCT", 113, 116], ["C", "GENE_OR_GENE_PRODUCT", 221, 222], ["Nile Delta", "ORGANISM", 358, 368], ["non-structural proteins", "PROTEIN", 4, 27], ["NSP1", "PROTEIN", 29, 33], ["4", "PROTEIN", 34, 35], ["5 0 -terminus", "DNA", 58, 71], ["subgenomic 26S RNA", "RNA", 102, 120], ["3 0 -end", "DNA", 130, 138], ["structural proteins", "PROTEIN", 170, 189], ["30-33 kDa capsid protein", "PROTEIN", 195, 219], ["C", "PROTEIN", 221, 222], ["45-58 kDa envelope glycoproteins", "PROTEIN", 233, 265], ["E1", "PROTEIN", 267, 269], ["E2", "PROTEIN", 274, 276], ["The non-structural proteins", "TEST", 0, 27], ["NSP1", "TEST", 29, 33], ["capsid protein", "TEST", 205, 219], ["C", "TEST", 221, 222], ["kDa envelope glycoproteins", "TEST", 239, 265], ["E2", "TEST", 274, 276], ["the Nile Delta", "TEST", 354, 368], ["any disease association", "PROBLEM", 429, 452], ["non-structural proteins", "OBSERVATION", 4, 27], ["genome", "ANATOMY", 79, 85], ["subgenomic", "OBSERVATION_MODIFIER", 102, 112], ["26S RNA", "OBSERVATION", 113, 120], ["disease", "OBSERVATION", 433, 440]]], ["It is now known to be the causative agent of mosquito-borne epidemic polyarthritis with accompanying rashes and when described in Northern Europe it was given the names Ockelbo disease, Pogosta disease, or Karelian fever when found in Sweden, Finland and Russia, respectively.", [["polyarthritis", "DISEASE", 69, 82], ["rashes", "DISEASE", 101, 107], ["Ockelbo disease", "DISEASE", 169, 184], ["Pogosta disease", "DISEASE", 186, 201], ["Karelian fever", "DISEASE", 206, 220], ["rashes", "PATHOLOGICAL_FORMATION", 101, 107], ["mosquito-borne epidemic polyarthritis", "PROBLEM", 45, 82], ["accompanying rashes", "PROBLEM", 88, 107], ["the names Ockelbo disease", "PROBLEM", 159, 184], ["Pogosta disease", "PROBLEM", 186, 201], ["Karelian fever", "PROBLEM", 206, 220], ["borne", "OBSERVATION_MODIFIER", 54, 59], ["epidemic", "OBSERVATION_MODIFIER", 60, 68], ["polyarthritis", "OBSERVATION", 69, 82], ["rashes", "OBSERVATION", 101, 107]]], ["Most infections occur during August-September, and larger outbreaks tend to appear with a seven-year interval (e.g. in Finland, 1282 serologically verified cases occurred in 1995, 600 cases in 2002; and in Sweden 50-65 cases are reported during peak years) [108, 109] , with a peak incidence (56%) in 50-year old females.", [["infections", "DISEASE", 5, 15], ["Most infections", "PROBLEM", 0, 15], ["larger outbreaks", "PROBLEM", 51, 67], ["a peak incidence", "PROBLEM", 275, 291], ["larger", "OBSERVATION_MODIFIER", 51, 57], ["outbreaks", "OBSERVATION", 58, 67], ["females", "OBSERVATION", 313, 320]]], ["The association of SINV with Pogosta disease was first discovered in the early 1960s and it is believed that the virus may have been distributed throughout Northern Europe around this time.", [["Pogosta disease", "DISEASE", 29, 44], ["SINV", "ORGANISM", 19, 23], ["SINV", "SPECIES", 19, 23], ["SINV", "PROBLEM", 19, 23], ["Pogosta disease", "PROBLEM", 29, 44], ["the virus", "PROBLEM", 109, 118], ["SINV", "OBSERVATION", 19, 23], ["Pogosta disease", "OBSERVATION", 29, 44], ["virus", "OBSERVATION", 113, 118]]], ["This conclusion is based on the evidence that thousands of human and bird sera collected during the early 1960s in Finland, were negative for SINV antibodies, whereas in the 1990s 2-5% of the population were SINVantibody positive [108] .", [["sera", "ANATOMY", 74, 78], ["human", "ORGANISM", 59, 64], ["bird sera", "ORGANISM", 69, 78], ["SINV", "ORGANISM", 142, 146], ["SINVantibody", "GENE_OR_GENE_PRODUCT", 208, 220], ["SINV antibodies", "PROTEIN", 142, 157], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["SINV", "SPECIES", 142, 146], ["bird sera", "TEST", 69, 78], ["SINV antibodies", "TEST", 142, 157], ["SINVantibody", "TEST", 208, 220]]], ["Antibodies to SINV without polyarthritis outbreaks have been recorded in Italy, Romania, Greece and the former Yugoslavia [109] .", [["polyarthritis", "DISEASE", 27, 40], ["SINV", "ORGANISM", 14, 18], ["SINV", "SPECIES", 14, 18], ["polyarthritis outbreaks", "PROBLEM", 27, 50], ["without", "UNCERTAINTY", 19, 26], ["polyarthritis", "OBSERVATION", 27, 40]]], ["However, human disease due to SINV has been recorded in South Africa, from where it may have originated.", [["SINV", "DISEASE", 30, 34], ["human", "ORGANISM", 9, 14], ["SINV", "ORGANISM", 30, 34], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["SINV", "SPECIES", 30, 34], ["human disease", "PROBLEM", 9, 22], ["SINV", "PROBLEM", 30, 34]]], ["SINV was isolated from mosquitoes in Sweden, Norway and Russia in the early 1980s [109] [110] [111] and SINV antibodies are found in wild tetraonic and migratory birds, most commonly (in Sweden) from Passeriformes such as redwing (Turdus iliacus), fieldfare (Turdus pilaris), blue tit (Parus caeluleus), chaffinch (Frinigilla coelebs), songthrush (Turdus philomelos); thrushes have been suggested to be a major candidate as an amplifying host [109, 112] .", [["SINV", "ORGANISM", 0, 4], ["SINV", "ORGANISM", 104, 108], ["birds", "ORGANISM", 162, 167], ["Turdus iliacus", "ORGANISM", 231, 245], ["Turdus pilaris", "ORGANISM", 259, 273], ["blue tit", "ORGANISM", 276, 284], ["Parus caeluleus", "ORGANISM", 286, 301], ["Frinigilla coelebs", "ORGANISM", 315, 333], ["Turdus philomelos", "ORGANISM", 348, 365], ["thrushes", "GENE_OR_GENE_PRODUCT", 368, 376], ["SINV antibodies", "PROTEIN", 104, 119], ["Turdus iliacus", "SPECIES", 231, 245], ["Turdus pilaris", "SPECIES", 259, 273], ["blue tit", "SPECIES", 276, 284], ["Parus caeluleus", "SPECIES", 286, 301], ["chaffinch", "SPECIES", 304, 313], ["Frinigilla coelebs", "SPECIES", 315, 333], ["songthrush", "SPECIES", 336, 346], ["Turdus philomelos", "SPECIES", 348, 365], ["SINV", "SPECIES", 0, 4], ["SINV", "SPECIES", 104, 108], ["Turdus iliacus", "SPECIES", 231, 245], ["Turdus pilaris", "SPECIES", 259, 273], ["blue tit", "SPECIES", 276, 284], ["Parus caeluleus", "SPECIES", 286, 301], ["Frinigilla coelebs", "SPECIES", 315, 333], ["Turdus philomelos", "SPECIES", 348, 365], ["SINV antibodies", "TEST", 104, 119], ["fieldfare (Turdus pilaris", "PROBLEM", 248, 273], ["blue tit (Parus caeluleus)", "PROBLEM", 276, 302], ["chaffinch (Frinigilla coelebs)", "PROBLEM", 304, 334], ["songthrush (Turdus philomelos", "PROBLEM", 336, 365], ["migratory birds", "OBSERVATION", 152, 167], ["iliacus", "ANATOMY", 238, 245], ["pilaris", "ANATOMY", 266, 273]]], ["In addition, antibodies are commonly found in Galliformes [109, 108] .", [["antibodies", "PROTEIN", 13, 23], ["antibodies", "TEST", 13, 23]]], ["Phylogenetically, SINV strains are similar in Northern Europe and South Africa (in the north to south dimension), but differ considerably from strains circulating in Asia and Australia, where SINV-associated rash-arthritis is not recorded.", [["rash", "DISEASE", 208, 212], ["arthritis", "DISEASE", 213, 222], ["SINV strains", "ORGANISM", 18, 30], ["SINV", "ORGANISM", 192, 196], ["SINV", "SPECIES", 18, 22], ["SINV", "SPECIES", 192, 196], ["SINV strains", "PROBLEM", 18, 30], ["strains", "PROBLEM", 143, 150], ["SINV", "PROBLEM", 192, 196], ["associated rash", "PROBLEM", 197, 212], ["arthritis", "PROBLEM", 213, 222], ["SINV strains", "OBSERVATION", 18, 30], ["similar", "OBSERVATION_MODIFIER", 35, 42], ["Northern", "OBSERVATION_MODIFIER", 46, 54], ["Europe", "OBSERVATION_MODIFIER", 55, 61], ["South", "OBSERVATION_MODIFIER", 66, 71], ["Africa", "OBSERVATION_MODIFIER", 72, 78], ["rash", "OBSERVATION", 208, 212], ["arthritis", "OBSERVATION", 213, 222]]], ["This is consistent with the notion of a north-south dispersal of SINV strains by migratory birds [113] .", [["SINV", "ORGANISM", 65, 69], ["SINV", "SPECIES", 65, 69], ["SINV strains", "PROBLEM", 65, 77], ["consistent with", "UNCERTAINTY", 8, 23], ["SINV strains", "OBSERVATION", 65, 77]]], ["Several bird species can be infected experimentally [114] .", [["Several bird species", "PROBLEM", 0, 20], ["bird species", "OBSERVATION", 8, 20]]], ["It is evident that SINV cycles between birds and ornithophilic (Culex and Culiseta) mosquitoes (Table 2) .", [["SINV", "ORGANISM", 19, 23], ["birds", "ORGANISM", 39, 44], ["Culiseta) mosquitoes", "ORGANISM", 74, 94], ["SINV", "SPECIES", 19, 23], ["SINV cycles", "TREATMENT", 19, 30], ["ornithophilic (Culex and Culiseta) mosquitoes", "TREATMENT", 49, 94], ["SINV cycles", "OBSERVATION", 19, 30]]], ["However, it may spill over to other hosts (evidence from many vertebrates from a frog to a bear) and vectors (including ticks and Aedes mosquitoes) [109] .Epidemiology and ecologyRecently, during an outbreak in Finland in 2002, the causative agent of Pogosta disease was isolated for the first time in Europe from skin biopsies and a blood sample of patients [115] ; the virus strains were most closely related to SINV strains isolated from mosquitoes in Sweden and Russia 20 years previously.Clinical picture and pathogenesisThe incubation period for the disease is about one week and the onset is accompanied by arthritis/arthralgia and itchy rash as the dominant symptoms, and also fatigue, mild fever, headache and muscle pain.", [["skin biopsies", "ANATOMY", 314, 327], ["blood sample", "ANATOMY", 334, 346], ["muscle", "ANATOMY", 719, 725], ["Pogosta disease", "DISEASE", 251, 266], ["arthritis", "DISEASE", 614, 623], ["arthralgia", "DISEASE", 624, 634], ["rash", "DISEASE", 645, 649], ["fatigue", "DISEASE", 685, 692], ["fever", "DISEASE", 699, 704], ["headache", "DISEASE", 706, 714], ["muscle pain", "DISEASE", 719, 730], ["frog", "ORGANISM_SUBDIVISION", 81, 85], ["Aedes mosquitoes", "ORGANISM", 130, 146], ["Pogosta disease", "CANCER", 251, 266], ["skin biopsies", "CANCER", 314, 327], ["blood", "ORGANISM_SUBSTANCE", 334, 339], ["patients", "ORGANISM", 350, 358], ["SINV", "ORGANISM", 414, 418], ["muscle", "ORGAN", 719, 725], ["patients", "SPECIES", 350, 358], ["Aedes mosquitoes", "SPECIES", 130, 146], ["SINV", "SPECIES", 414, 418], ["a frog to a bear) and vectors", "TREATMENT", 79, 108], ["Pogosta disease", "PROBLEM", 251, 266], ["skin biopsies", "TEST", 314, 327], ["a blood sample", "TEST", 332, 346], ["the virus strains", "PROBLEM", 367, 384], ["SINV strains", "PROBLEM", 414, 426], ["Clinical picture", "PROBLEM", 493, 509], ["pathogenesis", "PROBLEM", 514, 526], ["the disease", "PROBLEM", 552, 563], ["arthritis", "PROBLEM", 614, 623], ["arthralgia", "PROBLEM", 624, 634], ["itchy rash", "PROBLEM", 639, 649], ["the dominant symptoms", "PROBLEM", 653, 674], ["fatigue", "PROBLEM", 685, 692], ["mild fever", "PROBLEM", 694, 704], ["headache", "PROBLEM", 706, 714], ["muscle pain", "PROBLEM", 719, 730], ["skin", "ANATOMY", 314, 318], ["biopsies", "OBSERVATION", 319, 327], ["disease", "OBSERVATION", 556, 563], ["arthritis", "OBSERVATION", 614, 623], ["arthralgia", "OBSERVATION", 624, 634], ["mild", "OBSERVATION_MODIFIER", 694, 698], ["fever", "OBSERVATION", 699, 704], ["muscle", "ANATOMY", 719, 725], ["pain", "OBSERVATION", 726, 730]]], ["Hematological laboratory parameters are within the normal range and levels of C-reactive protein (CRP) are not elevated.", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 78, 96], ["CRP", "GENE_OR_GENE_PRODUCT", 98, 101], ["C-reactive protein", "PROTEIN", 78, 96], ["CRP", "PROTEIN", 98, 101], ["Hematological laboratory parameters", "TEST", 0, 35], ["C-reactive protein", "TEST", 78, 96], ["CRP", "TEST", 98, 101], ["elevated", "PROBLEM", 111, 119], ["normal range", "OBSERVATION_MODIFIER", 51, 63], ["not", "UNCERTAINTY", 107, 110], ["elevated", "OBSERVATION_MODIFIER", 111, 119]]], ["The rash is usually located on the trunk and thighs and lasts for a couple of days.", [["trunk", "ANATOMY", 35, 40], ["thighs", "ANATOMY", 45, 51], ["rash", "DISEASE", 4, 8], ["trunk", "ORGANISM_SUBDIVISION", 35, 40], ["thighs", "ORGANISM_SUBDIVISION", 45, 51], ["The rash", "PROBLEM", 0, 8], ["rash", "OBSERVATION", 4, 8], ["trunk", "ANATOMY", 35, 40], ["thighs", "ANATOMY", 45, 51]]], ["One third to a half of patients, suffer from joint pains for more than 12 months [116, 117] .", [["joint", "ANATOMY", 45, 50], ["joint pains", "DISEASE", 45, 56], ["patients", "ORGANISM", 23, 31], ["joint", "ORGANISM_SUBDIVISION", 45, 50], ["patients", "SPECIES", 23, 31], ["joint pains", "PROBLEM", 45, 56], ["joint", "ANATOMY", 45, 50], ["pains", "OBSERVATION", 51, 56]]], ["Usually several joints are affected, the most common being the ankle, wrists, knee, and finger joints (50% or more of patients), as well as hip, shoulder and elbow joints [118,119a,119b ].Diagnostics and preventionDiagnosis is based on serology using enzyme immunoassay, immunofluorescence assay or hemagglutinationinhibition, and detection of seroconversion or a 4-fold rise in titre between two samples, or positive IgM in a single sample.", [["joints", "ANATOMY", 16, 22], ["ankle", "ANATOMY", 63, 68], ["wrists", "ANATOMY", 70, 76], ["knee", "ANATOMY", 78, 82], ["finger joints", "ANATOMY", 88, 101], ["hip", "ANATOMY", 140, 143], ["shoulder", "ANATOMY", 145, 153], ["elbow joints", "ANATOMY", 158, 170], ["samples", "ANATOMY", 397, 404], ["joints", "MULTI-TISSUE_STRUCTURE", 16, 22], ["ankle", "ORGANISM_SUBDIVISION", 63, 68], ["wrists", "ORGANISM_SUBDIVISION", 70, 76], ["knee", "ORGANISM_SUBDIVISION", 78, 82], ["finger joints", "MULTI-TISSUE_STRUCTURE", 88, 101], ["patients", "ORGANISM", 118, 126], ["hip", "ORGANISM_SUBDIVISION", 140, 143], ["shoulder", "ORGANISM_SUBDIVISION", 145, 153], ["elbow joints", "MULTI-TISSUE_STRUCTURE", 158, 170], ["IgM", "GENE_OR_GENE_PRODUCT", 418, 421], ["IgM", "PROTEIN", 418, 421], ["patients", "SPECIES", 118, 126], ["serology", "TEST", 236, 244], ["enzyme immunoassay", "TEST", 251, 269], ["immunofluorescence assay", "TEST", 271, 295], ["hemagglutinationinhibition", "TEST", 299, 325], ["seroconversion", "PROBLEM", 344, 358], ["a 4-fold rise", "PROBLEM", 362, 375], ["positive IgM", "PROBLEM", 409, 421], ["joints", "ANATOMY", 16, 22], ["most common", "OBSERVATION_MODIFIER", 41, 52], ["ankle", "ANATOMY", 63, 68], ["wrists", "ANATOMY", 70, 76], ["knee", "ANATOMY", 78, 82], ["finger joints", "ANATOMY", 88, 101], ["hip", "ANATOMY", 140, 143], ["shoulder", "ANATOMY", 145, 153], ["elbow joints", "ANATOMY", 158, 170]]], ["The first sample is usually taken during the first week after onset of illness, another sample is required to diagnose or exclude SINV infection; IgM antibodies are detectable until approximately 6 days post-onset, and IgG antibodies can be detected approximately 10 days after onset of illness [119b,120] .", [["SINV infection", "DISEASE", 130, 144], ["illness", "DISEASE", 287, 294], ["SINV", "ORGANISM", 130, 134], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 146, 160], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 219, 233], ["IgM antibodies", "PROTEIN", 146, 160], ["IgG antibodies", "PROTEIN", 219, 233], ["SINV", "SPECIES", 130, 134], ["illness", "PROBLEM", 71, 78], ["SINV infection", "PROBLEM", 130, 144], ["IgM antibodies", "TEST", 146, 160], ["IgG antibodies", "TEST", 219, 233], ["illness", "PROBLEM", 287, 294], ["infection", "OBSERVATION", 135, 144]]], ["In some cases persisting IgM antibody can be detected years after infection [117] .", [["infection", "DISEASE", 66, 75], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 25, 37], ["IgM antibody", "PROTEIN", 25, 37], ["IgM antibody", "TEST", 25, 37], ["infection", "PROBLEM", 66, 75], ["IgM antibody", "OBSERVATION", 25, 37]]], ["For research purposes, the virus can be detected by 121] or isolated from skin biopsies [115] .", [["skin biopsies", "ANATOMY", 74, 87], ["skin biopsies", "CANCER", 74, 87], ["research purposes", "TEST", 4, 21], ["the virus", "PROBLEM", 23, 32], ["skin biopsies", "TEST", 74, 87], ["skin", "ANATOMY", 74, 78], ["biopsies", "OBSERVATION", 79, 87]]], ["No specific preventive measures are available, apart from avoiding mosquito bites.VirologyFlaviviruses comprise a diverse group of pathogens that have been traditionally classified as arthropodborne viruses.", [["mosquito bites", "DISEASE", 67, 81], ["arthropodborne viruses", "ORGANISM", 184, 206], ["VirologyFlaviviruses", "PROBLEM", 82, 102], ["pathogens", "PROBLEM", 131, 140], ["diverse", "OBSERVATION_MODIFIER", 114, 121]]], ["They are linear positive single-stranded RNA viruses with a monopartite genome (10-11 kb) that encodes 3 structural proteins: the 13 kDa capsid protein (C), the 51-59 kDa major envelope protein (E) and the 8.5 kDa glycoprotein M (in mature virions); and 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (Table 1, Fig. 1 ).", [["virions", "ANATOMY", 240, 247], ["C", "GENE_OR_GENE_PRODUCT", 153, 154], ["E", "GENE_OR_GENE_PRODUCT", 195, 196], ["glycoprotein M", "GENE_OR_GENE_PRODUCT", 214, 228], ["NS1", "GENE_OR_GENE_PRODUCT", 281, 284], ["NS2A", "GENE_OR_GENE_PRODUCT", 286, 290], ["NS2B", "GENE_OR_GENE_PRODUCT", 292, 296], ["NS3", "GENE_OR_GENE_PRODUCT", 298, 301], ["NS4A", "GENE_OR_GENE_PRODUCT", 303, 307], ["NS4B", "GENE_OR_GENE_PRODUCT", 309, 313], ["monopartite genome", "DNA", 60, 78], ["structural proteins", "PROTEIN", 105, 124], ["13 kDa capsid protein", "PROTEIN", 130, 151], ["C", "PROTEIN", 153, 154], ["51-59 kDa major envelope protein", "PROTEIN", 161, 193], ["E", "PROTEIN", 195, 196], ["8.5 kDa glycoprotein M", "PROTEIN", 206, 228], ["mature virions", "PROTEIN", 233, 247], ["non-structural proteins", "PROTEIN", 256, 279], ["NS1", "PROTEIN", 281, 284], ["NS2A", "PROTEIN", 286, 290], ["NS2B", "PROTEIN", 292, 296], ["NS3", "PROTEIN", 298, 301], ["NS4A", "PROTEIN", 303, 307], ["NS4B", "PROTEIN", 309, 313], ["NS5", "PROTEIN", 318, 321], ["Table 1", "PROTEIN", 324, 331], ["linear positive single-stranded RNA viruses", "PROBLEM", 9, 52], ["a monopartite genome", "PROBLEM", 58, 78], ["capsid protein", "TEST", 137, 151], ["C", "TEST", 153, 154], ["envelope protein", "TEST", 177, 193], ["the 8.5 kDa glycoprotein M", "TEST", 202, 228], ["non-structural proteins", "TEST", 256, 279], ["NS1", "TEST", 281, 284], ["NS2A", "TEST", 286, 290], ["NS2B", "TEST", 292, 296], ["NS3", "TREATMENT", 298, 301], ["NS4A", "TREATMENT", 303, 307], ["NS4B and NS5", "TREATMENT", 309, 321], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["positive", "OBSERVATION_MODIFIER", 16, 24], ["stranded RNA viruses", "OBSERVATION", 32, 52], ["monopartite genome", "OBSERVATION", 60, 78]]], ["Noncoding or untranslated regions flank the infectious RNA genome.", [["Noncoding or untranslated regions", "DNA", 0, 33], ["infectious RNA genome", "DNA", 44, 65], ["Noncoding or untranslated regions flank the infectious RNA genome", "PROBLEM", 0, 65], ["infectious", "OBSERVATION_MODIFIER", 44, 54], ["RNA genome", "OBSERVATION", 55, 65]]], ["When seen in the electron microscope flaviviruses appear as uniform spherical particles, 40-60 nm in diameter.", [["uniform", "OBSERVATION_MODIFIER", 60, 67], ["spherical", "OBSERVATION_MODIFIER", 68, 77], ["particles", "OBSERVATION_MODIFIER", 78, 87]]], ["The virus particles consist of a lipid envelope that has a surface covered by protrusions that contain envelope (E) and membrane (M) structural proteins, organized as dimers.", [["surface", "ANATOMY", 59, 66], ["membrane", "ANATOMY", 120, 128], ["membrane", "CELLULAR_COMPONENT", 120, 128], ["envelope (E) and membrane (M) structural proteins", "PROTEIN", 103, 152], ["The virus particles", "PROBLEM", 0, 19], ["a lipid envelope", "PROBLEM", 31, 47], ["protrusions", "PROBLEM", 78, 89], ["envelope (E) and membrane (M) structural proteins", "PROBLEM", 103, 152], ["virus particles", "OBSERVATION", 4, 19], ["lipid envelope", "OBSERVATION", 33, 47], ["surface", "OBSERVATION_MODIFIER", 59, 66], ["protrusions", "OBSERVATION", 78, 89], ["envelope", "OBSERVATION_MODIFIER", 103, 111]]], ["This envelope surrounds an isometric capsid protein of approximately 30 nm in diameter [122] [123] [124] .Ecology and epidemiologyThere are currently about 70 members in the family Flaviviridae [125] which have been found infecting a wide variety of organisms including mammals, arthropods, avian and amphibians.", [["avian", "ORGANISM", 291, 296], ["isometric capsid protein", "PROTEIN", 27, 51], ["avian", "SPECIES", 291, 296], ["an isometric capsid protein", "TEST", 24, 51], ["isometric", "OBSERVATION_MODIFIER", 27, 36], ["capsid protein", "OBSERVATION", 37, 51], ["30 nm", "OBSERVATION_MODIFIER", 69, 74]]], ["Many of these viruses are major pathogens of humans, domestic and farmed animals as well as wildlife species.", [["humans", "ORGANISM", 45, 51], ["humans", "SPECIES", 45, 51], ["humans", "SPECIES", 45, 51], ["viruses", "OBSERVATION", 14, 21]]], ["With the possible exception of the dengue viruses, the flaviviruses are zoonotic, depending almost entirely for their existence on wildlife vertebrate and in many cases, invertebrate species.", [["dengue", "DISEASE", 35, 41], ["flaviviruses", "DISEASE", 55, 67], ["dengue viruses", "ORGANISM", 35, 49], ["dengue viruses", "SPECIES", 35, 49], ["the dengue viruses", "PROBLEM", 31, 49], ["the flaviviruses", "PROBLEM", 51, 67], ["dengue viruses", "OBSERVATION", 35, 49], ["invertebrate species", "OBSERVATION", 170, 190]]], ["The type species of the genus is yellow fever virus (YFV), hence the term ''flavi'' from the Latin word flavus, which in turn describes the yellowish color of the skin in yellow fever infections [126] .Ecology and epidemiologyThe classification, and serological and phylogenetic studies of flaviviruses reflect the importance of the vector on the biology and evolution of this genus.", [["skin", "ANATOMY", 163, 167], ["yellow fever", "DISEASE", 33, 45], ["yellow fever", "DISEASE", 171, 183], ["infections", "DISEASE", 184, 194], ["yellow fever virus", "ORGANISM", 33, 51], ["YFV", "ORGANISM", 53, 56], ["skin", "ORGAN", 163, 167], ["yellow fever virus", "SPECIES", 33, 51], ["yellow fever virus", "SPECIES", 33, 51], ["YFV", "SPECIES", 53, 56], ["Latin word flavus", "SPECIES", 93, 110], ["yellow fever virus (YFV)", "PROBLEM", 33, 57], ["the term ''flavi''", "PROBLEM", 65, 83], ["the Latin word flavus", "PROBLEM", 89, 110], ["the yellowish color", "PROBLEM", 136, 155], ["yellow fever infections", "PROBLEM", 171, 194], ["The classification", "TEST", 226, 244], ["serological", "TEST", 250, 261], ["phylogenetic studies", "TEST", 266, 286], ["flaviviruses", "PROBLEM", 290, 302], ["genus", "ANATOMY", 24, 29], ["yellowish", "OBSERVATION_MODIFIER", 140, 149], ["skin", "ANATOMY", 163, 167]]], ["There are essentially three groups of flaviviruses: tick-borne, mosquito-borne and non-vectored flaviviruses, although this grouping is, to some extent, arbitrary since some mosquito-borne viruses are also transmitted by ticks and vice versa [127] (Table 2 ).", [["flaviviruses", "DISEASE", 38, 50], ["tick-borne", "DISEASE", 52, 62], ["mosquito-borne", "DISEASE", 64, 78], ["flaviviruses", "DISEASE", 96, 108], ["mosquito-borne viruses", "ORGANISM", 174, 196], ["flaviviruses", "PROBLEM", 38, 50], ["tick", "PROBLEM", 52, 56], ["non-vectored flaviviruses", "PROBLEM", 83, 108], ["some mosquito-borne viruses", "PROBLEM", 169, 196], ["flaviviruses", "OBSERVATION", 38, 50]]], ["Phylogenetic analysis also shows very strong correlations between genetic relationships, epidemiology and ecology of these viruses [128, 129] .Ecology and epidemiologySome flaviviruses are responsible for a significant proportion of the morbidity and mortality that is registered annually worldwide.", [["flaviviruses", "DISEASE", 172, 184], ["Phylogenetic analysis", "TEST", 0, 21], ["these viruses", "TEST", 117, 130], ["Some flaviviruses", "PROBLEM", 167, 184], ["the morbidity", "PROBLEM", 233, 246], ["flaviviruses", "OBSERVATION", 172, 184], ["morbidity", "OBSERVATION", 237, 246]]], ["They cause epidemic outbreaks that involve encephalitis and/or haemorrhagic fever, often fatal and involving millions of humans or in some case birds or mammals.", [["encephalitis", "DISEASE", 43, 55], ["haemorrhagic fever", "DISEASE", 63, 81], ["humans", "ORGANISM", 121, 127], ["humans", "SPECIES", 121, 127], ["humans", "SPECIES", 121, 127], ["epidemic outbreaks", "PROBLEM", 11, 29], ["encephalitis", "PROBLEM", 43, 55], ["haemorrhagic fever", "PROBLEM", 63, 81], ["encephalitis", "OBSERVATION", 43, 55], ["haemorrhagic", "OBSERVATION_MODIFIER", 63, 75], ["fever", "OBSERVATION", 76, 81]]], ["Important flaviviruses affecting humans are the dengue viruses, yellow fever virus, West Nile virus (WNV), tick-borne encephalitis virus (TBEV), Japanese encephalitis virus, Saint Louis encephalitis virus, and Murray Valley encephalitis virus among others.", [["dengue viruses", "DISEASE", 48, 62], ["yellow fever", "DISEASE", 64, 76], ["West Nile virus (WNV)", "DISEASE", 84, 105], ["tick-borne encephalitis", "DISEASE", 107, 130], ["TBEV", "DISEASE", 138, 142], ["Japanese encephalitis virus", "DISEASE", 145, 172], ["Saint Louis encephalitis", "DISEASE", 174, 198], ["Murray Valley encephalitis", "DISEASE", 210, 236], ["humans", "ORGANISM", 33, 39], ["dengue viruses", "ORGANISM", 48, 62], ["yellow fever virus", "ORGANISM", 64, 82], ["West Nile virus", "ORGANISM", 84, 99], ["WNV", "ORGANISM", 101, 104], ["tick-borne encephalitis virus", "ORGANISM", 107, 136], ["TBEV", "ORGANISM", 138, 142], ["Japanese encephalitis virus", "ORGANISM", 145, 172], ["Saint Louis encephalitis virus", "ORGANISM", 174, 204], ["Murray Valley encephalitis virus", "ORGANISM", 210, 242], ["humans", "SPECIES", 33, 39], ["yellow fever virus", "SPECIES", 64, 82], ["West Nile virus", "SPECIES", 84, 99], ["tick-borne encephalitis virus", "SPECIES", 107, 136], ["Japanese encephalitis virus", "SPECIES", 145, 172], ["Saint Louis encephalitis virus", "SPECIES", 174, 204], ["Murray Valley encephalitis virus", "SPECIES", 210, 242], ["humans", "SPECIES", 33, 39], ["dengue viruses", "SPECIES", 48, 62], ["yellow fever virus", "SPECIES", 64, 82], ["West Nile virus", "SPECIES", 84, 99], ["WNV", "SPECIES", 101, 104], ["tick-borne encephalitis virus", "SPECIES", 107, 136], ["TBEV", "SPECIES", 138, 142], ["Japanese encephalitis virus", "SPECIES", 145, 172], ["Saint Louis encephalitis virus", "SPECIES", 174, 204], ["Murray Valley encephalitis virus", "SPECIES", 210, 242], ["Important flaviviruses", "PROBLEM", 0, 22], ["the dengue viruses", "PROBLEM", 44, 62], ["yellow fever virus", "PROBLEM", 64, 82], ["West Nile virus (WNV", "PROBLEM", 84, 104], ["tick-borne encephalitis virus", "PROBLEM", 107, 136], ["TBEV", "PROBLEM", 138, 142], ["Japanese encephalitis virus", "PROBLEM", 145, 172], ["Saint Louis encephalitis virus", "PROBLEM", 174, 204], ["Murray Valley encephalitis virus", "PROBLEM", 210, 242], ["flaviviruses", "OBSERVATION", 10, 22], ["dengue viruses", "OBSERVATION", 48, 62]]], ["Dengue virus alone causes more than 50-100 million cases worldwide each year and some 2500 million people are now at risk from dengue infections [130] .Ecology and epidemiologyThe most important flavivirus in Europe is TBEV, which is endemic in many European countries, and also in Russia, ( Table 5 , Fig. 4 ) Northern China and Northern Japan [126,131a] .", [["Dengue", "DISEASE", 0, 6], ["dengue infections", "DISEASE", 127, 144], ["flavivirus", "DISEASE", 195, 205], ["TBEV", "DISEASE", 219, 223], ["Dengue virus", "ORGANISM", 0, 12], ["people", "ORGANISM", 99, 105], ["TBEV", "ORGANISM", 219, 223], ["Dengue virus", "SPECIES", 0, 12], ["people", "SPECIES", 99, 105], ["Dengue virus", "SPECIES", 0, 12], ["TBEV", "SPECIES", 219, 223], ["Dengue virus", "PROBLEM", 0, 12], ["dengue infections", "PROBLEM", 127, 144], ["TBEV", "PROBLEM", 219, 223], ["most important", "OBSERVATION_MODIFIER", 180, 194], ["flavivirus", "OBSERVATION", 195, 205], ["TBEV", "OBSERVATION", 219, 223], ["endemic", "OBSERVATION_MODIFIER", 234, 241]]], ["It affects thousands of people annually and has a significant impact on public health.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["thousands", "OBSERVATION_MODIFIER", 11, 20], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["impact", "OBSERVATION_MODIFIER", 62, 68]]], ["The virus is transmitted to humans mainly through a tick bite, however, the infection has also been reported to occur by drinking unpasteurised goat milk from viraemic animals [131b,131c].", [["milk", "ANATOMY", 149, 153], ["tick bite", "DISEASE", 52, 61], ["infection", "DISEASE", 76, 85], ["humans", "ORGANISM", 28, 34], ["goat", "ORGANISM", 144, 148], ["milk", "ORGANISM_SUBSTANCE", 149, 153], ["humans", "SPECIES", 28, 34], ["goat", "SPECIES", 144, 148], ["milk", "SPECIES", 149, 153], ["humans", "SPECIES", 28, 34], ["goat", "SPECIES", 144, 148], ["The virus", "PROBLEM", 0, 9], ["a tick bite", "PROBLEM", 50, 61], ["the infection", "PROBLEM", 72, 85], ["virus", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 76, 85]]], ["The virus is maintained in nature in a cycle involving ticks and wild vertebrate hosts and also by transovarial and transstadial transmission in its vector [126, 132] .", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["maintained", "OBSERVATION_MODIFIER", 13, 23], ["vertebrate hosts", "OBSERVATION", 70, 86]]], ["Serological evidence and viral isolations, as well as sequence similarities have suggested that migratory birds could also play a role in the transmission of TBEV from central Europe to Scandinavian countries; moreover, endemic areas of TBEV are regions of high migratory bird activity [133] .", [["TBEV", "DISEASE", 158, 162], ["TBEV", "DISEASE", 237, 241], ["birds", "ORGANISM", 106, 111], ["TBEV", "ORGANISM", 158, 162], ["TBEV", "ORGANISM", 237, 241], ["TBEV", "SPECIES", 158, 162], ["TBEV", "SPECIES", 237, 241], ["Serological evidence", "TEST", 0, 20], ["viral isolations", "PROBLEM", 25, 41], ["TBEV", "PROBLEM", 237, 241], ["viral isolations", "OBSERVATION", 25, 41], ["TBEV", "OBSERVATION", 237, 241], ["high", "OBSERVATION_MODIFIER", 257, 261], ["migratory", "OBSERVATION_MODIFIER", 262, 271]]], ["TBEV is classified taxonomically into three subtypes: European subtype, Far Eastern subtype, and Siberian subtype.", [["TBEV", "DISEASE", 0, 4], ["TBEV", "ORGANISM", 0, 4], ["TBEV", "SPECIES", 0, 4], ["European subtype", "OBSERVATION_MODIFIER", 54, 70], ["Siberian subtype", "OBSERVATION", 97, 113]]], ["The first subtype is transmitted mainly by Ixodes ricinus, and the last two by Ixodes persulcatus [134, 135] .", [["Ixodes ricinus", "ORGANISM", 43, 57], ["Ixodes persulcatus", "ORGANISM", 79, 97], ["Ixodes ricinus", "SPECIES", 43, 57], ["Ixodes persulcatus", "SPECIES", 79, 97], ["Ixodes ricinus", "SPECIES", 43, 57], ["Ixodes persulcatus", "SPECIES", 79, 97]]], ["The distribution of TBEV is well coordinated with the distribution of its vector, furthermore, different genotypes are located in distinct geographical areas and associated with specific vector hosts.", [["TBEV", "DISEASE", 20, 24], ["TBEV", "ORGANISM", 20, 24], ["TBEV", "SPECIES", 20, 24], ["TBEV", "PROBLEM", 20, 24], ["different genotypes", "PROBLEM", 95, 114], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["TBEV", "OBSERVATION", 20, 24], ["well coordinated", "OBSERVATION_MODIFIER", 28, 44], ["distinct", "OBSERVATION_MODIFIER", 130, 138], ["geographical", "OBSERVATION_MODIFIER", 139, 151]]], ["Recent data have shown the co-circulation of all three subtypes of TBEV in the same geographical region, specifically in Latvia, where the two vector Ixodes species habitats meet [136] .", [["TBEV", "DISEASE", 67, 71], ["TBEV", "SPECIES", 67, 71], ["Recent data", "TEST", 0, 11], ["TBEV", "PROBLEM", 67, 71], ["TBEV", "OBSERVATION", 67, 71]]], ["However, the endemic region in Europe is patchy and covers only part of the geographical range of e.g. Ixodes ricinus.", [["Ixodes ricinus", "ORGANISM", 103, 117], ["Ixodes ricinus", "SPECIES", 103, 117], ["Ixodes ricinus", "SPECIES", 103, 117], ["the endemic region", "PROBLEM", 9, 27], ["patchy", "PROBLEM", 41, 47], ["endemic", "OBSERVATION_MODIFIER", 13, 20], ["region", "OBSERVATION_MODIFIER", 21, 27], ["Europe", "OBSERVATION_MODIFIER", 31, 37], ["patchy", "OBSERVATION_MODIFIER", 41, 47]]], ["There has been an increase of the incidence of TBEV in many of its endemic areas but not in Austria where a countrywide successful vaccination campaign was established reducing the disease incidence to lower levels [131c,131d,137a].Clinical picture and pathogenesis of TBEVTBEV affects principally the nervous system and can cause several clinical features of different severity Table 5 Tick-borne enchephalitis viral infections in Europe per country through timeCountryYear 1990CountryYear 1995 Year 2000 Year 2002 Austria 89 109 60 60 Belarus -a 66 23 18 Croatia 23 59 18 30 Czech R. 193 744 719 647 Denmark --3 1 Estonia 37 175 272 90 Finland 9 23 41 38 France 2 6 0 2 Germany -226 133 including meningitis, meningoencephalitis, meningoencephalomyelitis and meningoradiculoneuritis.", [["nervous system", "ANATOMY", 302, 316], ["TBEV", "DISEASE", 47, 51], ["TBEVTBEV affects principally the nervous system", "DISEASE", 269, 316], ["viral infections", "DISEASE", 412, 428], ["meningitis", "DISEASE", 699, 709], ["meningoencephalitis", "DISEASE", 711, 730], ["meningoencephalomyelitis", "DISEASE", 732, 756], ["meningoradiculoneuritis", "DISEASE", 761, 784], ["TBEVTBEV", "CANCER", 269, 277], ["nervous system", "ANATOMICAL_SYSTEM", 302, 316], ["meningoradiculoneuritis", "CANCER", 761, 784], ["TBEV", "SPECIES", 47, 51], ["Czech R. 193 744 719 647", "SPECIES", 577, 601], ["TBEV", "PROBLEM", 47, 51], ["a countrywide successful vaccination campaign", "TREATMENT", 106, 151], ["the disease incidence", "PROBLEM", 177, 198], ["Clinical picture", "TEST", 232, 248], ["pathogenesis of TBEVTBEV affects", "PROBLEM", 253, 285], ["different severity Table", "PROBLEM", 360, 384], ["viral infections", "PROBLEM", 412, 428], ["Croatia", "TEST", 557, 564], ["Czech R.", "TEST", 577, 585], ["Denmark", "TEST", 602, 609], ["France", "TEST", 657, 663], ["Germany", "TEST", 672, 679], ["meningitis", "PROBLEM", 699, 709], ["meningoencephalitis", "PROBLEM", 711, 730], ["meningoencephalomyelitis", "PROBLEM", 732, 756], ["meningoradiculoneuritis", "PROBLEM", 761, 784], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["TBEV", "OBSERVATION", 47, 51], ["endemic", "OBSERVATION_MODIFIER", 67, 74], ["meningitis", "OBSERVATION", 699, 709], ["meningoencephalitis", "OBSERVATION", 711, 730]]], ["Hospitalization varies from days to months and in some cases years of treatment and rehabilitation are necessary as sequelae occur in approximately 1/3 of the patients.", [["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["treatment", "TREATMENT", 70, 79], ["rehabilitation", "TREATMENT", 84, 98]]], ["The incubation period of TBE is between 7 and 14 days.", [["TBE", "SPECIES", 25, 28], ["TBE", "PROBLEM", 25, 28], ["TBE", "OBSERVATION", 25, 28]]], ["The disease is characteristically biphasic.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["characteristically", "OBSERVATION_MODIFIER", 15, 33], ["biphasic", "OBSERVATION_MODIFIER", 34, 42]]], ["The first phase (day 2-4 of onset of symptoms) is viraemic and can be either asymptomatic or fever, malaise, headache, anorexia, nausea, and muscle pains may be present.", [["muscle", "ANATOMY", 141, 147], ["fever", "DISEASE", 93, 98], ["headache", "DISEASE", 109, 117], ["anorexia", "DISEASE", 119, 127], ["nausea", "DISEASE", 129, 135], ["muscle pains", "DISEASE", 141, 153], ["muscle", "ORGAN", 141, 147], ["symptoms", "PROBLEM", 37, 45], ["viraemic", "PROBLEM", 50, 58], ["asymptomatic", "PROBLEM", 77, 89], ["fever", "PROBLEM", 93, 98], ["malaise", "PROBLEM", 100, 107], ["headache", "PROBLEM", 109, 117], ["anorexia", "PROBLEM", 119, 127], ["nausea", "PROBLEM", 129, 135], ["muscle pains", "PROBLEM", 141, 153], ["muscle", "ANATOMY", 141, 147], ["pains", "OBSERVATION", 148, 153]]], ["The second phase occurs in up to 30% of the patients after about 8 days lag period (approximately 21 days after the tick-bite) as a neurological disease of which about 0.5% has a fatal outcome [137b,137c,137d].", [["neurological", "ANATOMY", 132, 144], ["neurological disease", "DISEASE", 132, 152], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["a neurological disease", "PROBLEM", 130, 152], ["second", "OBSERVATION_MODIFIER", 4, 10], ["phase", "OBSERVATION_MODIFIER", 11, 16]]], ["The neurological symptoms and severity vary: the clinical picture includes meningitis (in about half of the patients), meningoencephalitis, meningoencephalomyelitis and meningoradiculoneuritis.", [["neurological", "ANATOMY", 4, 16], ["meningitis", "DISEASE", 75, 85], ["meningoencephalitis", "DISEASE", 119, 138], ["meningoencephalomyelitis", "DISEASE", 140, 164], ["meningoradiculoneuritis", "DISEASE", 169, 192], ["patients", "ORGANISM", 108, 116], ["meningoradiculoneuritis", "CANCER", 169, 192], ["patients", "SPECIES", 108, 116], ["The neurological symptoms", "PROBLEM", 0, 25], ["the clinical picture", "PROBLEM", 45, 65], ["meningitis", "PROBLEM", 75, 85], ["meningoencephalitis", "PROBLEM", 119, 138], ["meningoencephalomyelitis", "PROBLEM", 140, 164], ["meningoradiculoneuritis", "PROBLEM", 169, 192], ["meningitis", "OBSERVATION", 75, 85], ["meningoencephalitis", "OBSERVATION", 119, 138]]], ["Hospitalization varies between days and months and in some cases years of treatment and rehabilitation are necessary in case of e.g. paresis.CountryAltogether, neuropsychiatric sequelae occur in approximately 1/3 of the patients.Description of other important flaviviruses in EuropeLouping ill virus (LIV) is endemic in Ireland, in the northern region of Great Britain and in Norway (Fig. 4) affecting principally sheep with a disease that is known as ovine encephalomyelitis, infectious encephalomyelitis of sheep, or trembling-ill.", [["paresis", "DISEASE", 133, 140], ["neuropsychiatric sequelae", "DISEASE", 160, 185], ["EuropeLouping ill", "DISEASE", 276, 293], ["ovine encephalomyelitis", "DISEASE", 452, 475], ["infectious encephalomyelitis", "DISEASE", 477, 505], ["trembling-ill", "DISEASE", 519, 532], ["patients", "ORGANISM", 220, 228], ["EuropeLouping ill virus", "ORGANISM", 276, 299], ["sheep", "ORGANISM", 414, 419], ["sheep", "ORGANISM", 509, 514], ["patients", "SPECIES", 220, 228], ["sheep", "SPECIES", 414, 419], ["sheep", "SPECIES", 509, 514], ["EuropeLouping ill virus", "SPECIES", 276, 299], ["LIV", "SPECIES", 301, 304], ["sheep", "SPECIES", 414, 419], ["sheep", "SPECIES", 509, 514], ["treatment", "TREATMENT", 74, 83], ["rehabilitation", "TREATMENT", 88, 102], ["paresis", "PROBLEM", 133, 140], ["neuropsychiatric sequelae", "PROBLEM", 160, 185], ["other important flaviviruses", "PROBLEM", 244, 272], ["EuropeLouping ill virus", "PROBLEM", 276, 299], ["a disease", "PROBLEM", 425, 434], ["ovine encephalomyelitis", "PROBLEM", 452, 475], ["infectious encephalomyelitis of sheep", "PROBLEM", 477, 514], ["paresis", "OBSERVATION", 133, 140], ["flaviviruses", "OBSERVATION", 260, 272], ["endemic", "OBSERVATION_MODIFIER", 309, 316], ["Great", "OBSERVATION_MODIFIER", 355, 360], ["Britain", "OBSERVATION", 361, 368], ["disease", "OBSERVATION", 427, 434], ["encephalomyelitis", "OBSERVATION", 458, 475], ["infectious", "OBSERVATION_MODIFIER", 477, 487]]], ["LIV is transmitted to sheep by the tick vector Ixodes ricinus.", [["LIV", "GENE_OR_GENE_PRODUCT", 0, 3], ["sheep", "ORGANISM", 22, 27], ["Ixodes ricinus", "ORGANISM", 47, 61], ["sheep", "SPECIES", 22, 27], ["Ixodes ricinus", "SPECIES", 47, 61], ["LIV", "SPECIES", 0, 3], ["sheep", "SPECIES", 22, 27], ["Ixodes ricinus", "SPECIES", 47, 61]]], ["The natural life cycle of LIV resembles that of TBEV, it can be sustained in the natural environment through non-systemic transmission of virus between ticks cofeeding on rodents and other wild animals, which in turn infect grazing animals such as sheep and goat as a zoonotic disease.", [["TBEV", "DISEASE", 48, 52], ["zoonotic disease", "DISEASE", 268, 284], ["LIV", "CANCER", 26, 29], ["TBEV", "ORGANISM", 48, 52], ["sheep", "ORGANISM", 248, 253], ["goat", "ORGANISM", 258, 262], ["sheep", "SPECIES", 248, 253], ["goat", "SPECIES", 258, 262], ["LIV", "SPECIES", 26, 29], ["TBEV", "SPECIES", 48, 52], ["sheep", "SPECIES", 248, 253], ["goat", "SPECIES", 258, 262], ["TBEV", "PROBLEM", 48, 52], ["virus", "PROBLEM", 138, 143], ["a zoonotic disease", "PROBLEM", 266, 284], ["zoonotic disease", "OBSERVATION", 268, 284]]], ["Louping ill virus has also been observed in a bird-tick-bird cycle involving the red grouse (Lagopus lagopus scoticus), ptarmigan bird species and the Ixodes tick [138] .Description of other important flaviviruses in EuropeInfection with LIV in sheep is characterised by a biphasic fever, depression, ataxia, muscular in-coordination, tremors, posterior paralysis, coma, and death.", [["muscular", "ANATOMY", 309, 317], ["Louping ill", "DISEASE", 0, 11], ["flaviviruses", "DISEASE", 201, 213], ["EuropeInfection", "DISEASE", 217, 232], ["fever", "DISEASE", 282, 287], ["depression", "DISEASE", 289, 299], ["ataxia", "DISEASE", 301, 307], ["muscular in-coordination", "DISEASE", 309, 333], ["tremors", "DISEASE", 335, 342], ["paralysis", "DISEASE", 354, 363], ["coma", "DISEASE", 365, 369], ["death", "DISEASE", 375, 380], ["red grouse", "ORGANISM", 81, 91], ["Lagopus lagopus scoticus", "ORGANISM", 93, 117], ["ptarmigan bird species", "ORGANISM", 120, 142], ["sheep", "ORGANISM", 245, 250], ["tick-bird", "SPECIES", 51, 60], ["Lagopus", "SPECIES", 93, 100], ["lagopus scoticus", "SPECIES", 101, 117], ["ptarmigan bird", "SPECIES", 120, 134], ["Ixodes tick", "SPECIES", 151, 162], ["sheep", "SPECIES", 245, 250], ["red grouse", "SPECIES", 81, 91], ["Lagopus lagopus scoticus", "SPECIES", 93, 117], ["Ixodes tick", "SPECIES", 151, 162], ["LIV", "SPECIES", 238, 241], ["sheep", "SPECIES", 245, 250], ["Louping ill virus", "PROBLEM", 0, 17], ["Lagopus lagopus scoticus", "TEST", 93, 117], ["a biphasic fever", "PROBLEM", 271, 287], ["depression", "PROBLEM", 289, 299], ["ataxia", "PROBLEM", 301, 307], ["muscular in-coordination", "PROBLEM", 309, 333], ["tremors", "PROBLEM", 335, 342], ["posterior paralysis", "PROBLEM", 344, 363], ["coma", "PROBLEM", 365, 369], ["death", "PROBLEM", 375, 380], ["ill virus", "OBSERVATION", 8, 17], ["flaviviruses", "OBSERVATION", 201, 213], ["LIV", "ANATOMY", 238, 241], ["biphasic", "OBSERVATION_MODIFIER", 273, 281], ["fever", "OBSERVATION", 282, 287], ["muscular", "ANATOMY", 309, 317], ["posterior", "ANATOMY_MODIFIER", 344, 353], ["paralysis", "OBSERVATION", 354, 363]]], ["There is evidence for infection by LIV in other domestic species and wildlife, i.e. cattle, horses, pigs, dogs, deer, shrews, wood-mice, voles, and hares [139,140a] .", [["infection", "DISEASE", 22, 31], ["horses", "ORGANISM_SUBDIVISION", 92, 98], ["pigs", "ORGANISM", 100, 104], ["dogs", "ORGANISM", 106, 110], ["deer", "ORGANISM_SUBDIVISION", 112, 116], ["shrews", "ORGANISM_SUBDIVISION", 118, 124], ["wood-mice", "ORGANISM", 126, 135], ["cattle", "SPECIES", 84, 90], ["horses", "SPECIES", 92, 98], ["pigs", "SPECIES", 100, 104], ["dogs", "SPECIES", 106, 110], ["deer", "SPECIES", 112, 116], ["mice", "SPECIES", 131, 135], ["LIV", "SPECIES", 35, 38], ["cattle", "SPECIES", 84, 90], ["pigs", "SPECIES", 100, 104], ["deer", "SPECIES", 112, 116], ["infection", "PROBLEM", 22, 31], ["evidence for", "UNCERTAINTY", 9, 21], ["infection", "OBSERVATION", 22, 31], ["LIV", "ANATOMY", 35, 38], ["domestic species", "OBSERVATION", 48, 64]]], ["It is generally believed that the majority of avian infections occur through a tick bite, however laboratory experiments and field observations have demonstrated that the red grouse can also become infected by feeding on infected ticks indicating that the vector bite is not the only route of infection [140b] .Description of other important flaviviruses in EuropeHumans are also susceptible to infection with LIV.", [["avian infections", "DISEASE", 46, 62], ["tick bite", "DISEASE", 79, 88], ["infection", "DISEASE", 293, 302], ["infection", "DISEASE", 395, 404], ["avian", "ORGANISM", 46, 51], ["red grouse", "ORGANISM", 171, 181], ["ticks", "ORGANISM", 230, 235], ["flaviviruses", "ORGANISM", 342, 354], ["EuropeHumans", "ORGANISM", 358, 370], ["red grouse", "SPECIES", 171, 181], ["LIV", "SPECIES", 410, 413], ["avian infections", "PROBLEM", 46, 62], ["a tick bite", "PROBLEM", 77, 88], ["laboratory experiments", "TEST", 98, 120], ["field observations", "TEST", 125, 143], ["the red grouse", "PROBLEM", 167, 181], ["the vector bite", "PROBLEM", 252, 267], ["infection", "PROBLEM", 293, 302], ["infection", "PROBLEM", 395, 404], ["LIV", "TREATMENT", 410, 413], ["infections", "OBSERVATION", 52, 62], ["infection", "OBSERVATION", 293, 302], ["flaviviruses", "OBSERVATION", 342, 354], ["infection", "OBSERVATION", 395, 404], ["LIV", "ANATOMY", 410, 413]]], ["However, the majority of the cases reported are accidentally acquired infections in laboratory workers.", [["infections", "DISEASE", 70, 80], ["accidentally acquired infections", "PROBLEM", 48, 80]]], ["The second most frequent infection results from handling infected animal carcasses.", [["infection", "DISEASE", 25, 34], ["The second most frequent infection", "PROBLEM", 0, 34], ["handling infected animal carcasses", "PROBLEM", 48, 82], ["most frequent", "OBSERVATION_MODIFIER", 11, 24], ["infection", "OBSERVATION", 25, 34], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["animal carcasses", "OBSERVATION", 66, 82]]], ["Infection with LIV in humans can cause a neurological disease resembling the clinical picture observed for TBEV infections, i.e. biphasic encephalitis, influenza-type illness, fever, articular pain, meningitis, myagia and poliomyelitis-like illness [141] .", [["neurological", "ANATOMY", 41, 53], ["articular", "ANATOMY", 183, 192], ["neurological disease", "DISEASE", 41, 61], ["TBEV infections", "DISEASE", 107, 122], ["encephalitis", "DISEASE", 138, 150], ["influenza-type illness", "DISEASE", 152, 174], ["fever", "DISEASE", 176, 181], ["articular pain", "DISEASE", 183, 197], ["meningitis", "DISEASE", 199, 209], ["myagia", "DISEASE", 211, 217], ["poliomyelitis", "DISEASE", 222, 235], ["illness", "DISEASE", 241, 248], ["humans", "ORGANISM", 22, 28], ["TBEV", "ORGANISM", 107, 111], ["articular", "TISSUE", 183, 192], ["humans", "SPECIES", 22, 28], ["LIV", "SPECIES", 15, 18], ["humans", "SPECIES", 22, 28], ["TBEV", "SPECIES", 107, 111], ["Infection", "PROBLEM", 0, 9], ["LIV in humans", "TREATMENT", 15, 28], ["a neurological disease", "PROBLEM", 39, 61], ["the clinical picture", "PROBLEM", 73, 93], ["TBEV infections", "PROBLEM", 107, 122], ["biphasic encephalitis", "PROBLEM", 129, 150], ["influenza", "PROBLEM", 152, 161], ["type illness", "PROBLEM", 162, 174], ["fever", "PROBLEM", 176, 181], ["articular pain", "PROBLEM", 183, 197], ["meningitis", "PROBLEM", 199, 209], ["myagia", "PROBLEM", 211, 217], ["poliomyelitis", "PROBLEM", 222, 235], ["LIV", "ANATOMY", 15, 18], ["neurological disease", "OBSERVATION", 41, 61], ["biphasic", "OBSERVATION_MODIFIER", 129, 137], ["encephalitis", "OBSERVATION", 138, 150], ["articular", "ANATOMY", 183, 192], ["meningitis", "OBSERVATION", 199, 209], ["poliomyelitis", "OBSERVATION", 222, 235]]], ["Other possible transmission routes for LIV infection to humans include drinking contaminated milk from goat or sheep in an acute phase of infection [142] , tick-bite, exposure to infective material, or through skin abrasions or wounds.", [["milk", "ANATOMY", 93, 97], ["skin", "ANATOMY", 210, 214], ["wounds", "ANATOMY", 228, 234], ["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 138, 147], ["tick-bite", "DISEASE", 156, 165], ["skin abrasions", "DISEASE", 210, 224], ["LIV", "ORGANISM", 39, 42], ["humans", "ORGANISM", 56, 62], ["milk", "ORGANISM_SUBSTANCE", 93, 97], ["goat", "ORGANISM", 103, 107], ["skin", "ORGAN", 210, 214], ["wounds", "PATHOLOGICAL_FORMATION", 228, 234], ["humans", "SPECIES", 56, 62], ["milk", "SPECIES", 93, 97], ["goat", "SPECIES", 103, 107], ["sheep", "SPECIES", 111, 116], ["LIV", "SPECIES", 39, 42], ["humans", "SPECIES", 56, 62], ["goat", "SPECIES", 103, 107], ["sheep", "SPECIES", 111, 116], ["transmission routes", "TREATMENT", 15, 34], ["LIV infection", "PROBLEM", 39, 52], ["infection", "PROBLEM", 138, 147], ["tick-bite", "PROBLEM", 156, 165], ["infective material", "PROBLEM", 179, 197], ["skin abrasions", "PROBLEM", 210, 224], ["wounds", "PROBLEM", 228, 234], ["infection", "OBSERVATION", 43, 52], ["acute phase", "OBSERVATION_MODIFIER", 123, 134], ["infection", "OBSERVATION", 138, 147], ["infective", "OBSERVATION", 179, 188], ["skin", "ANATOMY", 210, 214], ["abrasions", "OBSERVATION", 215, 224], ["wounds", "OBSERVATION", 228, 234]]], ["Antigenic and phylogenetic studies have shown that LIV is most closely related to strains of the Western European subtype of TBEV and it is estimated to have emerged from this lineage approximately 800 years ago [143] .Description of other important flaviviruses in EuropeWest Nile virus (WNV) was first discovered in 1937 in Uganda [144] .", [["TBEV", "DISEASE", 125, 129], ["LIV", "GENE_OR_GENE_PRODUCT", 51, 54], ["TBEV", "ORGANISM", 125, 129], ["flaviviruses", "ORGANISM", 250, 262], ["EuropeWest Nile virus", "ORGANISM", 266, 287], ["WNV", "ORGANISM", 289, 292], ["LIV", "DNA", 51, 54], ["EuropeWest Nile virus", "SPECIES", 266, 287], ["LIV", "SPECIES", 51, 54], ["TBEV", "SPECIES", 125, 129], ["EuropeWest Nile virus", "SPECIES", 266, 287], ["WNV", "SPECIES", 289, 292], ["Antigenic and phylogenetic studies", "TEST", 0, 34], ["TBEV", "PROBLEM", 125, 129], ["LIV", "ANATOMY", 51, 54], ["TBEV", "OBSERVATION", 125, 129], ["flaviviruses", "OBSERVATION", 250, 262]]], ["It occurs throughout Africa, the Middle East, Europe, Russia, India and Indonesia and was recently introduced into North America (New York) [126, 145] .", [["Middle", "ANATOMY_MODIFIER", 33, 39]]], ["In the Old World WNV is primarily considered to be an African virus which annually disperses northwards out of Africa when birds migrate to Europe, the Middle East and Asia [145] .", [["WNV", "DISEASE", 17, 20], ["Old World WNV", "ORGANISM", 7, 20], ["Old World WNV", "SPECIES", 7, 20], ["African virus", "SPECIES", 54, 67], ["an African virus", "PROBLEM", 51, 67], ["Middle", "ANATOMY_MODIFIER", 152, 158]]], ["In humans, the majority of WNV infections cause a nonsymptomatic or mild febrile illness; however some infections can cause encephalitis and in most severe cases can lead to death, particularly in elderly patients.", [["WNV infections", "DISEASE", 27, 41], ["febrile illness", "DISEASE", 73, 88], ["infections", "DISEASE", 103, 113], ["encephalitis", "DISEASE", 124, 136], ["death", "DISEASE", 174, 179], ["humans", "ORGANISM", 3, 9], ["WNV", "ORGANISM", 27, 30], ["patients", "ORGANISM", 205, 213], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 205, 213], ["humans", "SPECIES", 3, 9], ["WNV", "SPECIES", 27, 30], ["WNV infections", "PROBLEM", 27, 41], ["a nonsymptomatic or mild febrile illness", "PROBLEM", 48, 88], ["some infections", "PROBLEM", 98, 113], ["encephalitis", "PROBLEM", 124, 136], ["death", "PROBLEM", 174, 179], ["WNV", "OBSERVATION", 27, 30], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["febrile", "OBSERVATION_MODIFIER", 73, 80], ["illness", "OBSERVATION", 81, 88], ["infections", "OBSERVATION", 103, 113], ["encephalitis", "OBSERVATION", 124, 136]]], ["The incubation period is between 3 and 15 days after a mosquito bite (http://www.cdc.gov/ncidod/ dvbid/westnile/wnv_factsheet.htm).", [["a mosquito bite (http://www.cdc.gov/ncidod/ dvbid/westnile/wnv_factsheet.htm", "TREATMENT", 53, 129]]], ["West Nile virus is an illustrative example of the human impact on the dispersal and evolution of flaviviruses.", [["flaviviruses", "DISEASE", 97, 109], ["West Nile virus", "ORGANISM", 0, 15], ["human", "ORGANISM", 50, 55], ["West Nile virus", "SPECIES", 0, 15], ["human", "SPECIES", 50, 55], ["West Nile virus", "SPECIES", 0, 15], ["human", "SPECIES", 50, 55], ["flaviviruses", "PROBLEM", 97, 109], ["flaviviruses", "OBSERVATION", 97, 109]]], ["The virus appeared for the first time in the USA, in New York in 1999 causing sixty-two confirmed human infections and seven deaths [146] .", [["infections", "DISEASE", 104, 114], ["deaths", "DISEASE", 125, 131], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["The virus", "PROBLEM", 0, 9], ["human infections", "PROBLEM", 98, 114], ["virus", "OBSERVATION", 4, 9], ["infections", "OBSERVATION", 104, 114]]], ["The virus successfully over-wintered and during the next years dispersed widely throughout North America and now more recently also to Central America and the Caribbean.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["Central", "ANATOMY_MODIFIER", 135, 142]]], ["In North America the virus infects a very wide range of mosquito and animal species.", [["mosquito and animal species", "PROBLEM", 56, 83], ["virus infects", "OBSERVATION", 21, 34], ["very", "OBSERVATION_MODIFIER", 37, 41], ["wide", "OBSERVATION_MODIFIER", 42, 46]]], ["To date, more than 14 000 human cases and 586 deaths from WNV have been reported in the United Sates of America (http:// www.cdc.gov/ncidod/dvbid/westnile).", [["deaths", "DISEASE", 46, 52], ["WNV", "DISEASE", 58, 61], ["human", "ORGANISM", 26, 31], ["WNV", "ORGANISM", 58, 61], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["WNV", "SPECIES", 58, 61], ["WNV", "PROBLEM", 58, 61]]], ["In Europe, outbreaks caused by WNV have been recorded since the early 1950s, especially in Mediterranean countries, Romania and Southern Russia (Fig. 4) .", [["WNV", "DISEASE", 31, 34], ["WNV", "ORGANISM", 31, 34], ["WNV", "SPECIES", 31, 34], ["WNV", "PROBLEM", 31, 34], ["WNV", "OBSERVATION", 31, 34]]], ["Larger outbreaks (over 800 cases) have been reported since the mid 1990s in urban settings, especially a large outbreak in Bucharest, Romania in 1996 [145a,145b,145c] .", [["Larger outbreaks", "PROBLEM", 0, 16], ["outbreaks", "OBSERVATION_MODIFIER", 7, 16], ["large", "OBSERVATION_MODIFIER", 105, 110], ["outbreak", "OBSERVATION_MODIFIER", 111, 119]]], ["In Southern Russia, specifically in Volgograd, Astrakhan and Krasnodar regions, WNV has caused large epidemics of approximately 1000 human cases, with 4% mortality rate of reported cases.", [["WNV", "DISEASE", 80, 83], ["WNV", "ORGANISM", 80, 83], ["human", "ORGANISM", 133, 138], ["human", "SPECIES", 133, 138], ["WNV", "SPECIES", 80, 83], ["human", "SPECIES", 133, 138], ["WNV", "PROBLEM", 80, 83], ["Southern", "OBSERVATION_MODIFIER", 3, 11], ["Russia", "OBSERVATION", 12, 18], ["large", "OBSERVATION_MODIFIER", 95, 100], ["epidemics", "OBSERVATION_MODIFIER", 101, 110]]], ["Molecular epidemiological studies have shown that the latest large outbreaks in Volgograd were caused by strains genetically similar to that of Romania-1996 , Kenya-1998 and NewYork-1999 reflecting the widespread distribution capacity of these epidemic viral strains [149b,151b].", [["NewYork-1999", "CELL", 174, 186], ["Romania-1996", "SPECIES", 144, 156], ["Molecular epidemiological studies", "TEST", 0, 33], ["the latest large outbreaks in Volgograd", "PROBLEM", 50, 89], ["strains", "PROBLEM", 105, 112], ["NewYork", "TEST", 174, 181], ["these epidemic viral strains", "PROBLEM", 238, 266], ["large", "OBSERVATION_MODIFIER", 61, 66], ["outbreaks", "OBSERVATION", 67, 76], ["widespread", "OBSERVATION_MODIFIER", 202, 212], ["distribution", "OBSERVATION_MODIFIER", 213, 225], ["capacity", "OBSERVATION_MODIFIER", 226, 234]]], ["The incidence of WNV in Europe is largely unknown.", [["WNV", "DISEASE", 17, 20], ["WNV", "ORGANISM", 17, 20], ["WNV", "SPECIES", 17, 20], ["WNV", "PROBLEM", 17, 20], ["WNV", "OBSERVATION", 17, 20]]], ["Phylogenetic studies have showed that WNV has diverged into two main lineages, which form internal clusters or clades [149c,150a,150b,150c].", [["WNV", "ORGANISM", 38, 41], ["WNV", "SPECIES", 38, 41], ["Phylogenetic studies", "TEST", 0, 20], ["WNV", "PROBLEM", 38, 41], ["WNV", "OBSERVATION", 38, 41], ["main", "OBSERVATION_MODIFIER", 64, 68], ["lineages", "OBSERVATION_MODIFIER", 69, 77], ["internal", "OBSERVATION_MODIFIER", 90, 98], ["clusters", "OBSERVATION_MODIFIER", 99, 107], ["clades", "OBSERVATION_MODIFIER", 111, 117]]], ["More recently, a novel virus (Rabensburg virus), antigenically and genetically closely related to WNV was isolated from a Culex pipens mosquito pool in Czech Republic.", [["Rabensburg virus", "ORGANISM", 30, 46], ["WNV", "ORGANISM", 98, 101], ["Rabensburg virus", "SPECIES", 30, 46], ["Culex pipens", "SPECIES", 122, 134], ["Rabensburg virus", "SPECIES", 30, 46], ["WNV", "SPECIES", 98, 101], ["Culex pipens", "SPECIES", 122, 134], ["a novel virus (Rabensburg virus", "PROBLEM", 15, 46], ["WNV", "PROBLEM", 98, 101]]], ["This new virus could represent a third lineage of WNV, however more studies are needed to confirm this hypothesis or to determine whether or not this could represent a new member of the Flaviviridae family [151a] .Description of other important flaviviruses in EuropeUsutu virus (USUV) was first isolated from a mosquito in Africa in 1959 [148c].", [["WNV", "DISEASE", 50, 53], ["WNV", "ORGANISM", 50, 53], ["flaviviruses", "ORGANISM", 245, 257], ["EuropeUsutu virus", "ORGANISM", 261, 278], ["USUV", "ORGANISM", 280, 284], ["EuropeUsutu virus", "SPECIES", 261, 278], ["WNV", "SPECIES", 50, 53], ["EuropeUsutu virus", "SPECIES", 261, 278], ["USUV", "SPECIES", 280, 284], ["This new virus", "PROBLEM", 0, 14], ["a third lineage of WNV", "PROBLEM", 31, 53], ["other important flaviviruses in EuropeUsutu virus", "PROBLEM", 229, 278], ["virus", "OBSERVATION", 9, 14], ["could represent", "UNCERTAINTY", 15, 30], ["third lineage", "OBSERVATION_MODIFIER", 33, 46], ["WNV", "OBSERVATION", 50, 53], ["new", "OBSERVATION_MODIFIER", 168, 171], ["flaviviruses", "OBSERVATION", 245, 257]]], ["It was characterised serologically and classified within the Japanese encephalitis virus serocomplex.", [["encephalitis", "DISEASE", 70, 82], ["Japanese encephalitis virus", "ORGANISM", 61, 88], ["Japanese encephalitis virus", "SPECIES", 61, 88], ["Japanese encephalitis virus", "SPECIES", 61, 88], ["the Japanese encephalitis virus serocomplex", "PROBLEM", 57, 100], ["encephalitis", "OBSERVATION", 70, 82]]], ["Usutu virus had rarely been isolated since then, with only one reported human case and being present only in two regions of Africa.", [["Usutu virus", "ORGANISM", 0, 11], ["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["Usutu virus", "SPECIES", 0, 11], ["human", "SPECIES", 72, 77], ["Usutu virus", "PROBLEM", 0, 11], ["Africa", "PROBLEM", 124, 130], ["Africa", "OBSERVATION", 124, 130]]], ["However, in the late summer of 2001, USUV was found in Vienna in Austria during a study of an avian epidemic characterized by fatal encephalitis that was thought to be caused by WNV.", [["encephalitis", "DISEASE", 132, 144], ["WNV", "ORGANISM", 178, 181], ["USUV", "SPECIES", 37, 41], ["WNV", "SPECIES", 178, 181], ["a study", "TEST", 80, 87], ["fatal encephalitis", "PROBLEM", 126, 144], ["WNV", "PROBLEM", 178, 181], ["fatal", "OBSERVATION_MODIFIER", 126, 131], ["encephalitis", "OBSERVATION", 132, 144], ["thought to be", "UNCERTAINTY", 154, 167], ["WNV", "OBSERVATION", 178, 181]]], ["The virus caused die-off among the bird population, especially blackbirds, in Vienna (Fig. 4) and when isolated from birds and mosquitoes it showed 97% genetic identity to the African USUV [148b].", [["blackbirds", "ANATOMY", 63, 73], ["birds", "ORGANISM", 117, 122], ["The virus", "PROBLEM", 0, 9], ["die", "PROBLEM", 17, 20], ["the bird population", "PROBLEM", 31, 50], ["virus", "OBSERVATION", 4, 9]]], ["This is the first time USUV has been observed outside Africa and also the first time it has been associated with fatal disease in animals.", [["USUV", "CANCER", 23, 27], ["fatal disease in animals", "PROBLEM", 113, 137], ["associated with", "UNCERTAINTY", 97, 112], ["fatal", "OBSERVATION_MODIFIER", 113, 118], ["disease", "OBSERVATION", 119, 126]]], ["The virus re-appeared in the late summer of 2002 in the same region of Vienna [149a] .", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["Most recently, in 2003 the virus has been isolated from humans (associated with rash in one patient) and from birds in Austria and evidence exists as to the virus being able to overwinter establishing itself in this geographical area (Nowotny, N. Second European Congress of Virology, Eurovirology 2004).Imported flaviviruses in EuropeAs mentioned above the distribution of flaviviruses is worldwide, and we have described the zoonotic flaviviruses endemic to Europe.", [["rash", "DISEASE", 80, 84], ["Imported flaviviruses", "DISEASE", 304, 325], ["flaviviruses", "DISEASE", 374, 386], ["zoonotic flaviviruses", "DISEASE", 427, 448], ["humans", "ORGANISM", 56, 62], ["patient", "ORGANISM", 92, 99], ["humans", "SPECIES", 56, 62], ["patient", "SPECIES", 92, 99], ["humans", "SPECIES", 56, 62], ["the virus", "PROBLEM", 23, 32], ["rash", "PROBLEM", 80, 84], ["the virus", "PROBLEM", 153, 162], ["Imported flaviviruses in EuropeAs", "PROBLEM", 304, 337], ["flaviviruses", "PROBLEM", 374, 386], ["the zoonotic flaviviruses endemic", "PROBLEM", 423, 456], ["virus", "OBSERVATION", 27, 32], ["flaviviruses", "OBSERVATION", 313, 325], ["flaviviruses", "OBSERVATION", 374, 386], ["zoonotic", "OBSERVATION_MODIFIER", 427, 435], ["flaviviruses", "OBSERVATION", 436, 448]]], ["However, it is important to note the increasing incidence of imported flaviviruses totaling over 500 cases mainly due to changes in human behavior, such as increased travel to non-European destinations (http://www.eurosurveillance.org).Imported flaviviruses in EuropeThe dengue viruses (DENV) are a world-wide public health problem.", [["flaviviruses", "DISEASE", 70, 82], ["Imported flaviviruses", "DISEASE", 236, 257], ["dengue viruses", "DISEASE", 271, 285], ["DENV", "DISEASE", 287, 291], ["human", "ORGANISM", 132, 137], ["dengue viruses", "ORGANISM", 271, 285], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["dengue viruses", "SPECIES", 271, 285], ["DENV", "SPECIES", 287, 291], ["imported flaviviruses", "PROBLEM", 61, 82], ["changes in human behavior", "PROBLEM", 121, 146], ["Imported flaviviruses", "PROBLEM", 236, 257], ["DENV", "PROBLEM", 287, 291], ["flaviviruses", "OBSERVATION", 245, 257]]], ["They are transmitted to man by mosquitoes, particularly Aedes aegypti and cause a wide range of different clinical outcomes [151c,152a] .", [["man", "ORGANISM", 24, 27], ["Aedes aegypti", "ORGANISM", 56, 69], ["man", "SPECIES", 24, 27], ["Aedes aegypti", "SPECIES", 56, 69], ["Aedes aegypti", "SPECIES", 56, 69]]], ["It is estimated that 100 million cases of dengue fever (DF) and 250 000 of dengue hemorrhagic fever (DHF) cases occur annually [126] .", [["dengue fever", "DISEASE", 42, 54], ["DF", "DISEASE", 56, 58], ["dengue hemorrhagic fever", "DISEASE", 75, 99], ["DHF", "DISEASE", 101, 104], ["dengue hemorrhagic fever", "SPECIES", 75, 99], ["dengue fever (DF)", "PROBLEM", 42, 59], ["dengue hemorrhagic fever (DHF) cases", "PROBLEM", 75, 111], ["hemorrhagic", "OBSERVATION_MODIFIER", 82, 93], ["fever", "OBSERVATION", 94, 99]]], ["In a study based on the epidemiology and clinical course of 294 travellers with symptoms of dengue infection it was found that the incidence of DF among European travellers is underestimated, since diagnostic procedures, in general, for febrile patients often do not include tests for tropical arthropod-borne diseases, such as dengue virus [152b] .", [["dengue infection", "DISEASE", 92, 108], ["DF", "DISEASE", 144, 146], ["febrile", "DISEASE", 237, 244], ["arthropod-borne diseases", "DISEASE", 294, 318], ["dengue", "DISEASE", 328, 334], ["patients", "ORGANISM", 245, 253], ["dengue virus", "ORGANISM", 328, 340], ["patients", "SPECIES", 245, 253], ["dengue virus", "SPECIES", 328, 340], ["dengue", "SPECIES", 92, 98], ["dengue virus", "SPECIES", 328, 340], ["a study", "TEST", 3, 10], ["symptoms", "PROBLEM", 80, 88], ["dengue infection", "PROBLEM", 92, 108], ["DF", "PROBLEM", 144, 146], ["diagnostic procedures", "TEST", 198, 219], ["febrile patients", "PROBLEM", 237, 253], ["tests", "TEST", 275, 280], ["tropical arthropod-borne diseases", "PROBLEM", 285, 318], ["dengue virus", "PROBLEM", 328, 340], ["infection", "OBSERVATION", 99, 108]]], ["There have also been some imported cases of YFV to Europe mainly by tourists travelling from endemic areas.", [["YFV", "DISEASE", 44, 47], ["YFV", "ORGANISM", 44, 47], ["YFV", "SPECIES", 44, 47], ["YFV", "PROBLEM", 44, 47]]], ["However, the incidence of YFV as an imported disease is much lower than that of dengue infections (http://www.eurosurveillance.org) presumably because of the different nature of these diseases, DENV having spread worldwide throughout the tropics and YFV occurring only in its endemic regions in Africa and South America [152c].Diagnostics and preventionTraditionally, diagnosis of flaviviruses in Europe has been restricted to detecting TBEV infections through serological assays; IgM-capture enzyme immunoassay, hemagglutination inhibition-, and immunofluorescence assay.", [["YFV", "DISEASE", 26, 29], ["dengue infections", "DISEASE", 80, 97], ["DENV", "DISEASE", 194, 198], ["YFV", "DISEASE", 250, 253], ["flaviviruses", "DISEASE", 381, 393], ["TBEV infections", "DISEASE", 437, 452], ["YFV", "ORGANISM", 26, 29], ["YFV", "ORGANISM", 250, 253], ["TBEV", "ORGANISM", 437, 441], ["IgM", "PROTEIN", 481, 484], ["YFV", "SPECIES", 26, 29], ["dengue", "SPECIES", 80, 86], ["DENV", "SPECIES", 194, 198], ["YFV", "SPECIES", 250, 253], ["TBEV", "SPECIES", 437, 441], ["YFV", "PROBLEM", 26, 29], ["an imported disease", "PROBLEM", 33, 52], ["dengue infections", "PROBLEM", 80, 97], ["these diseases", "PROBLEM", 178, 192], ["DENV", "PROBLEM", 194, 198], ["YFV", "PROBLEM", 250, 253], ["flaviviruses", "PROBLEM", 381, 393], ["TBEV infections", "PROBLEM", 437, 452], ["serological assays", "TEST", 461, 479], ["IgM", "TEST", 481, 484], ["enzyme immunoassay", "TEST", 493, 511], ["hemagglutination inhibition", "TEST", 513, 540], ["immunofluorescence assay", "TEST", 547, 571], ["disease", "OBSERVATION", 45, 52], ["infections", "OBSERVATION", 87, 97], ["diseases", "OBSERVATION", 184, 192], ["endemic", "OBSERVATION_MODIFIER", 276, 283], ["flaviviruses", "OBSERVATION", 381, 393]]], ["IgM antibodies in serum, and in some cases in cerebrospinal fluid during the neurological disease usually provide the diagnosis.", [["serum", "ANATOMY", 18, 23], ["cerebrospinal fluid", "ANATOMY", 46, 65], ["neurological", "ANATOMY", 77, 89], ["neurological disease", "DISEASE", 77, 97], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 0, 14], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 46, 65], ["IgM antibodies", "PROTEIN", 0, 14], ["IgM antibodies", "TEST", 0, 14], ["serum", "TEST", 18, 23], ["some cases in cerebrospinal fluid", "PROBLEM", 32, 65], ["the neurological disease", "PROBLEM", 73, 97], ["cerebrospinal fluid", "OBSERVATION", 46, 65]]], ["RT-PCR is rarely positive at the second phase of the disease [153a].Diagnostics and preventionBecause of the close antigenic relatedness of flaviviruses, laboratory findings can easily lead to misdiagnosis [153b].", [["flaviviruses", "DISEASE", 140, 152], ["RT-PCR", "TEST", 0, 6], ["Diagnostics", "TEST", 68, 79], ["flaviviruses", "PROBLEM", 140, 152], ["misdiagnosis", "TEST", 193, 205], ["rarely", "OBSERVATION_MODIFIER", 10, 16], ["positive", "OBSERVATION", 17, 25], ["disease", "OBSERVATION", 53, 60], ["flaviviruses", "OBSERVATION", 140, 152]]], ["In a study conducted in Hungary, TBEV-positive serum panels were tested retrospectively against WNV and some sera were found to show higher titres to WNV than to TBEV when compared in serological assays (E. Ferenczi, personal communication).", [["serum", "ANATOMY", 47, 52], ["sera", "ANATOMY", 109, 113], ["TBEV", "ORGANISM", 33, 37], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["WNV", "ORGANISM", 96, 99], ["sera", "ORGANISM_SUBSTANCE", 109, 113], ["WNV", "ORGANISM", 150, 153], ["TBEV", "ORGANISM", 162, 166], ["TBEV", "SPECIES", 33, 37], ["WNV", "SPECIES", 96, 99], ["WNV", "SPECIES", 150, 153], ["TBEV", "SPECIES", 162, 166], ["E. Ferenczi", "SPECIES", 204, 215], ["a study", "TEST", 3, 10], ["TBEV", "TEST", 33, 37], ["serum panels", "TEST", 47, 59], ["WNV", "PROBLEM", 96, 99], ["some sera", "TEST", 104, 113], ["higher titres to WNV", "PROBLEM", 133, 153], ["serological assays", "TEST", 184, 202]]], ["As mentioned above, a study including travellers returning to Europe from tropical destinations proved that many cases remain undetected.", [["a study", "TEST", 20, 27]]], ["There is a need to improve the diagnosis for flaviviruses in order to determine the true incidence and prevalence of these infectious diseases in Europe, and to study the ecology of imported viruses to determine which viruses have been able to establish themselves in the continent and which are still continuously being imported from Africa or Asia.", [["flaviviruses", "DISEASE", 45, 57], ["infectious diseases", "DISEASE", 123, 142], ["flaviviruses", "PROBLEM", 45, 57], ["these infectious diseases", "PROBLEM", 117, 142], ["imported viruses", "PROBLEM", 182, 198], ["infectious", "OBSERVATION", 123, 133]]], ["Meanwhile anti-vector campaigns and vaccination for travellers to endemic areas are the only measures to prevent and control these infectious diseases [146] .", [["infectious diseases", "DISEASE", 131, 150], ["anti-vector campaigns", "TREATMENT", 10, 31], ["vaccination", "TREATMENT", 36, 47], ["travellers", "TREATMENT", 52, 62], ["endemic areas", "TREATMENT", 66, 79], ["these infectious diseases", "PROBLEM", 125, 150]]], ["There are effective vaccines for TBEV and YFV but a protective immunogen does not exist for DENV or WNV.", [["TBEV", "DISEASE", 33, 37], ["YFV", "DISEASE", 42, 45], ["TBEV", "ORGANISM", 33, 37], ["YFV", "ORGANISM", 42, 45], ["DENV", "ORGANISM", 92, 96], ["WNV", "ORGANISM", 100, 103], ["TBEV", "SPECIES", 33, 37], ["YFV", "SPECIES", 42, 45], ["DENV", "SPECIES", 92, 96], ["WNV", "SPECIES", 100, 103], ["effective vaccines", "TREATMENT", 10, 28], ["TBEV", "PROBLEM", 33, 37], ["YFV", "PROBLEM", 42, 45], ["a protective immunogen", "TREATMENT", 50, 72], ["DENV", "PROBLEM", 92, 96], ["WNV", "PROBLEM", 100, 103], ["effective", "OBSERVATION_MODIFIER", 10, 19], ["vaccines", "OBSERVATION", 20, 28]]], ["TBEV vaccines from two commercial manufacturers (Baxter and Chiron) are available and widely used, especially in Austria and Germany, both are based on formalin-inactivated virions, three injections are needed for full protection.", [["formalin", "CHEMICAL", 152, 160], ["TBEV", "ORGANISM", 0, 4], ["formalin", "SIMPLE_CHEMICAL", 152, 160], ["TBEV", "SPECIES", 0, 4], ["TBEV vaccines", "TREATMENT", 0, 13], ["Baxter and Chiron)", "TREATMENT", 49, 67], ["formalin-inactivated virions", "TREATMENT", 152, 180], ["three injections", "TREATMENT", 182, 198]]], ["Booster immunizations are recommended every 3-5 years for people living or spending holidays in endemic areas.Diagnostics and prevention3.3.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["Booster immunizations", "TREATMENT", 0, 21], ["Diagnostics", "TEST", 110, 121]]], ["Nairoviruses: Crimean-Congo hemorrhagic fever virusVirologyThe genus Nairovirus (family Bunyaviridae) is composed of 34 predominantly tick-borne viruses that have been divided into seven serogroups [154] including several associated with severe human and livestock diseases (especially Crimean-Congo hemorrhagic fever virus (CCHFV) and Nairobi sheep disease virus).", [["Crimean-Congo hemorrhagic fever", "DISEASE", 14, 45], ["Bunyaviridae", "DISEASE", 88, 100], ["human and livestock diseases", "DISEASE", 245, 273], ["Crimean-Congo hemorrhagic fever", "DISEASE", 286, 317], ["CCHFV", "DISEASE", 325, 330], ["sheep disease", "DISEASE", 344, 357], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 14, 51], ["human", "ORGANISM", 245, 250], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 286, 323], ["CCHFV", "ORGANISM", 325, 330], ["Nairobi sheep disease virus", "ORGANISM", 336, 363], ["Congo hemorrhagic fever virus", "SPECIES", 22, 51], ["human", "SPECIES", 245, 250], ["Crimean-", "SPECIES", 286, 294], ["Congo hemorrhagic fever virus", "SPECIES", 294, 323], ["sheep disease virus", "SPECIES", 344, 363], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 14, 51], ["tick-borne viruses", "SPECIES", 134, 152], ["human", "SPECIES", 245, 250], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 286, 323], ["CCHFV", "SPECIES", 325, 330], ["Nairobi sheep disease virus", "SPECIES", 336, 363], ["Nairoviruses", "TEST", 0, 12], ["Crimean", "TEST", 14, 21], ["Congo hemorrhagic fever virus", "PROBLEM", 22, 51], ["34 predominantly tick-borne viruses", "PROBLEM", 117, 152], ["severe human and livestock diseases", "PROBLEM", 238, 273], ["Congo hemorrhagic fever virus (CCHFV", "PROBLEM", 294, 330], ["Nairobi sheep disease virus", "PROBLEM", 336, 363], ["livestock diseases", "OBSERVATION", 255, 273]]], ["Of the pathogenic viruses only CCHFV causes significant human morbidity and mortality and is found in Europe.", [["CCHFV", "DISEASE", 31, 36], ["CCHFV", "ORGANISM", 31, 36], ["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["CCHFV", "SPECIES", 31, 36], ["human", "SPECIES", 56, 61], ["the pathogenic viruses", "PROBLEM", 3, 25], ["CCHFV", "PROBLEM", 31, 36], ["significant human morbidity", "PROBLEM", 44, 71], ["pathogenic", "OBSERVATION_MODIFIER", 7, 17], ["viruses", "OBSERVATION", 18, 25], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["human", "OBSERVATION_MODIFIER", 56, 61], ["morbidity", "OBSERVATION", 62, 71]]], ["Like other members of the Bunyaviridae family nairoviruses possess a tripartite single-stranded RNA genome of negative polarity consisting of large (L), medium (M) and small (S) segments.", [["nairoviruses", "GENE_OR_GENE_PRODUCT", 46, 58], ["Bunyaviridae family nairoviruses", "PROTEIN", 26, 58], ["tripartite single-stranded RNA genome", "DNA", 69, 106], ["large (L), medium (M) and small (S) segments", "PROBLEM", 142, 186], ["negative polarity", "OBSERVATION_MODIFIER", 110, 127], ["large", "OBSERVATION_MODIFIER", 142, 147], ["small", "OBSERVATION_MODIFIER", 168, 173], ["segments", "ANATOMY_MODIFIER", 178, 186]]], ["The 12 kb L segment encodes an RNA-dependent RNA polymerase (deduced size 448 kDa in CCHFV), the 4.9 kb M segment encodes the precursor for the two envelope glycoproteins Gn (75 kDa in CCHFV) and Gc (37 kDa in CCHFV), and the 1.7 kb S segment the viral nucleocapsid N (50 kDa) ( Table 1 , Fig. 1 ).", [["Gn (75 kDa", "GENE_OR_GENE_PRODUCT", 171, 181], ["12 kb L segment", "DNA", 4, 19], ["RNA-dependent RNA polymerase", "PROTEIN", 31, 59], ["4.9 kb M segment", "DNA", 97, 113], ["envelope glycoproteins", "PROTEIN", 148, 170], ["Gn", "PROTEIN", 171, 173], ["75 kDa", "PROTEIN", 175, 181], ["CCHFV", "PROTEIN", 185, 190], ["Gc", "PROTEIN", 196, 198], ["1.7 kb S segment", "DNA", 226, 242], ["viral nucleocapsid N", "PROTEIN", 247, 267], ["50 kDa", "PROTEIN", 269, 275], ["CCHFV", "SPECIES", 210, 215], ["The 12 kb L segment encodes an RNA-dependent RNA polymerase", "PROBLEM", 0, 59], ["CCHFV", "TEST", 85, 90], ["the 4.9 kb M segment encodes the precursor", "PROBLEM", 93, 135], ["Gn", "TEST", 171, 173], ["kDa", "TEST", 178, 181], ["CCHFV", "TEST", 185, 190], ["Gc", "TEST", 196, 198], ["kDa", "TEST", 203, 206], ["CCHFV", "TEST", 210, 215], ["the viral nucleocapsid N", "TEST", 243, 267], ["segment", "ANATOMY_MODIFIER", 12, 19], ["RNA", "OBSERVATION", 31, 34], ["dependent", "OBSERVATION_MODIFIER", 35, 44], ["RNA polymerase", "OBSERVATION", 45, 59], ["size", "OBSERVATION_MODIFIER", 69, 73], ["448 kDa", "OBSERVATION_MODIFIER", 74, 81]]], ["Like with other members of the Bunyaviridae viral messenger RNAs (mRNA) are not polyadenylated and are truncated relative to the genome RNAs at the 3 0 termini.", [["Bunyaviridae viral messenger RNAs", "RNA", 31, 64], ["mRNA", "RNA", 66, 70], ["genome RNAs", "RNA", 129, 140], ["3 0 termini", "DNA", 148, 159], ["the Bunyaviridae viral messenger RNAs", "PROBLEM", 27, 64], ["the genome RNAs", "PROBLEM", 125, 140], ["genome RNAs", "OBSERVATION", 129, 140]]], ["Messenger RNAs have 5 0 -methylated caps and 10-18 nontemplated nucleotides which are derived from host cell mRNAs.", [["cell", "ANATOMY", 104, 108], ["nucleotides", "CHEMICAL", 64, 75], ["host cell", "CELL", 99, 108], ["Messenger RNAs", "RNA", 0, 14], ["host cell mRNAs", "RNA", 99, 114], ["Messenger RNAs", "TEST", 0, 14], ["methylated caps", "TEST", 25, 40], ["nontemplated nucleotides", "TREATMENT", 51, 75], ["host cell mRNAs", "OBSERVATION", 99, 114]]], ["The nairovirus L segment encoding the RNA polymerase is conspicuously large, almost twice the size of many other members within the family Bunyaviridae, and may thus provide other functions such as viral helicase and a papain-like cysteine protease activity predicted from the nucleotide sequence [155, 156] .", [["nucleotide", "CHEMICAL", 277, 287], ["cysteine", "CHEMICAL", 231, 239], ["nucleotide", "CHEMICAL", 277, 287], ["nairovirus L", "GENE_OR_GENE_PRODUCT", 4, 16], ["papain", "GENE_OR_GENE_PRODUCT", 219, 225], ["nairovirus L segment", "DNA", 4, 24], ["RNA polymerase", "PROTEIN", 38, 52], ["viral helicase", "PROTEIN", 198, 212], ["papain", "PROTEIN", 219, 225], ["cysteine protease", "PROTEIN", 231, 248], ["The nairovirus L segment encoding the RNA polymerase", "PROBLEM", 0, 52], ["viral helicase", "TREATMENT", 198, 212], ["a papain-like cysteine protease activity", "PROBLEM", 217, 257], ["the nucleotide sequence", "TEST", 273, 296], ["L", "ANATOMY_MODIFIER", 15, 16], ["segment", "ANATOMY_MODIFIER", 17, 24], ["RNA polymerase", "OBSERVATION", 38, 52], ["conspicuously", "OBSERVATION_MODIFIER", 56, 69], ["large", "OBSERVATION_MODIFIER", 70, 75], ["size", "OBSERVATION_MODIFIER", 94, 98]]], ["Viral protein analysis has suggested that Gn and Gc may be derived from 85 and 140 kDa precursors, of which the latter contains an N-terminal region with a highly O-glycosylated mucin-like domain [157] .", [["N", "CHEMICAL", 131, 132], ["O", "CHEMICAL", 163, 164], ["Gn", "GENE_OR_GENE_PRODUCT", 42, 44], ["Gc", "GENE_OR_GENE_PRODUCT", 49, 51], ["mucin", "GENE_OR_GENE_PRODUCT", 178, 183], ["Gn", "PROTEIN", 42, 44], ["Gc", "PROTEIN", 49, 51], ["N-terminal region", "PROTEIN", 131, 148], ["O-glycosylated mucin", "PROTEIN", 163, 183], ["Viral protein analysis", "TEST", 0, 22], ["Gn", "PROBLEM", 42, 44], ["Gc", "TEST", 49, 51], ["kDa precursors", "TEST", 83, 97], ["Gn", "OBSERVATION", 42, 44], ["terminal", "ANATOMY_MODIFIER", 133, 141]]], ["The CCHFV nucleocapsid protein colocalizes and interacts with human MxA protein; this interaction may explain the antiviral effect of interferons on CCHFV [158] .", [["CCHFV", "ORGANISM", 4, 9], ["human", "ORGANISM", 62, 67], ["MxA", "GENE_OR_GENE_PRODUCT", 68, 71], ["CCHFV", "ORGANISM", 149, 154], ["CCHFV nucleocapsid protein", "PROTEIN", 4, 30], ["human MxA protein", "PROTEIN", 62, 79], ["interferons", "PROTEIN", 134, 145], ["human", "SPECIES", 62, 67], ["CCHFV", "SPECIES", 4, 9], ["human", "SPECIES", 62, 67], ["CCHFV", "SPECIES", 149, 154], ["The CCHFV nucleocapsid protein colocalizes", "PROBLEM", 0, 42], ["human MxA protein", "TREATMENT", 62, 79], ["the antiviral effect of interferons", "TREATMENT", 110, 145]]], ["Similar to the hantavirus-rodent association, the high genetic variation of viruses of the genus Nairovirus reflects the diversity of their predominant tick hosts [159] .", [["hantavirus", "DISEASE", 15, 25], ["Nairovirus", "GENE_OR_GENE_PRODUCT", 97, 107], ["the high genetic variation of viruses of the genus Nairovirus", "PROBLEM", 46, 107], ["hantavirus", "OBSERVATION", 15, 25], ["viruses", "OBSERVATION", 76, 83], ["genus Nairovirus", "OBSERVATION", 91, 107]]], ["Within CCHFV isolates, comparison between M and S segment phylogenetic groupings suggests that reassortment events have occurred in some virus lineages [160] .", [["CCHFV", "ORGANISM", 7, 12], ["CCHFV", "SPECIES", 7, 12], ["reassortment events", "PROBLEM", 95, 114], ["some virus lineages", "PROBLEM", 132, 151], ["reassortment", "OBSERVATION", 95, 107]]], ["Reverse genetics, recently established for CCHFV [161] , provides a unique opportunity to study the biology of nairoviruses and tailor optimal therapeutic and prophylactic measures against CCHFV infections.Ecology and epidemiologyCCHFV is transmitted most efficiently by Hyalomma ticks, followed by Rhipicephalus, Dermatocentor spp and many other species of ixodid (hard) and some argasid (soft) ticks (Table 2) .", [["CCHFV infections", "DISEASE", 189, 205], ["Hyalomma ticks", "DISEASE", 271, 285], ["CCHFV", "ORGANISM", 189, 194], ["Hyalomma ticks", "ORGANISM", 271, 285], ["Rhipicephalus", "ORGANISM", 299, 312], ["Dermatocentor spp", "ORGANISM", 314, 331], ["Dermatocentor spp", "SPECIES", 314, 331], ["CCHFV", "SPECIES", 43, 48], ["CCHFV", "SPECIES", 189, 194], ["Hyalomma ticks", "SPECIES", 271, 285], ["CCHFV", "PROBLEM", 43, 48], ["nairoviruses", "TREATMENT", 111, 123], ["prophylactic measures", "TREATMENT", 159, 180], ["CCHFV infections", "PROBLEM", 189, 205]]], ["Among ticks CCHFV is capable of transmitting infection both transovarially and transstadially.", [["CCHFV", "DISEASE", 12, 17], ["infection", "DISEASE", 45, 54], ["ticks CCHFV", "ORGANISM", 6, 17], ["CCHFV", "SPECIES", 12, 17], ["Among ticks CCHFV", "PROBLEM", 0, 17], ["transmitting infection", "PROBLEM", 32, 54], ["infection", "OBSERVATION", 45, 54]]], ["The life cycle of CCHFV also includes a tick-vertebrate host cycle involving both wild and domestic animals.", [["CCHFV", "DISEASE", 18, 23], ["CCHFV", "ORGANISM", 18, 23], ["CCHFV", "SPECIES", 18, 23], ["CCHFV", "PROBLEM", 18, 23], ["a tick", "TEST", 38, 44], ["CCHFV", "OBSERVATION", 18, 23], ["host cycle", "OBSERVATION", 56, 66]]], ["The virus or antibodies against it have been detected in rodents, hares, hedgehogs and some birds but human infections seem to be principally from contacts with livestock (mainly cattle, sheep, goats) including in Africa farmed ostriches and less often ticks [162, 163] .", [["infections", "DISEASE", 108, 118], ["birds", "ORGANISM", 92, 97], ["human", "ORGANISM", 102, 107], ["sheep", "ORGANISM_SUBDIVISION", 187, 192], ["goats", "ORGANISM", 194, 199], ["antibodies", "PROTEIN", 13, 23], ["human", "SPECIES", 102, 107], ["cattle", "SPECIES", 179, 185], ["sheep", "SPECIES", 187, 192], ["goats", "SPECIES", 194, 199], ["human", "SPECIES", 102, 107], ["cattle", "SPECIES", 179, 185], ["sheep", "SPECIES", 187, 192], ["goats", "SPECIES", 194, 199], ["Africa farmed ostriches", "SPECIES", 214, 237], ["The virus or antibodies", "PROBLEM", 0, 23], ["human infections", "PROBLEM", 102, 118], ["virus", "OBSERVATION", 4, 9], ["infections", "OBSERVATION", 108, 118]]], ["Thus CCHFV is more commonly seen in persons exposed to blood and tissues of infected animals during occupational activities, such as farming, herding, veterinary examination and abattoir work.", [["blood", "ANATOMY", 55, 60], ["tissues", "ANATOMY", 65, 72], ["CCHFV", "DISEASE", 5, 10], ["CCHFV", "ORGANISM", 5, 10], ["persons", "ORGANISM", 36, 43], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["tissues", "TISSUE", 65, 72], ["persons", "SPECIES", 36, 43], ["CCHFV", "SPECIES", 5, 10], ["CCHFV", "PROBLEM", 5, 10], ["veterinary examination", "TEST", 151, 173], ["CCHFV", "OBSERVATION", 5, 10], ["more commonly", "OBSERVATION_MODIFIER", 14, 27], ["infected", "OBSERVATION", 76, 84]]], ["Nosocomial infection is common and often results in small outbreaks.", [["Nosocomial infection", "DISEASE", 0, 20], ["Nosocomial infection", "PROBLEM", 0, 20], ["small outbreaks", "PROBLEM", 52, 67], ["infection", "OBSERVATION", 11, 20], ["small", "OBSERVATION_MODIFIER", 52, 57], ["outbreaks", "OBSERVATION", 58, 67]]], ["Yet, outdoor and recreational activities also represent a risk factor.", [["a risk factor", "PROBLEM", 56, 69]]], ["In addition, horizontal transmission of CCHFV from mother to child may occur [164] .Ecology and epidemiologyThe global distribution of CCHF follows closely that of Hyalomma spp. in the Middle East, Asia, Africa and Southeast Europe [162, 163] .", [["CCHFV", "DISEASE", 40, 45], ["CCHF", "DISEASE", 135, 139], ["CCHFV", "ORGANISM", 40, 45], ["Hyalomma spp.", "ORGANISM", 164, 177], ["Hyalomma spp.", "SPECIES", 164, 177], ["CCHFV", "SPECIES", 40, 45], ["Hyalomma spp.", "SPECIES", 164, 177], ["CCHF", "PROBLEM", 135, 139], ["Hyalomma spp.", "PROBLEM", 164, 177], ["CCHFV", "OBSERVATION", 40, 45], ["global", "OBSERVATION_MODIFIER", 112, 118], ["distribution", "OBSERVATION_MODIFIER", 119, 131], ["CCHF", "OBSERVATION", 135, 139], ["Middle", "ANATOMY_MODIFIER", 185, 191]]], ["Sequence analysis of CCHFV S RNA segments gives patterns following links between different geographic locations, in some cases suggesting links originating from trade in livestock and long-distance carriage of virus or infected ticks during bird migration [165] .", [["CCHFV", "SPECIES", 21, 26], ["Sequence analysis", "TEST", 0, 17], ["CCHFV S RNA segments", "PROBLEM", 21, 41], ["virus", "PROBLEM", 210, 215], ["infected ticks", "PROBLEM", 219, 233], ["infected", "OBSERVATION_MODIFIER", 219, 227]]], ["In Europe, CCHF occurs in the Balkan Peninsula (Albania, Bulgaria, Greece, Turkey, Yugoslavia) but also in Southern Russia, Hungary, France and Portugal [162, 166, 167] .Clinical picture and pathogenesisThe symptoms and signs of Crimean-Congo hemorrhagic fever are similar to those of other viral hemorrhagic fevers [162, 163] .", [["CCHF", "DISEASE", 11, 15], ["Crimean-Congo hemorrhagic fever", "DISEASE", 229, 260], ["viral hemorrhagic fevers", "DISEASE", 291, 315], ["Crimean-Congo", "ORGANISM", 229, 242], ["Congo hemorrhagic fever", "SPECIES", 237, 260], ["Crimean-Congo hemorrhagic fever", "SPECIES", 229, 260], ["CCHF", "PROBLEM", 11, 15], ["Clinical picture", "PROBLEM", 170, 186], ["pathogenesis", "PROBLEM", 191, 203], ["The symptoms", "PROBLEM", 203, 215], ["Crimean", "PROBLEM", 229, 236], ["Congo hemorrhagic fever", "PROBLEM", 237, 260], ["other viral hemorrhagic fevers", "PROBLEM", 285, 315], ["CCHF", "OBSERVATION", 11, 15], ["Balkan Peninsula", "ANATOMY", 30, 46], ["hemorrhagic", "OBSERVATION_MODIFIER", 243, 254], ["fever", "OBSERVATION", 255, 260], ["hemorrhagic", "OBSERVATION_MODIFIER", 297, 308], ["fevers", "OBSERVATION", 309, 315]]], ["The incubation period is generally short ranging usually from 2 to 9 days.", [["generally", "OBSERVATION_MODIFIER", 25, 34], ["short", "OBSERVATION_MODIFIER", 35, 40]]], ["There is typically a very sudden onset of illness with fever, rigors, chills, intense headache and backache or leg pains, myalgia, nausea, and vomiting.", [["leg", "ANATOMY", 111, 114], ["illness", "DISEASE", 42, 49], ["fever", "DISEASE", 55, 60], ["rigors", "DISEASE", 62, 68], ["chills", "DISEASE", 70, 76], ["headache", "DISEASE", 86, 94], ["backache", "DISEASE", 99, 107], ["leg pains", "DISEASE", 111, 120], ["myalgia", "DISEASE", 122, 129], ["nausea", "DISEASE", 131, 137], ["vomiting", "DISEASE", 143, 151], ["leg", "ORGANISM_SUBDIVISION", 111, 114], ["illness", "PROBLEM", 42, 49], ["fever", "PROBLEM", 55, 60], ["rigors", "PROBLEM", 62, 68], ["chills", "PROBLEM", 70, 76], ["intense headache", "PROBLEM", 78, 94], ["backache", "PROBLEM", 99, 107], ["leg pains", "PROBLEM", 111, 120], ["myalgia", "PROBLEM", 122, 129], ["nausea", "PROBLEM", 131, 137], ["vomiting", "PROBLEM", 143, 151], ["very", "OBSERVATION_MODIFIER", 21, 25], ["illness", "OBSERVATION", 42, 49], ["intense", "OBSERVATION_MODIFIER", 78, 85], ["headache", "OBSERVATION", 86, 94], ["backache", "ANATOMY", 99, 107], ["leg", "ANATOMY", 111, 114], ["pains", "OBSERVATION", 115, 120], ["myalgia", "OBSERVATION", 122, 129], ["nausea", "OBSERVATION", 131, 137]]], ["Patients may also present with photophobia, somnolence and menigism with confusion or aggression.", [["photophobia", "DISEASE", 31, 42], ["somnolence", "DISEASE", 44, 54], ["menigism", "DISEASE", 59, 67], ["confusion", "DISEASE", 73, 82], ["aggression", "DISEASE", 86, 96], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["photophobia", "PROBLEM", 31, 42], ["somnolence", "PROBLEM", 44, 54], ["menigism", "PROBLEM", 59, 67], ["confusion", "PROBLEM", 73, 82], ["aggression", "PROBLEM", 86, 96]]], ["Hemorrhages in the form of petecchiae, ecchymoses, epistaxis, melena and bleeding from various organs usually begin a few days later.", [["petecchiae", "ANATOMY", 27, 37], ["ecchymoses", "ANATOMY", 39, 49], ["organs", "ANATOMY", 95, 101], ["Hemorrhages", "DISEASE", 0, 11], ["ecchymoses", "DISEASE", 39, 49], ["epistaxis", "DISEASE", 51, 60], ["melena", "DISEASE", 62, 68], ["bleeding", "DISEASE", 73, 81], ["petecchiae", "CANCER", 27, 37], ["melena", "PATHOLOGICAL_FORMATION", 62, 68], ["organs", "ORGAN", 95, 101], ["Hemorrhages", "PROBLEM", 0, 11], ["petecchiae", "PROBLEM", 27, 37], ["ecchymoses", "PROBLEM", 39, 49], ["epistaxis", "PROBLEM", 51, 60], ["melena", "PROBLEM", 62, 68], ["bleeding from various organs", "PROBLEM", 73, 101], ["petecchiae", "OBSERVATION", 27, 37], ["ecchymoses", "OBSERVATION", 39, 49], ["epistaxis", "OBSERVATION", 51, 60], ["melena", "OBSERVATION", 62, 68], ["bleeding", "OBSERVATION", 73, 81]]], ["Tachycardia is common and lymphadenopathy is seen occasionally.", [["Tachycardia", "DISEASE", 0, 11], ["lymphadenopathy", "DISEASE", 26, 41], ["Tachycardia", "PROBLEM", 0, 11], ["lymphadenopathy", "PROBLEM", 26, 41], ["common", "OBSERVATION_MODIFIER", 15, 21], ["lymphadenopathy", "OBSERVATION", 26, 41]]], ["The case-fatality rate is 20-35%.", [["fatality rate", "TEST", 9, 22]]], ["The pathology consists of hemorrhagic and necrotic lesions in various organs as well as fibrin deposits.Diagnostics and preventionThe methods used for detection of CCHFV infection in humans or livestock include indirect immunofluorescence on virus-infected or N-expressing transfected cells.", [["necrotic lesions", "ANATOMY", 42, 58], ["organs", "ANATOMY", 70, 76], ["cells", "ANATOMY", 285, 290], ["hemorrhagic", "DISEASE", 26, 37], ["necrotic", "DISEASE", 42, 50], ["CCHFV infection", "DISEASE", 164, 179], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 42, 58], ["organs", "ORGAN", 70, 76], ["fibrin", "GENE_OR_GENE_PRODUCT", 88, 94], ["CCHFV", "ORGANISM", 164, 169], ["humans", "ORGANISM", 183, 189], ["cells", "CELL", 285, 290], ["N-expressing transfected cells", "CELL_LINE", 260, 290], ["humans", "SPECIES", 183, 189], ["CCHFV", "SPECIES", 164, 169], ["humans", "SPECIES", 183, 189], ["The pathology", "TEST", 0, 13], ["hemorrhagic and necrotic lesions in various organs", "PROBLEM", 26, 76], ["fibrin deposits", "PROBLEM", 88, 103], ["Diagnostics", "TEST", 104, 115], ["CCHFV infection in humans", "PROBLEM", 164, 189], ["indirect immunofluorescence", "TEST", 211, 238], ["virus", "PROBLEM", 242, 247], ["infected", "PROBLEM", 248, 256], ["expressing transfected cells", "PROBLEM", 262, 290], ["hemorrhagic", "OBSERVATION_MODIFIER", 26, 37], ["necrotic", "OBSERVATION_MODIFIER", 42, 50], ["lesions", "OBSERVATION", 51, 58], ["various", "ANATOMY_MODIFIER", 62, 69], ["organs", "ANATOMY", 70, 76], ["fibrin deposits", "OBSERVATION", 88, 103], ["CCHFV", "OBSERVATION_MODIFIER", 164, 169], ["infection", "OBSERVATION", 170, 179], ["transfected cells", "OBSERVATION", 273, 290]]], ["Both IgM and IgG antibodies reactive for CCHF appear within a week in patients [162, 168] .", [["CCHF", "DISEASE", 41, 45], ["IgM", "GENE_OR_GENE_PRODUCT", 5, 8], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["patients", "ORGANISM", 70, 78], ["IgM", "PROTEIN", 5, 8], ["IgG antibodies", "PROTEIN", 13, 27], ["patients", "SPECIES", 70, 78], ["Both IgM", "TEST", 0, 8], ["IgG antibodies", "TEST", 13, 27], ["CCHF", "PROBLEM", 41, 45], ["IgM", "OBSERVATION_MODIFIER", 5, 8]]], ["Alternatively a recombinant nucleocapsid protein-based enzyme immunoassay [169] [170] [171] may be used.", [["recombinant nucleocapsid protein", "PROTEIN", 16, 48], ["a recombinant nucleocapsid protein", "TEST", 14, 48], ["enzyme immunoassay", "TEST", 55, 73]]], ["Rapid detection and quantification of CCHFV RNA is possible by real-time reverse transcription PCR [172] .Diagnostics and preventionRibavirin is clearly effective in treatment of Crimean-Congo hemorrhagic fever [173, 174] but supportive treatment (blood, thrombocytes, coagulation factors) is equally important.", [["blood", "ANATOMY", 248, 253], ["thrombocytes", "ANATOMY", 255, 267], ["preventionRibavirin", "CHEMICAL", 122, 141], ["Crimean-Congo hemorrhagic fever", "DISEASE", 179, 210], ["preventionRibavirin", "CHEMICAL", 122, 141], ["CCHFV", "ORGANISM", 38, 43], ["preventionRibavirin", "SIMPLE_CHEMICAL", 122, 141], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["thrombocytes", "CELL", 255, 267], ["coagulation factors", "GENE_OR_GENE_PRODUCT", 269, 288], ["CCHFV RNA", "RNA", 38, 47], ["coagulation factors", "PROTEIN", 269, 288], ["Congo hemorrhagic fever", "SPECIES", 187, 210], ["CCHFV", "SPECIES", 38, 43], ["Crimean-Congo hemorrhagic fever", "SPECIES", 179, 210], ["Rapid detection", "TEST", 0, 15], ["CCHFV RNA", "PROBLEM", 38, 47], ["transcription PCR", "TEST", 81, 98], ["Diagnostics", "TEST", 106, 117], ["preventionRibavirin", "TREATMENT", 122, 141], ["Crimean", "TEST", 179, 186], ["Congo hemorrhagic fever", "PROBLEM", 187, 210], ["supportive treatment", "TREATMENT", 226, 246], ["blood", "TEST", 248, 253], ["thrombocytes", "TEST", 255, 267], ["coagulation factors", "TEST", 269, 288], ["CCHFV", "OBSERVATION", 38, 43]]], ["Immune plasma from recovered patients has also been used to treat patients but not in controlled studies with a follow-up of virus-neutralizing activities [162] .", [["Immune plasma", "ANATOMY", 0, 13], ["Immune plasma", "ORGANISM_SUBSTANCE", 0, 13], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 66, 74], ["Immune plasma", "TEST", 0, 13], ["virus", "PROBLEM", 125, 130]]], ["The most effective method of preventing infections is to take measure to avoid exposure to ticks (protective clothing, tick repellent, frequent body searches to remove ticks).", [["body", "ANATOMY", 144, 148], ["infections", "DISEASE", 40, 50], ["body", "ORGANISM_SUBDIVISION", 144, 148], ["infections", "PROBLEM", 40, 50], ["ticks (protective clothing", "TREATMENT", 91, 117], ["tick repellent", "TREATMENT", 119, 133], ["most effective", "OBSERVATION_MODIFIER", 4, 18], ["infections", "OBSERVATION", 40, 50]]], ["Inactivated virus prepared in mouse brains has been used on a limited scale as a vaccine in Southeastern Europe and the former USSR but the sporadic and unpredictable occurrence of the disease renders it difficult to identify target populations and has slowed development of a safe and modern vaccine [162] .VirologyOrthobunyaviruses belong to the family Bunyaviridae.", [["brains", "ANATOMY", 36, 42], ["Bunyaviridae", "DISEASE", 355, 367], ["mouse", "ORGANISM", 30, 35], ["brains", "ORGAN", 36, 42], ["mouse", "SPECIES", 30, 35], ["mouse", "SPECIES", 30, 35], ["Inactivated virus", "PROBLEM", 0, 17], ["the disease", "PROBLEM", 181, 192], ["a safe and modern vaccine", "TREATMENT", 275, 300], ["virus", "OBSERVATION", 12, 17], ["disease", "OBSERVATION", 185, 192]]], ["These enveloped viruses have a three-segmented negative-strand RNA genome.", [["-segmented negative-strand RNA genome", "DNA", 36, 73], ["These enveloped viruses", "PROBLEM", 0, 23], ["strand RNA genome", "PROBLEM", 56, 73], ["viruses", "OBSERVATION", 16, 23], ["strand RNA genome", "OBSERVATION", 56, 73]]], ["The 0.97 kb S segment encodes the 19-25 kDa nucleocapsid protein (N) and a 10-13 kDa nonstructural protein (Ns); the 4.5 kb M segment encodes the polyprotein precursor of two glycoproteins, G1 and G2 (108-210 kDa and 29-41 kDa, respectively), and a nonstructural protein NSm (15) (16) (17) (18) ; and the 6.9 kb L segment encodes the RNA polymerase (260 kDa) ( Table 1 , Fig. 1 ).", [["NSm (15) (16)", "GENE_OR_GENE_PRODUCT", 271, 284], ["0.97 kb S segment", "DNA", 4, 21], ["19-25 kDa nucleocapsid protein", "PROTEIN", 34, 64], ["N", "PROTEIN", 66, 67], ["10-13 kDa nonstructural protein", "PROTEIN", 75, 106], ["Ns", "PROTEIN", 108, 110], ["4.5 kb M segment", "DNA", 117, 133], ["polyprotein precursor", "PROTEIN", 146, 167], ["glycoproteins", "PROTEIN", 175, 188], ["G1", "PROTEIN", 190, 192], ["G2", "PROTEIN", 197, 199], ["29", "PROTEIN", 217, 219], ["6.9 kb L segment", "DNA", 305, 321], ["RNA polymerase", "PROTEIN", 334, 348], ["260 kDa", "PROTEIN", 350, 357], ["The 0.97 kb S segment encodes", "TEST", 0, 29], ["kDa nucleocapsid protein", "TEST", 40, 64], ["kDa nonstructural protein", "TEST", 81, 106], ["Ns", "TEST", 108, 110], ["the polyprotein precursor", "TEST", 142, 167], ["G2", "TEST", 197, 199], ["kDa", "TEST", 209, 212], ["kDa", "TEST", 223, 226], ["a nonstructural protein NSm", "TEST", 247, 274], ["the RNA polymerase", "TEST", 330, 348], ["kDa", "TEST", 354, 357], ["Table", "TEST", 361, 366]]], ["Viral messenger RNAs are not polyadenylated and are truncated relative to the genome RNAs at the 3 0 termini.", [["Viral messenger RNAs", "RNA", 0, 20], ["genome RNAs", "RNA", 78, 89], ["3 0 termini", "DNA", 97, 108], ["Viral messenger RNAs", "PROBLEM", 0, 20], ["messenger RNAs", "OBSERVATION", 6, 20], ["not", "UNCERTAINTY", 25, 28], ["polyadenylated", "OBSERVATION_MODIFIER", 29, 43], ["genome RNAs", "OBSERVATION", 78, 89]]], ["Messenger RNAs have 5 0 -methylated caps and some nontemplated nucleotides which are derived from host cell mRNAs.Ecology and epidemiologyOrthobunyaviruses are transmitted to humans by a variety of mosquito species, and in Europe two known human pathogenic representatives of the genus circulate, Tahyna virus and Inkoo virus (mostly transmitted by Aedes spp.) [109, 175, 176] (Table 2 ).", [["cell", "ANATOMY", 103, 107], ["nucleotides", "CHEMICAL", 63, 74], ["host cell", "CELL", 98, 107], ["Orthobunyaviruses", "GENE_OR_GENE_PRODUCT", 138, 155], ["humans", "ORGANISM", 175, 181], ["human", "ORGANISM", 240, 245], ["Tahyna virus", "ORGANISM", 297, 309], ["Inkoo virus", "ORGANISM", 314, 325], ["Aedes spp.", "ORGANISM", 349, 359], ["Messenger RNAs", "RNA", 0, 14], ["host cell mRNAs", "RNA", 98, 113], ["humans", "SPECIES", 175, 181], ["human", "SPECIES", 240, 245], ["Tahyna virus", "SPECIES", 297, 309], ["Inkoo virus", "SPECIES", 314, 325], ["Aedes spp.", "SPECIES", 349, 359], ["humans", "SPECIES", 175, 181], ["human", "SPECIES", 240, 245], ["Tahyna virus", "SPECIES", 297, 309], ["Inkoo virus", "SPECIES", 314, 325], ["Aedes spp.", "SPECIES", 349, 359], ["Messenger RNAs", "TEST", 0, 14], ["methylated caps", "PROBLEM", 25, 40], ["some nontemplated nucleotides", "PROBLEM", 45, 74], ["mosquito species", "PROBLEM", 198, 214], ["the genus circulate", "PROBLEM", 276, 295], ["Tahyna virus", "PROBLEM", 297, 309], ["Inkoo virus", "PROBLEM", 314, 325], ["host cell mRNAs", "OBSERVATION", 98, 113], ["genus circulate", "ANATOMY", 280, 295]]], ["These viruses belong to the California serogroup, and their incidence is associated with the distribution of the carrier mosquitoes.", [["These viruses", "PROBLEM", 0, 13], ["the carrier mosquitoes", "PROBLEM", 109, 131], ["viruses", "OBSERVATION", 6, 13], ["California", "OBSERVATION_MODIFIER", 28, 38], ["serogroup", "OBSERVATION_MODIFIER", 39, 48], ["carrier mosquitoes", "OBSERVATION", 113, 131]]], ["The natural cycle of these viruses involve also mammal hosts.", [["viruses", "OBSERVATION", 27, 34], ["mammal hosts", "OBSERVATION", 48, 60]]], ["Tahyna virus circulates throughout most of Europe, whereas Inkoo virus is mainly reported from northern Europe [109,177a] .Clinical picture and diagnosisTahyna virus causes an influenza-like disease which may also present as a meningitis.", [["Tahyna virus", "DISEASE", 153, 165], ["influenza-like disease", "DISEASE", 176, 198], ["meningitis", "DISEASE", 227, 237], ["Tahyna virus", "ORGANISM", 0, 12], ["Inkoo virus", "ORGANISM", 59, 70], ["Tahyna virus", "ORGANISM", 153, 165], ["Tahyna virus", "SPECIES", 0, 12], ["Inkoo virus", "SPECIES", 59, 70], ["Tahyna virus", "SPECIES", 153, 165], ["Tahyna virus circulates", "PROBLEM", 0, 23], ["Inkoo virus", "PROBLEM", 59, 70], ["Clinical picture", "TEST", 123, 139], ["Tahyna virus", "PROBLEM", 153, 165], ["an influenza-like disease", "PROBLEM", 173, 198], ["a meningitis", "PROBLEM", 225, 237], ["virus", "OBSERVATION", 7, 12], ["influenza", "OBSERVATION", 176, 185], ["meningitis", "OBSERVATION", 227, 237]]], ["The infection caused by Inkoo virus is mostly sub-clinical or a mild disease, although encephalitis has been reported.", [["infection", "DISEASE", 4, 13], ["encephalitis", "DISEASE", 87, 99], ["Inkoo virus", "ORGANISM", 24, 35], ["Inkoo virus", "SPECIES", 24, 35], ["The infection", "PROBLEM", 0, 13], ["Inkoo virus", "PROBLEM", 24, 35], ["a mild disease", "PROBLEM", 62, 76], ["encephalitis", "PROBLEM", 87, 99], ["infection", "OBSERVATION", 4, 13], ["Inkoo virus", "OBSERVATION", 24, 35], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["disease", "OBSERVATION", 69, 76], ["encephalitis", "OBSERVATION", 87, 99]]], ["The most typical symptoms associated with encephalitis or meningitis caused by Californian serogroup viruses include fever, headache, nausea, vomiting, convulsions and confusion.", [["encephalitis", "DISEASE", 42, 54], ["meningitis", "DISEASE", 58, 68], ["Californian serogroup viruses", "DISEASE", 79, 108], ["fever", "DISEASE", 117, 122], ["headache", "DISEASE", 124, 132], ["nausea", "DISEASE", 134, 140], ["vomiting", "DISEASE", 142, 150], ["convulsions", "DISEASE", 152, 163], ["confusion", "DISEASE", 168, 177], ["Californian serogroup viruses", "ORGANISM", 79, 108], ["Californian serogroup viruses", "SPECIES", 79, 108], ["The most typical symptoms", "PROBLEM", 0, 25], ["encephalitis", "PROBLEM", 42, 54], ["meningitis", "PROBLEM", 58, 68], ["Californian serogroup viruses", "PROBLEM", 79, 108], ["fever", "PROBLEM", 117, 122], ["headache", "PROBLEM", 124, 132], ["nausea", "PROBLEM", 134, 140], ["vomiting", "PROBLEM", 142, 150], ["convulsions", "PROBLEM", 152, 163], ["confusion", "PROBLEM", 168, 177], ["most typical", "OBSERVATION_MODIFIER", 4, 16], ["encephalitis", "OBSERVATION", 42, 54], ["meningitis", "OBSERVATION", 58, 68], ["Californian", "OBSERVATION_MODIFIER", 79, 90], ["serogroup viruses", "OBSERVATION", 91, 108]]], ["In Europe the seroprevalence for Californian serogroup viruses varies from 1% to 69%, depending on the geographic area [109] .", [["Californian serogroup viruses", "ORGANISM", 33, 62], ["Californian serogroup viruses", "SPECIES", 33, 62], ["Californian serogroup viruses", "PROBLEM", 33, 62]]], ["In Finland the seroprevalence against Inkoo virus varies from 2% to 6% (\u00c5 land islands) to 61-69% (Finnish Lapland) [109, Putkuri et al, unpublished results] .", [["Inkoo virus", "ORGANISM", 38, 49], ["Inkoo virus", "SPECIES", 38, 49], ["Inkoo virus", "PROBLEM", 38, 49]]], ["In disease-endemic areas the seropositivity of the population increases with age [177b].", [["disease", "OBSERVATION", 3, 10], ["endemic", "OBSERVATION_MODIFIER", 11, 18], ["areas", "OBSERVATION_MODIFIER", 19, 24], ["seropositivity", "OBSERVATION_MODIFIER", 29, 43], ["population", "OBSERVATION_MODIFIER", 51, 61], ["increases", "OBSERVATION_MODIFIER", 62, 71]]], ["The diagnosis of orthobunyaviruses is based on serology, either as a rise in IgG-antibody titers, or the presence of IgM antibodies.", [["orthobunyaviruses", "DISEASE", 17, 34], ["orthobunyaviruses", "CANCER", 17, 34], ["IgG", "GENE_OR_GENE_PRODUCT", 77, 80], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 117, 131], ["IgG", "PROTEIN", 77, 80], ["IgM antibodies", "PROTEIN", 117, 131], ["orthobunyaviruses", "PROBLEM", 17, 34], ["serology", "TEST", 47, 55], ["IgG", "TEST", 77, 80], ["antibody titers", "TEST", 81, 96], ["IgM antibodies", "PROBLEM", 117, 131], ["IgM antibodies", "OBSERVATION", 117, 131]]], ["Also RT-PCR methods are under development to detect viral RNA in cerebrospinal fluid samples of patients with encephalitis.VirologyPhleboviruses are one of the five groups within the family Bunyaviridae.", [["cerebrospinal fluid samples", "ANATOMY", 65, 92], ["encephalitis", "DISEASE", 110, 122], ["Bunyaviridae", "DISEASE", 190, 202], ["cerebrospinal fluid samples", "ORGANISM_SUBSTANCE", 65, 92], ["patients", "ORGANISM", 96, 104], ["viral RNA", "RNA", 52, 61], ["patients", "SPECIES", 96, 104], ["RT-PCR methods", "TEST", 5, 19], ["viral RNA in cerebrospinal fluid samples", "TEST", 52, 92], ["encephalitis", "PROBLEM", 110, 122], ["VirologyPhleboviruses", "TEST", 123, 144], ["viral RNA", "OBSERVATION", 52, 61], ["cerebrospinal fluid", "OBSERVATION", 65, 84], ["encephalitis", "OBSERVATION", 110, 122]]], ["They have a negative singlestranded RNA tripartite genome, namely: L (6.4 kb), M (3.2-4.2 kb) and S (1.7-1.9 kb).", [["negative singlestranded RNA tripartite genome", "DNA", 12, 57], ["M", "TEST", 79, 80], ["kb", "TEST", 90, 92], ["S", "TEST", 98, 99]]], ["The L segment encodes a single protein of 240 kDa (RNA polymerase) in the complementary sense.", [["L segment", "DNA", 4, 13], ["240 kDa", "PROTEIN", 42, 49], ["RNA polymerase", "PROTEIN", 51, 65], ["RNA polymerase", "TEST", 51, 65], ["L", "ANATOMY_MODIFIER", 4, 5], ["segment", "ANATOMY_MODIFIER", 6, 13]]], ["The M segment encodes a protein precursor of 130 kDa in the complementary sense which is cleaved into two glycoproteins G1 (56 kDa) and G2 (59 kDa).", [["M segment", "DNA", 4, 13], ["130 kDa", "PROTEIN", 45, 52], ["glycoproteins G1", "PROTEIN", 106, 122], ["56 kDa", "PROTEIN", 124, 130], ["G2", "PROTEIN", 136, 138], ["59 kDa", "PROTEIN", 140, 146], ["kDa", "TEST", 127, 130], ["G2", "TEST", 136, 138], ["130 kDa", "OBSERVATION_MODIFIER", 45, 52]]], ["The S segment has an ambisense coding arrangement, and it encodes the nucleocapsid protein (N) of 27 kDa in the complementary sense and a non-structural protein (NSs) of 30 kDa in the virion sense [178, 179] (Table 1, Fig. 1 ).", [["S segment", "DNA", 4, 13], ["nucleocapsid protein", "PROTEIN", 70, 90], ["N", "PROTEIN", 92, 93], ["27 kDa", "PROTEIN", 98, 104], ["non-structural protein", "PROTEIN", 138, 160], ["NSs", "PROTEIN", 162, 165], ["30 kDa", "PROTEIN", 170, 176], ["27 kDa", "PROBLEM", 98, 104], ["a non-structural protein (NSs", "TREATMENT", 136, 165], ["ambisense", "OBSERVATION", 21, 30]]], ["Viral messenger RNAs (mRNA) are not polyadenylated and are truncated relative to the genome RNAs at the 3 0 termini. mRNAs have 5 0 -methylated caps and some nontemplated nucleotides which are derived from host cell mRNAs.VirologyWhen seen under the electron microscope the virions are spherical and enveloped and approximately 80-110 nm in diameter.", [["cell", "ANATOMY", 211, 215], ["virions", "ANATOMY", 274, 281], ["nucleotides", "CHEMICAL", 171, 182], ["host cell", "CELL", 206, 215], ["virions", "CELLULAR_COMPONENT", 274, 281], ["Viral messenger RNAs", "RNA", 0, 20], ["mRNA", "RNA", 22, 26], ["genome RNAs", "RNA", 85, 96], ["3 0 termini", "DNA", 104, 115], ["mRNAs", "RNA", 117, 122], ["host cell mRNAs", "RNA", 206, 221], ["Viral messenger RNAs (mRNA)", "PROBLEM", 0, 27], ["the genome RNAs", "PROBLEM", 81, 96], ["mRNAs", "TEST", 117, 122], ["methylated caps", "PROBLEM", 133, 148], ["some nontemplated nucleotides", "PROBLEM", 153, 182], ["messenger RNAs", "OBSERVATION", 6, 20], ["not", "UNCERTAINTY", 32, 35], ["polyadenylated", "OBSERVATION_MODIFIER", 36, 50], ["genome RNAs", "OBSERVATION", 85, 96], ["nontemplated nucleotides", "OBSERVATION", 158, 182], ["host cell mRNAs", "OBSERVATION", 206, 221], ["spherical", "OBSERVATION_MODIFIER", 286, 295], ["enveloped", "OBSERVATION_MODIFIER", 300, 309], ["110 nm", "OBSERVATION_MODIFIER", 331, 337], ["diameter", "OBSERVATION_MODIFIER", 341, 349]]], ["Glycoprotein projections of 5-10 nm are also seen embedded in the membrane.", [["membrane", "ANATOMY", 66, 74], ["Glycoprotein", "GENE_OR_GENE_PRODUCT", 0, 12], ["membrane", "CELLULAR_COMPONENT", 66, 74], ["Glycoprotein projections", "TREATMENT", 0, 24], ["membrane", "ANATOMY_MODIFIER", 66, 74]]], ["There are between 200 and 1500 spikes per virion [178, 179] .Ecology and epidemiologyPhleboviruses are arthropod-borne viruses and are transmitted mainly by phlebotomine sandflies, hence the derivation of its name ''phlebo'' (Table 2) .", [["Phleboviruses", "GENE_OR_GENE_PRODUCT", 85, 98], ["arthropod-borne viruses", "PROBLEM", 103, 126], ["borne viruses", "OBSERVATION", 113, 126]]], ["However, mosquitoes and ticks can also transmit phleboviruses.", [["phleboviruses", "DISEASE", 48, 61], ["ticks", "ORGANISM", 24, 29], ["phleboviruses", "GENE_OR_GENE_PRODUCT", 48, 61]]], ["Phleboviruses are distributed throughout most of the world but have not been reported in Australia [180] .", [["Phleboviruses", "PROBLEM", 0, 13], ["distributed", "OBSERVATION_MODIFIER", 18, 29]]], ["The first documented record of a disease resembling those caused by phleboviruses dates back to the 1900s in the Mediterranean countries of Europe [178] .", [["a disease", "PROBLEM", 31, 40], ["disease", "OBSERVATION", 33, 40]]], ["However, the first virus isolation occurred for Rift Valley Fever virus in 1930 in Kenya [181] .", [["Rift Valley Fever", "DISEASE", 48, 65], ["Rift Valley Fever virus", "ORGANISM", 48, 71], ["Rift Valley Fever virus", "SPECIES", 48, 71], ["Rift Valley Fever virus", "SPECIES", 48, 71], ["the first virus isolation", "PROBLEM", 9, 34], ["Rift Valley Fever virus", "PROBLEM", 48, 71]]], ["Retrospective serological studies have indicated that outbreaks caused by phleboviruses have occurred since 1912 in the Sub-Saharan Africa region [182] .", [["phleboviruses", "DISEASE", 74, 87], ["Retrospective serological studies", "TEST", 0, 33], ["outbreaks", "PROBLEM", 54, 63], ["phleboviruses", "PROBLEM", 74, 87]]], ["Phleboviruses are major causal agents of encephalitis in humans, especially among children, in Mediterranean countries.", [["Phleboviruses", "DISEASE", 0, 13], ["encephalitis", "DISEASE", 41, 53], ["humans", "ORGANISM", 57, 63], ["children", "ORGANISM", 82, 90], ["humans", "SPECIES", 57, 63], ["children", "SPECIES", 82, 90], ["humans", "SPECIES", 57, 63], ["encephalitis", "PROBLEM", 41, 53], ["encephalitis", "OBSERVATION", 41, 53]]], ["They also have an important impact in livestock especially in African endemic areas.", [["important", "OBSERVATION_MODIFIER", 18, 27], ["impact", "OBSERVATION_MODIFIER", 28, 34], ["livestock", "OBSERVATION_MODIFIER", 38, 47]]], ["Infection of livestock is characterised by a high rate of abortions and pathologies associated with hemorrhagic illness (leukopenia, thrombocytopenia, fibrin thrombi, intravascular coagulopathy, etc.) [183] [184] [185] .", [["intravascular", "ANATOMY", 167, 180], ["Infection of livestock", "DISEASE", 0, 22], ["abortions", "DISEASE", 58, 67], ["hemorrhagic illness", "DISEASE", 100, 119], ["leukopenia", "DISEASE", 121, 131], ["thrombocytopenia", "DISEASE", 133, 149], ["thrombi", "DISEASE", 158, 165], ["intravascular coagulopathy", "DISEASE", 167, 193], ["fibrin", "GENE_OR_GENE_PRODUCT", 151, 157], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 167, 180], ["Infection of livestock", "PROBLEM", 0, 22], ["a high rate of abortions", "PROBLEM", 43, 67], ["pathologies", "PROBLEM", 72, 83], ["hemorrhagic illness", "PROBLEM", 100, 119], ["leukopenia", "PROBLEM", 121, 131], ["thrombocytopenia", "PROBLEM", 133, 149], ["fibrin thrombi", "PROBLEM", 151, 165], ["intravascular coagulopathy", "PROBLEM", 167, 193], ["livestock", "OBSERVATION", 13, 22], ["hemorrhagic", "OBSERVATION_MODIFIER", 100, 111], ["leukopenia", "OBSERVATION", 121, 131], ["thrombocytopenia", "OBSERVATION", 133, 149], ["fibrin thrombi", "OBSERVATION", 151, 165], ["intravascular coagulopathy", "OBSERVATION", 167, 193]]], ["The distribution of the disease follows that of its vector.", [["the disease", "PROBLEM", 20, 31], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["disease", "OBSERVATION", 24, 31]]], ["However the natural history of phleboviruses is largely unknown and for many species the amplifying host has not been identified [185] [186] [187] .Clinical picture and pathogenesisIn general, phlebovirus infections cause a 2-4 days illness characterised by an incubation period of 2-6 days followed by fever, general malaise, headache, photophobia, and back and joint pain [188] .", [["back", "ANATOMY", 354, 358], ["joint", "ANATOMY", 363, 368], ["phleboviruses", "DISEASE", 31, 44], ["phlebovirus infections", "DISEASE", 193, 215], ["illness", "DISEASE", 233, 240], ["fever", "DISEASE", 303, 308], ["headache", "DISEASE", 327, 335], ["photophobia", "DISEASE", 337, 348], ["pain", "DISEASE", 369, 373], ["phleboviruses", "CANCER", 31, 44], ["phleboviruses", "PROBLEM", 31, 44], ["many species", "PROBLEM", 72, 84], ["Clinical picture", "PROBLEM", 148, 164], ["pathogenesisIn", "PROBLEM", 169, 183], ["phlebovirus infections", "PROBLEM", 193, 215], ["fever", "PROBLEM", 303, 308], ["general malaise", "PROBLEM", 310, 325], ["headache", "PROBLEM", 327, 335], ["photophobia", "PROBLEM", 337, 348], ["back and joint pain", "PROBLEM", 354, 373], ["malaise", "OBSERVATION", 318, 325], ["back", "ANATOMY", 354, 358], ["joint", "ANATOMY", 363, 368]]], ["The illness occurs during the summer months when the activity of phlebotomine flies is high [178] .Clinical picture and pathogenesisThere are three recognised members of the genus Phlebovirus, associated with disease in humans.", [["illness", "DISEASE", 4, 11], ["Phlebovirus", "GENE_OR_GENE_PRODUCT", 180, 191], ["humans", "ORGANISM", 220, 226], ["humans", "SPECIES", 220, 226], ["humans", "SPECIES", 220, 226], ["The illness", "PROBLEM", 0, 11], ["phlebotomine flies", "TEST", 65, 83], ["Clinical picture", "PROBLEM", 99, 115], ["pathogenesis", "PROBLEM", 120, 132], ["the genus Phlebovirus", "PROBLEM", 170, 191], ["disease in humans", "PROBLEM", 209, 226], ["illness", "OBSERVATION", 4, 11], ["genus Phlebovirus", "OBSERVATION", 174, 191], ["disease", "OBSERVATION", 209, 216]]], ["Rift Valley fever virus (RVFV), which is the type species of the genus and is transmitted by mosquitoes, causing an influenza-like disease that affects domestic animals and humans.", [["Rift Valley fever", "DISEASE", 0, 17], ["influenza-like disease", "DISEASE", 116, 138], ["Rift Valley fever virus", "ORGANISM", 0, 23], ["RVFV", "ORGANISM", 25, 29], ["humans", "ORGANISM", 173, 179], ["Rift Valley fever virus", "SPECIES", 0, 23], ["humans", "SPECIES", 173, 179], ["Rift Valley fever virus", "SPECIES", 0, 23], ["RVFV", "SPECIES", 25, 29], ["humans", "SPECIES", 173, 179], ["Rift Valley fever virus (RVFV", "PROBLEM", 0, 29], ["an influenza-like disease", "PROBLEM", 113, 138], ["genus", "ANATOMY", 65, 70], ["influenza", "OBSERVATION", 116, 125]]], ["The majority of human infections are asymptomatic; however, in 0.5% of cases it can cause severe haemorrhagic fever, encephalitis and death.", [["human infections", "DISEASE", 16, 32], ["haemorrhagic fever", "DISEASE", 97, 115], ["encephalitis", "DISEASE", 117, 129], ["death", "DISEASE", 134, 139], ["human", "ORGANISM", 16, 21], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["human infections", "PROBLEM", 16, 32], ["asymptomatic", "PROBLEM", 37, 49], ["severe haemorrhagic fever", "PROBLEM", 90, 115], ["encephalitis", "PROBLEM", 117, 129], ["death", "PROBLEM", 134, 139], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["human", "OBSERVATION_MODIFIER", 16, 21], ["infections", "OBSERVATION", 22, 32], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["haemorrhagic", "OBSERVATION_MODIFIER", 97, 109], ["fever", "OBSERVATION", 110, 115], ["encephalitis", "OBSERVATION", 117, 129]]], ["The geographical distribution of RVFV includes Africa, Egypt, Saudi Arabia and Yemen and occurs as epizootics involving Aedes spp. mosquitoes and domestic animals [180] .Clinical picture and pathogenesisToscana virus (TSV) causes a mild influenza-like disease that can occasionally develop into an acute neurological disease, such as meningitis or meningoencephalitis in Italy and possibly other Mediterranean countries.", [["neurological", "ANATOMY", 304, 316], ["RVFV", "DISEASE", 33, 37], ["epizootics", "DISEASE", 99, 109], ["Toscana virus (TSV)", "DISEASE", 203, 222], ["influenza-like disease", "DISEASE", 237, 259], ["acute neurological disease", "DISEASE", 298, 324], ["meningitis", "DISEASE", 334, 344], ["meningoencephalitis", "DISEASE", 348, 367], ["RVFV", "ORGANISM", 33, 37], ["Aedes spp", "ORGANISM", 120, 129], ["Toscana virus", "ORGANISM", 203, 216], ["Toscana virus", "SPECIES", 203, 216], ["RVFV", "SPECIES", 33, 37], ["Toscana virus", "SPECIES", 203, 216], ["TSV", "SPECIES", 218, 221], ["RVFV", "PROBLEM", 33, 37], ["Africa", "PROBLEM", 47, 53], ["Clinical picture", "TEST", 170, 186], ["pathogenesisToscana virus", "PROBLEM", 191, 216], ["TSV", "TEST", 218, 221], ["a mild influenza-like disease", "PROBLEM", 230, 259], ["an acute neurological disease", "PROBLEM", 295, 324], ["meningitis", "PROBLEM", 334, 344], ["meningoencephalitis", "PROBLEM", 348, 367], ["geographical", "OBSERVATION_MODIFIER", 4, 16], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["RVFV", "OBSERVATION", 33, 37], ["mild", "OBSERVATION_MODIFIER", 232, 236], ["influenza", "OBSERVATION", 237, 246], ["acute", "OBSERVATION_MODIFIER", 298, 303], ["neurological disease", "OBSERVATION", 304, 324], ["meningitis", "OBSERVATION", 334, 344], ["meningoencephalitis", "OBSERVATION", 348, 367]]], ["A similar virus (Granada virus) was recently isolated in Spain [193] .", [["Granada virus", "ORGANISM", 17, 30], ["Granada virus", "SPECIES", 17, 30], ["A similar virus (Granada virus", "PROBLEM", 0, 30], ["virus", "OBSERVATION", 10, 15]]], ["TSV is the number one cause of encephalitis among children in Italy.", [["encephalitis", "DISEASE", 31, 43], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["encephalitis", "PROBLEM", 31, 43], ["encephalitis", "OBSERVATION", 31, 43]]], ["The distribution of the virus follows that of its vector, Phlebotomus perniciosus, found in Italy, Spain, Portugal, and Cyprus.", [["Phlebotomus perniciosus", "ORGANISM", 58, 81], ["Phlebotomus perniciosus", "SPECIES", 58, 81], ["Phlebotomus perniciosus", "SPECIES", 58, 81], ["the virus", "PROBLEM", 20, 29], ["Phlebotomus perniciosus", "PROBLEM", 58, 81], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["virus", "OBSERVATION", 24, 29]]], ["Human cases have also been reported from southern France and Greece.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5]]], ["The virus replicates in the sandfly vector population; however, experimental evidence suggests that an amplifying vertebrate host is needed to sustain the virus in the arthropod population [189] [190] [191] [192] [193] [194] .Clinical picture and pathogenesisSandfly fever virus (SFV) Sicilian and Naples viruses can cause a mild-influenza like disease.", [["Sandfly fever", "DISEASE", 259, 272], ["[189] [190] [191] [192] [193]", "CHEMICAL", 189, 218], ["Sandfly fever virus", "ORGANISM", 259, 278], ["SFV", "ORGANISM", 280, 283], ["Naples viruses", "ORGANISM", 298, 312], ["Sandfly fever virus", "SPECIES", 259, 278], ["Sandfly fever virus", "SPECIES", 259, 278], ["SFV", "SPECIES", 280, 283], ["Naples viruses", "SPECIES", 298, 312], ["The virus", "PROBLEM", 0, 9], ["an amplifying vertebrate host", "PROBLEM", 100, 129], ["the virus", "PROBLEM", 151, 160], ["Clinical picture", "TEST", 226, 242], ["pathogenesisSandfly fever virus (SFV)", "PROBLEM", 247, 284], ["Naples viruses", "TREATMENT", 298, 312], ["a mild-influenza like disease", "PROBLEM", 323, 352], ["virus", "OBSERVATION", 4, 9], ["mild", "OBSERVATION_MODIFIER", 325, 329], ["influenza", "OBSERVATION", 330, 339]]], ["The distribution of SFV also follows that of its vector, Phlebotomus papatasii, found in the Mediterranean basin extending to the Middle East and Arabian Peninsula, the Caucasus mountains, Pakistan and India [185] [186] [187] .Diagnosis and preventionDiagnostics of Phlebovirus is performed mainly by IgM-capture EIA and IFA.", [["SFV", "ORGANISM", 20, 23], ["Phlebotomus papatasii", "ORGANISM", 57, 78], ["IgM", "PROTEIN", 301, 304], ["Phlebotomus papatasii", "SPECIES", 57, 78], ["SFV", "SPECIES", 20, 23], ["Phlebotomus papatasii", "SPECIES", 57, 78], ["SFV", "PROBLEM", 20, 23], ["Phlebotomus papatasii", "PROBLEM", 57, 78], ["Phlebovirus", "PROBLEM", 266, 277], ["IgM", "TEST", 301, 304], ["SFV", "ANATOMY", 20, 23], ["Mediterranean", "ANATOMY", 93, 106], ["basin", "ANATOMY_MODIFIER", 107, 112], ["Middle", "ANATOMY_MODIFIER", 130, 136], ["East", "ANATOMY_MODIFIER", 137, 141], ["Arabian Peninsula", "ANATOMY", 146, 163], ["Phlebovirus", "OBSERVATION", 266, 277]]], ["The virus can be isolated using intracranial inoculation in suckling mice or using a susceptible tissue culture cell line (Vero, LLC-MK2, BHK-21) [178,195a] .", [["intracranial", "ANATOMY", 32, 44], ["tissue culture cell line", "ANATOMY", 97, 121], ["Vero", "ANATOMY", 123, 127], ["BHK-21", "ANATOMY", 138, 144], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 44], ["mice", "ORGANISM", 69, 73], ["tissue culture cell line", "CELL", 97, 121], ["Vero", "CELL", 123, 127], ["LLC-MK2", "CELL", 129, 136], ["BHK-21", "CELL", 138, 144], ["susceptible tissue culture cell line", "CELL_LINE", 85, 121], ["LLC", "CELL_LINE", 129, 132], ["MK2", "CELL_LINE", 133, 136], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["The virus", "PROBLEM", 0, 9], ["intracranial inoculation", "TREATMENT", 32, 56], ["a susceptible tissue culture cell line", "TREATMENT", 83, 121], ["Vero", "TEST", 123, 127], ["LLC", "TEST", 129, 132], ["BHK", "TEST", 138, 141], ["virus", "OBSERVATION", 4, 9], ["cell line", "OBSERVATION", 112, 121], ["LLC", "ANATOMY", 129, 132]]], ["Toscana virus and Naples Sandfly fever virus group together and are distinct antigenically and phylogenetically from Sicilian Sandfly fever virus [195b] .Diagnosis and preventionPrevention of infections by phleboviruses varies depending on the type species.", [["Sandfly fever", "DISEASE", 25, 38], ["Sandfly fever", "DISEASE", 126, 139], ["infections", "DISEASE", 192, 202], ["phleboviruses", "DISEASE", 206, 219], ["Toscana virus", "ORGANISM", 0, 13], ["Naples Sandfly fever virus", "ORGANISM", 18, 44], ["Sicilian Sandfly fever virus", "ORGANISM", 117, 145], ["Sandfly fever virus group", "SPECIES", 25, 50], ["Sandfly fever virus", "SPECIES", 126, 145], ["Toscana virus", "SPECIES", 0, 13], ["Naples Sandfly fever virus", "SPECIES", 18, 44], ["Sicilian Sandfly fever virus", "SPECIES", 117, 145], ["Toscana virus", "PROBLEM", 0, 13], ["Naples Sandfly fever virus group", "PROBLEM", 18, 50], ["Sicilian Sandfly fever virus", "PROBLEM", 117, 145], ["infections", "PROBLEM", 192, 202], ["phleboviruses varies", "PROBLEM", 206, 226], ["the type species", "PROBLEM", 240, 256], ["infections", "OBSERVATION", 192, 202]]], ["Immunising livestock with the formalin-inactivated or live-attenuated vaccines can prevent RVFV by avoiding epizootics and hence human infections [178, 196] .", [["formalin", "CHEMICAL", 30, 38], ["RVFV", "DISEASE", 91, 95], ["epizootics", "DISEASE", 108, 118], ["infections", "DISEASE", 135, 145], ["formalin", "CHEMICAL", 30, 38], ["formalin", "SIMPLE_CHEMICAL", 30, 38], ["RVFV", "ORGANISM", 91, 95], ["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["RVFV", "SPECIES", 91, 95], ["human", "SPECIES", 129, 134], ["the formalin", "TREATMENT", 26, 38], ["attenuated vaccines", "TREATMENT", 59, 78], ["RVFV", "PROBLEM", 91, 95]]], ["In the case of TSV and SFV, prevention is limited to controlling the vector population through insecticides and repellents [197, 198] .Concluding remarksWhat are the reasons for the appearance of all these emerging and re-emerging viruses?", [["TSV", "ORGANISM", 15, 18], ["SFV", "ORGANISM", 23, 26], ["TSV", "SPECIES", 15, 18], ["SFV", "SPECIES", 23, 26], ["TSV", "ANATOMY", 15, 18], ["SFV", "ANATOMY", 23, 26]]], ["The principal reasons are changes in the environment and human activity that have created new attacks with nature.", [["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["new", "OBSERVATION_MODIFIER", 90, 93], ["attacks", "OBSERVATION", 94, 101]]], ["Factors such as climate change, increasing intensity of agriculture, the building of dams and introduction of other irrigation measures which generate new breeding sites for mosquitoes, crises and wars which bring rodents and arthropods closer to humans, population growth and especially in suburban slums, and global air traffic are important factors generating such new contacts, or may affect the ecological cycles of these viruses.", [["humans", "ORGANISM", 247, 253], ["humans", "SPECIES", 247, 253], ["humans", "SPECIES", 247, 253], ["other irrigation measures", "TREATMENT", 110, 135], ["new breeding sites", "PROBLEM", 151, 169], ["mosquitoes", "PROBLEM", 174, 184], ["crises", "PROBLEM", 186, 192], ["global air traffic", "PROBLEM", 311, 329], ["these viruses", "PROBLEM", 421, 434], ["air traffic", "OBSERVATION", 318, 329], ["viruses", "OBSERVATION", 427, 434]]], ["Many epidemics may be unexpected outcomes of such changes.", [["such changes", "PROBLEM", 45, 57]]], ["Moreover, the new molecular biology techniques facilitate detection of new viral agents.Concluding remarksMany prevention and control measures, such as the anti-Aedes campaigns, have been abandoned in tropical countries.", [["new viral agents", "TREATMENT", 71, 87], ["control measures", "TREATMENT", 126, 142], ["new", "OBSERVATION_MODIFIER", 71, 74], ["viral agents", "OBSERVATION", 75, 87]]], ["The yellow-fever vaccination campaigns have been re-implemented just recently with the new outbreaks.", [["yellow-fever", "DISEASE", 4, 16], ["The yellow-fever vaccination campaigns", "PROBLEM", 0, 38], ["yellow", "OBSERVATION_MODIFIER", 4, 10], ["new", "OBSERVATION_MODIFIER", 87, 90], ["outbreaks", "OBSERVATION", 91, 100]]], ["This negligence has increased the chance of acquiring new infections from overseas and the chances of broadening the ecological niches for many diseases.", [["infections", "DISEASE", 58, 68], ["new infections", "PROBLEM", 54, 68], ["many diseases", "PROBLEM", 139, 152], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["new", "OBSERVATION_MODIFIER", 54, 57], ["infections", "OBSERVATION", 58, 68], ["diseases", "OBSERVATION", 144, 152]]], ["The new vector of many diseases is human transportation, which introduces the artificial migra-tion (or imports) of the vector (mosquitoes) usually as larvae.Concluding remarksThis review could not comprehensively cover all zoonotic agents in Europe, and new viruses with zoonotic transmission are continuously suggested, such as hepatitis E virus, found in rats and connected e.g. to eating deer meat [199] .", [["zoonotic transmission", "DISEASE", 272, 293], ["hepatitis E", "DISEASE", 330, 341], ["human", "ORGANISM", 35, 40], ["hepatitis E virus", "ORGANISM", 330, 347], ["rats", "ORGANISM", 358, 362], ["human", "SPECIES", 35, 40], ["hepatitis E virus", "SPECIES", 330, 347], ["rats", "SPECIES", 358, 362], ["human", "SPECIES", 35, 40], ["hepatitis E virus", "SPECIES", 330, 347], ["many diseases", "PROBLEM", 18, 31], ["the artificial migra-tion", "TREATMENT", 74, 99], ["new viruses", "PROBLEM", 255, 266], ["zoonotic transmission", "PROBLEM", 272, 293], ["hepatitis E virus", "PROBLEM", 330, 347], ["new", "OBSERVATION_MODIFIER", 4, 7], ["vector", "OBSERVATION_MODIFIER", 8, 14], ["many", "OBSERVATION_MODIFIER", 18, 22], ["diseases", "OBSERVATION", 23, 31], ["new", "OBSERVATION_MODIFIER", 255, 258], ["viruses", "OBSERVATION", 259, 266]]]]}